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The tight control of gene expression at the level of both transcription and 
post-transcriptional RNA processing is essential for mammalian development 
and altered in a multitude of human pathologies. We here investigate the role 
of protein arginine methyltransferase 5 (PRMT5), a putative splicing regulator 
and transcriptional cofactor, of high-interest to the cancer and drug discovery 
fields, yet of unclear function during mammalian development. !
We demonstrate that selective deletion of Prmt5 during organogenesis, in a 
conditional mouse model, is embryonically lethal causing widespread 
apoptosis and cell cycle arrest. Actively proliferating organs such as the liver, 
which during embryonic development is populated by Hematopoietic Stem 
Cells (HSCs), are particularly affected. Consistently, ex vivo PRMT5 depletion 
in HSCs impairs hematopoiesis. Since a variety of developmental diseases of 
the Central Nervous System (CNS) have been linked to either epigenetic or 
splicing defects we next focus our efforts on brain development in order to 
gain further insights into the physiological and molecular basis of PRMT5 
function in safeguarding proliferating cells homeostasis. PRMT5 depletion in 
the developing CNS leads to postnatal death in mice. Notably, Neural Stem/
Progenitor cells (NPCs) homeostasis is compromised and the activation of 
the apoptotic response can be fully rescued by deletion of the tumor 
suppressor protein p53. At the molecular level, the absence of PRMT5 results 
in reduced methylation of Sm proteins, aberrant constitutive splicing, and the 
alternative splicing of specific mRNAs with weak 5’ donor sites. Intriguingly, 
the products of these mRNAs are, among others, several proteins regulating 
cell cycle progression. We identify Mdm4 as one of these key mRNAs that 
senses the defects in the spliceosomal machinery and transduces the signal 
 vi
to activate the p53 response, providing a mechanistic explanation of the 
phenotype observed in vivo. Finally, we describe a correlation between the 
severity of the growth arrest phenotype, the rate of cell proliferation and the 
severity of the splicing defects. The identified mechanism is fully conserved in 
human cells.!
Our data demonstrate that PRMT5 is a master regulator of splicing in 
mammals and uncover a new early-warning system based on Mdm4 pre-
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Post-translational modifications (PTMs) have been shown to be crucial 
modulators of every known cellular process. By changing the biochemical and 
biophysical features of proteins, PTMs deeply impact on the proteome 
complexity fine-tuning and regulating protein fate, localization, stability, 
activity and interaction. Protein methylation is one of the most studied and 
abundant PTM and almost 2% of protein coding genes in prokaryotes and 
eukaryotes encode methyltransferases (Katz et al., 2003; Petrossian and 
Clarke, 2009; Petrossian and Clarke, 2011; Wlodarski et al., 2011). In 
eukaryotes, the most commonly methylated residues are lysines and 
arginines and a study conducted in rat liver nuclei estimates that 2% of 
arginine residues are methylated (Boffa et al., 1977).!
The two terminal guanidino-groups (NH2) of the arginine side chain mediate 
protein-protein, protein-DNA and protein-RNA interaction by formation of 
hydrogen bonds (Luscombe et al., 2001). Addition of methyl moieties to the 
guanidino-groups does not change the cationic charge of the residue, but 
rather increases its hydrophobicity and reshape the amino acid making it 
bulkier. Moreover, each methyl group abolishes a potential hydrogen bond 
donor (Hughes and Waters, 2006; Stetler et al., 2006). The methylation of 
one guanidino-group generates a ω‐NG‐monomethylarginine (MMA), which 
can be dimethylated either on the same guanodino-group giving rise to ω‐
NG,NG‐asymmetric dimethylarginine (ADMA), or on the other guanidine group 
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Figure 1.1: Types of arginine methylation. Adapted from (Yang and 
Bedford, 2013). All protein methyltranferases (Type I, II and III) can methylate 
arginine one of the terminal (ω) guanidino nitrogen atoms generating 
monomethylarginine (MMA). The generation of symmetric dimethylraginine 
(SDMA) is catalyzed by Type II enzymes, whereas Type I PRMTs generate 
asymmetric dimethylarginine methylating the same terminal (ω) guanidino 
nitrogen atom methylated in the first methylation event. !!!!!!!!!!!
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1.2 Protein arginine methyltransferases!
!
Arginine methylation is catalyzed by the protein arginine methyltransferase 
(PRMT) family of proteins. Nine seven-beta-strand PRMTs have been 
identified in mammals until now, PRMT1-9, and we cannot exclude that other 
PRMTs have yet to be discovered. These enzymes have been grouped in 
three different classes:  type I, type II and type III PRMTs. All the PRMTs are 
able to catalyze MMA, while type I PRMTs (PRMT1, 2, 3, 4, 6 and 8) 
specifically dimethylate arginines asymmetrically. On the other hand type II 
PRMTs catalyze symmetric arginine dimethylation. PRMT5 is unquestionably 
the better studied type II PRMT (Yang and Bedford, 2013), whereas it is not 
clear whether PRTM7 is a type II PRMT or a type III PRMT simply able to 
monomethylate arginines (Zurita-Lopez et al., 2012; Bedford and Clarke, 
2009). The catalytic specificity of PRMT9 has not been characterized (Fig. 
1.1) (Fig. 1.2). !
The most active type I and type II PRMTs, PRMT1 and PRMT5 respectively, 
are conserved from yeast to human and are essential for mouse and cell 
viability (Yu et al., 2009; Tee et al., 2010; Wang and Li, 2012). PRMTs appear 
to be ubiquitously expressed, with the exception of PRMT8, a brain specific 
prologue of PRMT1, conserved in vertebrates (Lee et al., 2005; Wang and Li, 
2012). !
PRMTs display high activity in vitro, they are able to methylate multiple target 
proteins on multiple arginine sites and their substrate specificity is much 
broader compared to that of lysine methyltransferases (Bedford and Clarke, 
2009). These enzymes preferentially methylates arginines within the glycine-
arginine-rich (GAR) motif and within the proline-glycine-methionine-rich 
(PGM) motif. Despite the absence of a specific consensus targeted by 
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individual PRMTs and the fact that most of the PRMTs share substrates in 
vitro, they are not redundant in vivo, as they affect cell growth and 
differentiation in different ways (Hyllus et al., 2007; Swiercz et al., 2007; 
Yadav et al., 2003; Yu et al., 2009).!
Initial attempts to identify arginine-methylated proteins have generated lists of 
putative PRMT targets (Boisvert et al., 2003; Ong et al., 2004; Bremang et al., 
2013). These studies failed to identify residues methylated by specific PRMT 
family members and to distinguish between symmetric and asymmetric 
dimethylation. However, they did shed light on the relevance of arginine 
methylation in numerous cellular processes including cytoskeleton formation, 
signaling, DNA transcription, protein translation and pre-mRNA processing. 
Key methylated targets regarding the latter are components of the constitutive 
splicing machinery (e.g., Sm proteins), several additional regulators of 
alternative splicing (e.g., FUS/TLS, SF2, and members of the heterogeneous 




Figure 1.2: The mammalian PRMT family. Adapted from (Yang and 
Bedford, 2013). Type I enzymes PRMT1, PRMT2, PRMT3, PRMT4, PRMT6, 
PRMT8, are in the red box. The only Type II enzyme, PRMT5, is in the yellow 
box. It is not clear whether PRMT7 is either a Type II or a Type III PRMT 
(yellow and orange dashed box). PRMT9 catalytic activity has not been 
characterized yet. The vertical lines represent the typical PRMT motifs 
indicated in the legend.!!!!
1.3 PRMT5 structure and activity!
!
PRMT5 is the human homolog of the Schizosaccaromyces pombe Skb1, and 
Saccharomyces cerevisiae Hsl7 protein. It was discovered in a yeast two-
hybrid screening as a Janus kinase 2 binding protein and therefore called 
JBP1 (Pollack et al., 1999). After the discovery of its catalytic activity as an 
arginine methyltransferase towards Myelin basic protein, Fibrillarin and 
histones H2A and H4 in vitro, JBP1 has been renamed PRMT5 (Rho et al., 
2001). Sequence homology analysis, and concomitant biochemical studies 
unveiled that the C-terminal PRMT5 domain contains the domains I 
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(GXGRGP motif), II, III and the post-I domain typical of the S-Adenosyl-L-
Methionine (SAM) binding proteins. SAM is the most common methyl group 
donor cofactor and mutation in the PRMT5 SAM-binding domain motif I 
dramatically reduced PRMT5 catalytic activity. Finally, the N-terminal domain 
is necessary for the interaction with the C-terminal domain and the formation 
of functional homo-oligomeric complexes (Branscombe et al., 2001; Pollack 
et al., 1999; Rho et al., 2001). PRMT5 has been described as a binding 
partner for several proteins and this is partially explained by the recent finding 
that PRMT5 is a major contaminant of the FLAG immunoprecipitation 
(Nishioka and Reinberg, 2003). MEP50 (methylosome protein 50) is a WD-
repeat-containing  protein which has been constantly detected as a PRMT5 
binding partner in different experimental conditions and is now considered 
and essential PRMT5 coactivator (Antonysamy et al., 2012; Friesen et al., 
2002). Further evidence regarding the decisive contribution of MEP50 to 
PRMT5 activity have been recently collected by Liu and colleagues. While 
focusing on the role of constitutive active mutants of JAK2 in 
myeloproliferative neoplasms they discovered that phosphorylation of PRMT5 
disrupted the PRMT5 MEP50 association impairing PRMT5 catalytic activity 
(Liu et al., 2011). In addition to MEP50, other proteins associate with PRMT5 
conferring its context-dependent substrate specificity. COPR5 redirect 
PRMT5 activity specifically towards histone H4 (Lacroix et al., 2008) while 
DAL-1/4.1B stimulates PRMT5-mediated methylation of myelin basic protein 
(Jiang et al., 2005). pICln is a key component of the PRMT5 complex 
responsible for the methylation of the spliceosome Sm proteins (Grimm et al., 
2013) while RioK1, which is mutually exclusive with pICln, redirects PRMT5 
methylation  towards Nucleolin (Guderian et al., 2011).!
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Recent structural studies generated significant insights into PRMT5 
dimerization properties, interaction with MEP50, active site and substrate 
recognition (Antonysamy et al., 2012; Ho et al., 2013; Sun et al., 2011). !
Human PRMT5 has been co-crystallized in complex with MEP50 and the 
structure revealed the formation of a hetero-octamer (PRMT5)4(MEP50)4 in 
which the four PRMT5 monomers are tightly packed in the central catalytic 
core of the complex and the four MEP50 molecules bind the outer surface 
(Antonysamy et al., 2012). PRMT5 is composed of four domains: the N-
terminal TIM barrel domain, the middle Rossmann-fold domain, and the C-
terminal β-barrel domain containing a small dimerization domain (Fig. 1.3). 
MEP50 adopts a seven bladed WD40 β-propeller conformation and interacts 
with PRMT5 solely through the PRMT5 N-terminal TIM barrel domain 
(Antonysamy et al., 2012; Ho et al., 2013). The TIM barrel domain is also 
required for PRMT5 homo-dimerization enabling head-to-tail interactions with 
the C-terminal β-barrel domain of a different PRMT5 monomer. Another 
important event in PRMT5 homo-dimerization is the direct interaction 
between the two dimerization domains of adjacent PRMT5 monomers.!
PRMT5-substrate interaction has been explored using a peptide mimicking 
the N-terminal tail of histone H4. The H4 peptide contacts a cavity on the 
PRMT5 β-barrel domain and the arginine side chain enters the active site 
through a narrow tunnel where hydrogen bonds between protein backbones 
stabilize the interaction of the H4 peptide with residues within the PRMT5 β-
barrel domain and the Rossmann-fold domain (Antonysamy et al., 2012). 
Moreover, electron microscopy studies suggest a crucial role for MEP50 in 
substrate recognition as they revealed direct contact between MEP50 and the 
substrate Nucleophosmin (NPM) (Ho et al., 2013). The catalytic site has been 
identified by co-crystallization of PRMT5 with different SAM analogs and lies 
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in the Rossmann-fold domain. Two glutamate residues (in human Glu 435 
and Glu 444) conserved among all the PRMTs and located on a double-E 
loop are necessary for the enzymatic activity. They contact the substrate 
arginine forming salt bridges and are likely responsible for the activation of 
the nitrogen atom. Furthermore, the most important residue determinant of 
the symmetry of methylation has been identified in the active site. The 
phenylalanine 375, in human PRMT5, is replaced by a methionine residue in 
the type I PRMTs and ensure the correct orientation of the arginine to be 
symmetrically dimethylated (Antonysamy et al., 2012; Sun et al., 2011). !
Importantly, in contrast to the asymmetric dimethylation catalyzed by PRMT1, 
the methylation reaction carried out by PRMT5 is not a processive 
mechanism. PRMT5 methylates the substrate in a distributive fashion with a 
rapid equilibrium random kinetic. Two distinct methylation events occur with 
release of the substrate prior the second methylation. Thus the concentration 
of un-methylated and mono-methylated substrate are crucial (Antonysamy et 




Figure 1.3: Structure of PRMT5. Adapted from (Sun et al., 2011). A ribbon 
representation of C. elegans PRMT5 dimer. The SAH is shown in the 
Rossmann-fold domain (pink). The dimer surface is traced by the red line.!!
!
!
1.4 PRMT5 and transcriptional regulation!
!
PRMT5 is a highly versatile enzyme and participates in the regulation of 
many cellular processes methylating a multitude of substrates. PRMT5 role in 
transcriptional regulation is undoubtedly its most studied function and it is 
clear that it acts as a transcriptional cofactor modifying histones and 
modulating the activity of several transcription factors. In contrast to the 
majority of the chromatin remodeling enzymes, PRMT5 is not univocally 
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classified as coactivator or corepressor of gene expression, but the 
transcriptional outcome rather depends on the arginine residue being 
methylated, on PRMT5 binding partners and in some cases on the chromatin 
landscape.!
!!
1.4.1 PRMT5 and histone methylation!
!
Eukaryotes condense the DNA into highly ordered chromatin fibers. The basic 
repeating unit of chromatin is the nucleosome, consisting of a core of eight 
histones ((H2A)2(H2B)2(H3)2(H4)2) around which 147 base pairs of DNA wrap 
(Kornberg and Lorch, 1999; Luger et al., 1997). Besides packaging the DNA, 
allowing its storage into the nucleus, chromatin plays a fundamental role in 
regulating DNA accessibility during several processes such as replication, 
DNA repair as well as transcription initiation, elongation and pre-mRNA 
splicing. Histone post translational modifications, DNA methylation and ATP-
dependent chromatin remodelers modify the chromatin landscape 
determining nucleosome-DNA interaction, therefore chromatin condensation, 
and recruiting factors essential for the regulation of the genetic information 
(Strahl and Allis, 2000; Workman and Kingston, 1998). PRMT5 is an unusual 
histone-modifying enzyme, as it is able to catalyze symmetric dimethylation of 
at least four different arginine residues of different histones: arginine 3 on 
histone H4 (H4R3me2s), arginine 3 on histone H2A (H2AR3me2s), arginine 8 






Since its discovery, H4R3me2s has been associated with transcriptional 
repression. The first study describing H4R3me2s identifies PRMT5 as a 
component of an atypical E2F complex which represses cyclin E1 promoter 
via histone methylation resulting in inhibition of cell proliferation (Fabbrizio et 
al., 2002). The Sif group later co-purified PRMT5 in association with the Brg1 
and hBrm-based hSWI/SNF chromatin remodeler complex, and with the 
mSin3A histone deacetylase (HDAC) 2. As part of this complex PRMT5 
catalyses both H4R3me2s and H3R8me2s ensuring repression of the c-Myc 
target genes Nucleolin and Cad as well as of the tumor suppressor genes 
St7, Nm23, and some genes of the RB family of tumor suppressors in 
lymphoid cancer cells, hence supporting tumor proliferation (Pal et al., 2007; 
2004; 2003; Wang et al., 2008). The direct mechanism linking H4R3me2s to 
transcriptional silencing has been recently elucidated. Zhao and colleagues 
showed that DNMT3A directly interacts with H4R3me2s through the PHD 
finger motif within its ADD domain. As a consequence, PRMT5-mediated 
dimethylation of histone H4 is required for DNA methylation, a well-
established mechanism of gene repression (Zhao et al., 2009). Moreover, in 
erythroid cells PRMT5 binds the promoter of the ɣ-globin gene and 
methylation of histone H4 is required not only for DNMT3A DNA methylation, 
but also for the establishment of a repressive chromatin landscape through 
the recruitment of multiple repressor proteins such as the histone H4 lysine 
20 methyltransferase SUV4-20h1, casein kinase 2α, HDAC1 and mSin3A 
(Rank et al., 2010). 
Additional evidence supporting the repressive role of H4R3me2s has been 
collected in other cell systems and more tumor suppressor and cell cycle 
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regulator genes, such as Smad7, Cul4A/B, Cdnka and Cdh, have been 
identified as PRMT5 targets (Aggarwal et al., 2010; Gurung et al., 2013; Patel 
et al., 2011; Tabata et al., 2009) (Fig. 1.4). However, all the above-mentioned 
studies rely on PRMT5 knock-down experiments and focus on a limited 
number of genomic loci. Tee and colleagues described the role of PRMT5 in 
mouse embryonic stem (mES) cells and PRMT5 knock-down experiments, 
which phenocopied the PRMT5 knock-out mES cells (as will be discussed 
later), did not show any reduction in H4R3me2s (Tee et al., 2010). 
Furthermore, the Feil group recently took advantage of chromatin 
immunoprecipitation coupled with DNA deep sequencing in order to elucidate 
the genome wide distribution of H4R3me2s. Surprisingly, their data show that 
the observed enrichment of H4R3me2s at G+C-rich regions does not 





H3R8me2s, in combination with H4R3me2s, has been associated with gene 
silencing in lymphoid cancer cells (Pal et al., 2004; 2007), whereas during 
myogenic differentiation and adipogenesis it is required for gene expression 
and PRMT5 acts as a transcriptional coactivator (Dacwag et al., 2009; 2006; 
LeBlanc et al., 2012). The nature of this dual function is still unclear, since no 
direct H3R8me2s binding partner has been identified and genome-wide 
studies have yet to be performed. Moreover, whether there is a PRMT5 
cofactor specifically restricting PRMT5 activity towards H3R8 is still unknown. 
A possible explanation could be found considering the crosstalk between 
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H3R8 and the proximal residues within the N-terminal tail of histone H3. 
Histone acetylation positively regulates gene transcription and PRMT5 
preferentially methylates  hypoacetylated histones. In vitro, H3R8 methylation 
is inhibited by acetylation of both lysine 9 (H3K9) and lysine 14 on histone H3 
and this observation is consistent with repression of gene expression induced 
by co-recruitment of PRMT5 and HDACs (Pal et al., 2003; 2004; Rank et al., 
2010). !
Conversely, H3K9 methylation is a hallmark of silent chromatin and the 
trimethylated form of H3K9 is directly bound by HP1 which promote chromatin 
condensation. H3R8me2s blocks G9a-mediated methylation of lysine 9 on 
histone H3 in vitro (Rathert et al., 2008). Moreover, HP1 co-crystallization with 
histone H3 revealed structural insights about the requirement for 
unmethylated arginine 8 (Fig. 1.4).  In this context H3R8me2s likely interferes 
with the establishment of repressed chromatin therefore acting as an activator 
of transcription (Jacobs and Khorasanizadeh, 2002; Nielsen et al., 2002). 




Despite PRMT5 ability to methylate histones H2A and H4 in vitro has been 
described more than a decade ago (Rho et al., 2001), it is only recently that in 
vivo evidence of H2AR3me2 existence has been collected (Ancelin et al., 
2006) and its function has been investigated (Tee et al., 2010). Notably, the 
N-terminal of histone H2A and the N-terminal tail of histone H4 have 
significant sequence similarity, and we now know that many commercial 
antibodies raised against H4R3me2s cross-react with H2AR3me2s. 
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Consequently, it is possible that chromatin immunoprecipitation and 
immunofluorescence experiments investigating H4R3me2s have been 
misinterpreted. PRMT5 knock-down in mES cells showed the conspicuous 
reduction of H2AR3me2s rather than H4R3me2s. Interestingly, PRMT5 in 
mES cells localizes and methylates H2A in the cytoplasm. H2AR3m2s is 
dispensable for chromatin assembly and its deposition on repressed 
promoters appears to be required for maintenance of transcriptional inhibition 





H3R2me2s has been discovered in our lab. It is conserved throughout 
evolution and marks open chromatin regions. H3R2me2 inhibits recruitment 
of several transcription co-repressors and is directly bound by WDR5, a 
component of the MLL complex which trimethylates lysine 4 on histone H3 
(H3K4me3) (Migliori et al., 2012). H3K4me3 is a hallmark of gene activation 
and its genomic distribution correlates with H3R2me2s distribution in yeast 
and mouse (Yuan et al., 2012). Both PRMT5 and PRMT7 are able to produce 
H3R2me2s in vitro and the double knock-down results in a dramatic reduction 
of this histone modification in vivo (Migliori et al., 2012) (Fig. 1.4). This result 
can be explained considering the controversial nature of PRMT7 catalytic 







Figure 1.4: PRMT5-mediated histone modifications. Schematic 
representation of the mechanism of action of the histone modification 
catalyzed by PRMT5. H4R3me2s has been shown to be recognized by 
DNMT3A (dashed line) which in turn methylates (dashed line) the DNA (grey) 
establishing a repressive chromatin landscape. Few illustrative examples of 
repressed target genes in different cell lines are indicated. H2AR3me2s is 
catalyzed in the cytoplasm, then imported into the nucleus (dashed line) and 
assembled into nucleosomes which mark repressed genes. H3R8me2s has 
been linked with both activation and repression of transcription. H3R8me2s -
mediated activation of transcription is thought to occur by the inhibition of the 
association between chromatin and repressive components such as HP1 and 
the enzyme G9a. The mechanism through which H3R8me2s inhibits 
transcription has not been characterized. H3R2me2s has been shown to be 
catalyzed by both PRMT5 and PRMT7. It is bound by WDR5, a component of 









1.4.2 PRMT5 and transcription factors!
!
PRMT5 is overexpressed in many cancer types and appears to be essential 
for cancer cells, not only for its role as a chromatin-modifying enzyme, but 
also for its direct regulation of transcription factors involved in regulation of 
growth, inflammation and development. !
p53, also called “the guardian of the genome”, is a transcription factor 
considered to be the master regulator of DNA damage and stress response. 
Its targets are apoptotic genes and cell cycle inhibitors. The p53 gene is 
ubiquitously expressed and its protein levels are finely regulated by a 
feedback loop with the protein that regulates its stability, the E3 ubiquitin 
ligase MDM2. MDM2 acts in combination with its heterodimeric partner 
MDM4 which is also involved in inhibition of p53 transcriptional activity (Wade 
et al., 2010). !
Through the interaction with the p53 cofactor Strap, PRMT5 modulates the 
p53 DNA damage-induced response directly methylating p53 on three 
adjacent arginine residues. In human cancer cell lines, following DNA 
damage, PRMT5 depletion appears to restrict p53 transcriptional activation 
towards apoptotic genes, inducing cell death rather than cell cycle arrest. 
However, it is not yet clear the molecular mechanism by which arginine 
methylation directs p53 activity (Jansson et al., 2008).!
PRMT5 has been shown to methylate another transcription factor involved in 
cell cycle progression and induction of apoptosis, E2F-1. The absence of 
PRMT5 stabilizes E2F-1 and induces apoptosis through activation of E2F-
responsive genes, such as p73. Consistently, in several human tumor cell 
lines, reduction of E2F-1 by PRMT5-mediated arginine methylation has been 
observed upon DNA damage allowing the activation of the DNA damage 
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response (Cho et al., 2012). A recent study clarifies that upon DNA damage, 
PRMT1 asymmetrically dimethylates E2F-1 counteracting methylation by 
PRMT5. Moreover, PRMT1-E2F-1 association is inhibited by Cyclin A. The 
E2F-1 symmetric dimethyl arginines are recognized by the tudor domain of 
p100-TSN, which binds E2F-1, reduces its half-life and modulates its 
apoptotic activity targeting a subset of E2F-responsive genes (Zheng et al., 
2013).!
In analogy with what has been observed for p53 and E2F-1, PRMT5 
regulates the transcriptional activity of  NF-κB and HOXA9 in a stimulus-
dependent manner. NF-κB is a transcription factor critical for immune and 
inflammatory response as well as for tumorigenesis. Following stimulation 
with IL-1β, PRMT5 binds and methylates the arginine 30 of the NF-κB subunit 
p65. This methylation event reduces the binding of p65 to the κB element 
causing changes in gene expression. Notably, microarray analysis revealed 
that overexpression of the NF-κB R30A mutant leads to dowregulation of 
many NF-κB responsive genes, and approximately 85% of them are 
downregulated also in cells lacking PRMT5 (Wei et al., 2013).!
Similarly, inflammation signal in endothelial cells (EC) induces PRMT5 
association with the transcription factor HOXA9, following its methylation on 
arginine 140. This association is transient and occurs on selective target gene 
promoters. It does not affect HOXA9 DNA recognition, but rather modulates 
its transcriptional activity promoting the expression of pro-inflammatory 
endothelial-leukocytes adhesion molecules (ELAM) such as E-selectin and 
VCAM1. Thus, PRMT5 is potentially important in inflammation and 




1.5 PRMT5 and RNA splicing !
!
As they are transcribed into precursor mRNAs (pre-mRNAs), most eukaryotic 
genes need to be edited in order to remove non coding regions (introns) 
ligating together regions destined to become a part of mature messenger (m) 
RNA sequence (exons). This essential multistep editing process called 
splicing is carried out by the spliceosome, a multi-megadalton 
ribonucleoprotein (RNP) complex. Importantly, not all the  exons are 
constitutively included in the mature transcript. Proper functioning of all 
splicing-associated proteins allows a highly coordinated spatiotemporal exon 
selection (alternative splicing) generating multiple mRNA isoforms that 
significantly increase the complexity of the cell proteome. On the other hand, 
mutations in proteins involved in RNA processing have been causally linked 
to many human diseases such as spinal muscular atrophy (SMA) and 
amyotrophic lateral sclerosis (ALS), to mention a few (Da Cruz and 
Cleveland, 2011; Novoyatleva et al., 2006; Vance et al., 2009; Ward and 
Cooper, 2010; Zhang et al., 2008). !
The spliceosome contains the small nuclear RNPs (snRNPs) U1,U2, U5, U4 
(which belong to the Sm class of snRNP), U6 and a multitude of non-snRNP 
proteins. U6 belongs to the LSm-like class of snRNPs. The core of each Sm 
snRNP is formed by a unique snRNP-specific small nuclear RNA (snRNA) 
and seven Sm proteins (B/B’, D3, D2, D1, E, F and G). In the cytoplasm, 
PRMT5 acts together with pICln and MEP50 as part of the methylosome, 
which mainly methylates Sm proteins B/B’, D1, and D3 regulating snRNPs 




1.5.1 Arginine methylation and core snRNPs biogenesis!
!
The maturation pathway of the Sm-class snRNPs is summarized in Fig. 1.5 
and reviewed by (Matera et al., 2007). The uridine-rich, non-polyadenylated U 
snRNAs are transcribed by RNA Polymerase II (Pol II) and exported to the 
cytoplasm by a specialized snRNA-export complex. In the cytoplasm the Sm 
proteins are assembled as a heptameric ring around the Sm motif of the 
snRNAs. This fundamental step is orchestrated by the Spinal Motor Neuron 
(SMN) protein complex which recognizes the 3’ stem-loop and the Sm protein 
binding site of the snRNAs, and the symmetrically dimethylated arginines of 
the Sm proteins B/B’, D1 and D3. Subsequently the 5’ ends of the snRNAs 
are hypermethylated by trimethylguanosine syntase-1 (TGS1) forming the 
2,2,7-trimethylguanosine (TMG) cap. The Sm core and the TMG cap are 
necessary signals for the import into the nucleus carried out by the import 
complex which is comprised of snurportin-1 (SPN) and importin-b (Imp-b). 
Following the import, the core snRNPs localize in the nuclear compartments 
called Cajal bodies where small Cajal body-specific RNAs (scaRNAs) guide 
site-specific modification of the snRNAs and where a variable number of 
particle-specific proteins bind the core snRNPs completing the maturation 
process. Notably, also Coilin, which is the structural scaffold protein of the 
Cajal bodies, contains symmetrically dimethylated arginines required for SMN 
binding and essential for Cajal bodies formation (Boisvert, 2002; Hebert et al., 
2002).!
Symmetrically dimethylated arginines within the RG repeats located in the C-
terminal regions of SmB/B’, D1 and D3 were identified by the Luhrmann 
group (Brahms et al., 2001; 2000). PRMT5, the catalytic component of the 
methylosome, binds the RG domain of the Sm proteins and catalyses these 
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methylations in the cytoplasm. Whereas MEP50 appears to be a general 
coactivator of PRMT5, stimulating its activity, the role played by pICln is 
multifaceted, specifically required for snRNP maturation process and 
inhibition of histone methylation (Friesen et al., 2001b; 2002; Meister et al., 
2001; Meister and Fischer, 2002; Pesiridis et al., 2009).  !
!!
  !!
Figure 1.5: The maturation pathway of small nuclear RNPs. Adapted from 
(Matera et al., 2007). Following transcription by RNA Polymerase II (Pol II), a 
specialized  snRNA-export complex, exports the Sm-class snRNA to the 
cytoplasm. Gemin5, a component of the SMN complex, recruits the snRNA 
and the SMN complex assembles the Sm proteins, three of which (SmB/B’, 
D1 and D3) pre-methylated by the methylosome (PRMT5/pICln/MEP50), 
around the snRNA in a ring-like structure. Next, TGS1 hypermethylates the 
5‘end of the snRNA, forming the so called TMG cap. Both the Sm ring and the 
TMG cap are necessary signals for the import into the nucleus, carried out by 
SPN and Imp-b. On nuclear re-entry, the snRNPs localize in the Cajal bodies 
where further maturation steps take place before the snRNPs participate in 
splicing.!!!!
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pICln binds the Sm domain of the Sm proteins and gel filtration studies 
revealed that it is part of two complexes, the 20S and the 6S complex, 
composed of different subset Sm proteins. The 20S complex, also known as 
the PRMT5 complex, is formed by PRMT5, MEP50, and all the Sm proteins 
recruited by pICln. The formation of this complex is considered as the 
beginning of the Sm ring formation and as the step required for the 
methylation of SmB/B’, D1 and D3 (Grimm et al., 2013). The Sm proteins D1, 
D2, released by the 20S complex, and SmE, F, G are the other constituent of 
the 6S complex. pICln preferentially binds Sm D1 and D2 stabilizing their 
interaction with SmE, G and F to form the 6S complex unable to associate 
with the U snRNAs (Fischer, 2008). X-ray crystallography uncovered that 
such complex adopts a ring-like structure, very similar to the assembled Sm 
ring, in which pICln mimics the SmB/B’, D3 heterodimer (Grimm et al., 2013). 
Subsequently, the SMN complex recruits both the 6S and the heterotrimer 
pICln, SmB/B’, D3, and dissociates pICln to assemble the Sm ring onto 
snRNA (Fischer, 2008; Grimm et al., 2013). Importantly, seven other proteins 
are part of the SMN complex, the Gemins, which are critical for binding the U 
snRNAs (Gemin5) and for associating with the Sm proteins (Gemin2) (Battle 
et al., 2006; Gubitz et al., 2004).!
The first evidence that suggested a crucial role for the C-terminal RG domain 
of Sm D1 and D3 in snRNP biogenesis was the finding of their interaction with 
the Tudor domain of SMN (Friesen and Dreyfuss, 2000; Selenko et al., 2001). 
Concomitant experiments highlighting the importance of symmetrically 
dimethylated arginines for the recognition of the Sm proteins by SMN 
(Friesen et al., 2001b; 2001a; Meister et al., 2001; Meister and Fischer, 2002) 
led to the discovery of the functional role of the basic SMN Tudor domain as a 
methyl-arginine binding protein module (Côté and Richard, 2005). The 
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aromatic cage formed by this Tudor domain specifically favors the recognition 
of the sDMA planar guanidine group by electrostatic stabilization. 
Furthermore, such domain achieves high affinity for the Sm proteins by 
binding cooperativity resulting from multiple sDMA present within the short 
RG domain (Tripsianes et al., 2011).!
Collectively, the aforementioned evidence underline the importance of 
symmetric arginine dimethylation for SMN-Sm proteins interaction in vitro. 
However, they do not completely clarify the precise role that this PTM play for 
the snRNPs biogenesis in vivo.!
The Matera group explored such matter in Drosophila melanogaster using a 
fly strain mutant for dart5 (the ortholog of human PRMT5). As expected, they 
observed a dramatic reduction of symmetric dimethylarginine within the Sm 
proteins. In accordance with previous studies SMN binding to Sm proteins 
was reduced, and similar effects were observed in the valois (the ortholog of 
human MEP50) mutant flies. Surprisingly, when steady state levels of mature 
snRNPs were analyzed, no differences were detected (Gonsalvez et al., 
2006).!
Further studies in HeLa cells elucidated a critical difference between humans 
and drosophila. PRMT5 knockdown experiments showed, besides decreased 
Sm protein arginine methylation and the impairment of SMN-Sm proteins 
interaction, striking reduction in the kinetic of snRNP biogenesis similar to 
SMN knockdown experiments. Moreover, Cajal bodies were disrupted and 
Coilin was delocalized. Importantly, PRMT7 knockdown resembled the 
PRMT5 knockdown results, but PRMT7 overexpression did not ameliorate 
the effects observed in PRMT5 depleted cells, suggesting that the functions 
of the two type II PRMTs are not redundant in the Sm core maturation 
process (Gonsalvez et al., 2007). Sm protein methylation by PRMT7 was 
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confirmed in drosophila where, consistently with the data collected in the 
dart5 depleted flies, snRNP biogenesis was not affected. Notably, mutant flies 
harboring arginine to lysine substitutions in the RG domain of SmD1 did not 
show any defect in Sm core assembly, despite the reduced binding of SMN to 
the mutant SmD1, suggesting that in Drosophila methylation of the Sm 
proteins is dispensable for snRNP maturation (Gonsalvez et al., 2008).!
In order to understand the downstream consequences for pre-mRNA splicing 
defects induced by perturbation of the key components of the snRNP core 




1.5.2 Constitutive splicing mechanism!
!
Intron length can vary tremendously and sequence conservation is low, but 
some elements are indispensable to ensure correct splicing: the 5’ splice 
junction (5’ss, donor site) and the 3’ splice junction (3’ss, acceptor site), 
typically preceded by a string of pyrimidines (PPT) and the A branch site 
(Black, 2003; Chen and Manley, 2009; Pandya-Jones, 2011; Wang and 
Burge, 2008). Intron removal is achieved by two transesterification reactions 
catalyzed by the spliceosome, which assembles in a highly coordinated 
sequential manner. Initially the 5’ss is recognized through RNA 
complementarity by the U1 snRNP, whereas two subunits of the non-snRNP 
protein U2AF bind to the acceptor site and the PPT, while SF1 binds to the A 
branch point. Following the formation of this early complex (E complex), the 
U2 snRNP displaces SF1, associates with the branch site and then interacts 
with the U1 snRNP in a process that turns the intron into a loop bringing the 
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two exons in close proximity (A complex). After the A complex is formed, three 
more snRNPs are recruited, U4, U5 and U6 (U4/U6.U5 tri-snRNP). This 
complex of five snRNPs, known as the B complex, undergoes extensive 
rearrangements and ultimately the U1 snRNP and the U4 snRNP are 
released giving rise to the active B complex. This is the complex that 
catalyses the first transesterification. The bond between the exon and the 5’-
end of the intron at the donor site is cleaved and the 5’-end joins the A branch 
point by 5’ to 2’ phosphodiester bond. This unusual bond results in a 
branched lariat structure forming the C complex. The second 
transesterfication is catalyzed by the C complex. The C complex cleaves the 
bond at the 3’ at the end of the intron, the acceptor site, and forms  a 
phosphodiester bond between the two exons. The intron is released, the 
spliceosome disassembles and additional rounds of splicing take place (Fig. 
1.6).!
This splicing pathway model is called the canonical cross-intron pathway, as 
the spliceosome particles assemble across the intron recognizing its 5’ss and 
3’ss, and it is credible for introns that do not exceed the 250 bases in length. 
In higher metazoans introns are generally longer, and a more plausible model 
relies on cross exon assembly of the spliceoseome and it is therefore called 
the exon definition model. The entire canonical splicing process has been 






Figure 1.6: The constitutive splicing mechanism. The splicing process 
begins with the formation of the E complex, in which U1 snRNP binds the 
5’ss, SF1 binds the A branch site (BP) and the two subunits of U2AF bind to 
the acceptor site and the polypyrimidine tract (PPT). Following this first step, 
U2 snRNP replaces SF1, associates with the A branch site and then interacts 
with the U1 snRNP bringing the two exons in close proximity (A complex). 
Three more snRNPs are then recruited, U4, U5 and U6 (U4/U6.U5 tri-snRNP) 
to form the B complex which undergoes extensive rearrangements and 
ultimately releases U1 snRNP and U4 snRNP. The resulting catalytic complex 
(C complex) completes the splicing process joining the two exons together 





Each exon within a transcriptional unit has the possibility of being included or 
excluded in the final transcript. This process of differential selection of splice 
site pairs is called alternative splicing and is an invaluable source of 
complexity which contributes to cell identity and fate. Whereas several exons 
are almost  invariably included in a transcript (constitutive exons), others are 
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instead selectively included or skipped (alternative  exons), giving rise to 
multiple final mRNA products.!
Unlike lower organisms,  the vast majority of human genes undergoes 
alternative splicing and this splicing flexibility is a remarkable product of 
evolution. Within all human organs, the number of alternative splicing events 
occurring in the brain distinctively distinguishes the human species from 
others and such complexity overall correlates with the number of cell types 
and species evolution (Barbosa-Morais et al., 2012; Braunschweig et al., 
2013; Dillman et al., 2013).  If on one hand splicing complexity sets us apart 
from other species, such flexibility, granted by  interconnected layer of post-
transcritional regulation, is also a liability. Indeed cancer cells take advantage 
of alternative splicing to bypass apoptosis and cell cycle arrest, and to 
stimulate tumor progression and invasion (David and Manley, 2010).!
Five different types of single alternative splicing events can occur within the 
same pre-mRNA: alternative 5’ splice site, alternative 3’ splice site, cassette 
exon, retained intron and back-splicing (Fig. 1.7). Combination of multiple 
alternative splicing events gives rise to complex patterns, as for example 
mutually exclusive exons (Black, 2003; Keren et al., 2010; Memczak et al., 
2013; Nilsen and Graveley, 2010). Moreover, splicing across two different pre-
mRNAs (trans-splicing) has been described (Lasda and Blumenthal, 2011). !
The intrinsic strength of the 5‘ss and of the A branch point sequence are 
determined by their degree of complementary to the recognition sequences of 
the snRNAs U1 and U2, respectively, while the polypyrimidine tract has to 
comply with U2AF complex consensus binding site (Wu et al., 1999). 
Besides, a multitude of auxiliary cis-acting RNA motives, complement the 
constitutive “splicing code”, functioning as exonic/intronic splicing enhancers 
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(ESE/ISE) or exonic/intronic silencers (ESS/ISS) (Braunschweig et al., 2013). 
These elements are recognized by non-snRNP RNA binding proteins which 
modulate alternative splicing stimulating or preventing the selection of a 
proximal splice site (Wang and Burge, 2008). The two most characterized 
families of trans-acting proteins are the SR proteins and the heterogeneous 
ribonucleoproteins (hnRNPs) (Fig. 1.8). In addition the function of several 
other tissue-specific splicing regulatory factors such as NOVA, RBFOX and 
MBLN, regulatory factors has been extensively characterized (Irimia and 
Blencowe, 2012; Licatalosi and Darnell, 2010; Long and Caceres, 2009; 
Martinez-Contreras et al., 2007). Finally, an additional layer of regulation is 
given by RNA secondary structures which can either facilitate or hinder the 





Figure 1.7: Types of alternative splicing. Schematic representation of 
alternative splicing events: alternative 5’ (A), alternative 3’ (B), cassette exon 
(C), retained intron (D) and back-splicing/circular RNA (E). Orange lines and 
arrows indicate the canonical splicing, whereas the purple lines and arrows 
indicate the alternative splicing pattern and outcome.!!!!
Another important aspect of splicing regulation is the crosstalk between 
transcription, chromatin landscape and splicing factors, since a large fraction 
of the splicing occurs co-transcriptionally (Ameur et al., 2011; Khodor et al., 
2012; 2011; Tilgner et al., 2012; Vargas et al., 2011). The C-terminal domain 
of the RNA polymerase II (Pol II) has been shown to favor splicing and to 
associate with several splicing regulators (David et al., 2011; Hirose et al., 
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1999; Hsin and Manley, 2012). Furthermore, the recruitment of the splicing 
machinery has been linked to Pol II transcriptional elongation rate, which is in 
turn  modulated by chromatin structure (Schor et al., 2013). Additionally, 
chromatin, in particular histone positioning, histone variants and histone 
modifications, have been linked to exon/intron definition and recruitment of 
the splicing components (Andersson et al., 2009; Huff et al., 2010; Luco et al., 





Figure 1.8: Co-transcriptional and post-transcriptional regulation of 
splice site selection. Schematic representation of the crosstalk between 
transcription, chromatin landscape and splicing factors. Auxiliary cis-acting 
RNA motives, function as exonic/intronic splicing enhancers (ESE/ISE) or 
exonic/intronic silencers (ESS/ISS). The trans-acting factors SR proteins and 
heterogeneous ribonucleoproteins (hnRNPs) bind to either splicing enhancers 
or splicing silencers respectively and stimulating or preventing spliceosome 
assembly. The C-terminal domain (CTD) of the RNA polymerase II (Pol II) 
promotes splicing recruiting several splicing regulators. The recruitment of the 
splicing machinery has been linked also to Pol II transcriptional elongation 
rate, which can be modulated by chromatin modification (dashed line). 








1.5.4 Core snRNP assembly proteins and alternative splicing!
!
Changes in splicing patterns, due to modulation of the expression of 
spliceosomal components, have been observed in yeast, flies and mammals 
(Clark et al., 2002; Gabanella et al., 2007; Park et al., 2004; Pleiss et al., 
2007; Zhang et al., 2008). However, only the recent development of genome-
wide approaches, in particular exon microarrays and RNA sequencing, has 
shed light on the global regulation of splicing, induced by altered levels of 
core Sm assembly proteins.!
Genetic alterations of the SMN1 gene in human result in spinal muscular 
atrophy (SMA). Despite the fact that SMN is widely expressed in all tissues 
the mechanism leading to the motor neuron-selective phenotype remains 
unclear. The Dreyfuss group performed a genome wide splicing analysis 
(exon microarray) in a mouse model of type II SMA (moderate phenotype) 
and made several major discoveries. Firstly, they detected tissue-specific 
changes in the abundance of the snRNAs and a marked decrease in snRNP 
assembly capacity. Secondly, they observed tissue-specific splicing defects in 
all the studied tissues. Hundreds of pre-mRNAs were alternatively spliced, 
especially those containing a large number of introns and encoding for 
membrane transporters and extracellular matrix proteins (Zhang et al., 2008). !
Similarly, investigating the effects induced by knock-down of SmB/B’ in HeLa 
cells, Saltzman and colleagues observed altered levels of the snRNAs 
(Saltzman et al., 2011). Interestingly, they discovered that SmB promotes the 
inclusion of a mini-exon within its own pre-mRNA. Mutations in a mini-gene 
resembling this exon, either strengthening the 3’ss or the 5’ss, promote the 
exon inclusion, but only the strong 5’ss was able to rescue the exon skipping 
induced by SmB downregulation. Further genome-wide experiments (RNA-
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sequencing) focusing on exon inclusion/exclusion events revealed the critical 
role played by SmB in ensuring exon inclusion of alternative cassette exons, 
rather than constitutive exons. Bioinformatic analysis of the skipped exons 
showed that these exons are shorter than average, enriched in genes 
involved in RNA processing and that the average strength of their 5’ss is 
slightly lower than average (Saltzman et al., 2011). !
Despite the established biochemical role of sDMA in snRNPs biogensis, 
evidence for a global regulation of splicing by PRMT5 in mammals is still 
missing. Nevertheless interesting data have been collected studying 
Arabidopsis thaliana and Drosophila as model systems. Deng and colleagues 
identified symmetric dimethylated arginines in Arabidopsis Sm Proteins 
demonstrating conservation from plants to human (Deng et al., 2010). RNA 
sequencing analysis of atprmt5 (the Arabidopsis thaliana homolog of human 
PRMT5) mutant plants revealed an increased number of retained introns. 
Consistent with the analysis performed in the SMA mouse model (Zhang et 
al., 2008), pre-mRNAs with a higher number of introns were generally more 
affected. The alternatively spliced genes belong to several biological 
processes including RNA metabolism and flowering. As a result, plants 
lacking atprmt5 displayed pleiotropic developmental defects including growth 
retardation and delayed flowering time. A previous work demonstrated that 
the late flowering phenotype was caused by reduced levels of the Flowering 
locus KH domain protein (FLK), a critical inhibitor of the flowering repressor 
Flowering locus C (FLC) (Pei et al., 2007). Deng and colleagues discovered 
that such protein reduction is caused by intron retention in the Flk pre-mRNA. 
Notably, no difference in the levels of H4R3me2s was observed in plants 
lacking atprmt5 when compared to wild type plants (Deng et al., 2010). !
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A concomitant study by the Yanovsky group led to similar conclusions 
(Sanchez et al., 2010). Using tiling array they discovered almost 500 intron 
retention events in plants lacking atprmt5 when compared to wild type plants. 
To gain further detail they performed high-resolution RT-PCR on a panel of 
288 splicing events including known alternative splicing events. They found 
widespread splicing changes, but mainly the switch to alternative 5’ss. 
Bioinformatic analysis showed that PRMT5 regulates recognition of weak 5’ss 
characterized by decrease frequency of the G base at the -1 position of the 
5’ss and randomization at the -2, and +5 position. Analogous experiments in 
Drosophila revealed similar defects: increased intron retention and decrease 
in the frequency of the G in the -1 position of the 5’ss. Furthermore, the 
phenotype caused by lack of PRMT5 in the two model systems is related. 
PRMT5 depletion in Arabidopsis thaliana causes splicing defects in the 
Pseudo response regulator 9 (Prr9) pre-mRNA, a core clock component, 
resulting in impaired circadian rhythms. Similarly, in Drosophila alteration in 
splicing, induced by disruption of dart5, involves a subset of major component 
of the clock pathway, including period. As a consequence dart5 mutant flies 
display defective circadian rhythms in locomotor activity (Sanchez et al., 
2010).!
!!
1.6 PRMT5 in development!
!
In the mentioned studies, PRMT5 has been associated with a variety of 
targets and biological processes, highlighting the versatility of this eclectic 
protein. However, none of these reports clarify the downstream effects of 
PRMT5 modulation in vivo.!
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The first animal model harboring PRMT5 deletion has been generated by the 
Matera group. Focusing on the role of symmetric arginine methylation of Sm 
proteins in Drosophila, they made the surprising discovery that PRMT5-
depleted flies are viable (Gonsalvez et al., 2006). Notably, when crossed with 
flies either homozygous or heterozygous for a Smn hypomorphic allele, 
PRMT5 null flies show strong synthetic lethality (Gonsalvez et al., 2008).!
!!
 1.6.1 PRMT5 in germ cells!
!
Although PRMT5 mutants Drosophila are viable, male flies display dramatic 
defects in spermatocytes maturation, leading to absence of sperm in the 
seminal vesicles and consequently resulting in complete sterility. On the other 
hand, female flies display only minor fecundity reduction. Nonetheless, one 
third of the embryos suffer segmentation defects, whereas the remaining two 
thirds are agametic, therefore sterile. As such, PRMT5 mutation can be 
considered as a “grandchildless” mutation and importantly, is phenotypically 
similar to Valois (the Drosophila homolog of human MEP50). During oocytes 
development, the localization of specific components in the pole plasm, the 
cytoplasmic posterior end of the Drosophila oocyte, is crucial for the formation 
of polar granules, which are then sequestered in the pole cells. One such 
component is Tudor and in both PRMT5 and Valois mutant oocytes, its 
localization is defective. Moreover, the phenotype of Tudor mutant flies is very 
similar to that of PRMT5 mutant embryos. Pole cells are the precursors of 
Drosophila primordial germ cells (PGCs). During development they colonize 
the gonads and eventually give rise to adult germ cells. Consistent with the 
grandchildless classification, PRMT5 mutant embryos display lack of pole 
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cells (Anne et al., 2007; Breitwieser et al., 1996; Findley et al., 2003; 
Gonsalvez et al., 2006). Additionally, the requirement of PRMT5/Valois 
mediated methylation of SmB, has been proved essential for pole cells 
development and gonad formation (Anne, 2010). !
The requirement for PRMT5 in mammalian germ cells is still unexplored, but 
two studies suggest different nonexclusive mechanisms by which PRMT5 
might play a critical role in mammalian PGCs development similar to the role 
PRMT5 plays in Drosophila. Ancelin and colleagues discovered that PRMT5 
interacts with Blimp1, a DNA binding protein and major regulator of mouse 
PGCs specification (Ohinata et al., 2005; Vincent et al., 2005). Co-localization 
and chromatin immunoprecipitation experiments uncovered a dynamic 
regulation of the Blimp1-PRMT5 complex correlating with histone modification 
patterns and expression of putative Blimp1 target genes involved in germ-line 
development (Ancelin et al., 2006). Vagin and colleagues focused their work 
on the identification of the murine Piwi complexes (Vagin et al., 2009). The 
mouse Piwi proteins MILI, MIWI and MIWI2, belong to the Argonaute family of 
proteins and their expression is restricted to the germ cell lineage where their 
best characterized function is to suppress mobile genetic elements by two 
mechanisms: epigenetic transcriptional repression of transposons expression 
and piwi-interacting RNA (piRNA) directed  cleavage of transposon mRNAs 
(Aravin et al., 2007a; 2007b; Brennecke et al., 2007; 2008; Kuramochi-
Miyagawa et al., 2008). Mass spectrometry analysis of the PIWI complexes 
from germ cells of transgenic mice expressing epitope tagged MILI, MIWI and 
MIWI2 under their own endogenous promoter, revealed their interaction with 
PRMT5/MEP50 and the presence of symmetric dimethyl arginines within the 
RG sites at their N-termini. These methylated arginines are bound by the 
Tudor domain family of proteins, most of which, just like the Piwi proteins, are 
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essential for male fertility (Chuma et al., 2006; Pan et al., 2005; Vasileva et 
al., 2009). These data suggest a possible role for PRMT5 in safeguarding 
genomic stability in germ cells (Vagin et al., 2009). Similar conclusions arise 
from studies in Caenorhabditis elegans. Both RNAi experiments and genetic 
depletion of  the prmt-5 gene (the C. elegant homolog of mammalian PRMT5) 
do not cause developmental defect besides a minor reduction in growth rate. 
However, ɣ-irradiation and other DNA damaging agents induce strong CEP-1 
(the C. elegant homolog of mammalian p53) dependent germ cell apoptosis 
in PRMT-5 depleted worms. Notably, PRMT-5 displays nuclear localization in 
the germ line, but the histone modification H4R3me2s is not reduced upon 
PRMT-5 inhibition and PRMT-5 is not able to methylate H3 in vitro. PRMT-5 
interacts with, but does not methylate CEP-1. Conversely, the CEP-1 
interactor CBP-1 (the C. elegant homolog of mammalian p300/CBP) forms a 
complex with PRMT-5 and CEP-1, contributes to the activation of the cell 
death pathway and is methylated by PRMT-5. As a consequence, Cbp-1 
RNAi suppresses the apoptosis induced by PRMT-5 deletion in germ cells 
following DNA damage (Yang et al., 2009).!
!!
1.6.2 PRMT5 in pluripotent stem cells!
!
As the number of publications demonstrate, the interest around PRMT5 has 
been rapidly growing in the past ten years. Developmental and cancer 
biologists, whose work heavily rely on mouse models, greatly contributed to 
uncover the role of PRMT5 in molecular pathways involved in cellular growth 
control and differentiation. However, only one work, by the Surani group, has 
so far taken advantage of mouse genetics (Tee et al., 2010). Surprisingly, 
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different from the Drosophila and C. elegans phenotype, but similar to many 
mouse knockout models of proteins involved in chromatin remodeling, 
signaling pathways and splicing regulation, mice lacking PRMT5 are early 
embryonic lethal. To generate the PRMT5 knockout model, Tee and 
colleagues used heterozygous embryonic stem (ES) cells harboring a gene 
trap within the methyltransferase domain obtained from Baygenomics. 
PRMT5 heterozygous mice are viable and fertile, whereas PRMT5 null mice 
display extensive developmental defects at embryonic day (E) 6.5. 
Consistently, albeit E3.5 PRMT5-null blastocysts appear morphologically 
normal and present at the expected Mendelian ratio, their inner cell mass is 
not able to outgrowth when cultured in vitro, revealing a critical role for 
PRMT5 in stem cells biology. Consistently, PRMT5-null ES cells could not be 
obtained and studied, leaving the above mentioned observations as the only 
data regarding PRMT5 knock-out mice described in the literature so far. 
PRMT5 is maternally inherited and during mouse preimplantation 
development, its nuclear/cytoplasmic localization, rather than its expression, 
appears to be dynamically regulated. In embryonic stem cells PRMT5 is 
cytoplasmic and RNAi experiments resulted in upregulation of differentiation 
genes and loss of pluripotency. Unexpectedly, analysis of histone 
modifications showed selective PRMT5 dimethylation of histone H2A on the 
arginine 3 in the cytoplasm. Further studies using histone mutants shed light 
on a possible mechanism of deposition of symmetrically arginine methylated 
histone H2A at the promoter of differentiation genes ensuring their repression 
(Tee et al., 2010). !
In accordance with the loss of pluripotency following PRMT5 depletion, a 
screening for the reprogramming activity of factors involved in PGCs 
development identified PRMT5 as a critical gene for the generation of 
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induced pluripotent stem cells (iPS). When coexpressed in mouse embryonic 
fibroblasts (MEFs) together with KLF4 and OCT3/4, PRMT5 promoted 
somatic cell reprogramming into Nanog-GPF positive iPS colonies that were 
able to form teratomas, and exhibited germ line transmission in chimeric 
mice. Furthermore, PRMT5 knockdown in MEFs exogenously expressing the 
four canonical reprogramming factors SOX2, KLF4, OCT3/4 and MYC 
impaired iPS generation (Nagamatsu et al., 2011).!
Additionally, work in Planaria has expanded our knowledge regarding the 
conservation of the role of PRMT5 in pluripotent cells maintenance.  !
Planaria is a flatworm with incredible regenerative capabilities which rely on 
the neoblasts, a widespread population of adult stem cells, required for tissue 
homeostasis and organismal growth. A unique feature of these cells is the 
presence of chromatoid bodies, cytoplasmic ribonucleoprotein granules. 
Rouhana and colleagues discovered that chromatoid bodies are enriched 
with symmetrically arginine dimethylated proteins methylated by the S. 
Mediterranea Smed-PRMT5, homolog of human PRMT5. Among the 
identified methylated proteins proteins they detected homologs of mammalian 
PIWI and Sm proteins. Smed-PRMT5 is expressed in brain, neoblasts and 
testis of sexual planarians. Longterm Smed-PRMT5 inhibition experiments by 
RNA interference resulted in size and head defects, reduction of the number 
of neoblasts and impaired regeneration (Rouhana et al., 2012).!
!!
1.6.3 PRMT5 in tissue-specific stem cells and differentiation !
!
The evidence regarding PRMT5 function in germ cells specification and 
embryonic stem cells maintenance, point to PRMT5 as a general regulator of 
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proliferating cells homeostasis and pluripotency, nevertheless several studies 
focusing on the role of PRMT5 as transcriptional co-regulator challenge this 
hypothesis. Investigation of tissue-specific cell proliferation and differentiation 
processes, combining human and mouse tissue culture approaches with 
localization and knockdown techniques, render a more complex picture 
further complicating our understanding. PRMT5 displayed an ambiguous 
function as both coactivator and corepressor of transcription and additionally 
it has been reported to participate in signal-transduction pathways, inducing 
or inhibiting cell differentiation. !
Using cell culture model, Le Blanc and colleagues explored the role of 
PRMT5 during adipogenesis. Knock-down of PRMT5 in mesenchymal stem 
cells and preadipocytes inhibited activation of adipogenic genes, whereas 
PRMT5 overexpression enhanced adipogenic differentiation. In this specific 
case, PRMT5 acts as a transcriptional coactivator, binding multiple 
adipogenesis-specific promoters, and methylating arginine 8 of histone H3 
(H3R8)  (LeBlanc et al., 2012).!
Similarly, during muscle differentiation PRMT5 promotes the expression of 
myogenic-specific genes and induces skeletal muscle generation. 
Overexpression of MyoD in the immortalized mouse fibroblast cells 3T3, 
leads to the transcription of the early muscle marker Myogenin, and of the 
late differentiation genes Desmin and skeletal α-Actin. PRMT5 knock-down in 
this cells, represses this process. Interacting with MyoD, PRMT5 binds the 
Myogenin promoter, methylates H3R8 and is required for Brg1 recruitment 
and Myogenin activation. Importantly, this observation has been confirmed in 
primary adult satellite cells (the quiescent muscle progenitor cells) (Dacwag 
et al., 2006). Also the promoters of late differentiation genes, such as MCK 
and Desmin, are bound by PRMT5 and methylated on H3R8 in a MyoD-
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dependent manner. However, when muscle differentiation is induced in 3T3 
cells by overexpression of Myogenin/Mef2D1b, thus bypassing MyoD, 
PRMT5 methylation is not occurring and is not necessary anymore. 
Therefore, it is not clear to what extent PRMT5 is important for the completion 
of the skeletal muscle differentiation process (Dacwag et al., 2009). Notably, 
morpholino-mediated PRMT5 downregulation in zebrafish showed that 
PRMT5 regulates slow and fast fiber formation by controlling the early 
myogenic genes Myod and Myf5 as well as Myogenin (Batut et al., 2011).!
In a different way, PRMT5 negatively regulates keratinocytes differentiation 
modulating the Mitogen-activated protein kinases/Extracellular signal-
regulated kinases (MAPK/ERK) signaling pathway. The balance between 
p38δ and ERK is of vital importance in determining keratinocytes fate. While 
ERK1/2 activation is necessary to sustain keratinocytes proliferation and 
survival, activation of p38δ by Protein kinase C δ (PKCδ)-mediated 
phosphorylation stimulates differentiation markers such as Involucrin and 
reduces the levels of ERK1/2 (Dashti et al., 2001; Eckert et al., 2003; Efimova 
et al., 2003; 2004). Kanade and colleagues showed that PRMT5 is part of the 
p38δ complex and that PRMT5 methylates one of its components. This 
methylation event inhibited p38δ phosphorylation, thus repressed its 
activation and ensured high levels of ERK1/2. Accordingly, PRMT5 knock-
down induced keratinocytes differentiation, whereas PRMT5 overexpression 
suppressed the differentiation process (Kanade and Eckert, 2012).!
This work is not the only one reporting a connection between PRMT5 and the 
MAPK/ERK signaling pathway. Using different cell lines Andreu-Perez and 
colleagues discovered that PRMT5 is able to methylate the RAF proteins 
CRAF and BRAF, key components of the RAS signaling cascade upstream of 
the MAPK kinases MEK1/2 (Hornberg et al., 2005; Lewis et al., 1998), 
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enhancing their degradation. Thereby the amplitude and  the duration of 
ERK1/2 activity were modulated in response to different growth factors 
(Andreu-Perez et al., 2011). Importantly and different from what observed in 
keratinocytes, in PC12 cells, a rat cell line commonly used as a model for 
neuronal differentiation, inhibition of PRMT5 promoted ERK1/2 activity 
inducing differentiation (Andreu-Perez et al., 2011).!
Finally, the Nimer group, focusing on the role of the Janus kinase 2 (JAK2) 
mutant JAK2V617F in myeloproliferative neoplasms, unveiled a regulatory 
mechanism for PRMT5 activity. They showed that phosphorylation of PRMT5 
by this oncogenic kinase impaired PRMT5 methyltransferase activity 
disrupting its association with MEP50. Surprisingly, further experiment in 
human hematopoietic stem/progenitor cells (HPCs), revealed that in this 
specific system PRMT5 negatively regulates both proliferation and erythroid 
differentiation (Liu et al., 2011).!
!!
1.6.4 PRMT5 in brain development!
!
The central nervous system arises from the neural ectoderm and its proper 
development and functionality rely on a temporally and spatially regulated 
sequence of events. At embryonic day 10.5 (E10.5) of mouse gestation the 
neuroepithelium consists mainly of neural stem/progenitor cells (NPCs), 
which proliferate and maintain an undifferentiated state. This cell population 
progressively expands and generates all the cells that will eventually 
compose the brain: neurons and glial cells. In the mouse brain cortex, 
neurogenesis precedes gliogenesis and begins at approximately E12.5. This 
event is defined by multiple asymmetric divisions of NPCs which give rise to a 
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NPC and a post-mitotic neuron. Notably, as the differentiation process takes 
place in the CNS, the multipotency of the NPC population diminishes, 
establishing the premises for a temporally controlled development (Guillemot, 
2007; Okano and Temple, 2009; Qian et al., 2000; Shen et al., 2006). At 
E15.5, different layers of cells are readily recognizable in the mouse cortex, 
where NPCs are located in the ventricular and sub-ventricular zone, while the 
post-mitotic neurons organize in the subplate as well as in the cortical plate 
(Dehay and Kennedy, 2007).!
In order to gather some insight about the possible role of PRMT5 during brain 
development, Chittka characterized the levels of H4R3me2s and H4R3me2a 
in mouse cortical sections. Immunofluorescence staining revealed that 
H4R3me2s is the prevalent histone modification in the NPC population, 
whereas both H4R3me2s and H4R3me2a are associated with post-mitotic 
neurons and differentiating oligodendrocyte progenitor cells (Chittka, 2010).!
In a separate study, Chittka and colleagues explored the possible role of the 
putative transcription factor Positive regulatory domain 4 (PRDM4) in 
mammalian brain development. PRDM4 knock-down induced neuronal 
differentiation of primary rat neural stem cells. Importantly, they showed that 
PRDM4 recruits PRMT5 to mediate histone methylation and their interaction 
was required to regulate the timing of neural stem cells differentiation (Chittka 
et al., 2012). In contrast to these data, a recent study revealed that PRDM4 
knock-out mice develop normally (Bogani et al., 2013).!
Huang and colleagues instead explored the function of PRMT5 in postnatal 
brain. They observed that PRMT5 expression increases with age and 
correlates with the onset of myelination. Oligodendrocytes are glial cells and 
they are the myelinating cells in the CNS. PRMT5 is highly expressed in 
oligodendrocytes as well as in neuron and astrocytes. To study the role of 
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PRMT5 in glial cells maturation they used the rat glioma cell line C6. These 
cells express oligodendrocyte markers and can be stimulated to elevate 
myelin gene expression levels inducing glial cells differentiation. PRMT5 
knockdown increased the expression of the Inhibitor of differentiation 
transcription factors Id2 and Id4 leading to immature and undifferentiated 
proliferating cells. Consistently, in a differentiation assay performed using 
primary oligodendrocytes progenitor cells, PRMT5 knockdown prevented 
primary oligodendrocytes maturation and differentiation. Finally, they showed 
that PRMT5 directly binds the promoters of Id2 and Id4 and that lack of 
PRMT5 is associated with hypomethylation of the CpG regions of these 











PRMT5 is one of the most studied protein arginine methyltransferases, yet 
the full repertoire of targets and regulated cellular processes remains largely 
unexplored. PRMT5 is currently considered the only mammalian enzyme able 
to generate symmetrically dimethylated arginine, and given its overexpression 
in multiple cancer types, it’s an extremely attractive therapeutic target. 
However, the multitude of potentially regulated pathways and its function in 
vital cellular processes, such as the early steps of the spliceosome assembly, 
question PRMT5 druggability as a feasible strategy in chemotherapy. !
Surprisingly, 15 years after its discovery and despite the rapidly expanding 
literature, the only notion we have regarding the role of PRMT5 in mouse 
development is that PRMT5 null mice are early embryonic lethal. 
Furthermore, contradictory evidence has been collected in tissue-culture 
approaches. As a result, the role of PRMT5 in mammalian development is 
poorly understood and its major cellular function is still unclear.!
Combining the use of knock-out mouse models and next generation 
sequencing technologies, the objectives of this thesis are to: !!
- Investigate to what extent PRMT5 is required during mouse development;!
- Focus on relevant organs in which PRMT5 is expressed, to further explore 
its physiological function; !
- Elucidate the major molecular mechanism responsible for the observed 
phenotype;!








The PRMT5 KO first mice were obtained from EUCOMM (http://
www.knockoutmouse.org) To generate the PRMT5 FLOX allele, the βgal-
neomycin cassette was removed by crossing PRMT5 KO first mice with β-
actin–Flpe transgenic mice (Rodríguez et al., 2000) [strain name: B6.Cg-
Tg(ACTFLPe) 9205Dym/J; stock no.: 005703; The Jackson Laboratory]. They 
were then crossed to Nestin-CRE (B6.Cg-Tg(Nes-cre)1Kln/J - JAX Lab). 4-
Hydroxytamoxifen (4-OHT)-inducible conditional knockouts were created by 
crossing PRMT5F/F mice with Rosa26-CreERT2 transgenic mice (Hameyer et 
al., 2007) (in mixed C57BL/6 X 129S1/SvlmJ background). The p53+/- mice 
(B6.129S2-Trp53tm1Tyj/J - JAX lab), in pure C57BL/6 background, were 
obtained from the Tergaonkar lab (IMCB, Singapore).!
Mice were housed in compliance with the Institutional Animal Care and Use 
Committee (IACUC) guidelines. All procedures involving the use of mice were 
approved by the local Institutional Animal Care and Use Committee (IACUC) 




Mouse genotyping was performed on genomic DNA using a standard 
protocol. Briefly, mouse tail (2 mm) was lysed in 500 μL of lysis buffer (100 
mM sodium chloride, 10 mM TRIS pH8.0, 25 mM EDTA, 0.5% SDS) and 2.5 
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μL proteinase K (Promega, V302B) overnight, shaking at 50°C in a 
thermomixer. Samples were spun down at 13000 rpm for 5 minutes and 500 
μL of supernatant was transferred to new eppendorf tubes containing 500 μL 
of 2–propanol (EMSURE®, 1.09634.2500).  Tubes were inverted a few times 
to mix well and then spun down at 13000rpm for 10 minutes. Supernatant 
were discarded and DNA pellets were left to dry for approximately 10 minutes 
at 37°C heating block. 300 μL of TRIS buffer pH 8.0 was added to the DNA 
pellet and samples were incubated for 30 minutes at 50°C. Embryos were 
genotyped using HotSHOT lysis (Truett et al., 2000).!
For PCR reactions, 12.5 μL of DreamTaq Green PCR master mix 2X (Thermo 
Scientific (#K1082), 1.25 μL of forward and reverse primer mix (10μM), 5μL of 
RNAse free water and 5 μL of DNA (approximately 100ng) were used. All 
PCRs except those involving Rosa26-CreERT2 were performed with initial 
holding temperature of 95°C for 5 minutes, 35 cycles of denaturation at 95°C 
for 45 seconds, annealing at 60°C for 30 seconds and elonagation at 72°C for 
40 seconds and a final elongation temperature of 72°C for 4 minutes and 4°C 
holding temperature. For Rosa26-CreERT2 primers, PCRs were performed 
with initial holding temperature of 95°C for 3 minutes 95°C for 30 seconds, 
annealing at 55°C for 30 seconds and elongation at 72°C for 30 seconds and 
a final elongation temperature of 72°C for 2 minutes and 4°C holding 
temperature. 1.5% agarose gels (agarose powder, 1st base, BIO-1000-500g, 
1X TAE buffer 1st base,BUF-3000-50X4L) with 6 μL of ethidium bromide 
(Promega, H5041) for every 100 mL of agarose solution were prepared. PCR 
products were then loaded onto the gels and bands on gels were visualized 
using ImageQuant RT ECL imager (GE healthcare). The primers used are 
indicated in Table 3.1.!
!
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Table 3.1: Primers used for genotyping!!!
3.3 Southern blot!
!
PRMT5+/- genomic DNA was extracted from liver tissues using DNeasy blood 
& tissue kit (Cat#69504, Qiagen). Genomic DNA (20 μg) was digested 
overnight with 100 units of restriction enzyme (XhoI, Cat#R0146, NEB) in a 
400 μL volume and then re-digested with 100 units of enzyme for 4 hours. 
Digested genomic DNA was precipitated with isopropanol and resuspended in 
20 μL water. Samples were then loaded on 0.7% TBE agarose gels and run 
for 16 hours at 45 mA in 1x TBE buffer. The gels were then denaturated for 
1 hour in 1.5 M NaCl; 0.5 M NaOH, neutralized for 1 hour in 0.5 M Tris-HCl 
pH 7; 3 M NaCl, washed with 2× SSC, and blotted for 24 h with 10× SSC on 
Hybond N+ membranes (Cat#RPN203B, GE Healthcare). !
The membranes were then washed with 2× SSC, UV-cross-linked, and stored 
at 4°C. β-gal probe (510bp) was generated through PCR from the genomic 
Strain Target sequence Forward Reverse
NESTIN-CRE CRE GCCTGCATTACCGGTCGATGCAACGA 
GTGGCAGATGGCGCGGCAACAC
CATT
p53 wt ACAGCGTGGTGGTACCTTAT GTAGTGGATGGTGGTATACTCAGAGCCGGCCT
neo ACAGCGTGGTGGTACCTTAT GTGGCGGACCGCTATCAGGACATAGCGTTGGCT
PRMT5 KO first b-gal TGGTCGCTGGGGAATGAATC CTGCTGCTGGTGTTTTGCTT
loxP AGCTCTTGAAATTGGAGCTGAC TCACACCCAGTCTCTTAC
FLPE CACTGATATTGTAAGTAGTTTGC CTAGTGCGAAGTAGTGATCAGG











DNA of PRMT5F/+; forward primer: TGGTCGCTGGGGAATGAATC; reverse 
primer: CTGCTGCTGGTGTTTTGCTT. Membranes were incubated for 2 
hours at 65°C with pre-hybridization buffer that contained 6x SSPE, 5x 
Denhardt’s reagent, 0.5% SDS and 50 μg/mL denatured salmon sperm DNA. 
Radioactive probes were generated using the High Prime DNA Labeling Kit 
(Cat#11585584001, Roche Applied Science), with 32P and then purified with 
illustra MicroSpin G-50 Columns (Cat#27-5330-01, GE healthcare). Labeled 
probes were heat denatured and added to the pre-hybridization buffer for 
overnight incubation at 65°C in a rotating oven. !
Washing steps were done as follow: 2 times with 2x SSPE, 0.1% SDS for 15 
minutes each, followed by 2 times with 1x SSPE, 0.1% SDS for 30 minutes 
each. All washing steps was performed at 65°C with pre-warmed buffers 
under shaking. The membranes were then exposed to phosphor screen for 
few days before scanning with Molecular Imager PharosFX™ Plus System 
(Cat#170-9460, Bio-rad).!
!!
3.4 β-Galactosidase staining of whole organs!
!
Adult male mice were euthanized by accepted IACUC protocol. Brain, heart, 
kidney liver, spleen and testis were dissected and briefly washed in PBS. The 
organs were next fixed in Fixative Solution (0.2% Glutaraldehyde, 2 mM 
MgCl2, 5 mM EGTA in 0.1 M phosphate buffer pH7,3) on ice for 45 minutes. 
The fixed organs were rinsed 4 times for 20 minutes in Rinse Buffer (0.02% 
Igepal, 0.01% Sodium Deoxycholate, 2 mM MgCl2 in 0.1 M phosphate buffer 
pH 7.3) and then stained overnight in the dark at 37°C in freshly prepared 
Staining Solution (0.02% Igepal, 0.01% Sodium Deoxycholate, 5mM 
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Potassium Ferricyanide, 5 mM Potassium Ferrocyanide, 2 mM MgCl2 and 
1mg/mL X-Gal in dimethylformamide [Promega] in 0.1 M phosphate buffer pH 
7.3). The stained organs were extensively washed in PBS, post-fixed 
overnight in 4% paraformaldehyde in PBS at 4°C and again washed in PBS. 




A single pulse of 2mg Tamoxifen (SIGMA, T5648) plus 1mg Progesteron 
(SIGMA, P8783) in mineral oil (SIGMA, M5904) was given intraperitoneally to 
pregnant females at E10.5. Females were euthanized by accepted IACUC 




In order to confirm the deletion of PRMT5 exon 7 upon CRE activation in 




Qiagen DNeasy Blood & Tissue Kit (69504) was used to extract DNA from 
cell pellets. DNA from different organs was extracted using the mouse 
genotyping protocol as mentioned above. PCR reactions and gels were 
prepared the same way as mentioned above. All PCRs were performed with 
initial holding temperature of 95°C for 5 mintues, 37 cycles of denaturation at 
95°C for 45s, annealing at 60°C for 30s and elongation at 72°C for 55s and a 
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final elongation temperature of 72°C for 4 minutes and 4°C holding 
temperature. 1.3% agarose gels (agarose powder, 1st base, BIO-1000-500 g, 
1X TAE buffer 1st base,BUF-3000-50X4L) with 5 μL of ethidium bromide 
(Promega, H5041) for every 100 mL of agarose solution were prepared. PCR 
products were then loaded onto the gels and bands on gels were visualized 
using ImageQuant RT ECL imager (GE healthcare).!
!!
3.7 Histopathology and immunohistochemistry (IHC)!
!
Haematoxylin and Eosin staining and Immunohistochemistry staining were 
performed in collaboration with the IMCB Histopathology Facility / Advanced 
Molecular Pathology Lab (AMPL).!
!!
3.7.1 Haematoxylin and eosin slide preparation!
!
After fixation in 4% paraformaldehyde (48 hours), the tissues were trimmed at 
the appropriate levels to a thickness of approximately 3 mm and processed 
into paraffin wax using the Tissue-Tek® VIP™5 tissue processor and 
embedded into paraffin blocks. Sections were cut at 5 µm thickness and 
stained with Haematoxylin and Eosin. Brains were sectioned either midline 
sagittal or in cross section at the level of the mid cerebellum and the 







Automated IHC staining and counterstaining was performed on the Leica 
Bond-MaxTM autostainer. Slides were de-waxed and rehydrated through a 
descending series of alcohols. Heat-induced epitope retrieval was performed 
at either pH6 or pH9 followed by endogenous peroxidase blocking and 
washing. Slides were incubated with primary antibody at the appropriate 
concentration for 45 minutes. For rabbit primary antibodies, a secondary 
antibody polymer solution containing anti-rabbit poly-HRP-IgG in 10% animal 
serum was added for 10 minutes.  For mouse primary antibodies, a rabbit 
anti-mouse IgG in 10% animal serum was added for 3 minutes followed by a 
polymer containing anti-rabbit poly-HRP-IgG in 10% animal serum for 3 
minutes. After washing the sections, the slides were developed in DAB 
solution (DAKO, K3468) for 3 minutes. Hematoxylin was used as a nuclear 
counterstain and the sections were dehydrated and mounted in synthetic 
mounting media. All the microscope slide images were captured and 
digitalized using the Ariol high resolution brightfield scanner. The primary 
antibodies used are indicated in Table 3.2.!
Detailed protocol for each marker:!!
PRMT5. Slides were deparaffinized in BondTM Dewax Solution and 
rehydrated through 100% ethanol to 1X BondTM Wash Solution. Heat-induced 
epitope retrieval was performed using BondTM Epitope Retrieval Solution 1 
(pH 6) for 40 minutes at 100°C. Slides were then cooled to room temperature 
with 4 washes of 1X BondTM Wash Solution. Endogenous peroxidase blocking 
was performed for 15 minutes at room temperature in 3-4% (v/v) H2O2, 
followed by 3 rinses in 1X BondTM Wash Solution. Slides were incubated with 
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primary antibody at the appropriate concentration for 45 min. At the end of the 
incubation, the slides were rinsed 3 times in 1X BondTM Wash Solution. 
Polymer solution containing anti-rabbit poly-HRP-IgG in 10% animal serum 
was then added for 10 minutes. The slides were rinsed 4 times in 1X BondTM 
Wash Solution, and washed once in deionized water. BondTM Mixed DAB 
Refine was applied for 3 minutes, following which the slides were rinsed in 
deionized water to stop the DAB reaction. Counterstaining with hematoxylin 
was performed for 5 minutes. After which the slides were rinsed in deionized 
water and 1X BondTM Wash Solution. Slides were finally dehydrated and 
mounted in synthetic mounting media. !
!
Ki67. Slides were deparaffinized in BondTM Dewax Solution and rehydrated 
through 100% ethanol to 1X BondTM Wash Solution. Heat-induced epitope 
retrieval was performed using BondTM Epitope Retrieval Solution 1 (pH 6) for 
40 minutes at 100°C. Slides were then cooled to room temperature with 4 
washes of 1X BondTM Wash Solution. Endogenous peroxidase blocking was 
performed for 30 minutes at room temperature in 3-4% (v/v) H2O2, followed 
by 3 rinses in 1X BondTM Wash Solution. Slides were incubated with primary 
antibody at the appropriate concentration for 60 minutes. At the end of the 
incubation, the slides were rinsed 3 times in 1X BondTM Wash Solution. Post-
primary solution containing rabbit anti-mouse IgG in 10% animal serum was 
added for 5 minutes, followed by 3 rinses in 1X BondTM Wash Solution. 
Polymer solution containing anti-rabbit poly-HRP-IgG in 10% animal serum 
was then added for 5 minutes. The slides were rinsed 4 times in 1X BondTM 
Wash Solution, and washed once in deionized water. BondTM Mixed DAB 
Refine was applied for 3 minutes, following which the slides were rinsed in 
deionized water to stop the DAB reaction. Counterstaining with hematoxylin 
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was performed for 5 minutes. The slides were next rinsed in deionized water 
and 1X BondTM Wash Solution. Slides were finally dehydrated and mounted in 
synthetic mounting media. !
!
SOX2. Manual IHC. Slides were deparaffinized in xylene and rehydrated 
through descending percentages of ethanol to water. Heat-induced epitope 
retrieval was performed using 10 mM Citrate Buffer (Dako, S2369) for 40 min 
using the pressure cooker (2100 retriever, >120oC). Slides were cooled to 
room temperature then washed 3 x 5 minutes in TBS-T. Endogenous 
peroxidase blocking was performed for 15 min in 3% (v/v) H2O2, followed by a 
rinse for 5 minutes in water and a rinse in TBS-T.  Serum block with 5% rabbit 
serum in PBS was performed for 30 minutes. Slides were incubated with 
primary antibody at the appropriate concentration for 60 minutes. At the end 
of the incubation, the slides were washed in gentle running deionized water 
for 10 minutes, followed by a rinse in TBS-T for 5 min. Secondary antibody 
incubation using rabbit anti-goat HRP (Dako, P0160, 1:100) was performed 
for 30 minutes. The slides were washed in gentle running deionized water for 
10 min, followed by a rinse in TBS-T for 5 minutes. The slides were incubated 
with DAB detection reagent (DAKO, K3468) for 5 minutes, and then rinsed in 
deionized water for 5 minutes to stop the DAB reaction. The slides were then 
counterstained with hematoxylin, dehydrated, cleared and mounted in 
synthetic mounting media. !
!
Cleaved Caspase 3 (CC3). Slides were deparaffinized in BondTM Dewax 
Solution and rehydrated through 100% ethanol to 1X BondTM Wash Solution. 
Heat-induced epitope retrieval was performed using BondTM Epitope Retrieval 
Solution 1 (pH 6) for 40 minutes at 100°C. Slides were then cooled to room 
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temperature with 4 washes of 1X BondTM Wash Solution. Endogenous 
peroxidase blocking was performed for 30 minutes at room temperature in 
3-4% (v/v) H2O2, followed by 3 rinses in 1X BondTM Wash Solution. Serum 
block using 10% goat serum was performed for 30 min. Slides were then 
incubated with primary antibody at the appropriate concentration for 45 
minutes. At the end of the incubation, the slides were rinsed 3 times in 1X 
BondTM Wash Solution. Polymer solution containing anti-rabbit poly-HRP-IgG 
in 10% animal serum was then added for 10 minutes. The slides were rinsed 
4 times in 1X BondTM Wash Solution, and washed once in deionized water. 
BondTM Mixed DAB Refine was applied for 5 minutes, following which the 
slides were rinsed in deionized water to stop the DAB reaction. 
Counterstaining with hematoxylin was performed for 5 minutes. After which 
the slides are rinsed in deionized water and 1X BondTM Wash Solution. Slides 
were finally dehydrated and mounted in synthetic mounting media.!
!!
Table 3.2: Primary antibodies used for immunohistochemistry!!!!!
Immunohistochemistry staining
Target protein Source Cat# Host Conditions
Ki67 Novocastra Leica
NCL-Ki67-




Technologies D175 #9661S Rabbit 1:100 pH6
SOX2 Santa Cruz Biotechnology sc-17320 Goat 1:200 pH6




Cells were lysed directly in 1X Laemmli buffer and sonicated with 3 short 
pulses prior to loading on SDS-Polyacrylamide Gels. Mouse tissues were 
lysed in RIPA buffer (50mM Tris-HCl pH7.4, 1% NP-40, 0.5% Na-
deoxycholate, 0.1% SDS, 150mM NaCl, 2mM EDTA, protease inhibitors 
[Merck-Calbiochem, 539134-IML]) for 30 minutes on ice, and mechanically 
homogenized using a Polytron homogenizer (PT-MR 1600E, Kinematica AG). 
Protein concentration was determined using the RC DC Protein Assay (BIO-
RAD). 15-50 μg of protein extract were loaded on 6-15% SDS-PAGE and 
subsequently transferred onto nitrocellulose membranes (Whatman 
PROTRAN, 10401396) using a semi-dry system. !
The membranes were blocked either in 5% dry milk (SIGMA, 70133)/PBS or 
5% BSA (MP Biomedicals, 0219989890)/PBS and incubated overnight with 
primary antibodies, followed by secondary-HRP conjugated secondary 
antibodies (see Table 3.3). The blots were developed using SuperSignal 
West Pico Chemiluminescent Substrate (Thermo Scientific, 34080).!
!
Western Blot! Primary antibodies
Target 
protein Source Cat# Host Blocking solution
H4R3me2s abcam ab5823 Rabbit 5% dry milk/PBS
H3R2me2s IMCB Rabbit 5% dry milk/PBS
H3R8me2s IMCB Rabbit 5% dry milk/PBS
H2AR3me2s IMCB Mouse 5% dry milk/PBS
GFAP abcam ab53554 Goat 5% dry milk/PBS
MDM4 abcam ab16058-100 Rabbit 5% dry milk/PBS
Smith 
Antigen Y12 abcam ab3138 Mouse 5% dry milk/PBS
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Table 3.3: Antibodies used for Western blotting!
SNRPB abcam ab85534 Rabbit 5% dry milk/PBS
SNRPD1 abcam ab50940 Rabbit 5% dry milk/PBS
SNRPD3 abcam ab121129 Rabbit 5% dry milk/PBS
TBR1 abcam ab31940 Rabbit 5% dry milk/PBS
TBR2 abcam  ab23345 Rabbit 5% dry milk/PBS
PARP Cell Signaling Technologies #9542S Rabbit 5% dry milk/PBS
p53 Cell Signaling Technologies
(1C12) 
#2524S Mouse 5% dry milk/PBS
TUJ1 Covance MMS-435P Mouse 5% dry milk/PBS
gammaH2AX Millipore JBW300 05-636 Mouse 5% dry BSA/PBS
beta-actin Santa Cruz Biotechnology (C4) sc-47778 Mouse 5% dry milk/PBS
p21 Santa Cruz Biotechnology (F-5) sc-6246 Mouse 5% dry milk/PBS
P-p53 Santa Cruz Biotechnology
(FP3.2) 
sc-51690 Mouse 5% BSA/PBS
PRMT5 Santa Cruz Biotechnology
(C20) 
sc-22132 Goat 5% dry milk/PBS
SMN Santa Cruz Biotechnology
(2B1) 




T5168 Mouse 5% dry milk/PBS
SYM10 Upstate 07-412 Rabbit 5% dry milk/PBS
Western Blot! Secondary antibodies
Target 
















3.9.1 Neural Stem/Progenitor Cells (NPCs)!
!
Neurosphere cultures were established as previously described (Lim and 
Kaldis, 2012). Briefly, E14.5 embryos were harvested and cortices carefully 
dissected in ice-cold PBS and incubated in trypsin (Invitrogen, 25300120) for 
10 min at 37°C. The tissue was then mechanically dissociated into single cell 
suspension and passed through a 40 μm cell strainer (BD Falcon, 352340) 
into complete NSC medium (DMEM, Life Technologies, 11965118 + 2% B-27, 
Life Technologies, 17504-044), 1% penicillin-streptomycin (Life Technologies, 
15140122), 20 ng/mL recombinant human epidermal growth factor (EGF, 
Peprotech, 100-15) and 20 ng/mL recombinant human fibroblast growth 
factor-basic (FGF-2, Peprotech, 100-18B). Serial passages: 3x105 cells were 
seeded at each passage in a T75 culture flask and the total number of viable 
cells was determined after 4 days using an automated cell counter (Z2 cell 
and particle counter, Beckman Coulter). PRMT5F/F ER day4 neurospheres 
were treated with either 50 nM 4-OHT (H7904; Sigma) or the equivalent 
volume of ethanol for 24 hours before splitting to induce PRMT5 knockout.!
!!
3.9.2 Mouse Embryonic Fibroblasts (MEFs)!
!
Primary MEFs were prepared from E14.5 embryos as previously described 
(Xu, 2005). Briefly, the embryos were harvested from the uterine horns and 
processed separately. The head and all the tissues into the body cavity were 
removed and the remainder of the embryo was finely minced with a razor 
blade in trypsin on ice. The tissue chunks were incubates 30 minutes at 37°C 
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in trypsin and then carefully homogenized using a syringe. The cell supention 
was washed twice in PBS by centrifugation for 5 minutes at 1200 rpm and 
then maintained in a humidified 5% CO2 atmosphere at 37°C in DMEM (Life 
Technologies, 11965118) supplemented with 10% fetal bovine serum (FBS, 
Hyclone, SH30070.03) and 1% penicillin-streptomycin (Life Technologies, 
15140122). !
To perform the RNA-sequencing, MEFs (passage 1) were grown to 
confluence in 15 cm-dishes, and treated with either 50nM 4-OHT (H7904; 
Sigma) or the equivalent volume of ethanol for 24 hours before splitting. 
3x105 cells were seeded in a 10 cm-culture dish and collected after 4 days of 
culture. !
For the cell cycle and cell proliferation analysis, MEFs (passage 1) were 
grown in 15 cm-dishes and acute depletion of PRMT5 was induced in 
exponentially growing cells by treatment with either 50nM 4-OHT (H7904; 
Sigma) or the equivalent volume of ethanol for 24 hours before splitting. After 
the treatment 2x106 cells were seeded in a 10 cm-culture dish in 0.5% FBS 
medium, 5x105 cells were cultured in 5% FBS medium, 3x105  and 1x106 cells 
were cultured in 10% FBS and 20% FBS medium respectively to perform cell 
cycle analysis and RNA extraction.!
!!
3.9.3 Hematopoietic Progenitor Cells (HPCs)!
!
Pregnant females were euthanized by accepted IACUC protocol and the 
embryos were harvested at E14.5 following either Tamoxifen or EtOH 
injection at E10.5. Fetal liver from E14.5 embryos were dissected and finely 
minced in Iscove’s MDM medium (GIBCO). The cell suspension was 
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homogenized using a syringe (21g needle) and washed twice in 15 mL of 
Iscove’s MDM medium with 2% FBS by centrifugation for 10 minutes at 1200 
rpm. The cell pellet was resuspended in 10 mL of Iscove’s MDM medium with 
2% FBS and the viable cells were counted using the automated Vi-CELL XR, 
Beckman Coulter to determine the fetal liver cellularity. !
To perform the colony formation assay 105 fetal liver Prmt5+/+ER cells, from 
E14.5 embryos treated with either Tamoxifen or EtOH injection at E10.5, 
were added to 3 mL of Methocult M3434 medium (Stem Cell Technologies) 
and plated into 35 mm culture dishes following the manufacturer’s instruction. 
The culture were placed in an incubator at 37°C, 5% CO2 and the colonies 
were identified and counted after 12 days.!
In order to deplete PRMT5 ex vivo, we isolated fetal liver Prmt5+/+ER cells 
from E14.5 embryos and cultured them 24 hours with either EtOH or 4-OH-
Tamoxifen (OHT) 50 nM in HSC medium (80% B-cell medium [for 500 mL]: 
225 mL Dulbecco’s modified Eagle Medium (DMEM, Gibco), 225 mL Iscove’s 
modified Dulbecco’s Medium (IMDM, Gibco), 10% FCS, 4 mM L-glutamine, 
100 μM 2-mercaptoethanol, 100 U/mL penicillin, 100 μg/mL streptomycin; 
20% 5X Hematopoietic stem cell supplemement: IMDM (Gibco), 50 mL FCS, 
10 mL WEHI-3B (murine myelomonocytic leukemia cell line) conditioned 
medium [0.45 μm filtered] as a source of IL-3, [WEHI-3B, from Warren S. 
Pear, MIT, were grown in IMDM, 5% FBS, 2 mM L-glutamine, 25 μM 2-
mercaptoethanol], 100 U/mL penicillin,100 μg/mL streptomycin, 1 ng/mL 
recombinant murine IL-3 (Research Diagnostics Inc., Flanders, NJ, # 
RDI-2113), 10 ng/mL recombinant murine IL-6 (Research Diagnostics Inc., # 
RDI-2166), 100 ng/mL recombinant murine stem cell factor(Research 
Diagnostics Inc., # RDI-2503). After the treatment, the cells were washed in 
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HSC medium and the methocult assay was performed as previously 
described.!
!!
3.9.4 Human cell lines!
!
HEK293T, Phoenix-Eco, A549, U87, U2OS, HCT116, were obtained from 
ATCC cultured in an incubator at 37°C, 5% CO2 and propagated according to 
ATCC data sheets.!
!!
3.10 Vectors, transfections and infections!
!
pMXs-IRES-Blasticidin Retroviral Vector (Cell Biolabs Inc., RTV-016) was 
used to overexpress PRMT5, PRMT5(AAA) and MDM4. To generate the 
catalytically dead PRMT5(AAA) we used pCEP4flag-PRMT5 (Wild-type) as a 
template and carried out side directed mutations to generate: pCEP4flag-
PRMT5(R368A). This was then used as template for second SDM generating 
pCEP4flag-PRMT5(R368A)(G367A), which in turn was used as template for 
the 3rd SDM forming pCEP4flag-PRMT5 (R368A)(G367A)(G365A). The 
codon changes were as follows: GGA to GCA (G365A); GGA to GCA 
(G367A); CGG to GCG (R368A). To test the methyltransferase activity, both 
the WT and the triple mutant were expressed in Insect cells with flag-tags in 
conjunction (co-expression) with His-tagged WDR77 (MEP50). Flag purified 
protein preps (200nM) in 50mM Tris-Cl, pH7.5, 150mM NaCl, 10% glycerol, 
1mM DTT were tested for arginine methyltransferase activity using Epigenase 
PRMT Methyltransferase (Type II-specific) Activity/Inhibition Assay Kit (cat # 
P-3088). Flag-tagged WT PRMT5 or PRMT5 (G365A;G367A;R368A) were 
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also expressed in HEK293 cells and purified using anti-flag M2 resin. !
Phoenix-Eco packaging cells were transfected with the overexpressing 
vectors together with VsVg expressing plasmid. Cells were incubated for 18 
hours, then fresh medium was added to the cells. After 24 and 48 hours, the 
medium, containing the viral particles, was collected, filtered using a 0.22 μm 
filter, concentrated by ultracentrifugation for 2 hours at 4°C at 23000 rpm and 
resuspended in HBSS. The infected neural stem cells were selected using 
blasticidin (1μg/mL, Life Technologies, R21001) -containing medium for 6 
days. !
pLKO-1 Mission lentiviral vectors (Sigma) were used for PRMT5 knock-down 
in human cell lines and for SmB/B’ knock-down in both human and mouse 
cells. The target sequence of the PRMT5 KD shRNA construct used was: 
“CCTCAAGAACTCCCTGGAATA”. A scrambled shRNA (Scr) was used as a 
control. HEK293T cells were transfected with pLKO vector together with 
packaging vectors VsVg and delta8.9. Cells were incubated for 18 h, then 
fresh medium was added to the cells. After 24 and 48 hours, the medium, 
containing the viral particles, was collected, filtered using a 0.22 μm filter, 
concentrated by ultracentrifugation for 2 hours at 4°C at 23000 rpm and 
resuspended in HBSS. The concentrated virus was added to the cells 
supplemented with 10 μg mL−1 of polybrene (SIGMA, H9268). Twenty-four 
hours after the last infection, the medium was replaced with fresh growth 
medium containing puromycin (Merck-Calbiochem, 540411). Cells were 





Whole or mechanically dissociated neurospheres (single cells) were seeded 
onto poly-D-lysine coated glass slides. After 4 hours incubation at 37°C, cells 
were fixed with 4% PFA/PBS for 15 min at room temperature, permeabilized 
with 0.25% Triton X-100/PBS, blocked with 1% BSA in 0.1% Triton X-100/
PBS and incubated with primary antibody against Cleaved Caspase 3 (Cell 
Signaling Technologies, D175 #9661S, rabbit polyclonal) overnight at 4°C. 
Secondary antibody incubation was done for 1 hour at room temperature 
using anti-rabbit Alexa Fluor® 488 (Life Technologies, A212006, donkey 
polyclonal). !
The slides were mounted with Vectashield mounting medium for fluorescence 
with DAPI (Vector Laboratories, Inc., H-1200). Images were captured using 





The cRNA for microarray analysis was prepared starting from 500 ng of total 
RNA, isolated as previously described, using the Illumina® TotalPrep™ RNA 
Amplification Kit (Ambion®). We performed the experiment at the BSF 
(Biopolis Shared Facilities) microarray facility using the Illumina platform. The 
bioinformatic analysis was performed in collaboration with J. Müller, a post 
doc in the lab).!
The expression data from quadruplicate Illumina MouseRef-8 V2 microarrays 
were quantile normalized using the beadarray package v2.8.1 in R (Dunning 
et al., 2007) and annotated with the illuminaMousev2.db package. Probes 
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with the label bad or no match were excluded from the analysis. p-values 
were multiple testing corrected using Benjamini and Hochberg (Benjamini and 
Yekutieli, 2001) control of the false positive rate. log2 fold changes were 
computed and only transcripts with an absolute fold change greater than 1.5 
fold (1251 up and 2123 down) and a q-value of smaller than 0.01 were 
labelled as significantly differentially expressed.!
!!
3.13 Quantitative real time PCR (qRT-PCR)!
!
Total RNA was isolated from the cells using PureLink RNA Mini Kit (Ambion, 
12183-018A) and quantified using the NanoDrop 2000 (Thermo Scientific). 
Embryonic tissues were homogenized in 1 mL of TRIzol® Reagent (Life 
Technologies) and 0.2 mL of chloroform was added. Each sample was 
vortexed vigorously for 15 seconds, incubated at room temperature for 2 
minutes and spun down at 4°C at 13200 rpm for 15 minutes. The upper 
phase was collected and one volume of 70% EtOH was added. RNA was 
then isolated using PureLink RNA Mini Kit (Ambion, 12183-018A) and 
quantified using the NanoDrop 2000 (Thermo Scientific).!
1μg RNA was used to prepare cDNA using Vilo cDNA kit (Invitrogen). The 
cDNA prepared was subjected to qRT-PCR (ABI PRISM 7500), using SYBR 
Green PCR Supermix (Invitrogen). The final reaction volume was 20 μL: 10 
μL 2X SYBR Green PCR Supermix, 4 μL forward and reverse primer mix 
(final concentration 200nM) and 6 μL cDNA (20 ng). The primer sequences 
are in Table 3.4. Data were expressed as relative mRNA levels normalized to 
housekeeper (TBP, GAPDH) expression levels in each sample. !
!
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Table 3.4: Primers used for quantitative real time PCR!!!
3.14 5-Bromodeoxyuridine (BrdU) labeling and flow cytometry 
analysis!
!
MEFs were trypsinized and washed with PBS. Neurospheres were collected 
by centrifugation, washed with PBS and the cell pellet was thoroughly 
dissociated into single cells and passed through a 40 μm cell strainer (BD 
Falcon, 352340). The collected cells were fixed in 70% ice-cold ethanol 
overnight at -20°C. Fixed cells were subsequently stained with 20 μg/mL 
Gene Organism Forward Reverse
p53 mouse CGCTGCTCCGATGGTGAT TGGCGAAAAGTCTGCCTGTC
Mdm2 mouse TGGAGTCCCGAGTTTCTCTG AGCCACTAAATTTCTGTAGATC
Mdm4 mouse AGTCAGGTGCGGCCAAAA CCCAAAAGATCTCCACCACA
Ptprv mouse GGAGCGCTCATTTTGTCTTC TGAGGCTAAGGCGGTAAGAA
p21 mouse CTGGGAGGGGACAAGAG GCTTGGAGTGATAGAAATCTG
Perp mouse CAGAGCCTCATGGAGTACGC GAGAATGAAGCAGATGCACAGG
Puma mouse ATGGCGGACGACCTCAAC AGTCCCATGAAGAGATTGTACATGAC
Noxa mouse CGGGCAGAGCTACCACCT CGAGCGTTTCTCTCATCACA
TRP53inp1 mouse ACCTTCTCATTGAACATCCC TGCTTCCCCATTTCACTCT
Zmat3 mouse CCCTGGAGGAGCTGTGTAA CGTAGTTTCTTGCCATGGT
p19  ARF mouse GGGTTTTCTTGGTGAAGTTCG TTGCCCATCATCATCACCT
Ccng1 mouse CAGTTCTTTGGCTTTGACAC CTTTCCTCTTCAGTCGCTTT
Gapdh mouse CATCTTCTTGTGCAGTGCCAG GGCAACAATCTCCACTTTGCC
Tbp mouse CTGGAATTGTACCGCAGCTT TCCTGTGCACACCATTTTTC
Prmt5 mouse GATCCGAAGGAACTCTGAAGG GCTGGAAGACCCAGATATGC
SmB/B' mouse CTTGGTCTGGTGTTGCTT CTTCCTTGTGGGGTCATC
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Propidium Iodide, 0.1% Triton X-100/PBS, and 0.2 mg/mL RNAse A (Sigma- 
Aldrich, R6513) for 30 minutes at 22°C. For BrdU staining, cells were fixed 
after 1 hour of incubation with 100 μM BrdU. Fixed cells were then incubated 
for 30 minutes at room temperature in 2M Hydrochloric acid/0.1% Triton 
X-100 to denature the DNA, followed by neutralization with 0.1 M Sodium 
tetraborate, pH9.0. Cells were subsequently stained with anti-BrdU antibody 
conjugated with Alexa Fluor ® 488 (Cat#B35130, Life Technologies) in 0.5% 
Tween 20/PBS, 1% BSA for 1 hour at 22°C, followed by Propidium Iodide 
staining and flow cytometry analysis (Beckton & Dickson LSRII Flow 
Cytometry Analyser).!
!!
3.15 Nucleus and cytoplasmic fractionation!
!
NPCs were harvested and washes twice in PBS. The cell pellet was 
resuspended in cold buffer A (1 mM Hepes pH 7.9, 5 mM MgCl2, 0.25 M 
sucrose, 100 mM NaCl, 0.1 % NP-40), passed through a 18G needle four 
times and incubated on ice for 10 minutes. After incubation the cell 
suspension was spun down at 4000 rpm for 10 minutes at 4°C. The 
supernatant, cytosolic fraction, was collected and 5X Laemmli buffer was 
added to achieve the final concentration of 1X Laemmli buffer. The pellet, 
nuclear fraction, was washed once in buffer A and resuspended in 1X 
Laemmli buffer to achieve the same total volume as the cytoplasmic fraction. 
20 μL protein extract were loaded on 6-15% SDS-PAGE and western blot 





To generate antibodies specific for H3R8me2s and H2AR3me2s we 
collaborated with the IMCB antibody facility. KLH-coupled peptides mimicking 
the first 10 amino acids of H2A, symmetrically dimethylated on R3, were used 
to immunized 5 mice, while similarly designed peptides mimicking H3R8me2s 
were used to immunized 5 rabbits (Mimotopes, Australia). The best bleeds 
obtained were affinity purified using SulfoLink Coupling Resin (Thermo 
Scientific, 20401). Briefly, 2 mL of resin bed were equilibrated with 8 mL of 
Coupling buffer (50 mM Tris HCl pH 8.5, 5 mM EDTA-Na pH 8.5) using a 
purification column. 5 mg of cysteine-tagged peptide mimicking either 
H2AR3me2s or H3R8me2s (Mimotopes, Australia) were diluted in Coupling 
buffer, added to the column and incubated at room temperature. After 2 hour 
rotation the resin was washed in coupling buffer and then blocked with 50 mM 
L-Cysteine HCl diluted in Coupling buffer. The crude serum to be purified was 
next incubated with the prepared column for 2 hours at room temperature, 
extensively washed in Coupling buffer and finally, the purified antibody was 
eluted in Elution buffer (0.2 M Glycine HCL, pH 2.5) and neutralized with 50 
μL/mL of Neutralization buffer (1 M Tris HCl, pH 8.5). !
!!
3.17 Peptide dot blot!
!
Peptides mimicking the histone modification H2AR3me1, H2AR3me2a, 
H2AR3me2s, H4R3me1, H4R3me2a, H4R3me2s, H3R2me1, H3R2me2a, 
H3R2me2s, H3R8me2s, H3R17me2a, H4R26me2a, and the histone tails of 
histone H2A, H3 and H4 (Mimotopes, Australia) were resuspended in PBS to 
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a final concentration of 2 mg/mL. 2 μL of a 1:10 dilution (400 ng) were spotted 
on PVDF membranes and dried at room temperature. The membranes were 
then blocked with 5% dry milk in PBS for 30 minutes at room temperature and 
incubated overnight with the primary antibody, followed by secondary-HRP 
conjugated secondary antibodies (see Table 3.3). The blots were developed 




3.18 Micrococcal Nuclease (MNase) assay!
!
Nuclei from Prmt5F/FER NPCs either untreated or treated with OHT were 
obtained as previously described (paragraph 3.15), and resuspended in 
digestion buffer (0.32 M sucrose, 50 mM Tris-HCl pH7.5, 4mM MgCl2, 1mM 
CaCl2, 5mM Na butyrate, 0.1 mM PMSF). After DNA quantification the nuclei 
were resuspended in digestion buffer to achieve a final DNA concentration of 
0.2 mg/mL. 20 μL of MNase (1U/μL Promega) was added to 500 μL of nuclei 
(0.1 mg DNA) and incubated at 37°C for 5, 10, 15, 20 or 40 minutes. At the 
end of the incubation period the digestion reactions were stopped adding 13.3 
μL of 0.2 M EDTA pH 8. DNA was purified using a standard phenol extraction 
protocol and 8 μg of DNA were loaded onto a 2% agarose gel and bands on 




Neurospheres were collected by centrifugation, washed once in PBS and 
lysed on ice in IP Lysis Buffer (300 mM NaCl, 50 mM Tris pH8, 0.4% NP-40, 
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10 mM MgCl2, 2.5 mM CaCl2) containing protease inhibitors (Merck-
Calbiochem, 539134-IML) for 30 minutes. The lysate were briefly sonicated 
and an equal volume of IP Dilution Buffer (50 mM Tris pH8, 0.4% NP-40) was 
added. After incubation for 20 to 60 minutes the lysate were centrifuged for 10 
minutes at 4°C at 14000 rpm. Antibodies (anti-SMN: SantaCruz 
Biotechnology, 2B1 sc-32313, mouse monoclonal; normal mouse IgG, 
SantaCruz Biotechnology, sc-2025) were added to the extract and incubated 
overnight on a rotating wheel at 4°C. Protein G-Sepharose beads (GE 
Healthcare cat#17-0618-02) were added to the mix and incubated for an 
additional 4 hours. The beads were pelleted, washed 5 times with IP buffer, 
and boiled in Laemmli buffer before loading onto SDS-PAGE.!
!!
3.20 2,2,7-Trimethylguanosine (TMG) pull down!
!
The [35S]methionine and [35S]cysteine pulse-chase assay was performed as 
described previously (Winkler, 2005) with minor modifications. The chase time 
was reduced from 1 h to 45 min and NPCs were grown as described above. 
The newly synthesized snRNPs were purified using anti-2,2,7-
Trimethylguanosine (TMG) agarose conjugate antibody (mouse, K121 NA02A 
Millipore) from total extract as described in the Immunoprecipitation section 
above.!
!!
3.21 Small nuclear RNA (snRNA) quantification by real time PCR!
!
Neurospheres were washed twice in PBS, homogenized in 1 mL of TRIzol® 
Reagent (Life Technologies) and 0.2 mL of chloroform was added. Each 
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sample was vortexed vigorously for 15 seconds, incubated at room 
temperature for 2 minutes and spun down at 4°C at 13200 rpm for 15 
minutes. The upper phase was collected and one volume of 100% EtOH was 
added. RNA was then isolated using PureLink RNA Mini Kit (Ambion, 
12183-018A) and quantified using the NanoDrop 2000 (Thermo Scientific). 
Reverse transcription and real time PCR were performed as described by 
(Zhang et al., 2008). Briefly, The list of primers used for qRT-PRC is in Table 
3.5 and the same reverse primers were used for the reverse transcription, 
which was performed using the SuperScript® II Reverse Transcriptase 
(Invitrogen™). For the U1, U2, U4, U5, and U6 snRNAs, and for the 5s and 
5.8s rRNAs, 100 ng of total RNA was utilized as a template, whereas for the 
U11, U12, U4atac and U6atac reverse transcription, the starting amount of 
RNA was 375 ng. qRT-PCR was performed as previously described using 
one percent of the cDNA.!
!
Gene Organism Forward Reverse
U1 snRNA mouse human GATACCATGATCACGAAGGTGGTT CACAAATTATGCAGTCGAGTTTCC





U4 snRNA mouse human GCGCGATTATTGCTAATTGAAA AAAAATTGCCAATGCCGACTA
U5 snRNA mouse TACTCTGGTTTCTCTTCAGATCGTATAAAT
AATTGGTTTAAGACTCAGAGTTGTTC
CT
U6 snRNA mouse human GCTTCGGCAGCACATATACTAAAAT ACGAATTTGCGTGTCATCCTT










Table 3.5: Primers used for snRNAs quantitative real time PCR!!!
3.22 RNA-Sequencing library preparation and splicing analysis!
!
For RNA-Sequencing (RNA-seq) library preparation we followed the Illumina 
TruSeq RNA Sample Preparation Kit v2 manual. The bioinformatic analysis 
was performed in collaboration with J. Müller, a post doc in the lab). At least 
70 million, 51bp long paired end reads were mapped to the NCBI37/mm9 
version of the mouse genome per replicate using tophat 2.03 (Trapnell et al., 
2009) allowing for 2 read miss matches. In total more than 40 million read 
could be aligned unambiguously per replicate. Differential expression analysis 
was performed using cuffdiff 2.01 (Trapnell et al., 2012) and only genes with a 
p-value of less than 0.05 and a fold change of greater than 1.5 were labelled 
as significantly differentially expressed.!
To determine differential splicing events, MATS 3.0.6 (Shen et al., 2012) beta 
was used counting junction reads and reads falling into the tested region 
within ENSEMBL v65 gene definitions. Matching embryos were analyzed 
individually and only significant events occurring in at least two replicates 
were considered. Splicing events were labelled significant if the sum of the 
reads supporting a specific event exceeded 10 reads, the p-value was lower 
than 0.05 and the minimum inclusion level difference as determined by MATS 
was higher than 0.2. All other parameters were left at the default value. 





5 S rRNA mouse human CGGCCATACCACCCTGAAC GCGGTCTCCCATCCAAGTAC
5.8 S rRNA mouse human CGGCTCGTGCGTCGAT CCGCAAGTGCGTTCGAA
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Senapathy, 1987). Briefly, the frequency of the first 6Bp of the Intron and the 
first 3Bp of the Exon were compared to reference donors. As reference 
donors, all canonical GT donors in the ENSEMBL v65 genome were utilized.  !
Intron read maps were generated on merged read counts using the package 
TransView 1.4.1. in R. Read maps were generated omitting overlapping 
known exons and converted into RPKM per intron. Only introns with a length 
between 0.1kBp and 10kBp and a RPKM of at least 1 were considered. All 
fold change values were log2 converted and log2 fold change values of the 
surrounding gene were subtracted to normalize for expression changes. All 
sequencing and microarray data have been submitted to the GEO repository 




The functional annotation of the significant Microarray and RNA-Seq genes 
was performed with DAVID (Huang et al., 2009), using KEGG pathway 
(Kanehisa et al., 2012) representations.!
!!
3.24 RNA sequencing validation, splicing PCR!
!
Primer were designed using CLC Main Workbench 5 (http://www.clcbio.com/)
(Table 3.6, 3.7 and 3.8). All PCRs were performed with initial holding 
temperature of 95°C for 5 minutes, 26 cycles of denaturation at 95°C for 45 
seconds, annealing at 58°C for 30 seconds and elonagation at 72°C for 40 
seconds and a final elongation temperature of 72°C for 4 minutes and 4°C 
holding temperature. PCR products were ran in a range of 1.7% to 2.5% 
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agarose gels with 7 μL of ethidium bromide for every 100 mL of agarose 
solution prepared. PCR products were then loaded onto the gels and bands 
on gels were visualized using ImageQuant RT ECL imager (GE healthcare). 
Band intensities were quantified using ImageJ software (Schneider et al., 
2012) and the percentage of exon or intron inclusion was calculated dividing 
the intensity value of the upper band by the sum of the intensity values of the 
two bands.!
!
Gene Forward Reverse Transcript accession number
Eif4e CTACCACTAATCCCCCACC CGTCCTCCTCGTTTGTTTT Eif4e NM_007917
Exon number: 5 chr3:138213227-138213290
fibp AGCTGACCCACAATAAGGA CGGAGGGAGGAAGGAAAA Fibp NM_021438
Exon number: 9 chr19:5464334-5464431
Epn1 GCTATGAGCAAGGAGGAGG TCTATTGCCATCTGCAGCC Epn1 NM_010147
Exon number: 6 chr7:5044914-5044988
Syce2 AGAGCATCGGCAGAGTGA CTTTGCCATCTTCTGGGT Syce2 NM_001168246
Exon number: 3 chr8:87407330-87407483
Pkd1 GCTGTCCTGTTCCTCTTCC CACCATCTTCCTCTGAGCC Pkd1 NM_013630
Exon number: 31 chr17:24724124-24724237
Bin1 CTCCCAAACACACCCCATC AAGGTCTCCACCACCACA Bin1 NM_001083334
Exon number: 12 chr18:32591325-32591396
Gphn AGTAAAGGAGGTGCATGATGA GGAGTAGTGCTAAGGGAGG Gphn NM_145965.2
Exon number: 8 chr12:79594937-79595044
Mink1 GGAACAAAGCCAAGCCTGA CCTTCCTCCTCCTCCTCTT Mink1 NM_176893
Exon number: 20 chr11:70422910-70422933
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Table 3.6: Primers used for the RNA-sequencing validation, skipped 
exons!!!!
Zfml AGTTGGAGATGAGGAAGATGG GTCTTGAGTCTTCCTGCGT Zfml NM_00116637.1
Exon number: 23 chr6:83931678-83931779
Rnf38 CGCAGGTGAAGTGATGATGT GGGGCTGCCTATTTGATGT Rnf38 NM_001038993
Exon number: 2 chr4:44171775-44171924
Rfx3 CAACTACTCCTCTCCTCCTCC GCACTTGCTGTACCACCT Rfx3 NM_001166414.1
Exon number: 2 chr19:27997698-27997756
Nnat CACCCACTTTCGGAACCA TGTCGGTGCTGCTTTTCT Nnat NM_010923.2




TTGTGGCGTGGGATCTAGG AGAACAGCACATCGAAGCA 2410004N09Rik NM_038151
Exon number: 2 chr18:33955037-33955099
Lmtk3 CGCTGCCTGATGTCTATATT GTTCCTTCACCACCACCT Lmtk3 NM_001005511
Exon number: NA 5-6 chr18:53043016-53043128
Cask CGCTAACCAAACAGTGGA GGGTGGTTGATGGCAAGT Cask NM_009806
Exon number: NA 17-18 chrX:13129499-13129567
Isca2 CCGCTGGGAAACAACATCT    GCTGGGCTTGAGGGTTATT    Isca2 NM_028863
Exon number: 3 chr12:86114743-86114858
Mpdu1 CTACAGCATCACCAACAACTTC CACCACGGCAGGTACATT    Mpdu1 NM_011900
Exon number: 4 chr11:69471438-69471523
Mdm4 TGTGGTGGAGATCTTTTGGG TCAGTTCTTTTTCTGGGATTGG Mdm4 NM_008575
Exon number: 7 chr1:134901231-134901298
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Gene Forward Reverse Transcript accession number
Gtf3c2 CTTCGACGACCTTATGAACCA CGAGGTAACCGGCATCAA Gtf3c2 NM_027901
Exon number: 14-15 chr5:31461894-31462073
Txlna AACAGCATAACGAGCGAAAC ACTCCACCGCTTCCTTCA Txlna NM_001199695
Exon number: 7-8 chr4:129308598-129308835
Gdi1 AACGACGCTTCCGAAAAT AGGCCATACAGTGGGTATAAA Gdi1 NM_010273
Exon number: 5-6 chrX:71553209-71553469
Fxc1 GCGAGACTTCCTGTTGGT GCGAGTCTCTGGTCTGTT Fxc1 NM_019502
Exon number: 2-3 chr7:112789371-112789542
Setdb1 TGAATTTCTGGTTGGCTGTG TGGCCTGGATAGTTAGCTG Setdb1 NM_018877
Exon number: 13-14 chr3:95141187-95142268
Ppp1r12c ATCACTCTGTTCCACCCT CCACCTTTTCTGCTTCCTT Ppp1r12c NM_029834










Exon number: 8-9 chr4:43582533-43582702
H2-Ke6 GTGGTTGCATTCTTGGCAT CACCCCTGCCTTCCATATT H2-Ke6 NM_013543
Exon number: 8-9 chr17:34163170-34163341
Cep110 GAACACTGGCGTGGAGAA GGCAGACTGGGTGATGAT Cep110 NM_12018
Exon number: 41-42 chr2:35031120-35031648
Ampd2 CAAAAGTGTGGTTCGGGC TCACAGTGCTCATACGGG Ampd2 NM_028779
Exon number: 6-7 chr3:107882244-107882505
Fancg CTTCTGACTGCATTTGCCT TCTGCTGCTCTGTCTCCT Fancg NM_053081
Exon number: 5-6; 6-7 chr4:43019986-43020140; chr4:43019768-43019856
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Table 3.7: Primers used for the RNA-sequencing validation, retained 
introns!!!!!!!!!
Trmt1 CGAATTCATCTTGGGGCCA TCACAGATCTCACCCACTGC Trmt1 NM_198020
Exon number: 3-4 chr8:87214471-87214710
Skiv2l GGAGGTGACGAGGATGAAG TGAGGTGGAGGTTTGGGAG Skiv2l NM_021337
Exon number: 8-9 chr17:34983940-34984088
Ddx51 ACAGAAGTCGCTGGCTAA ATCCTGGAGTCTGGTCAA Ddx51 NM_027156
Exon number: 6-7 chr5:111084432-111084584
Prpf40b GAGAGGGAACGGGAAAAGGA ACTCCAGGGTGATCTGCT Prpf40b NM_018786
Exon number: 20-21 chr15:99145411-99145622
Gpaa1 TCTCCCGCAAACTACCCT GCCAACAACAACCCCACA Gpaa1 NM_010331
Exon number: 3-4 chr15:76162701-76162914
Rabl2 AATCACCTATAAGAACCTGG AGCCGAGACAAAGTACA Rabl2 NM_026817
Exon number: 6-7 chr15:89414438-89414710
Phkg2 GAGCTACCGGTGATGAGTT CGTAGGAATCGATGAGGG Phkg2 NM_026888
Exon number: 3-4 chr7:134721224-134721489
Dvl1 (3-4) GGTGGTGAAGGAGGAGAT CGGCTACTGGCAACATTT Dvl1 NM_010091
Exon number: 3-4 chr4:155227867-155228092
Dvl1 (4-5) GGGACGGAATGGACAATGA GATGCACTGTCTGGAGGTA Dvl1 NM_010091
Exon number: 4-5 chr4:155228195-155228439
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The polysome purification was performed in collaboration with Leah A. 
Vardy (Institute of Medical Biology - IMB, A*STAR, Singapore). 
Polysomes were isolated and separated as previously described (Zhang et 
al., 2012). Briefly, 2 million cells were incubated for 10 minutes with 100 ug/
mL cyclohexamide (Sigma, Cat C4859). On harvesting, the cells were 
resuspended in 2XRSB (20 mM Tris-HCl, pH 7.4, 20 mM NaCl, 30 mM MgCl2, 
200 μg/mL cycloheximide, 1000 unit/mL SUPERase•In - Ambion), and then 
lysed for 8 minutes on ice with 2X lysis buffer (20 mM Tris-HCl, pH 7.4, 20 
mM NaCl, 300 mM MgCl2, 1 % Triton X-100, 2% Tween-20, 1% 
deoxycholate). Following centrifugation at 12,000g for 10 minutes, cell 
extracts were loaded onto linear 10 – 50 % sucrose gradients (prepared in 10 
mM Tris-HCl pH 7.4, 75 mM KCl and 1.5mM MgCl2), and centrifuged at 36 k 
rpm for 70 minutes at 8°C in a SW60 rotor (Beckman Coulter). 6 fractions 
were collected from the top of the gradient using a piston gradient fractionator 
(BioComp Instruments). Following fractionation SDS was added to 1% and 5 
μL of proteinase K (10 mg/mL Invitrogen) was added to each fraction, and 
Gene Forward Reverse
Human Mdm4 
exon 6 TGTGGTGGAGATCTTTTGGG    GCAGTGTGGGGATATCGT    
Human Gapdh GAAGGTGAAGGTCGGAGTC GAAGATGGTGATGGGATTTC
Mouse Gapdh CATCTTCTTGTGCAGTGCCAG GGCAACAATCTCCACTTTGCC
Mouse b-Actin CAGCTTCTTTGCAGCTCCTT CACGATGGAGGGGAATACAG 
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incubated for 30 minutes at 42°C. RNA was purified by phenol-chloroform 
extraction followed by ethanol precipitation. cDNA was made using 
Superscript III with a mix of Random hexamers and Oligo dT.!
!!
3.26 Cell viability assay!
!
Following 24 hours EtOH/OHT treatment, MEFs were plated in 96 well 
plates(5000 cells/well) at different serum concentrations (0.5%, 5%, 10%, 
20% FBS). 4 days after plating, the cell viability assay CellTiter 96®AQueous 
One Solution Cell Proliferation Assay (Promega G3580) was performed 




The expression constructs used for the minigene construction was kindly 
provided by E.Makeyev. RI (drRed2-Intron) (Makeyev et al., 2007). It contains 
a CMV or CAGGS promoter driving transcription of the dsRed2 fluorescent 
protein coding sequence interrupted by an intron. We refer to this vector as 
"Empty". To generate the RI-Mdm4 plasmid, a fragment containing mouse 
Mdm4 exon 7 and parts of introns 6 and 7 were inserted into the intron of the 
RI vector at the PmeI-SpeI sites. The fragment was amplified by PCR 
(Platinum® Taq DNA Polymerase High Fidelity, Invitrogen) from C57BL/6 




We refer to this vector as "Exon 7". Primers used to check for alternative 




The minigene constructs were transfected into MEFs using Lipofectamine 






4.1 A mouse model to study PRMT5 role in development!
!
To study the role of PRMT5 in mammalian development we made use of a 
mouse model generated by the European Conditional Mouse Mutagenesis 
Program (EUCOMM). This is a conditional knock-out (KO) first mouse model 
(Testa et al., 2004) harboring LoxP (F/F) sequences flanking exon 7 in the 
Prmt5 gene. The KO first strategy relies on the insertion of a removable 
cassette (βgal cassette) within two FRT sequences, containing a strong 
splicing acceptor (EN2) followed by the coding sequence of the β-
galactosidase gene, a selectable marker and the polyadenilation site. The β-
gal cassette interrupts the transcription of the Prmt5 gene generating a 
chimeric pre-mRNA, thus resulting in the depletion of PRMT5 protein 
expression and allowing detection of Prmt5 transcript distribution in vivo. The 
cross of mice heterozygous for the KO first allele (Prmt5+/-) with mice 
expressing the Flippase recombinase gene (FLP) results in the excision of 
the βgal cassette and the generation of heterozygous PRMT5 conditional KO 
mice (Prmt5+/F) (Fig. 4.1A). !
Single site insertion of the βgal cassette in the Prmt5+/- mice was verified by 
Southern blotting (Fig. 4.1B). As expected, the Prmt5+/- mice are viable, fertile 
and do not show any evident developmental defect, whereas Prmt5-/- mice 
are early embryonically lethal (Tee et al., 2010).!
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Figure 4.1: Inactivation of the Prmt5 Gene: The PRMT5 conditional 
knock-out first allele. (A) Schematic representation of the EUCOMM 
constructs used in the study (Figure adapted from the EUCOMM website: 
http://www.knockoutmouse.org. (B) Southern Blot M: λ DNA-HindIII Digested 
Marker; U: Undigested Prmt5+/- genomic DNA D: XhoI-Digested Prmt5+/- 
genomic DNA. The red arrow indicates the band at the expected size. !!!!!
4.2 PRMT5 expression in adult mouse tissues!
!
PRMT5 expression patterns have not been studied in the mouse, thus, as a 
first step, we decided to characterize PRMT5 distribution in mouse adult 
tissues. We took advantage of the βgal cassette and performed β-
galactosidase staining in adult Prmt5 +/+ and Prmt5 +/- brain, heart, kidney, liver 
spleen and testis (Fig. 4.2). While the wild type (wt) tissues did not show any 
staining (besides a minimal background staining in the testis), in Prmt5 +/- 
tissues PRMT5 expression was seen primarily in the brain. No expression 
was observed in the heart and in the liver, whereas β-galactosidase staining 
was detected in the kidney, spleen and testis although at lower intensity 
compared to the brain. !
To better characterize PRMT5 protein distribution and to confirm the results of 
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the β-galactosidase staining we used an anti-PRMT5 antibody to stain an 
expanded panel of mouse tissues (Fig. 4.3). By immunohistochemistry (IHC) 
we confirmed low levels of PRMT5 in the liver and in the heart. On the 
contrary, PRMT5 staining in testis resulted in a very strong nuclear signal. 
High levels of PRMT5 were also detected in the crypts of Lieberkühn and in 
the lining epithelium of the gatro-intestinal tract. The presence of PRMT5 
protein was also confirmed in the central Nervous System (CNS), particularly 
in the Purkinje cells in the cerebellum, and in the nuclei of neurons populating 
the cerebrum and the spinal cord. Weaker PRMT5 expression was also 
detected in the cytoplasm of cells within the Islet of Langherans of the 
pancreas, and in kidney tubules. Staining was observed in the spleen, in 
some cells of the germinal center, in the white pulp and in the surrounding 




Figure 4.2: Prmt5 Gene expression pattern in adult mouse organs. β-
galactosidase staining of whole brain, heart, kidney, liver, spleen and testis 
from 2 month old Prmt5 +/+ and Prmt5 +/- mice.!!!
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Figure 4.3: PRMT5 protein expression pattern in adult mice. PRMT5 
ImmunoHistoChemistry (IHC) staining in various tissues from adult wild type 
mice.!!!!
4.3 PRMT5 deletion during organogenesis causes embryonic 
lethality!
!
The analysis of PRMT5 distribution in multiple adult mouse organs revealed a 
complex expression pattern, and suggested a possible role for PRMT5 in 
tissues rising from different embryonic layers: ectoderm, mesoderm and 
endoderm. Therefore, we decided to start investigating the role of PRMT5 in 
mammalian development in an unbiased manner, systemically deleting 
PRMT5 during organogenesis. In order to achieve our goal, we generated a 
conditional KO strain by crossing the Prmt5F/F mice to the ROSA26:CreERt2 
(ER) mice, which allows the triggering of a recombination event in both live 
animals, or ex vivo, in primary cells, by using Tamoxifen (TAM) or 4-OH-
Tamoxifen (OHT) respectively. Prmt5 was selectively deleted in Prmt5F/FER 
embryos from pregnant Prmt5F/F females, crossed to Prmt5+/FER males, 
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following Tamoxifen (TAM) injection at the stage of midgestation E10.5 (Fig. 
4.4A upper panel). The Prmt5+/FER littermates, or Ethanol (EtOH) treated 
Prmt5F/FER embryos were used as a control. CRE-ER was activated 
efficiently in different organs (Fig. 4.4A lower panel). Notably, upon TAM 
injection no Prmt5F/FER pups were born alive, thus we analyzed the embryos 
at E17.5 and E15.5. The mutant embryos were readily recognizable by their 
smaller size and pale color (Fig. 4.4B). Instead of an organ-specific defect we 
observed growth retardation, suggesting a role for PRMT5 in maintaining the 
pool of proliferating cells, rather than driving specific differentiation programs. 
To test our hypothesis we examined actively proliferative organs such as lung 
and liver. The latter, at this stage of development, is populated by 
Hematopoietic Progenitor Cells (HPCs), recognizable by their dark-purple 
color in the H&E staining. Impairment of their homeostasis is evident in the 
TAM treated embryos and consistent with the pale color of the PRMT5 
depleted embryos (Fig. 4.5 top left panel). Phenotypically, we observed 
activation of the apoptotic response by staining the apoptotic marker Cleaved 
Caspase 3 (CC3) (Kuida et al., 1996) and dramatic exit from the cell cycle 




Figure 4.4: PRMT5 depletion during midgestation induces embryonic 
lethality. (A) Experimental strategy used to delete PRMT5 at midgestation 
(E10.5). Embryos were analyzed at E15.5 and E17.5. Upon TAM injection no 
pups were born alive. Bottom panel: Efficiency of CRE recombination taking 
place in different organs detected by genomic PCR. (B) Weight of PRMT5 wt 
(EtOH treated) or deleted (TAM treated) whole embryos at E15.5 and E17.5. 




Figure 4.5: PRMT5 depletion induces cell cycle arrest and apoptosis in 
different tissues. Hematoxylin and eosin (H&E) staining of wild-type and 
knockout E15.5 lung and liver sections. In the liver light purple-stained 
hepatocytes and dark purple-stained hematopoietic precursor cells are easily 
detectable. Note the dramatic loss of the latter and the corresponding loss of 
ki67 staining. Below each (H&E) staining: ImmunoHistoChemistry (IHC) 
staining of Lung and Liver sections from a representative embryo. Cleaved 
Caspase 3 (CC3) is used to detect apoptotic cells and Ki67 to detect 
proliferating cells.!!!!!
4.4 Complete PRMT5 loss impairs hematopoiesis!
!
Since the deletion of PRMT5 in utero significantly affected the fetal liver, the 
site of embryonic hematopoiesis, reducing proliferation and increasing 
apoptosis, we decided to expand these findings inspecting E14.5 livers and 
testing the ability of treated and untreated HPCs to form hematopoietic 
colonies in vitro. As expected, upon TAM injection we observed striking 
reduction in fetal liver cellularity (Fig. 4.6A). Accordingly, these cells were 
severely impacted in their ability to form hematopoietic colonies in vitro (Fig. 
4.6B left panel). To determine whether this phenotype was cell autonomous, 
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we isolated E14.5 fetal liver HSCs from Prmt5F/FER embryos, grew them in 
EtOH or OHT containing HPC medium for 24 hours and plated them for 
colony formation assay. Remarkably, we observed dramatic reduction in the 
colony formation ability of the hematopoietic cells treated with OHT proving 
that PRMT5 plays a vital role for HPCs homeostasis during mouse 
development (Fig. 4.6B left panel).!
!!
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Figure 4.6: PRMT5 depletion impairs hematopoiesis. (A) Total number of 
live cells collected from E14.5 Prmt5+/+ER and Prmt5F/FER fetal livers 
following TAM injection at E10.5. Each bar represents an average of at least 3 
experiments. (B) Colony formation assay. Left panel: Liver cells as in (A) were 
cultured in M3434 Methocult for 11 to 14 days. Colonies were counted and 
classified based on they morphology. Right Panel: Liver cells from E14.5 
Prmt5F/FER fetal livers were culture in HSC specific medium  containing either 
EtOH or OHT 50nM for 24 hours. Cells were then cultured in M3434 
Methocult for 11 to 14 days. Colonies were counted and classified based on 
they morphology. Data are as representative duplicates. !!!!!
4.5 PRMT5 deficiency in the CNS results in early postnatal 
lethality!
!
In order to gain further insights into the physiological and molecular basis of 
PRMT5 function in safeguarding proliferating cells homeostasis we next 
chose to focus our efforts on brain development for the following reasons: !
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- PRMT5 has been shown to methylate histones and core components of the 
spliceosomal machinery and a variety of developmental diseases of the 
CNS have been linked to either epigenetic or splicing defects (Castello et 
al., 2013; Gao and Taylor, 2012; Jakovcevski and Akbarian, 2012);!
- PRMT5 is expressed in mouse brain and there is no direct evidence linking 
PRMT5 to either brain development or brain tumor development; !
- In cancer cells PRMT5 is involved in the regulation of pathways critical for 
cell cycle regulation and apoptosis. Among these p53 pathway, has been 
extensively studied using mouse models in mouse CNS development (De 
Clercq et al., 2010; Doumont et al., 2005; Francoz et al., 2006; Migliorini et 
al., 2002; Xiong et al., 2006); !
- In the developing brain, proliferating and differentiated cells are organized in 
a  well characterized temporally and spatially ordered manner, allowing us to 
dissect the role of PRMT5 in both proliferation and differentiation;!
- The proliferating cell population of the developing brain (Neural Stem/
Progenitor Cells) can be isolated and cultured in tissue cultured condition, 
expanded to high number of cells amenable for a variety of molecular 
biology experiments.!
!
To specifically delete PRMT5 in the CNS we used a Nestin-Cre (Nes) 
transgenic mouse strain, which expresses Cre recombinase under a neural-
specific enhancer of the Nestin promoter, leading to an efficient 
recombination event in precursors of neurons and glia, starting at embryonic 
day E10.5 (E10.5) (Graus-Porta et al., 2001). All the Prmt5F/FNes mice were 
obtained from Prmt5F/F x Prmt5+/FNes crosses and, as expected, the Prmt5+/
FNes mice were viable, fertile, and we could not observe any evident defects. 
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CNS-specific deletion of PRMT5 was confirmed by genomic PCR (Fig. 4.7A) 
and by western blotting (Fig. 4.7B).!
Prmt5F/FNes transgenic mice were born at the expected Mendelian frequency, 
but displayed smaller size (Fig. 4.8A), balance disorders, tremors and 
akinesis. Prmt5F/FNes mice died within 14 days after birth, likely because of 
feeding problems as no milk was observed in their stomach. CNS 
development was impaired as evident from differences in brain size and 
weight, which was detectable starting at E17.5 (Fig. 4.8B and C). !
At postnatal day 10 (P10), the external granular layer (EGL) of the 
cerebellum, an actively proliferating area at this age, was missing in mutant 
mice, as evident from both sagittal and coronal sections. The lateral ventricles 
were morphologically enlarged and disrupted, and the thickness of the cortex 
was reduced in size (Fig. 4.9).!
To better examine the onset of this dramatic phenotype we next focused on 
two earlier developmental stages. We analyzed the cellularity of the cortex of 
E15.5 and P0 brains. While we could not appreciate any significant 
differences in E15.5 brains, the cortex of P0 Prmt5F/FNes brains had a lower 
cellularity count both in the Cortical Plate (CP) and in the Ventricular/Sub 
Ventricular Zone (VZ/SVZ), the area populated by Neural Stem/Progenitor 
cells (NPCs) (Fig. 4.10). !
To confirm the effect of PRMT5 deletion in NPCs, we performed staining of 
E15.5 and P0 cortexes with antibodies recognizing the Neural Stem Cell 
specific transcription factor SOX2 and the marker of proliferation Ki67. 
Consistent with data regarding the cellularity of the cortex, we did not 
observed an obvious reduction of SOX2/Ki67 staining in E15.5 Prmt5F/FNes 
brains (Fig. 4.11A left panel), whereas P0 mutant brains showed lower 
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number of SOX2/Ki67 positive proliferating NPCs compared to controls 
(PRMT5F/F) (Fig. 4.11A right panel). !
Since the reduction detected in the P0 NPC population did not seem to 
originate from cell cycle exit of NPC at earlier stages, we decided to focus on 
the apoptotic response. To test the occurrence of cell death, we stained brain 
sections for Cleaved Caspase 3 (CC3). Despite the fact that changes in brain 
size and in thickness of the VZ/SVZ layer are not evident at E15.5, we did 
detect apoptotic death, specifically in the VZ/SVZ zone and in the ganglionic 
eminence, both areas containing proliferating NPCs (Fig. 4.11B). !
The data suggested that the apoptosis induced in NPCs by the absence of 
PRMT5 could be the cause for the reduce brain size of Prmt5F/FNes animals, 
however we could not exclude the induction of premature differentiation, thus 
a combination of cell death and loss of multipotency. To test this hypothesis 
we extracted proteins from Prmt5F/F and Prmt5F/FNes P0 and P10 brains and 
tested the expression of NPCs markers (SOX2), intermediate progenitor 
markers (TBR2), as well as neuronal and glia marker (TBR1/TuJ and GFAP 
respectively). We did observe a significant decrease of SOX2 and TBR2 
levels upon PRMT5 deletion, while the levels of differentiated neurons and 
glia markers were similar in both control and mutant brains (Fig. 4.12) 
suggesting a role for PRMT5 as inhibitor of apoptosis rather than regulator of 




Figure 4.7: PRMT5 depletion in the brain. (A) PCR showing the efficiency 
of CRE recombination taking place specifically in the Brain. Intestine is used 
as a negative control. (B) PRMT5 protein levels in the CNS of Prmt5F/F and 
Prmt5F/FNes 10 days old mice. Protein extracts from muscles were used as 
controls.!!!
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Figure 4.8: PRMT5 deficiency in the CNS results in early postnatal 
lethality. Nestin-Cre-induced deletion of the PRMT5 gene in the CNS: (A) 
Post natal day 10 (P10) Prmt5F/F (on the left) and Prmt5F/F Nes mice (on the 
right). (B) Brain size of P10 Prmt5F/F and Prmt5F/F Nes mice are shown as an 
example. (C) Weight in mg of wild type (Prmt5F/F) and Prmt5 deleted (Prmt5F/F 
Nes) brains at three different time points (E17.5, P0 and P10).!
 89
  !
Figure 4.9: PRMT5 deficiency in the CNS results in widespread brain 
defects. Hematoxylin and Eosin (H&E)-stained Sagittal and Coronal sections 
of P10 Cerebrum (Cr), and the Cerebellum (Cb) from Prmt5F/F (right) and 
Prmt5F/F Nes (left).!!!
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Figure 4.10: PRMT5 deficiency in the CNS results in reduced cellularity 
in neonatal brain. H&E coronal sections of Prmt5F/F and Prmt5F/FNes E15.5 
and P0 brains. Cellularity of CP/SP and VZ/SVZ zones are indicated in wt 
(black) and mutant (red) brains. MZ=Marginal Zone, CP=Cortical Plate, 
SP=Subplate, IZ=Intermediate Zone, SVZ=Sub Ventricular Zone, 




Figure 4.11: PRMT5 deficiency in the CNS results in depletion of the 
NPC population. (A) SOX2 and Ki67 IHC staining in coronal sections of 
E15.5 and P0 brains. (B) Cleaved Caspase 3 (CC3) staining is shown in both 
the cortex and the Gangliomic Eminence. MZ=Marginal Zone, CP=Cortical 
Plate, SP=Subplate, IZ=Intermediate Zone, SVZ=Sub Ventricular Zone, 
VZ=Ventricular Zone.!!!!
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Figure 4.12: PRMT5 deficiency in the CNS does not alter the levels of 
neuronal and astrocyte markers. Protein levels (Antibodies used are 
indicated on the left of each panel) in the CNS (whole brain) of P0 and P10 
Prmt5F/F and Prmt5F/FNes mice.!
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4.6 PRMT5 is required for Neural Stem/Progenitor Cell 
homeostasis!
!
To further define whether PRMT5 is required for normal cell cycle regulation 
and survival and to protect cells from apoptosis, we derived NPCs from the 
dorsal telencephalon of E14.5 mice. NPCs can be efficiently grown in vitro as 
neurospheres and their self-renewal capacity can be assessed by sequential 
passaging. The number of primary spheres was significantly reduced in 
Prmt5F/FNes as opposed to controls. Furthermore, the number of cells in 
Prmt5F/FNes spheres was markedly reduced (Fig. 4.13A) and, importantly, 
their self renewal potential was impaired as highlighted by the fact that, 
following replating, virtually no secondary spheres could be derived (Fig. 
4.13B). To confirm the results obtained in vivo, we first counted the 
percentage of pyknotic nuclei, typical feature of cells undergoing either 
necrosis or apoptosis, and next stained Prmt5F/FNes derived NPCs for 
Cleaved Caspase 3, to verify that they were undergoing apoptosis. As 
expected, we detected a dramatic increase of pyknotic nuclei in Prmt5F/FNes 
derived NPCs and the majority of the the cells forming the small primary 
mutant spheres were positive for CC3, confirming the requirement for PRMT5 
to suppress cell death (Fig. 4.13C).!
To test whether PRMT5 catalytic activity was necessary for the observed 
phenotype we infected primary NPCs derived from Prmt5F/FNes mice with 
wild-type human PRMT5 (hPRMT5), or a catalytically inactive mutant 
(hPRMT5AAA) and passaged them to derive secondary spheres. PRMT5 
levels of expression were confirmed by western blot (Fig. 4.14A) and notably. 
only cells infected with hPRMT5 were able to grow and could be propagated 
into secondary spheres. When expanded into tertiary spheres cells 
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expressing hPRMT5 grew as efficiently as NPCs derived from Prmt5F/F 
control litters (Fig. 4.14B).!
!
  !
Figure 4.13: PRMT5 is required for Neural Stem/Progenitor Cell 
homeostasis. (A) Number of Primary Neurosphere and total number of cells 
from cultures of E14.5 dorsal telencephalon NPCs derived from Prmt5F/F and 
Prmt5F/F Nes embryos. Each bar represents an average of at least 3 
experiments. (B) Number of secondary Neurosphere as in A. (C) 
Neurospheres derived from Prmt5F/F or Prmt5F/F Nes NPCs were stained with 
DAPI and CC3 and the percentage of pyknotic nuclei was counted.!!!
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Figure 4.14: PRMT5 catalytic activity is essential to rescue the growth 
defect phenotype in NPCs. (A) Primary Neurospheres from Prmt5F/F Nes 
mice were infected with Empty Vector (EV), wild-type PRMT5 (hPRMT5), or a 
catalytically inactive PRMT5 mutant (hPRMT5AAA) and PRMT5 protein 
levels were measured by western blot. (B) Number of secondary 
neurospheres formed by cells infected as in A (left panel) and number of 
tertiary neurospheres formed by Prmt5F/F Nes NPCs infected with human 
PRMT5 passaged to derive Tertiary Neurospheres compared with tertiary 
neurospheres formed by Prmt5F/F NPCs. Each bar represents an average of 
at least 3 experiments.!!!!!
4.7 Depletion of PRMT5 in Neural Stem/Progenitor Cell activates 
the p53 response !
!
To understand the molecular mechanism underpinning the observed 
apoptotic phenotype we next performed a gene expression analysis of 
Prmt5F/FNes NPCs using the Illumina microarray platform. Primary spheres 
were cultured for four days post-isolation and cRNA libraries from total RNA 
were prepared following the manufacturer instructions. Approximately 2500 
genes were differentially expressed when compared to control. Functional 
annotation of differentially expressed genes showed downregulation of genes 
involved in cell cycle progression and replication, consistent with the 
observed phenotype. On the other hand, among others, the p53 signaling 
pathway was one of the most significantly upregulated (Fig. 4.15A) 
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(Appendix B) (Bezzi et al., 2013). !
p53 is a transcription factor that drives the expression of several downstream 
targets involved in cell cycle arrest and apoptosis, in response to a variety of 
stimuli, including activation of the DNA damage response (DDR) (Lane, 
1992). Much is known about the regulation of p53 by post-translational 
modifications and many of them, including phosphorylation and acetylation, 
are known to regulate its protein stability, leading to transcriptional activation. 
As mentioned in the introduction, also PRMT5 has been shown to modulate 
p53 transcriptional activity skewing the p53 response towards activation of 
apoptotic genes (Jansson et al., 2008). However, quantitative real time PCR 
validation of the activated of p53 target genes revealed that besides 
upregulation of known apoptotic genes such as Puma, Noxa, TRP53inp1 and 
Perp, the cell cycle regulator genes p21 and Ccng1 were equally upregulated 
(Fig. 4.15B). Moreover, the La Thangue group demonstrated that the 
PRMT5-p53 connection was restricted to the DNA damage induced response 
(Jansson et al., 2008), suggesting that the phenotype we observed might be 
a consequence of the hypothetical dual function of PRMT5 in ensuring 
genome stability and in directly modulating p53 itself. Therefore, we switched 
to the Prmt5 F/FER system for three main reasons: firstly it allowed us to look 
at cell-autonomous defects, secondly we could derive a much larger number 
of cells amenable for further mechanistic studies, and thirdly it allowed us to 
focus on early time points after PRMT5 depletion, in order to detect causal 
defects. In all experiments described hereafter, in which Prmt5F/FER derived 
cells were analyzed, we have always used the ROSA26:CreERt2 (ER) 
counterparts as negative controls, making sure that the addition of OHT or 
Tamoxifen was not toxic.!
We first checked whether upon PRMT5 deletion, Prmt5F/FER NPCs 
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responded similarly to the Prmt5F/FNes NPCs. This was indeed the case, as 
primary spheres formed after 24 hours treatment with OHT were not reduce in 
number, but they were smaller and contained a significantly lower number of 
cells. Accordingly, their capacity to form secondary spheres was dramatically 
impaired (Fig. 4.16A).!
Secondly, we wanted to check whether we could detect DDR activation and 
whether p53 would be stabilized. We did observe a modest p53 protein 
stabilization and p53 phosphorylation (P-p53) and basal levels of H2AX 
phosphorylation (γH2AX). As a positive control we used a DNA damaging 
agent (Etoposide), which as expected, greatly stabilized p53 and increased 
the levels of γH2AX. Notably, despite a minor activation of the DDR response, 
the absence of PRMT5 caused an even greater induction of the p53 target 
gene p21, if compared to Etoposide (Fig. 4.16B). This is in contrast to what 
has previously been observed using siRNA/shRNA strategies to reduce the 
levels of PRMT5 in human cancer lines (Allende-Vega et al., 2013; 
Scoumanne et al., 2009). Moreover, it is in contrast with the observation of 
the La Thangue group (Jansson et al., 2008), suggesting that we might have 




Figure 4.15: Microarray analysis of Prmt5F/FNes NPCs. (A) Functional 
annotation of differentially expressed genes. Clusters based on significantly 
up and down regulated genes in Prmt5F/FNes NPCs compared to Prmt5F/F are 
indicated as black and red bars respectively. Upregulation of the p53-
signaling and down regulation of cell cycle and DNA replication genes are 
indicated by arrows. (B) Quantitative Real Time PCR validation of the 
activation of some gene involved in the p53 response activated in Prmt5F/F 
Nes NPCs (grey) normalized on the Ct values obtained from Prmt5F/F NPCs 
and on the housekeeper gene TBP. Each bar represents an average of at 
least 3 experiments. The bioinformatic analysis was performed in 




Figure 4.16: Activation of the p53 response in Prmt5F/FER NPCs treated 
with OHT. (A) Number of Primary and Secondary Neurosphere and total 
number of cells from cultures of E14.5 dorsal telencephalon NPCs derived 
from Prmt5F/FER embryos. The cells were treated with either OHT or EtOH for 
24 hours and then plated for sphere formation assay. Each bar represents an 
average of at least 3 experiments. Representative images of the spheres are 
shown. (B) Protein levels upon treatment with OHT and subsequent PRMT5 
depletion for 4 days. Antibodies used are indicated on the right of each panel. 
As a positive control p53 and the DDR response were induced by treating 
cells with Etoposide 10 μM for 2h.!!
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4.8 p53 deletion partially rescues Prmt5F/FNes developmental 
defects!
!
The data indicated that PRMT5 deficiency triggered a p53 response and that 
the phenotypic outcome in NPCs led to cell death. To formally prove this 
conclusion we crossed Prmt5F/FNes mice into a p53 null background. Prmt5 F/
FNes;p53-/- mice displayed improved balance, increase in size (Fig. 4.17A) 
and milder tremors and akinesis when compared to Prmt5F/FNes mice. 
Accordingly, Prmt5 F/FNes;p53-/- mice survived on average one week longer 
than Prmt5 F/FNes;p53wt, while mice heterozygous for p53 (Prmt5 F/
FNes;p53+/-) displayed an intermediate phenotype (Fig. 4.17B).!
Analysis of P10 brains showed a partial rescue of the developmental defects. 
EGL morphogenesis in the cerebellum improved dramatically, the same was 
true for the thickness of the cortex and the overall size of the brain was 
increased compared to Prmt5F/FNes brains (Fig. 4.18A).!
When stained for activated Caspase 3, E15.5 Prmt5F/FNes;p53-/- embryos 
showed a complete rescue of the apoptotic response, with levels of staining 
similar to wild type (Fig. 4.18B compare to FIg. 4.11B). Importantly the 
number of SOX2 positive cells in the VZ/SVZ zone of Prmt5F/FNes;p53-/- 
embryos was increased when compared to Prmt5F/FNes;p53wt brains (Fig. 
4.18C compare to Fig. 4.11A). However, we did not observe a significant 
rescue of proliferating Ki67 positive cells, suggesting a p53-independent 
impairment in cell cycle progression, which most likely accounts for the 
lethality of the animals 20-22 days after birth (Fig. 4.18C).!
This results demonstrate that p53 plays an important role in regulating the 
apoptotic response in Prmt5F/FNes brains. The fact that we still observed 
death of the animals, although significantly delayed, however pointed at 
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additional proliferative defects in targeted cells. To gain further insight we first 
checked by RT-qPCR the level of transcriptional upregulation of p53 targets in 
both Prmt5 F/FNes and Prmt5 F/FER NPCs in a p53-/- background. !
When we derived NPCs from Prmt5F/FNes mice with different p53 
backgrounds and cultured them as neurospheres, p53 deficiency led to a 
significant, but not complete rescue in the number of proliferating cells, 
consistent with the evidence collected in vivo (Fig. 4.19A). Activation of cell 
cycle inhibitor p21, pro-apoptotic Noxa, Puma (Akhtar et al., 2006) and 
several other target genes was completely muted in the absence of p53, 
excluding compensation by other transcription factors, such as p53 family 
members p63 and p73 (Levrero et al., 2000) (Fig. 4.19B). Moreover, flow 
cytometry analysis in Prmt5 F/FER NPCs further confirmed that PRMT5 
depletion in the absence of p53 led to a striking reduction in the number of 
apoptotic cells (Fig. 4.19C) and that the activation of p53 target genes was 
completely p53-dependent (Fig. 4.19C). !
Propidium iodide (PI) staining followed by flow cytometry analysis revealed 
the almost complete rescue of the apoptotic response upon p53 deletion (Fig. 
4.20A). In order to gain a better picture of the cell cycle profile, we next 
treated the different NPCs population with 5-Bromodeoxyuridine (BrdU), 
which is incorporated only by the replicating cells. Flow cytometry analysis 
carried out following PI/anti-BrdU staining showed significant reduction of the 
number of BrdU positive cells, suggesting defects in the DNA replication 
process and explaining the modality of their exit from the cell cycle (Fig. 
4.20B). These data confirm that, despite inactivation of the p53 response, a 
second mechanism prevents these cells from proliferating. To mechanistically 
understand what causes the observed phenotype and to clarify whether 
PRMT5 acts on the p53 signaling or on the cell cycle regulation through 
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Figure 4.17: p53 deletion increases the survival of Prmt5F/FNes mice. (A) 
Weight in mg of 14 days old Prmt5F/F Nes mice in p53 wt: n = 8, het (+/-): n = 
8 or null (-/-): n= 8 background. (B) Kaplan-Meier survival analysis of Prmt5F/
FNes mice in p53 wt: n = 14, het (+/-): n = 24 or null (-/-): n= 14 background.!!!
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Figure 4.18: p53 deletion partially rescues Prmt5F/FNes developmental 
defects. (A) Hematoxylin and Eosin (H&E)-stained coronal brain sections of 
Prmt5F/FNes mice with different p53 backgrounds. The cerebellum is shown at 
higher magnification in the inset. (B) Coronal sections of E15.5 brains stained 
for Cleaved Caspase 3 (CC3) and (C) and P0 brains stained for SOX2 and 
Ki67 to identify stem cells and assess their proliferation status. Antibodies 
used are indicated for each panel.!
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Figure 4.19: p53 deletion fully rescues the activation of p53 target 
genes. (A) Total number of NPC cells grown as Primary Neurospheres 
derived from Prmt5F/FNes;p53wt, Prmt5F/FNes;p53+/- and Prmt5F/FNes;p53-/- as 
indicated. (B) Expression of p53 upregulated target genes in NPCs from 
different genotypes as indicated. The activation of the genes is expressed as 
the average fold change of 3 embryos/NPCs, normalized against Prmt5F/
FNes;p53wt and HK. (C) Prmt5F/FER NPCs treated with OHT to delete PRMT5 
were stained with propidium iodide and subjected to flow cytometry analysis. 
Bars indicate the increase in sub-G1/apoptotic cell populations, normalized to 
EtOH treated cells. P53 genotypes are indicated. (D) Expression of p53 
upregulated target gens in NPCs (EtOH/OHT) from Prmt5F/FER;p53wt (black/
red), Prmt5F/FER;p53+/- (white/orange). Prmt5F/FER;p53-/- (grey/yellow). The 
activation of the genes is expressed as the average fold change of at least 3 
embryos/NPCs, normalized against Prmt5F/F;p53wt and HK. Each bar 





Figure 4.20: PRMT5 deletion induces cell cycle exit in p53 null NPCs. (A) 
Flow cytometry analysis on Prmt5F/FER (EtOH/OHT) in the indicated p53 
genetic backgrounds. (B) Cells were stained with BrdU and the percentage of 
cells that are actively replicating (BrdU+) or not (in the G1 or G2/M phase of 
the cell cycle) is indicated by the bar plot. Each bar is the average of three 
independent experiments.!!!!!
4.9 PRMT5 deletion in the brain reduces the levels of H2AR3me2s!
!
PRMT5 has been shown to function in both the nucleus and the cytoplasm, 
methylating histones and non-histone proteins. We performed nuclear/
cytoplasmic fractionation in NPCs, and observed high levels of PRMT5 in the 
cytoplasm and lower amounts in the nucleus (Fig. 4.21A). To confirm this 
localization pattern in vivo, we stained for PRMT5 in E15.5 brains. In the 
NPCs of the ventricular and subventricular zone PRMT5 was strongly present 
in the cytoplasm and localized also in the nucleus, whereas in the post mitotic 
neurons populating the intermediate zone, the cortical plate and the subplate 
it mainly localized in the nucleus (Fig. 4.21B), suggesting a possible function 
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for PRMT5-mediated histone modifications in brain development. !
To assess PRMT5 role as histone methyltransferase in the mouse brain we 
decided to check the levels of the histone modifications H3R2me2s, 
H3R8me2s, H4R3me2s and H2AR3me2s. In order to perform this experiment 
we sought to raise specific H3R8me2s and H2AR3me2s antibodies, as we 
did for H3R2me2s (Migliori et al., 2012). In collaboration with the IMCB 
antibody facility, 5 mice were immunized with KLH-coupled peptides 
mimicking H2AR3me2s, as well as 5 rabbits were immunized with KLH-
coupled peptides mimicking H3R8me2s. The bleeds obtained were tested by 
peptide blots and the most promising sera were affinity purified and further 
tested performing peptide blots, competition assays and western blots on 
cellular nuclear extracts. Peptide blots for the two best antibodies against 
H2AR3me2s and H3R8me2s are displayed in Fig. 4.22A. Surprisingly, when 
we checked the levels of these PRMT5-mediated histone methylation events 
in vivo, the only modification significantly reduced in the PRMT5 depleted 
mouse brain was H2AR3me2s (Fig. 4.22B). Notably, albeit the anti-
H2AR3me2s antibody was cross-reacting with the  H4R3me2s peptide (Fig. 
4.22A), it did not recognize histone H4 in total or nuclear cellular extract. 
Therefore, we decided to study the role of H2AR3me2s in chromatin 
regulation as we did for H3R2me2s (Migliori et al., 2012), by performing 
ChIP-sequencing in NPCs and peptide pull down assays from total NPCs 
lysate labelled with stable isotopes (SILAC) couple to mass spectrometry. 
Unfortunately, the ChIP-sequencing analysis (performed by J. Müller, a post 
doc in the lab) did not show any particular enrichment of H2AR3me2s in the 
promoter, intragenic or enhancer regions, and there was no correlation with 
the transcriptional changes observed in the Prmt5 F/FNes NPCs. Moreover, 
the peptide pull down assays coupled to mass spectrometry (the analysis was 
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performed by the IMCB Quantitative Proteomics Facility) did not detect any 
specific H2AR3me2s binding partner. Since H2AR3me2s has been shown to 
be catalyzed in the cytoplasm (Tee et al., 2010), thus methylation precedes 
deposition into chromatin, we decided to investigate whether this post 
translational modification plays any role in chromatin assembly. Micrococcal 
nuclease assay in wt or depleted PRMT5 NPCs was performed and it did not 
show any significant difference in the digestion patterns suggesting that the 
absence of PRMT5, and as a consequence of H2AR3me2s, does not impact 
chromatin assembly (Fig. 4.22C). Our data were therefore inconclusive and 
we decided to look at other possible methylated targets that could be linked to 
the observed phenotype.!
  !
Figure 4.21: PRMT5 cellular localization in NPCs. (A) Nuclear/cytoplasmic 
fractionation of NPCs. PRMT5 protein levels are shown. SOX2 has been 
used as a control for the Nuclear fraction (N), while Nestin has been used as 
a control for the Cytosolic fraction (C). (B) PRMT5 IHC staining in coronal 
sections of Prmt5F/F and Prmt5F/FNes E15.5 brains. MZ=Marginal Zone, 




Figure 4.22: PRMT5 depletion in NPCs has minor effects on chromatin 
dynamics. (A) Characterization of the H2AR3me2s and the H3R8me2s 
antibodies by peptide dot blot analysis. Synthetic peptides mimicking 
previously identified histone arginine methylated sites (indicated on the left) 
were spotted on PVDF membrane and incubated with the indicated antibody. 
(B) Histone modification levels (antibodies used are indicated on the left of 
each panel) in the brain and in the muscle (used as a control) of P10 Prmt5F/F 
and Prmt5F/FNes mice. (C) Micrococcal Nuclease (MNase) assay. Nuclei from 
Prmt5F/FER NPCs either untreated or treated with OHT to delete PRMT5, 
where incubated with MNase (20U/0.1mg of DNA) for the time indicated. 
MNase digests the DNA within nucleosome linker regions and the bands are 
approximately the size of the DNA wrapped around one (lower band) or more 
(upper bands) nucleosomes.!!!!
4.10 PRMT5 depletion in NPCs affects snRNP assembly!
!
Looking for defects that could mechanistically underpin both the activation of 
the p53 pathway and the additional proliferation defects we sought to 
examine the putative role of PRMT5 in mammalian pre-mRNA splicing. In 
plants, Drosophila and HeLa cells, PRMT5 was known to symmetrically 
dimethylate Sm proteins (Deng et al., 2010; Gonsalvez et al., 2006; 2007; 
Sanchez et al., 2010). We first tested whether this was also relevant during 
mammalian development. We treated Prmt5F/FER NPCs with either EtOH or 
OHT and observed that despite constant levels of SmD1 and D3 proteins, 
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there was a reduction in the levels of symmetric arginine dimethylation by day 
4, as detectable by two well characterized independent antibodies (SYM10 
and Y12), which detect the symmetrically arginine dimethylated Sm proteins 
B/B’, D1 and D3 (Fig. 4.23A). !
Consistent with the fact that the SMN1 Tudor Domain binds arginine-
methylated SmB/B’, D1 and D3, 4 days after the OHT treatment (Prmt5 
deletion) we observed a reduced binding of SMN1 to SmD1 and SmD3 (Fig. 
4.23B), suggesting that PRMT5-depleted NPCs would have suboptimal 
snRNP maturation. To test this hypothesis we replicated in Prmt5 F/FER NPCs 
the TMG pulldown experiment, following pulse-chaise protein radioactive 
labeling, performed by the Matera group in HeLa cells treated with PRMT5 
siRNA (Gonsalvez et al., 2007). Our data confirmed that in mammalian cells 
the absence of PRMT5 reduces the kinetic of snRNP assembly as evident 
from the marked reduction of the bands in the OHT treated NPCs (Fig. 
4.23C). !
Notably, in both a SMA mouse model, in which SMN levels are dramatically 
reduced (Zhang et al., 2008), and in SmB/B’ knock down studies (Saltzman et 
al., 2011) the levels of the snRNAs were significantly altered compared to the 
respective controls. Thus, we quantified the amount of the snRNAs in NPCs 
after 2 and 4 days of PRMT5 depletion and we did not observed significant 
changes (Fig. 4.23D). This result confirmed that the reduced amount of 
assembled snRNPs were not a cause of lower levels of snRNAs, but rather 
impairment of the snRNP assembly and maturation process. Moreover, this 
relatively early time point, 4 days, was suitable to investigate direct defects 
induced by PRMT5 deletion in the splicing pattern ruling out indirect effects 
caused by altered levels of the snRNAs. Therefore, we selected cells at 4 
days post OHT treatment, for further experiments.!
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Figure 4.23: PRMT5 depletion in NPCs affects snRNP assembly. (A) 
PRMT5, SmD1, SmD3 and SMN1 levels were assessed in Prmt5F/FER NPC 
cells depleted of PRMT5 after 2, 3 and 4 days post OHT treatment. Levels of 
Symmetric Arginine Dimethylation was assessed by staining SmB/B’, SmD1 
and SmD3 with SYM10 and Y12 antibodies. (B) Co-ImmunoPrecipitation 
between SMN and SmD3 and SmD1, as indicated, in the presence (E: 
Ethanol) or absence of PRMT5 (O: OHT). (C) Prmt5F/FER NPCs were treated 
for 24 h with either Ethanol (E) or OHT (O) and cultured for 4 days before 35S 
pulse-chase assay. The cells were harvested and the snRNPs from total 
lysate were immunoprecipitated using anti-TMG antibody–coated beads or 
control IgG. (D) Expression of snRNAs in NPCs Prmt5F/FER, 2 (black) and 4 
days (grey) post OHT treatment. The amount of the genes is expressed as 
the average fold change of at least 3 embryos/NPCs, normalized against 
Prmt5F/FER EtOH treated NPCs and 5.8s rRNA. Each bar represents an 
average of at least 3 experiments.!!!!!
4.11 PRMT5 loss leads to malfunction of the constitutive splicing 
machinery and to Alternative Splicing events!
!
In order to mechanistically understand what could link the snRNP assembly 
defects to apoptosis, we generated libraries for Pair End RNA-sequencing 
from samples treated with either EtOH or OHT. We identified 2416 genes 
being differentially expressed between the two conditions (Appendix C) 
(Bezzi et al., 2013). Consistently, the functional annotation of the up- and 
downregulated genes were similar to the one from Prmt5F/FNes cells and 
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showed the activation of the p53 pathway as the top upregulated category 
(Fig. 4.24). Notably, samples submitted for RNA-sequencing, were collected 
at an earlier time point, compared to  the Prmt5F/FNes NPCs, in which PRMT5 
deletion occurred in utero at approximately E10.5. In latter dataset, we 
observed upregulation of important developmental pathways, such as the 
MAPK signaling pathway, and genes involved in NPC differentiation (i.e. axon 
guidance), which were not detected by RNA-seq, suggesting either a late 
activation of these pathways, an indirect activation caused by the onset of 
phenotype or a non cell autonomous effect.!
In contrast to what reported in plants and drosophila, where PRMT5 regulates 
splice site selection without greatly affecting constitutive pre-mRNA splicing 
(Sanchez et al., 2010), we observed that the compiled number of reads in 
introns was elevated in the absence of PRMT5, with 1682 introns being 
significantly affected (Fig. 4.25A). We then proceeded to characterize in more 
detail the splicing defects, using Multivariate Analysis of Transcript Splicing 
(MATS)  (Shen et al., 2012) (Appendix A) (Bezzi et al., 2013). Prmt5F/FER 
mice are not on pure C57BL/6 genetic background, hence we sequenced 
three independent NPC populations, and first checked the variability in 
splicing among embryos. In the absence of PRMT5 we observed an overlap 
of 320 genes affected by Alternative Splicing in 2/3 embryos (Fig. 4.25B). 
PRMT5 depletion triggered a majority of Retained Introns (RI) and Skipped 
Exons (SE) events in all 3 embryos (Fig. 4.25C), and we could validate 18/20 
SE events (Fig. 4.26) and 21/21 RI events (Fig. 4.27), confirming that despite 
the observed embryo to embryo variability, we identified a robust set of 
conserved alternatively spliced events. Importantly, all the alternative splicing 
events validated by real time PCR occurred also in Prmt5F/FER;p53-/- NPCs 
post OHT treatment, which do not undergo apoptosis, ruling out the possibility 
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that these splicing defects were indirectly induced by the cell death.!
Both the RI (Fig. 4.28A left panel) and SE (Fig. 4.28A right panel) events 
detected in the absence of PRMT5 are characterized by a weak 5’-donor site, 
as quantified by their low CV score (Shapiro score) (Shapiro and Senapathy, 
1987), their low MaxEntScan (Yeo and Burge, 2004) (Fig. 4.28B) and H-Bond 
(Freund et al., 2003) (Fig. 4.28C) scores, and an overall randomization of the 
key bases at position -1, -2, +4 and +5.!
What distinguishes SE from RI events is the length of the affected intron, 
which is significantly shorter in the case of RI events (Fig. 4.28D). Hence, 
absence of PRMT5 leads to selective retention of introns and skipping of 
exons with weak donor sites. !
These Alternatively Spliced genes are not random, but belonged to specific 
biological pathways. Importantly, network analysis revealed that these genes 
are involved in post-transcriptional RNA processing, membrane organization 
and negative regulation of cell cycle processes (Fig. 4.29A). The latter 
included transduction of the p53 signaling pathway, suggesting that early 
problems with the core splicing machinery can be sensed by key alternatively 




Figure 4.24: RNA-sequencing analysis of differentially expressed genes 
in Prmt5F/FER  NPCs. Functional annotation of differentially expressed genes 
from Fig. 4.15A (left panel) compared to gene expression analysis and 
functional annotation (RNA-seq data) of Prmt5F/FER NPCs 4 days post 
treatment with either EtOH or OHT to delete Prmt5. The bioinformatic 
analysis was performed in collaboration with J. Müller.!!!!!!!!!
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Figure 4.25: PRMT5 loss leads to malfunction of the constitutive 
splicing machinery and to alternative splicing events. (A) Total number of 
reads in introns (red) or genes (blue) expressed as fold change of the events 
in NPCs lacking PRMT5 over control (wild- type PRMT5). A smooth density 
estimate is drawn as calculated by a Gaussian kernel. (B) Number of genes 
affected by alternative splicing events in each NPC population (derived from 
independent embryos). (C) Quantification of the Alternative Splicing defects 
observed in wt (EtOH) vs mutant (OHT) NPCs. The specific Alternative 
Splicing events, as classified by MATS, are indicated by the bar plots, for 
each embryo. In red are the number of Excluded/Skipped events upon 
PRMT5 deletion, while green indicates the included events (less abundant in 
PRMT5 wt conditions). A3S: alternative 3’ splice site; A5S: alternative 5’ splice 
site; MXE: mutually exclusive exon; RI: retained intron; SE: skipped exon. 
The bioinformatic analysis was performed in collaboration with J. Müller.!!!
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Figure 4.26: PCR validation of the Skipped Exon events. PCR validation 
and relative quantification of the Skipped Exon (SE) events taking place on 
the indicated genes (classified by MATS as SE events), upon Prmt5 deletion 
(E: Ethanol; O: OHT). Black/Red: p53 wt; Grey/Yellow: p53-/- background. 
The affected exons/introns number and genomic coordinates are indicated in 
Appendix A and Table 3.6!!
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Figure 4.27: PCR validation of the Retained Intron events.  PCR validation 
and relative quantification of the Retained Intron (RI) events taking place on 
the indicated genes (classified by MATS as RI events), upon Prmt5 deletion 
(E: Ethanol; O: OHT). Black/Red: p53 wt; Grey/Yellow: p53-/- background. 
The affected exons/introns number and genomic coordinates are indicated in 
Appendix A and Table 3.7.!!
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Figure 4.28: PRMT5 depletion impairs the correct splicing of alternative 
exons with weak 5’ donor site. (A) Left panel: Shapiro (CV) score of 59 
donor sites of the RI events in NPCs identified by MATS. A smooth density 
estimate is drawn as calculated by a Gaussian kernel. The top panels depict 
the sequence logo of the 59 donor of all RI events (left) and the 59 donor of 
the RI events detected upon PRMT5 deletion (right, indicated by the red 
arrow). The CV score of the downstream donor site is displayed for direct 
comparison. Right panel: same as in the left panel. Shapiro (CV) score of 59 
donor sites of the SE events (in red). The CV scores of the exclusion site (left, 
indicated by the blue arrow) and the downstream donor site (right, indicated 
by the green arrow) are displayed for direct comparison. (B) H-Bond score 
(indicator for the capability to form H-bonds with U1 snRNA) of RI and SE 
events in the upper and lower panel respectively. At each splice site (with a 
significant splicing event upon Prmt5 depletion) we scored for the 3Bp within 
the exon and 8Bp within the intron. The result is drawn as calculated by a 
Gaussian kernel. In (C), MaxEntScan was used for scoring, comparing the 
altered splice sites upon Prmt5 depletion to a model based on all human 
canonical splice sites (3Bp in the exon direction and 6Bp in the intron 
direction were used for scoring). (D) Boxplot of intron lengths of the intron 
included in OHT RI splicing events and  of the two introns excluded in OHT 




Fig 4.29: PRMT5 deletion induces alternative splicing events in genes 
involved in negative regulation of the cell cycle. (A) Network 
representation of the differentially spliced genes upon Prmt5 deletion in 
NPCs. The Gene Ontology terms are represented as nodes based on their 
kappa score. The edges represent the relationships between the GO terms 
and the shared genes  (B) Enlargement of the network showing the genes 
involved in negative regulation of the cycle. The bioinformatic analysis was 
performed in collaboration with J. Müller.!
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4.12 Mdm4 AS event is a sensor of PRMT5 depletion and of 
defects in the constitutive splicing machinery!
!
MDM4 (also known as MDMX) has been reported to be downregulated upon 
direct depletion of spliceosome components (Allende-Vega et al., 2013) and 
perturbation of its levels stood out as potentially recapitulating the activation 
of the p53 response that we observed in vivo. Importantly, the phenotype of 
the Mdm4-/- conditional CNS deletion is remarkably similar to what was 
observed for Prmt5F/FNes, and the most upregulated gene in the absence of 
PRMT5 is Ptprv (Appendix C), which was originally identified as deregulated 
in Mdm4-/- embryos (Doumont et al., 2005).!
We thus decided to focus our attention on the Alternative Splicing of Mdm4 
(Fig. 4.26) for the rest of the study. MDM4 is a direct regulator of p53-activity, 
it binds to p53 and inhibits its function by blocking its transactivation 
capabilities (Francoz et al., 2006; Xiong et al., 2006). Mdm4 undergoes 
alternative splicing at exon 7, in Prmt5F/FER OHT-treated cells, resulting in the 
production of a shorter MDM4 isoform that has been previously described in 
the literature as MDM4S (Lenos and Jochemsen, 2011; Rallapalli et al., 2003) 
(Fig. 4.30A upper panel). Importantly, the Mdm4 Exon 7 skipping results in a 
frame-shift which encodes for a Premature Termination Codon (PTC) within 
Mdm4 Exon 8. Mdm4 Exon 7 is located within a 1kb genomic region that is 
highly conserved in vertebrates (as assessed by PhyloP) (Fig. 4.30A lower 
panel), suggesting a common mechanism to regulate the abundance of the 
differentially spliced isoform.!
To verify that the Alternative Splicing event of Mdm4/Mdm4s was also 
occurring in vivo we derived Prmt5F/FNes NPCs with different p53 
backgrounds. Reassuringly, the exon skipping was induced in Prmt5F/FNes 
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NPCs  and the degree of alternative splicing was even greater in p53-/- cells 
(Fig. 4.30B). A possible explanation for this observation is that the cells in 
which Mdm4 AS takes place are rapidly eliminated due to p53 activation.!
The literature on the MDM4S protein isoform is quite controversial (Lenos and 
Jochemsen, 2011; Rallapalli et al., 2003), with reports suggesting its possible 
role as a potent p53 inhibitor, and others stating that the MDM4S product is 
unstable. Notably, all the data is based on forced overexpression experiments 
and negative results (failure to detect the endogenous protein product). We 
thus decided to address this issue by looking at the Mdm4s mRNA stability. 
We performed polysome profiling of cells upon PRMT5 deletion and noted 
that the full length Mdm4 product was present in the polysome fractions 
(F4-5), while the Mdm4s mRNA was associated with fractions containing 
significantly fewer polysomes (F3-4) (Fig. 4.30C). !
This result suggested two possibilities: either a low level of translation of the 
Mdm4s RNA, or the fact that this RNA would be targeted for Nonsense 
Mediated Decay (NMD), the typical fate for isoforms with a PTC (Lareau et 
al., 2007; Lewis et al., 2003). To test the latter possibility we treated cells with 
Cyclohexamide (CHX), an inhibitor of protein synthesis, known to block NMD-
mediated mRNA degradation, and later with Actinomycin D, which blocks 
RNA Pol II transcription. The data in (Fig. 4.30D), demonstrates that the 
Mdm4s isoform is less stable than the full-length product and it is targeted for 
NMD.!
Our data suggests that upon PRMT5 depletion, the Mdm4 mRNA undergoes 
Alternative Splicing, giving rise to the unstable Mdm4s product. Indeed this 
leads to the reduction of the full length MDM4 protein (Fig. 4.31A). To extend 
our findings beyond perturbation of the splicing machinery through PRMT5, 
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we treated NPCs with well-characterized splicing inhibitors (TG003 and 
Spliceostatin A) (Kaida et al., 2007; Muraki et al., 2004), and consistently 
observed Mdm4/Mdm4s alternatively splicing. As controls, neither p53-
activation by Nutlin, nor the induction of DNA damage by Etoposide 
generated similar results (Fig. 4.31B). These results are in contrast with 
previous literature  (Allende-Vega et al., 2013) and provide a direct 
mechanistic link between perturbation of the splicing machinery and 
downstream activation of p53.!
To further confirm our hypothesis we demonstrated that the p53 
transcriptional response (Fig. 4.31C), and the induction of apoptosis (Fig. 
4.31D), caused by PRMT5 deletion, could be rescued by re-introducing full 
length MDM4 into NPCs. Not surprisingly, the rescue was only partial due to 




Figure 4.30: Mdm4 alternative splicing event is a sensor of PRMT5 
deletion and Mdm4s is targeted by the NMD pathway. (A) Upper panel: 
Representative example using MATS analysis and Sashimi plots (for 
visualization) of Mdm4 gene alternatively spliced in Prmt5F/FER derived NPCs 
with wt (Red) or deleted (Yellow) Prmt5. Lower panel: Degree of sequence 
conservation across species of the indicated genomic region surrounding 
Mdm4 Exon7. (B) PCR validation and relative quantification of the alternative 
splicing event taking place on the Mdm4 mRNA upon PRMT5 deletion in 
different p53 genetic backgrounds. (C) Polysome profiling of cells upon 
PRMT5 deletion (OHT). RNA is detected by semiquantitative PCR. p21, a 
short gene, was used as a control to exclude the possibility of a length bias 
between the Mdm4 and Mdm4s distribution. (D) Semiquantitative PCR of the 
indicated transcripts upon CHX (100 mg/mL) treatment to block NMD. Cells 
were pretreated for 3 h and then for the indicated time with 5 mg/mL 
Actinomycin D to block transcription. The polysome purification was 
performed in collaboration with Leah A. Vardy.!!!
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Figure 4.31: Mdm4 pre-mRNA is a sensor of defects in the splicing 
machinery. (A) MDM4 full-length protein levels are reduced upon PRMT5 
deletion. (O) OHT. Tubulin was used as a loading control. (B) PCR detecting 
both Mdm4 and Mdm4s in wild-type (wt) and mutant NPCs upon inhibition of 
the splicing machinery, 100 mM TG003, and 30 ng/mL Spliceostatin A (SSA), 
or p53 stabilization (Nutlin and 5 mM etoposide). (D) DMSO; (M) MetOH. (C) 
Full-length Mdm4, re-expressed in PRMT5-depleted NPCs, is able to partially 
rescue the activation of the p53 response. PCR quantification of p53 target 
genes upon PRMT5 deletion in cells re-expressing full-length Mdm4 (gray 
and blue bars) or negative control, empty vector plasmid (black and red bars). 
A representative experiment of three is shown as an example. (D) NPCs 
infected with a retroviral vector stably expressing MDM4 or empty vector (EV) 
control. PRMT5 was deleted (OHT), and cells were stained with propidium 
iodide and subjected to flow cytometry analysis. Bars indicate the increase in 
sub-G1/apoptotic cell populations, normalized to EtOH-treated cells.!!!!!!
!
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4.13 PRMT5 depletion triggers Mdm4 AS and p53 activation in 
multiple tissues!
!
So far we have dissected the role of PRMT5 in the developing CNS, and 
showed that it plays a key role in ensuring the proper splicing of Mdm4, in 
proliferating NPCs. The phenotype observed in other organs, such as lung 
and liver (Fig.4.5), upon PRMT5 deletion during organogenesis, was 
remarkably similar to what we observed in the brain, in terms of apoptosis 
and cell cycle arrest. Thus, we next asked what would be the effect of 
deleting PRMT5 on the p53 pathway and on Mdm4 splicing in different organs 
in the mouse embryo. !
Comparing different organs from E15.5 Prmt5F/FER embryos, following either 
EtOH or Tamoxifen injection at E10.5, we did observe a switch in the ratio of 
the full length over the Mdm4s isoform in most samples (Fig. 4.32 bottom 
panel). Importantly, the degree of Mdm4 Alternative Splicing, upon PRMT5 
deletion, correlates with upregulation of p53 targets (Fig. 4.32 top panel). !
Consistent with the phenotype described in Fig.4.5, the effect was more 
pronounced in actively proliferative organs such as lung and liver. Notably, in 
the brain the Mdm4 isoform switch was not so obvious. These data suggested 
that the splicing defects were specifically occurring in replicating cells. 
Therefore, we hypothesized that when analyzed using RNA from total tissue 
the Mdm4 isoform switch was clear in organs with abundant pool of 
proliferating cells, and instead masked by the RNA of non proliferating cells in 
tissues where the pool of growing cells was smaller (e.g. in brain). Moreover, 
elimination of the cells in which the Mdm4 isoform switch occurred, through 
p53 activation, and the constant degradation of the Mdm4s isoform (NMD) 





Figure 4.32: PRMT5 depletion triggers Mdm4 AS and p53 activation in 
multiple tissues. Quantitative PCR (qPCR) quantification of p53 targets in 
the indicated organs upon PRMT5 deletion. (Bottom panel) PCR validation of 
the alternative splicing event taking place on the Mdm4 mRNA upon PRMT5 
deletion in the same organs.!!!!!
4.14 The severity of PRMT5 depletion-induced splicing defects 
correlates with the cell proliferation rate.!
!
In order to gain further insights regarding the mechanism linking splicing 
defect to the severity of the phenotype observed in proliferating cells, we 
used Mouse Embryonic Fibroblasts (MEFs) to determine whether cells with 
different growth rates would be differentially affected by loss of PRMT5.!
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First we could confirm in MEFs most of what observed in NPCs (Fig. 4.33). 
Methylation of the Sm proteins was dramatically reduced 4 days post OHT 
treatment (Fig. 4.33A) and the compiled number of reads in introns 
increased in the absence of PRMT5 (Fig. 4.33B). The most notable 
difference was that MEFs displayed less splicing defects when compared to 
NPCs. Despite this difference the overlap of genes with increased intronic 
reads was remarkable (57%) (Fig. 4.33C and) (Appendix D) (Appendix E) 
(Bezzi et al., 2013). Similar to what observed in NPCs, both the RI (Fig. 
4.33D left panel) and SE (Fig. 4.33D right panel) events detected using 
Multivariate Analysis of Transcript Splicing (MATS) (Shen et al., 2012) are 
characterized by a weak 5’-donor site, as quantified by their low CV score 
(Shapiro score) (Shapiro and Senapathy, 1987) scores, and an overall 
randomization of the key bases at position -1, -2, +4 and +5.!
We next grew MEFs in four different serum (FBS) conditions (0.5%, 5%, 
10%, 20%) to regulate their growth rate. We initially decided to focus on 
one specific event, the alternative splicing of Mdm4, in order to elucidate 
the extent of p53 dependency of the response. Cells that exit the cell cycle 
(0.5%) did not express high levels of Mdm4, but cells that were serum-
stimulated (0.5%-20%), increased the Mdm4fl isoform (Fig. 4.34A upper 
panel), which corresponded to an increase in MDM4 protein levels (Fig. 
4.34A lower panel). In the absence of PRMT5, MDM4 upregulation was 
absent and p53 target genes were activated in a p53-dependent manner  in 
normal growth condition (10% FBS) (Fig. 4.34B).!
MEFs underwent G1 arrest and apoptosis and the effect of PRMT5 
depletion was more severe in growing cells, whereas it had no effect in 
resting cells. To study the p53-dependency of this response, we repeated 
these experiments in p53-/- MEFs. PRMT5 depletion in p53-/- MEFs caused 
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a less severe change in cell cycle profile (Fig. 4.34C). Consistently, cell 
growth was also reduced in p53 wt cells, and to a lesser extent in p53-/- 
cells. In both cases (p53 wt or p53-/- MEFs), the reduction in cell growth was 
proportional to serum levels (Fig. 4.34D). !
Given that in p53 null background, PRMT5 depletion in NPCs induced cell 
cycle arrest, we assessed the alternative splicing of several genes with 
weak 5’-Donor in both p53 wt and p53-/- cells, which likely contribute to the 
p53-independent effects observed in different growing condition. Notably 
the splicing efficiency of the majority of these genes was improved upon 
serum stimulation (Fig. 4.35 green line), while PRMT5 depletion (Fig. 4.35 
red line) increased exon skipping and intron inclusion in both p53 wt and 
p53-/- cells in a serum-dependent manner. Thus, similar to the phenotype, 
the splicing defects observed upon PRMT5 depletion are more severe in 
actively growing cells and they are likely the cause, either due to activation 
of the MDM4-p53 axis or to p53-independent perturbation of several other 
pathways, rather than the consequence of the observed growth defects.!
!
Finally, we decided to use MEFs to prove that the Mdm4 splice switch 
observed at endogenous level was a direct effect of splicing defects. 
Minigene constructs are crucial tools for the analysis of splicing regulatory 
factors that control splicing efficiency and alternative splicing. Therefore, we 
generated a minigene carrying just exon 7 of Mmd4 and the region 
surrounding it (Fig. 4.36A). Reassuringly, exon 7 was skipped upon PRMT5 
depletion (OHT) in MEFs, confirming the specific alternative splicing event 




Figure 4.33: PRMT5 depletion induces splicing defects in MEFs. (A) 
PRMT5, SMN1, SmB/B’, SmD1 and SmD3 levels were assessed in MEFs 
depleted of PRMT5 (OHT). Levels of Symmetric Arginine Dimethylation were 
assessed by staining SmB, SmD1 and SmD3 with SYM10 and Y12 
antibodies. MEFs isolated from two different embryos are shown, (B) Total 
number of reads in genes (blue) or introns (red), expressed as fold change of 
the events in MEFs lacking PRMT5 over control (wt PRMT5). A smooth 
density estimate is drawn as calculated by a Gaussian kernel. (C) Venn 
diagram: Overlap between the affected genes in NPCs (total of 1682) vs 
MEFs (total of 391). (D) Shapiro (CV) score of 5’ donor sites of the RI (left) 
and SE (right) events in MEFs, identified by MATS. A smooth density estimate 
is drawn as calculated by a Gaussian kernel. The top panels depict the 
sequence logo of the 5’donor sites as indicated by the arrows. The 
bioinformatic analysis was performed in collaboration with J. Müller.!!!
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Figure 4.34: PRMT5 depletion results in a more severe phenotype in 
actively growing MEFs. (A) Gel electrophoresis images showing Mdm4 
splice isoforms in Prmt5F/FER MEFs cultured under varying serum 
concentrations following PRMT5 deletion (upper panel) and immunoblots 
showing a corresponding decrease in MDM4 protein levels (lower panel). (B) 
Expression of p53 upregulated target gens in MEFs growing in 10% FBS 
medium, from Prmt5F/FER;p53wt treated with EtOH/OHT (black/red) or Prmt5F/
FER;p53-/- (grey/yellow). The activation of the genes is expressed as the 
average fold change of at least 3 embryos/MEFs, normalized against HK and 
to the EtOH levels. (C). Cell cycle analysis of p53wt (left panel) and p53-/- 
(right panel), Prmt5F/FER MEFs under varying serum concentrations following 
PRMT5 deletion. (D) Cell viability of p53wt, Prmt5F/FER MEFs (left panel) and 
p53-/-, Prmt5F/FER MEFs (right panel) following OHT treatment.!
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Figure 4.35: PRMT5 depletion results in more severe splicing defects in 
actively growing MEFs. Gel electrophoresis images (lower panels) and 
quantification (upper panels) showing aberrant splicing patterns in several 
genes in Prmt5F/FCreER MEFs with different p53 background, cultured under 
varying serum concentrations following PRMT5 depletion.!!
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Figure 4.36: A minigene carrying Mdm4 exon7 recapitulates the splice 
switch occurring at the level of endogenous Mdm4 pre-mRNA. (A) 
Diagram of the Mdm4 minigenes. (B) MEFs cells (isolated from embryos I 
and II) transfected with the indicated constructs. Cells were treated with either 
EtOH or OHT and the total RNAs were analyzed by PCR to examine the 
transgenic Exon 7 inclusion. Endogenous Mdm4 splicing is shown in the 
bottom panel.!!!!!
4.15 Mdm4 pre-mRNA senses defects in the spliceosomal 
machinery in cancer lines.!
Activation of the p53 pathway is important in cell homeostasis, as well as in 
development, but it is certainly best known for its aberrant deregulation in 
human cancer. PRMT5 has been described as a potential oncogene in 
human malignancies (Karkhanis et al., 2011). Given the high degree of 
conservation of the region around the AS exon 7 on mouse Mdm4, we tested 
whether the orthologous human exon 6 conserved a similar sensing 
mechanism. Upon PRMT5 knock down, and treatment with the splicing 
inhibitor TG003, we observed a similar AS event occurring on the human 
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Mdm4 transcript in cancer cell lines derived from different tissues 
(osteosarcoma, gastric, breast and glioma) (Fig. 4.37A).!
Notably, perturbation of the splicing machinery by knockdown of SmB/B’, a 
target of PRMT5 and component of the core snRNP, led to Mdm4 alternative 
splicing in both U2OS and NPCs (Fig. 4.37B-D). Further investigation of the 
phenotype induced in NPCs by downregulation of SmB/B’ revealed high 
similarity with the phenotype observed in PRMT5 null NPCs. Several p53 
target genes were upregulated (Fig. 4.36E) and the number of apoptotic cells 
increased significantly (Fig. 4.36F).!
Overall we believe our data uncover a key mechanism of PRMT5 function 





Figure 4.37: PRMT5 depletion triggers Mdm4 AS and p53 activation in 
multiple tissues. (A) PCR quantification of the alternative splicing event 
taking place on the Mdm4 mRNA upon PRMT5 knockdown (KD). Scramble 
shRNA was used as a control (Scr). Treatment with the splicing inhibitor 
TG003 (or with DMSO vehicle control) was used as an alternative way of 
perturbing the splicing machinery. The experiments were performed in the 
indicated human cancer cells (shown at the top). GAPDH was used as a 
loading control. (B) Quantification of Mdm4fl/ Mdm4s splicing levels 4 d after 
infection and 2-d selection in 1 mg/mL puromycin upon knockdown with three 
different shRNA lentiviral constructs (Sh1–Sh3) in U2OS cells. (Scr) 
Scrambled control shRNA.(C) SmB/B’ expression levels in NPCs as 
quantified by Real Time PCR 4 days post-infection and 2 days selection in 
puromycin (0.2mg/mL) upon Knock Down with 4 different sh-RNA lentiviral 
constructs (KD1-4). Scr = Scrambled control sh-RNA. In the same experiment 
we have (D) Quantified Mdm4fl/Mdm4s splicing, (E) the expression levels of 
p53 targets and (F) the increase in SubG1 population in infected cells relative 





5.1 Role of PRMT5 in development!
!
The role of PRMT5 in vivo has been studied in Planaria, C. elegans, 
Drosophila and plants. However, the lack of PRMT5, results in distinct 
phenotypes in different systems. In Planaria, PRMT5 depletion results in 
defects in homeostasis, growth and regeneration (Rouhana et al., 2012). In 
C. elegans PRMT5 prevents DNA damage-induced apoptosis, and its 
inactivation leads to apoptosis in the germline, following ionizing radiation 
(Yang et al., 2009). In flies, it leads to problems in germ cell specification and 
circadian rhythm (Gonsalvez et al., 2006; Sanchez et al., 2010), while in 
plants to defects in flowering and circadian rhythm (Deng et al., 2010; 
Sanchez et al., 2010). Similarly, in mammalian cell lines, modulation of the 
expression of PRMT5 in tissue-specific cell proliferation and differentiation 
experiments, resulted in apparently contradictory phenotypes. PRMT5 has 
been shown to be required for adipogenesis (LeBlanc et al., 2012), 
myogenesis (Dacwag et al., 2009) and oligodendrocyte maturation and 
differentiation (Huang et al., 2011), whereas in keratinocytes (Kanade and 
Eckert, 2012) and in mouse embryonic stem cells (Tee et al., 2010), PRMT5 
is crucial for the maintenance of the undifferentiated state. Conversely, in the 
hematopoietic system PRMT5 appears to be a negative regulator of 
hematopoietic stem/progenitor cell proliferation and erythroid differentiation 
(Liu et al., 2011). !
 132
We show for the first time data on a PRMT5 conditional KO-mouse model. 
We performed acute depletion of PRMT5 during organogenesis, tissue-
specific depletion in the CNS, and ex vivo depletion in neural stem/progenitor 
cells, hematopoietic stem/progenitor cells and mouse embryonic fibroblasts. 
Our studies demonstrate that PRMT5 safeguards the homeostasis of 
proliferating cells, rather than controlling tissue-specific stem cell multipotency 
and differentiation, inhibiting both apoptosis and the activation of negative 
regulators of the cell cycle. !
The discrepancy between our results and previous observations can be 
reconciled by two considerations. Firstly, PRMT5 could be differentially 
required in different organisms and to some extent the putative type II PRMT, 
PRMT7, or other unknown PRMTs, might compensate the loss of PRMT5. 
PRMT7 is an essential gene in drosophila (unlike PRMT5) (Gonsalvez et al., 
2008), while in HeLa cells it has been shown to be important for the 
methylation of Sm proteins and to have non-redundant functions in 
cytoplasmic snRNP biogenesis (Gonsalvez et al., 2007). Our data suggest 
that, at least in mouse development, PRMT7 is not compensating for the 
absence of PRMT5, but to which extent, if any, PRMT7 plays a role in 
mammalian splicing in vivo remains to be addressed.!
Secondly, we are looking at a full deletion of PRMT5, as opposed to the 
knock-down studies reported so far. Albeit modest alteration of the relative 
stoichiometry of splicing regulatory proteins leads to alternative splicing 
patterns (Black, 2003; Hou et al., 2002; Licatalosi and Darnell, 2006; 
Martinez-Contreras et al., 2006; Paradis et al., 2007), the KO-mouse models 
of some of these proteins have shown a more dramatic phenotype. 
Particularly, full SMN KO has an early embryonic phenotype similar to the 
PRMT5 full KO (Hsieh-Li et al., 2000; Tee et al., 2010). In contrast 
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hypomorphic mouse models expressing different levels of SMN display spinal 
muscular atrophy (SMA) with different degrees of severity and neurospheres 
derived from the these mice did not differ in number when compared to wild 
type (Shafey et al., 2008). This threshold effect is confirmed in tissue culture 
where a dramatic reduction of SMN (>85%) is required to observe cell death 
(Zhang et al., 2008).!
!!
5.2 Role of PRMT5 in stem cell biology!
!
A previous publication has reported the constitutive KO of PRMT5 using a 
gene trap model (Tee et al., 2010). Phenotypically, lack of PRMT5 leads to 
de-repression of differentiation genes in mouse Embryonic Stem cells (mES) 
due, at least in part, to the lack of symmetric arginine 3 methylation on 
histone H2A (H2AR3me2s). However, because of the early embryonic 
lethality, the authors were not able to perform large-scale molecular 
experiments, and thus whether PRMT5 plays any role in controlling splicing in 
mES remained to be explored. It is of note that PRMT5 has been used to 
improve iPS derivation in combination with klf4 and Oct3/4 (Nagamatsu et al., 
2011). Reducing p53 activity is known to be very important to enhance iPS 
derivation (Hong et al., 2009; Kawamura et al., 2009). We thus believe that 
our data, which link PRMT5 methyltransferase activity to the regulation of 
MDM4 abundance, by controlling its alternative splicing, will provide new 
insights to this expanding field of research. Furthermore, recent studies 
highlight the decisive function of splicing regulatory protein, such as SON and 
MBNL, and  the importance of alternative splicing programs in pluripotency 
and reprogramming (Gabut et al., 2011; Han et al., 2013; Lu et al., 2013).!
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5.3 Role of PRMT5 in histone modifications!
!
PRMT5 has shown a remarkable versatility towards histone substrates in 
vitro, and gene expression regulatory properties have been investigated for 
four PRMT5-mediated histone modifications: H4R3me2s, H3R8me2s, 
H2AR3me2s and H3R2me2s (Bedford and Clarke, 2009; Karkhanis et al., 
2011). Surprisingly, analysis of the bulk levels of these histone modifications 
in PRMT5 null brain revealed the reduction of only one of them, H2AR3me2s. 
This data suggest that PRMT5 is not the only type II symmetric arginine 
methyltransferase in higher eukaryotes. Further studies are needed in order 
to clearly define the catalytic nature of PRMT7 and PRMT9 and likely other 
type II PRMTs are yet to be discovered. An alternative explanation for the 
stability of these PTMs is that there are no existing arginine demethylases 
and thus erasure occurs upon histone exchange or protein degradation. The 
fact that in the absence of PRMT5 the overall levels of H4R3me2s, 
H3R8me2s and H3R2me2s do not change, does not exclude the fact that 
these histone modifications play a critical role in transcriptional regulation. 
Moreover, we cannot rule out the possibility that PRMT5 methylates histones 
of a subset of specific genes. In this case more work needs to be done to find 
specific PRMT5 target genes and to identify chromatin binding partners which 
restrict PRMT5 activity toward these promoters.!
We were not able to link H2AR3me2s to either transcriptional regulation or 
chromatin assembly. Moreover, we did not investigate the H2AR3me2s 
methylation event in other chromatin related processes such as replication, 
mitosis, and in chromatin configuration in the nucleus. Therefore, we believe 
that the role of H2AR3me2s is yet to be discovered and the fact that this 
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histone modification has been shown to be catalyzed in the cytoplasm (Tee et 
al., 2010) expand the prospect of potential functions.!
Our data do not exclude a role for PRMT5 in transcriptional regulation, 
however its function as a chromatin remodeler might be more restricted, but 
at the same time more complex than expected.!
!!
5.4 Role of PRMT5 in splicing regulation!
!
Despite the discovery of PRMT5 involvement in the methylation of the Sm 
core is one of the first evidence collected regarding its activity, most of the 
following studies ignored the potential function of PRMT5 in splicing 
regulation, and confirmation in mammals of this anticipated role has been 
lacking so far. !
We have shown, by using a conditional KO-mouse-model and a combination 
of in vitro and in vivo approaches that PRMT5 is an essential regulator of 
splicing in mammals. The first key finding is that shortly after the dramatic 
reduction of the levels of symmetric arginine dimethylated Sm proteins, 
caused by lack of PRMT5, an increase of intron reads was readily detected 
by RNA-sequencing, suggesting a primary function in ensuring correct 
constitutive splicing. In accordance with previous studies, our data place 
PRMT5 upstream of SMN in the maturation cycle of Sm proteins in vivo. 
Unfortunately, neither the Dreyfuss group, which performed splicing analysis 
in tissues from a SMA mouse model (Zhang et al., 2008), nor the Blencowe 
group, which analyzed the transcriptome-wide effects of a SmB/B’ knock-
down in HeLa cells (Saltzman et al., 2011), focused their attention on retained 
introns. Therefore we could not cross-compare our results. Reassuringly, 
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increased intronic retention upon PRMT5 depletion was observed in both 
plants and Drosophila (Deng et al., 2010; Sanchez et al., 2010).  !
The second key finding is that besides safeguarding constitutive splicing, 
PRMT5 promotes the inclusion of exons, as well as the exclusion of introns, 
characterized by weak 5‘ donor site. Importantly, this PRMT5 function is not 
restricted to the CNS, as in the absence of PRMT5 we could validate the 
skipping of some of these exons and the inclusion of some of these introns in 
other tissues. Although SMA is often referred to as a motor neuron disease, 
recent evidence suggest that the splicing defects are present in multiple 
organs (Zhang et al., 2008) and this can lead to disease-relevant phenotypes 
in cells other than motor neurons (Hayhurst et al., 2012). However, the 
aforementioned study by the Dreyfuss group did not uncover any specific 
feature of the splicing sites of alternative spliced exons (Zhang et al., 2008). A 
possible explanation is that while we inspected a specific cell population 
shortly after PRMT5 depletion, they analyzed the splicing patterns using RNA 
extracted from whole mouse tissues, therefore making the comparison 
between the two dataset difficult. On the other hand, our data are consistent 
with the splicing defects observed in exons with weak 5’ donor site, rather 
than weak 3’ acceptor site, upon SmB/B’ knock-down in HeLa cells and 
PRMT5 depletion in plants and Drosophila (Deng et al., 2010; Saltzman et al., 
2011; Sanchez et al., 2010). !
Although accumulation of introns in the transcriptome, and skipping of exons 
with weak 5’ donor site are in accordance with the idea of on an overall 
reduction of splicing efficiency due to problems in the snRNPs maturation 
process, an alternative and non exclusive hypothesis which could explain the 
data we collected comes to mind: PRMT5 might control splicing more broadly 
than simply through regulating the maturation of snRNPs. In this respect the 
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splicing regulator CA150 (Cheng et al., 2007) has been identified as a 
PRMT5 target, and this could be the case for other splicing proteins, which 
are known to be arginine methylated (Boisvert et al., 2003; Bremang et al., 
2013; Ong et al., 2004). Another intriguing hypothesis is that PRMT5-
mediated methylation of the Sm proteins directly modulates the weak 5’ splice 
site recognition promoting RNA-RNA interactions. In yeast, SmB, SmD1 and 
SmD3 has been shown to directly bind the pre-mRNA in proximity of the 
donor site, stabilizing its interaction with the U1snRNA (Zhang et al., 2001).!
Finally, considering the fact that we were not able to elucidate the role of 
H2AR3me2s in transcriptional regulation, we cannot exclude that this histone 
modification is involved indirectly in splicing regulation by affecting chromatin 
structure at specific loci.!
!!
5.5 Role of PRMT5 in regulating cell cycle progression and cell 
death!
!
We have here described how cells can sense general defects in the core 
splicing machinery, such as the one caused by PRMT5 depletion, by 
regulating the alternative splicing of a key p53 activator such as Mdm4. This 
alternative splicing event reduces the full length MDM4 protein and gives rise 
to the unstable MDM4S product (Lenos and Jochemsen, 2011), thus 
activating the p53 transcriptional program. Our findings describe for the first 
time the link between the methylosome (Friesen et al., 2001b), the core 
splicing machinery, alternative splicing and activation of a p53 response in 
mammalian development.!
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What we have uncovered here is, indeed, a much broader picture, of how 
cells can activate the alternative splicing of sensor mRNAs (eg. Mdm4), at 
key exons, characterized by weak 5’ donor sites. This occurs upon 
perturbation of the general splicing machinery, whether because of PRMT5 
deletion, or chemical inhibition (Figure 4.31B), to arrest growth and/or induce 
apoptosis. Besides Mdm4 there are other mRNAs that can potentially play a 
similar role. To mention a few, the SE event observed in the mRNA of 5' cap-
binding protein eIF4E, which is a rate limiting component in the translation 
process, could affect genes involved in apoptosis and cell cycle arrest 
(Mamane et al., 2004) (Figure 4.26), while the RI events observed in Dvl1 
might lead to the inactivation of the Wnt/Dvl1/b-catenin signaling pathway 
which is known to support NPCs growth and self-renewal potential (Faigle 
and Song, 2013) (Figure 4.27). It would be equally interesting to explore 
whether the modulation of the splicing of some of the identified genes 
suffering aberrant splicing results in functional consequences to splicing 
related diseases.!
We have described that the complete deletion of PRMT5 in mouse cells leads 
to a minor induction of γH2AX, but to a strong activation of p53 target genes, 
such as p21, even when compared to Etoposide. This is in contrast to what 
has previously been observed using siRNA/shRNA strategies to reduce the 
levels of PRMT5 in human cancer lines (Jansson et al., 2008; Scoumanne et 
al., 2009). This discrepancy could be due to differences between mouse and 
human cells, between primary cells and cancer cells and to the fact that 
PRMT5 levels have to fall below a certain threshold in order to observe an 
activation of the p53 pathway. The latter concept has already been observed 
for other splicing regulators such as SMN (Zhang et al., 2008). Both the 
concept that perturbation of the core splicing machinery can lead to regulation 
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of alternative splicing (Saltzman et al., 2011) and that apoptosis is regulated 
by alternative splicing (Moore et al., 2010; Schwerk and Schulze-Osthoff, 
2005) have previously been described. The fundamental advance we 
described here is that the two pathways are directly linked because Mdm4, 
the target of alternative splicing, unlike Bcl2-like factors, caspases, death 
receptors and proapoptotic ligands, is as a direct upstream regulator of p53.!
Splicing disorders have been estimated to occur in 50% of tumors (David and 
Manley, 2010; Ritchie et al., 2008; Ward and Cooper, 2010). These can 
contribute to tumor progression by giving rise to alternative isoforms of 
oncogenes or tumor suppressors. At the same time, while the perturbation of 
the splicing machinery was known to activate the p53 pathway, the underlying 
mechanisms by which this occurred were unknown (Allende-Vega et al., 
2013). Our data uncover the mechanism of p53 activation by identifying 
Mdm4 as a key sensor mRNA. We believe this data to be extremely relevant 
for the entire p53 field. Mdm4 is indeed upregulated in several p53wt tumors 
(Gembarska et al., 2012), and our findings provide new therapeutic avenues 






We were able to show, by combining in vivo studies in conditional mouse 
models and high-throughput techniques, that PRMT5 is essential for 
proliferating cells homeostasis rather than pluripotency, mostly by ensuring 
correct pre-mRNA processing. Moreover, we discovered a noncanonical, DNA 
damage-independent, splicing efficiency-dependent mechanism of p53 
response activation. This mechanism relies on the alternative splicing of the 
Mdm4 pre-mRNA, which shortly after PRMT5 deletion senses the reduction in 
splicing efficiency (Fig. 6.1). This work expands our understanding of the 
complex network regulating correct splicing and cell fate decisions in 
mammalian development, as well as in human cancer lines, providing new 
possibilities to target the arginine methyltransferase family to treat 
neurodegenerative diseases (Dredge et al., 2001; Tollervey et al., 2011) and 
cancer (David and Manley, 2010; Ritchie et al., 2008; Ward and Cooper, 
2010). Recent GWAS studies have uncovered a high rate of mutations in 
splicing regulators (Damm et al., 2012; Papaemmanuil et al., 2011; Yoshida et 
al., 2012), pinpointing their potential involvement as driver oncogenes. As a 
consequence there has been growing interest in drugging the spliceosome 
machinery for anti cancer therapy (Bonnal et al., 2012). Our results shed light 
on the possible reason why PRMT5 is required by cancer cells, and at the 
same time they warn that targeting PRMT5 might induce undesirable side 
effects linked to adult stem cells homeostasis. Therefore, further studies are 




Figure 6.1. Schematic model of the data presented in the study: Upon 
PRMT5 deletion (or reduction), we observed a loss of symmetric arginine 
dimethylation at key components of the splicing machinery (SmB/B’, SmD1, 
SmD3, and possibly others). This leads to aberrant snRNP maturation. The 
consequence is the activation of a sensing mechanism, which is linked to 
alternative splicing of key mRNAs (mainly RIs and SEs). As an example, we 
show Mdm4, which induces a potent p53 transcriptional activation. (Bottom) 
Other alternative splicing events might be equally important and will ultimately 
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90310029|90310183|90311466|90311548#I#A3SS 0.748 1 -0.252 3.45156E-11 Inclusion 28
A3SS Gtpbp3 ENSMUSG00000007610#chr8#+#74014553|74014866|74014793|74014866|74014233|74014436#I#A3SS 0.239 0.478 -0.239 0.048924486 Inclusion 24
A3SS Gtpbp3 ENSMUSG00000007610#chr8#+#74014553|74014866|74014793|74014866|74014233|74014436#I#A3SS 0.189 0.439 -0.25 0.007787578 Inclusion 28
A3SS Prmt2 ENSMUSG00000020230#chr10#-#75699456|75699569|75699456|75699566|75700494|75700610#I#A3SS 0 0.429 -0.429 1.11183E-06 Inclusion 26
A3SS Prmt2 ENSMUSG00000020230#chr10#-#75699456|75699569|75699456|75699566|75700494|75700610#I#A3SS 0 0.24 -0.24 0.013528117 Inclusion 28
A3SS Tsc1 ENSMUSG00000026812#chr2#+#28534471|28534638|28534486|28534638|28533681|28533725#E#A3SS 0.908 0.29 0.618 0.010743791 Exclusion 24
A3SS Tsc1 ENSMUSG00000026812#chr2#+#28534471|28534638|28534486|28534638|28533681|28533725#E#A3SS 0.732 0.235 0.497 0.000678307 Exclusion 26
A3SS Ccnl2 ENSMUSG00000029068#chr4#+#155192647|155194537|155194437|155194537|155192031|155192096#I#A3SS 0.502 0.771 -0.269 4.81117E-07 Inclusion 26
A3SS Ccnl2 ENSMUSG00000029068#chr4#+#155192647|155194537|155194437|155194537|155192031|155192096#I#A3SS 0.523 0.854 -0.331 2.49465E-07 Inclusion 28
A3SS Cdv3 ENSMUSG00000032803#chr9#-#103255432|103258359|103255432|103257643|103258609|103258769#I#A3SS 0.701 1 -0.299 1.40337E-08 Inclusion 26
A3SS Cdv3 ENSMUSG00000032803#chr9#-#103255432|103258359|103255432|103257643|103258609|103258769#I#A3SS 0.715 1 -0.285 1.21879E-05 Inclusion 28
A3SS Iffo1 ENSMUSG00000038271#chr6#+#125101812|125102789|125102631|125102789|125101402|125101543#I#A3SS 0.208 0.512 -0.304 0.000466979 Inclusion 26
A3SS Iffo1 ENSMUSG00000038271#chr6#+#125101812|125102789|125102631|125102789|125101402|125101543#I#A3SS 0.243 0.531 -0.288 0.010925383 Inclusion 28
A3SS Iffo1 ENSMUSG00000038271#chr6#+#125102461|125102789|125102631|125102789|125101402|125101543#I#A3SS 0.236 0.488 -0.252 0.013796421 Inclusion 26
A3SS Iffo1 ENSMUSG00000038271#chr6#+#125102461|125102789|125102631|125102789|125101402|125101543#I#A3SS 0.179 0.478 -0.299 0.012152286 Inclusion 28
A3SS Arfrp1 ENSMUSG00000038671#chr2#-#181098718|181098900|181098718|181098801|181099015|181099103#I#A3SS 0.13 0.332 -0.202 1.00544E-05 Inclusion 26
A3SS Arfrp1 ENSMUSG00000038671#chr2#-#181098718|181098900|181098718|181098801|181099015|181099103#I#A3SS 0.119 0.357 -0.238 1.83922E-05 Inclusion 28
A3SS Usp48 ENSMUSG00000043411#chr4#+#137193674|137193805|137193679|137193805|137190812|137190923#E#A3SS 1 0.756 0.244 6.70433E-05 Exclusion 26
A3SS Usp48 ENSMUSG00000043411#chr4#+#137193674|137193805|137193679|137193805|137190812|137190923#E#A3SS 1 0.789 0.211 0.003416318 Exclusion 28
A3SS Hipk2 ENSMUSG00000061436#chr6#-#38671453|38671596|38671453|38671593|38679919|38680041#I#A3SS 0.773 1 -0.227 0.029242637 Inclusion 26
A3SS Hipk2 ENSMUSG00000061436#chr6#-#38671453|38671596|38671453|38671593|38679919|38680041#I#A3SS 0.75 1 -0.25 0.021380028 Inclusion 28
A3SS Sox13 ENSMUSG00000070643#chr1#-#135285025|135285140|135285025|135285137|135285505|135285574#I#A3SS 0 0.571 -0.571 0.038784838 Inclusion 24
A3SS Sox13 ENSMUSG00000070643#chr1#-#135285025|135285140|135285025|135285137|135285505|135285574#I#A3SS 0.267 0.813 -0.546 0.006586536 Inclusion 28
A5SS Mettl17 ENSMUSG00000004561#chr14#+#52508821|52509072|52508821|52508892|52509202|52509310#I#A5SS 0.267 0.495 -0.228 0.033699469 Inclusion 26




84654922|84655126|84653762|84653937#I#A5SS 0.58 0.819 -0.239 0.003961512 Inclusion 24
A5SS Ggnbp2
ENSMUSG00000020530#chr11#-#84654916|84655126|
84654922|84655126|84653762|84653937#I#A5SS 0.635 0.838 -0.203 0.000162959 Inclusion 26
A5SS Mtch1 ENSMUSG00000024012#chr17#-#29473111|29473256|29473162|29473256|29470902|29470950#I#A5SS 0.356 0.56 -0.204 4.50307E-08 Inclusion 26
A5SS Mtch1 ENSMUSG00000024012#chr17#-#29473111|29473256|29473162|29473256|29470902|29470950#I#A5SS 0.377 0.602 -0.225 8.61798E-07 Inclusion 28
A5SS Nrxn1 ENSMUSG00000024109#chr17#-#90458815|90458903|90458824|90458903|90436416|90436724#E#A5SS 0.43 0.226 0.204 0.033077991 Exclusion 26
A5SS Nrxn1 ENSMUSG00000024109#chr17#-#90458815|90458903|90458824|90458903|90436416|90436724#E#A5SS 0.424 0.131 0.293 0.002307033 Exclusion 28
A5SS Luc7l ENSMUSG00000024188#chr17#+#26389910|26391333|26389910|26390036|26391975|26392070#I#A5SS 0.434 0.85 -0.416 0.001348594 Inclusion 24
A5SS Luc7l ENSMUSG00000024188#chr17#+#26389910|26391333|26389910|26390036|26391975|26392070#I#A5SS 0.311 0.804 -0.493 2.43203E-11 Inclusion 26
A5SS Luc7l ENSMUSG00000024188#chr17#+#26389910|26391333|26389910|26390036|26391975|26392070#I#A5SS 0.512 0.817 -0.305 0.007846918 Inclusion 28
A5SS Ccnt2 ENSMUSG00000026349#chr1#+#129694417|129694773|129694417|129694463|129695966|129696130#I#A5SS 0.46 0.741 -0.281 0.001295887 Inclusion 26
A5SS Ccnt2 ENSMUSG00000026349#chr1#+#129694417|129694773|129694417|129694463|129695966|129696130#I#A5SS 0.435 0.71 -0.275 0.004054835 Inclusion 28
A5SS Ccnl1 ENSMUSG00000027829#chr3#-#65759051|65759198|65759125|65759198|65755355|65755476#I#A5SS 0.273 0.606 -0.333 0.00548507 Inclusion 26
A5SS Ccnl1 ENSMUSG00000027829#chr3#-#65759051|65759198|65759125|65759198|65755355|65755476#I#A5SS 0.18 0.472 -0.292 0.009124999 Inclusion 28
A5SS Trim24 ENSMUSG00000029833#chr6#+#37895520|37895789|37895520|37895687|37899221|37899398#I#A5SS 0.376 0.583 -0.207 0.000441244 Inclusion 26
A5SS Trim24 ENSMUSG00000029833#chr6#+#37895520|37895789|37895520|37895687|37899221|37899398#I#A5SS 0.344 0.553 -0.209 0.002603105 Inclusion 28
A5SS Sorbs2 ENSMUSG00000031626#chr8#+#46885063|46885155|46885063|46885152|46886318|46886365#I#A5SS 0 0.909 -0.909 0.013934306 Inclusion 24
A5SS Sorbs2 ENSMUSG00000031626#chr8#+#46885063|46885155|46885063|46885152|46886318|46886365#I#A5SS 0 0.409 -0.409 0.0229736 Inclusion 28
A5SS Tecr ENSMUSG00000031708#chr8#-#86097607|86097821|86097769|86097821|86097309|86097354#I#A5SS 0.074 0.312 -0.238 5.02177E-05 Inclusion 24
A5SS Tecr ENSMUSG00000031708#chr8#-#86097607|86097821|86097769|86097821|86097309|86097354#I#A5SS 0.039 0.423 -0.384 0 Inclusion 26
A5SS Mrps17
ENSMUSG00000034211#chr5#+#130221558|130221816|
130221558|130221785|130222601|130222741#I#A5SS 0.389 0.645 -0.256 0.003450069 Inclusion 26
A5SS Mrps17
ENSMUSG00000034211#chr5#+#130221558|130221816|
130221558|130221785|130222601|130222741#I#A5SS 0.351 0.595 -0.244 0.03908612 Inclusion 28
A5SS Neto2 ENSMUSG00000036902#chr8#-#88187285|88187330|88187306|88187330|88187077|88187205#E#A5SS 0.649 0.36 0.289 0.014808359 Exclusion 24
A5SS Neto2 ENSMUSG00000036902#chr8#-#88187285|88187330|88187306|88187330|88187077|88187205#E#A5SS 0.55 0.284 0.266 0.00195195 Exclusion 26
A5SS Neto2 ENSMUSG00000036902#chr8#-#88187285|88187330|88187306|88187330|88187077|88187205#E#A5SS 0.687 0.257 0.43 6.24506E-06 Exclusion 28
A5SS Rps16 ENSMUSG00000037563#chr7#+#29137195|29137429|29137195|29137292|29137512|29137715#I#A5SS 0.397 1 -0.603 0.012595136 Inclusion 26
A5SS Rps16 ENSMUSG00000037563#chr7#+#29137195|29137429|29137195|29137292|29137512|29137715#I#A5SS 0.244 1 -0.756 0.012599165 Inclusion 28
A5SS Hnrnpf ENSMUSG00000042079#chr6#+#117856799|117857226|117856799|117856857|117867487|117867616#I#A5SS 0.544 1 -0.456 2.32439E-05 Inclusion 24
A5SS Hnrnpf ENSMUSG00000042079#chr6#+#117856799|117857226|117856799|117856857|117867487|117867616#I#A5SS 0.603 1 -0.397 9.05509E-10 Inclusion 26
A5SS Ubr3 ENSMUSG00000044308#chr2#+#69829481|69829694|69829481|69829682|69831732|69831869#E#A5SS 0.655 0.369 0.286 0.022560573 Exclusion 26




103487339|103487411|103467537|103467707#E#A5SS 0.529 0 0.529 0.000184592 Exclusion 26
A5SS Mapk10
ENSMUSG00000046709#chr5#-#103487312|103487411|
103487339|103487411|103467537|103467707#E#A5SS 1 0.146 0.854 0.011660447 Exclusion 28
A5SS Ankrd16
ENSMUSG00000047909#chr2#+#11701303|11701524|
11701303|11701450|11703103|11705383#I#A5SS 0.474 0.84 -0.366 0.0024282 Inclusion 26
A5SS Ankrd16
ENSMUSG00000047909#chr2#+#11701303|11701524|
11701303|11701450|11703103|11705383#I#A5SS 0.477 0.833 -0.356 0.024281553 Inclusion 28
A5SS Ldlrad3
ENSMUSG00000048058#chr2#-#101953689|101953836|
101953785|101953836|101910089|101910215#E#A5SS 1 0.604 0.396 0.005974263 Exclusion 24
A5SS Ldlrad3
ENSMUSG00000048058#chr2#-#101953689|101953836|
101953785|101953836|101910089|101910215#E#A5SS 0.911 0.639 0.272 0.006398212 Exclusion 26
A5SS Bdp1 ENSMUSG00000049658#chr13#-#100819590|100819984|100819814|100819984|100816680|100816794#E#A5SS 0.659 0.391 0.268 0.009530614 Exclusion 26
A5SS Bdp1 ENSMUSG00000049658#chr13#-#100819590|100819984|100819814|100819984|100816680|100816794#E#A5SS 0.784 0.344 0.44 0.00031667 Exclusion 28
A5SS Tia1 ENSMUSG00000071337#chr6#+#86374955|86375197|86374955|86375064|86375443|86375539#I#A5SS 0.131 0.353 -0.222 3.27486E-05 Inclusion 24
A5SS Tia1 ENSMUSG00000071337#chr6#+#86374955|86375197|86374955|86375064|86375443|86375539#I#A5SS 0.151 0.38 -0.229 2.25907E-09 Inclusion 26



















































































90310029|90310183|90311466|90311548#I#RI 0.734 1 -0.266 2.03005E-11 Inclusion 28
RI Trmt1 ENSMUSG00000001909#chr8#+#87214415|87214846|87214415|87214471|87214709|87214846#I#RI 0.207 0.451 -0.244 0.000468471 Inclusion 24
RI Trmt1 ENSMUSG00000001909#chr8#+#87214415|87214846|87214415|87214471|87214709|87214846#I#RI 0.177 0.39 -0.213 3.0974E-06 Inclusion 26
RI Trmt1 ENSMUSG00000001909#chr8#+#87214415|87214846|87214415|87214471|87214709|87214846#I#RI 0.226 0.431 -0.205 0.002336542 Inclusion 28
RI Slc1a5 ENSMUSG00000001918#chr7#+#17381106|17381507|17381106|17381301|17381372|17381507#I#RI 0.337 1 -0.663 0.001728613 Inclusion 24
RI Slc1a5 ENSMUSG00000001918#chr7#+#17381106|17381507|17381106|17381301|17381372|17381507#I#RI 0.353 1 -0.647 0.000982165 Inclusion 28
RI Tmem161a
ENSMUSG00000002342#chr8#+#72704604|72704948|
72704604|72704748|72704834|72704948#I#RI 0.112 0.69 -0.578 3.82649E-05 Inclusion 24
RI Tmem161a
ENSMUSG00000002342#chr8#+#72704604|72704948|
72704604|72704748|72704834|72704948#I#RI 0.167 0.4 -0.233 0.001799367 Inclusion 26
RI Tpra1 ENSMUSG00000002871#chr6#+#88860144|88860395|88860144|88860255|88860334|88860395#I#RI 0.178 0.416 -0.238 0.046319457 Inclusion 26
RI Tpra1 ENSMUSG00000002871#chr6#+#88860144|88860395|88860144|88860255|88860334|88860395#I#RI 0.077 0.588 -0.511 5.10148E-05 Inclusion 28
RI Dgkq ENSMUSG00000004815#chr5#-#109078843|109079398|109078843|109078944|109079219|109079398#I#RI 0.177 0.665 -0.488 2.61763E-07 Inclusion 26
RI Dgkq ENSMUSG00000004815#chr5#-#109078843|109079398|109078843|109078944|109079219|109079398#I#RI 0.212 0.473 -0.261 0.029575559 Inclusion 28
RI Plod3 ENSMUSG00000004846#chr5#+#137466020|137466409|137466020|137466146|137466287|137466409#I#RI 0.012 0.23 -0.218 0 Inclusion 26
RI Plod3 ENSMUSG00000004846#chr5#+#137466020|137466409|137466020|137466146|137466287|137466409#I#RI 0.029 0.292 -0.263 9.33298E-12 Inclusion 28
RI Rrnad1 ENSMUSG00000004896#chr3#-#87728265|87729353|87728265|87728450|87728868|87729353#I#RI 0.634 1 -0.366 0.003329894 Inclusion 24
RI Rrnad1 ENSMUSG00000004896#chr3#-#87728265|87729353|87728265|87728450|87728868|87729353#I#RI 0.556 0.911 -0.355 0.000107141 Inclusion 26
RI Rrnad1 ENSMUSG00000004896#chr3#-#87728265|87729353|87728265|87728450|87728868|87729353#I#RI 0.626 1 -0.374 0.000314529 Inclusion 28
RI Wdr83 ENSMUSG00000005150#chr8#-#87603687|87604124|87603687|87603736|87604018|87604124#I#RI 0.258 0.591 -0.333 6.5912E-07 Inclusion 26
RI Wdr83 ENSMUSG00000005150#chr8#-#87603687|87604124|87603687|87603736|87604018|87604124#I#RI 0.215 0.563 -0.348 2.2863E-05 Inclusion 28
RI Neu1 ENSMUSG00000007038#chr17#+#35069510|35071130|35069510|35069773|35070947|35071130#I#RI 0.135 0.453 -0.318 0.00078676 Inclusion 24
RI Neu1 ENSMUSG00000007038#chr17#+#35069510|35071130|35069510|35069773|35070947|35071130#I#RI 0.124 0.49 -0.366 4.79213E-11 Inclusion 26
RI Neu1 ENSMUSG00000007038#chr17#+#35069510|35071130|35069510|35069773|35070947|35071130#I#RI 0.267 0.529 -0.262 0.0310446 Inclusion 28
RI Hps5 ENSMUSG00000014418#chr7#-#54030183|54031321|54030183|54030307|54031134|54031321#I#RI 0.092 1 -0.908 6.25679E-06 Inclusion 24
RI Hps5 ENSMUSG00000014418#chr7#-#54030183|54031321|54030183|54030307|54031134|54031321#I#RI 0.16 0.367 -0.207 0.04764147 Inclusion 28
RI Gdi1 ENSMUSG00000015291#chrX#+#71553010|71553600|71553010|71553209|71553468|71553600#I#RI 0.281 0.562 -0.281 2.0953E-08 Inclusion 24
RI Gdi1 ENSMUSG00000015291#chrX#+#71553010|71553600|71553010|71553209|71553468|71553600#I#RI 0.317 0.564 -0.247 2.30815E-13 Inclusion 26
RI Gdi1 ENSMUSG00000015291#chrX#+#71553010|71553600|71553010|71553209|71553468|71553600#I#RI 0.233 0.651 -0.418 0 Inclusion 28
RI Setdb1 ENSMUSG00000015697#chr3#-#95141070|95142954|95141070|95141187|95142267|95142954#I#RI 0.177 0.516 -0.339 1.40394E-07 Inclusion 24
RI Setdb1 ENSMUSG00000015697#chr3#-#95141070|95142954|95141070|95141187|95142267|95142954#I#RI 0.229 0.527 -0.298 4.05789E-09 Inclusion 26
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RI Setdb1 ENSMUSG00000015697#chr3#-#95141070|95142954|95141070|95141187|95142267|95142954#I#RI 0.203 0.5 -0.297 2.23738E-08 Inclusion 28
RI Surf1 ENSMUSG00000015790#chr2#-#26768902|26769178|26768902|26769025|26769096|26769178#I#RI 0.084 0.464 -0.38 6.46128E-08 Inclusion 26
RI Surf1 ENSMUSG00000015790#chr2#-#26768902|26769178|26768902|26769025|26769096|26769178#I#RI 0.076 0.436 -0.36 7.03042E-05 Inclusion 28
RI Ctsa ENSMUSG00000017760#chr2#+#164659529|164659931|164659529|164659708|164659819|164659931#I#RI 0.031 0.33 -0.299 1.3179E-09 Inclusion 24
RI Ctsa ENSMUSG00000017760#chr2#+#164659529|164659931|164659529|164659708|164659819|164659931#I#RI 0.01 0.283 -0.273 6.66134E-16 Inclusion 28
RI Ppp1r12c
ENSMUSG00000019254#chr7#-#4435075|4435335|4435075|
4435159|4435244|4435335#I#RI 0.108 0.373 -0.265 1.41617E-05 Inclusion 24
RI Ppp1r12c
ENSMUSG00000019254#chr7#-#4435075|4435335|4435075|
4435159|4435244|4435335#I#RI 0.077 0.297 -0.22 8.90199E-11 Inclusion 26
RI Ppp1r12c
ENSMUSG00000019254#chr7#-#4435075|4435335|4435075|
4435159|4435244|4435335#I#RI 0.085 0.335 -0.25 2.06208E-07 Inclusion 28
RI Pafah1b1
ENSMUSG00000020745#chr11#-#74487451|74493116|
74487451|74491244|74492959|74493116#I#RI 0.045 1 -0.955 0 Inclusion 24
RI Pafah1b1
ENSMUSG00000020745#chr11#-#74487451|74493116|
74487451|74491244|74492959|74493116#I#RI 0.029 1 -0.971 0 Inclusion 26
RI Tmem44
ENSMUSG00000022537#chr16#-#30540824|30543574|
30540824|30540995|30543487|30543574#I#RI 0.22 0.519 -0.299 2.099E-06 Inclusion 24
RI Tmem44
ENSMUSG00000022537#chr16#-#30540824|30543574|
30540824|30540995|30543487|30543574#I#RI 0.189 0.558 -0.369 0 Inclusion 26
RI Tmem44
ENSMUSG00000022537#chr16#-#30540824|30543574|
30540824|30540995|30543487|30543574#I#RI 0.162 0.533 -0.371 0 Inclusion 28
RI Adck5 ENSMUSG00000022550#chr15#+#76424582|76424877|76424582|76424714|76424793|76424877#I#RI 0.038 0.74 -0.702 0.00192554 Inclusion 24
RI Adck5 ENSMUSG00000022550#chr15#+#76424582|76424877|76424582|76424714|76424793|76424877#I#RI 0.125 0.426 -0.301 0.009885559 Inclusion 26
RI Adck5 ENSMUSG00000022550#chr15#+#76424582|76424877|76424582|76424714|76424793|76424877#I#RI 0 0.533 -0.533 1.05755E-05 Inclusion 28
RI Gpaa1 ENSMUSG00000022561#chr15#+#76162589|76163061|76162589|76162701|76162913|76163061#I#RI 0.192 0.426 -0.234 0.002959909 Inclusion 24
RI Gpaa1 ENSMUSG00000022561#chr15#+#76162589|76163061|76162589|76162701|76162913|76163061#I#RI 0.181 0.447 -0.266 4.2544E-08 Inclusion 26
RI Gpaa1 ENSMUSG00000022561#chr15#+#76162589|76163061|76162589|76162701|76162913|76163061#I#RI 0.164 0.46 -0.296 2.09818E-06 Inclusion 28
RI Rabl2 ENSMUSG00000022621#chr15#-#89414340|89414821|89414340|89414438|89414709|89414821#I#RI 0.191 0.424 -0.233 0.018711761 Inclusion 24
RI Rabl2 ENSMUSG00000022621#chr15#-#89414340|89414821|89414340|89414438|89414709|89414821#I#RI 0.204 0.732 -0.528 1.65253E-11 Inclusion 26
RI Rabl2 ENSMUSG00000022621#chr15#-#89414340|89414821|89414340|89414438|89414709|89414821#I#RI 0.215 0.782 -0.567 5.81561E-09 Inclusion 28
RI Lmbr1l ENSMUSG00000022999#chr15#-#98738950|98739190|98738950|98739027|98739106|98739190#I#RI 0.085 0.457 -0.372 0.000230104 Inclusion 26
RI Lmbr1l ENSMUSG00000022999#chr15#-#98738950|98739190|98738950|98739027|98739106|98739190#I#RI 0 0.433 -0.433 0.000240227 Inclusion 28
RI Prpf40b
ENSMUSG00000023007#chr15#+#99145273|99145717|
99145273|99145411|99145621|99145717#I#RI 0.105 0.389 -0.284 0.002555533 Inclusion 24
RI Prpf40b
ENSMUSG00000023007#chr15#+#99145273|99145717|
99145273|99145411|99145621|99145717#I#RI 0.141 0.349 -0.208 0.000732996 Inclusion 26
RI Prpf40b
ENSMUSG00000023007#chr15#+#99145273|99145717|
99145273|99145411|99145621|99145717#I#RI 0.155 0.466 -0.311 0.000407326 Inclusion 28
RI Prmt5 ENSMUSG00000023110#chr14#-#55134942|55135452|55134942|55135028|55135333|55135452#I#RI 0.034 0.384 -0.35 7.68439E-07 Inclusion 24
RI Prmt5 ENSMUSG00000023110#chr14#-#55134942|55135452|55134942|55135028|55135333|55135452#I#RI 0.037 0.442 -0.405 1.27676E-14 Inclusion 26































24357196|24357255|24357461|24357560#I#RI 0.063 0.312 -0.249 0.014849602 Inclusion 28
RI Snrpc ENSMUSG00000024217#chr17#+#27977408|27979323|27977408|27977451|27979214|27979323#E#RI 1 0.026 0.974 0.000615055 Exclusion 26
RI Snrpc ENSMUSG00000024217#chr17#+#27977408|27979323|27977408|27977451|27979214|27979323#E#RI 1 0.015 0.985 0.000923936 Exclusion 28
RI Zfp523 ENSMUSG00000024220#chr17#+#28338205|28339293|28338205|28338385|28339059|28339293#I#RI 0.278 0.525 -0.247 0.007628416 Inclusion 26
RI Zfp523 ENSMUSG00000024220#chr17#+#28338205|28339293|28338205|28338385|28339059|28339293#I#RI 0.271 0.66 -0.389 0.001086391 Inclusion 28
RI Adamts10
ENSMUSG00000024299#chr17#+#33675012|33675355|
33675012|33675118|33675208|33675355#I#RI 0.491 1 -0.509 4.79708E-08 Inclusion 26
RI Adamts10
ENSMUSG00000024299#chr17#+#33675012|33675355|
33675012|33675118|33675208|33675355#I#RI 0.48 1 -0.52 8.35715E-05 Inclusion 28
RI Mus81 ENSMUSG00000024906#chr19#-#5483454|5483665|5483454|5483558|5483634|5483665#I#RI 0.183 0.456 -0.273 0.003465341 Inclusion 26
RI Mus81 ENSMUSG00000024906#chr19#-#5483454|5483665|5483454|5483558|5483634|5483665#I#RI 0.154 0.486 -0.332 0.001790184 Inclusion 28
RI Mbd6 ENSMUSG00000025409#chr10#-#126724451|126724746|126724451|126724594|126724682|126724746#I#RI 0.167 0.506 -0.339 0.011542965 Inclusion 26
RI Mbd6 ENSMUSG00000025409#chr10#-#126724451|126724746|126724451|126724594|126724682|126724746#I#RI 0.141 0.621 -0.48 0.002576984 Inclusion 28
RI Wdr73 ENSMUSG00000025722#chr7#-#88045529|88046120|88045529|88045597|88046070|88046120#I#RI 0.35 0.686 -0.336 0.044659849 Inclusion 24












26013605|26013684|26013894|26014114#I#RI 0.497 0.759 -0.262 0.025727393 Inclusion 28
RI Wdr75 ENSMUSG00000025995#chr1#+#45874107|45875109|45874107|45874288|45875014|45875109#I#RI 0.039 1 -0.961 4.81837E-14 Inclusion 26
RI Wdr75 ENSMUSG00000025995#chr1#+#45874107|45875109|45874107|45874288|45875014|45875109#I#RI 0.033 1 -0.967 1.57697E-11 Inclusion 28
RI Glb1l ENSMUSG00000026200#chr1#-#75205261|75205797|75205261|75205412|75205630|75205797#I#RI 0.259 1 -0.741 0.005249216 Inclusion 24
RI Glb1l ENSMUSG00000026200#chr1#-#75205261|75205797|75205261|75205412|75205630|75205797#I#RI 0.273 1 -0.727 0.001045687 Inclusion 26
RI Golga1 ENSMUSG00000026754#chr2#-#38902542|38903286|38902542|38902654|38903116|38903286#I#RI 0.086 0.304 -0.218 3.5293E-06 Inclusion 26
RI Golga1 ENSMUSG00000026754#chr2#-#38902542|38903286|38902542|38902654|38903116|38903286#I#RI 0.147 0.366 -0.219 0.002931971 Inclusion 28
RI Fxr1 ENSMUSG00000027680#chr3#+#33956945|33957153|33956945|33957003|33957090|33957153#E#RI 1 0.392 0.608 1.19604E-08 Exclusion 24
RI Fxr1 ENSMUSG00000027680#chr3#+#33956945|33957153|33956945|33957003|33957090|33957153#E#RI 1 0.351 0.649 2.55351E-15 Exclusion 28
RI Ampd2 ENSMUSG00000027889#chr3#-#107882102|107882691|107882102|107882244|107882504|107882691#I#RI 0.238 0.606 -0.368 0.000189937 Inclusion 24
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RI Ampd2 ENSMUSG00000027889#chr3#-#107882102|107882691|107882102|107882244|107882504|107882691#I#RI 0.249 0.616 -0.367 1.12607E-10 Inclusion 26
RI Ampd2 ENSMUSG00000027889#chr3#-#107882102|107882691|107882102|107882244|107882504|107882691#I#RI 0.223 0.528 -0.305 1.12186E-05 Inclusion 28
RI Fancg ENSMUSG00000028453#chr4#-#43019855|43020275|43019855|43019986|43020139|43020275#I#RI 0.072 1 -0.928 0.000454379 Inclusion 24
RI Fancg ENSMUSG00000028453#chr4#-#43019855|43020275|43019855|43019986|43020139|43020275#I#RI 0.081 0.749 -0.668 1.76959E-06 Inclusion 26
RI Fancg ENSMUSG00000028453#chr4#-#43019855|43020275|43019855|43019986|43020139|43020275#I#RI 0.13 0.68 -0.55 0.000661507 Inclusion 28
RI Gba2 ENSMUSG00000028467#chr4#-#43582360|43582827|43582360|43582533|43582701|43582827#I#RI 0.069 0.383 -0.314 5.86329E-05 Inclusion 24
RI Gba2 ENSMUSG00000028467#chr4#-#43582360|43582827|43582360|43582533|43582701|43582827#I#RI 0.089 0.309 -0.22 0.000565167 Inclusion 28
RI Gba2 ENSMUSG00000028467#chr4#-#43582908|43583320|43582908|43583062|43583217|43583320#I#RI 0.15 0.47 -0.32 0.000140603 Inclusion 24
RI Gba2 ENSMUSG00000028467#chr4#-#43582908|43583320|43582908|43583062|43583217|43583320#I#RI 0.09 0.393 -0.303 3.78697E-13 Inclusion 26
RI Gba2 ENSMUSG00000028467#chr4#-#43582908|43583320|43582908|43583062|43583217|43583320#I#RI 0.061 0.464 -0.403 6.10623E-15 Inclusion 28
RI Mutyh ENSMUSG00000028687#chr4#+#116490492|116490887|116490492|116490642|116490845|116490887#I#RI 0.396 0.816 -0.42 0.003751198 Inclusion 26
RI Mutyh ENSMUSG00000028687#chr4#+#116490492|116490887|116490492|116490642|116490845|116490887#I#RI 0.287 0.853 -0.566 0.009732033 Inclusion 28
RI Ccnl2 ENSMUSG00000029068#chr4#+#155192031|155194537|155192031|155192096|155194437|155194537#I#RI 0.459 0.731 -0.272 1.0907E-06 Inclusion 26
RI Ccnl2 ENSMUSG00000029068#chr4#+#155192031|155194537|155192031|155192096|155194437|155194537#I#RI 0.483 0.827 -0.344 3.42264E-07 Inclusion 28
RI Dvl1 ENSMUSG00000029071#chr4#+#155227745|155228195|155227745|155227867|155228091|155228195#I#RI 0.128 0.628 -0.5 1.66278E-09 Inclusion 24
RI Dvl1 ENSMUSG00000029071#chr4#+#155227745|155228195|155227745|155227867|155228091|155228195#I#RI 0.174 0.644 -0.47 5.55112E-16 Inclusion 26
RI Dvl1 ENSMUSG00000029071#chr4#+#155227745|155228195|155227745|155227867|155228091|155228195#I#RI 0.161 0.592 -0.431 1.95475E-10 Inclusion 28
RI Gtf3c2 ENSMUSG00000029144#chr5#-#31461806|31462234|31461806|31461894|31462072|31462234#I#RI 0.07 0.355 -0.285 1.29751E-11 Inclusion 24
RI Gtf3c2 ENSMUSG00000029144#chr5#-#31461806|31462234|31461806|31461894|31462072|31462234#I#RI 0.107 0.391 -0.284 1.11022E-16 Inclusion 26
RI Gtf3c2 ENSMUSG00000029144#chr5#-#31461806|31462234|31461806|31461894|31462072|31462234#I#RI 0.079 0.398 -0.319 0 Inclusion 28
RI Slc30a9
ENSMUSG00000029221#chr5#+#67733332|67735808|
67733332|67733468|67735768|67735808#I#RI 0.103 0.305 -0.202 0.000453577 Inclusion 24
RI Slc30a9
ENSMUSG00000029221#chr5#+#67733332|67735808|
67733332|67733468|67735768|67735808#I#RI 0.08 0.3 -0.22 3.07688E-11 Inclusion 26
RI Slc30a9
ENSMUSG00000029221#chr5#+#67733332|67735808|
67733332|67733468|67735768|67735808#I#RI 0.08 0.364 -0.284 2.13227E-11 Inclusion 28
RI Ddx51 ENSMUSG00000029504#chr5#+#111084325|111084692|111084325|111084432|111084583|111084692#I#RI 0.069 0.333 -0.264 0.002567733 Inclusion 24
RI Ddx51 ENSMUSG00000029504#chr5#+#111084325|111084692|111084325|111084432|111084583|111084692#I#RI 0.052 0.305 -0.253 3.24941E-05 Inclusion 26
RI Ddx51 ENSMUSG00000029504#chr5#+#111084325|111084692|111084325|111084432|111084583|111084692#I#RI 0.042 0.352 -0.31 1.73311E-05 Inclusion 28
RI Wbp1 ENSMUSG00000030035#chr6#-#83070178|83070870|83070178|83070281|83070765|83070870#I#RI 0.097 0.299 -0.202 4.2517E-05 Inclusion 24
RI Wbp1 ENSMUSG00000030035#chr6#-#83070178|83070870|83070178|83070281|83070765|83070870#I#RI 0.091 0.372 -0.281 9.12381E-13 Inclusion 28
RI Fam98c
ENSMUSG00000030590#chr7#-#29938340|29939554|
29938340|29938508|29939437|29939554#I#RI 0.17 0.543 -0.373 9.09503E-06 Inclusion 26
RI Fam98c
ENSMUSG00000030590#chr7#-#29938340|29939554|
29938340|29938508|29939437|29939554#I#RI 0.229 0.752 -0.523 0.000248088 Inclusion 28
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RI Phkg2 ENSMUSG00000030815#chr7#+#134721048|134721543|134721048|134721224|134721488|134721543#I#RI 0.267 0.596 -0.329 3.50088E-05 Inclusion 26
RI Phkg2 ENSMUSG00000030815#chr7#+#134721048|134721543|134721048|134721224|134721488|134721543#I#RI 0.268 0.533 -0.265 0.00803002 Inclusion 28
RI Renbp ENSMUSG00000031387#chrX#-#71174454|71175856|71174454|71175601|71175746|71175856#I#RI 0 0.251 -0.251 0.011750228 Inclusion 24
RI Renbp ENSMUSG00000031387#chrX#-#71174454|71175856|71174454|71175601|71175746|71175856#I#RI 0 0.207 -0.207 0.000326781 Inclusion 26
RI Adamts7
ENSMUSG00000032363#chr9#+#90087862|90089107|
90087862|90088703|90088880|90089107#I#RI 0.331 0.583 -0.252 0.002253733 Inclusion 26
RI Adamts7
ENSMUSG00000032363#chr9#+#90087862|90089107|
90087862|90088703|90088880|90089107#I#RI 0.408 0.678 -0.27 0.003870919 Inclusion 28
RI Parl ENSMUSG00000033918#chr16#-#20285837|20287142|20285837|20285908|20286992|20287142#I#RI 0.034 1 -0.966 1.99549E-08 Inclusion 24
RI Parl ENSMUSG00000033918#chr16#-#20285837|20287142|20285837|20285908|20286992|20287142#I#RI 0.039 1 -0.961 3.33067E-16 Inclusion 26
RI Mrps17
ENSMUSG00000034211#chr5#+#130221558|130222741|
130221558|130221785|130222601|130222741#I#RI 0.377 0.678 -0.301 0.005040861 Inclusion 24
RI Mrps17
ENSMUSG00000034211#chr5#+#130221558|130222741|
130221558|130221785|130222601|130222741#I#RI 0.354 0.672 -0.318 2.02017E-06 Inclusion 26
RI Mrps17
ENSMUSG00000034211#chr5#+#130221558|130222741|
130221558|130221785|130222601|130222741#I#RI 0.359 0.659 -0.3 0.000559077 Inclusion 28
RI Ccdc106
ENSMUSG00000035228#chr7#+#5011097|5012387|5011097|
5011307|5011808|5012387#E#RI 1 0.175 0.825 0.000584666 Exclusion 24
RI Ccdc106
ENSMUSG00000035228#chr7#+#5011097|5012387|5011097|
5011307|5011808|5012387#E#RI 0.47 0.113 0.357 1.58035E-05 Exclusion 26
RI Ccdc106
ENSMUSG00000035228#chr7#+#5011097|5012387|5011097|
5011307|5011808|5012387#E#RI 0.52 0.204 0.316 0.032997048 Exclusion 28
RI Ankrd13b
ENSMUSG00000037907#chr11#-#77285950|77286379|
77285950|77286114|77286226|77286379#I#RI 0.12 0.454 -0.334 5.62411E-08 Inclusion 26
RI Ankrd13b
ENSMUSG00000037907#chr11#-#77285950|77286379|
77285950|77286114|77286226|77286379#I#RI 0.152 0.573 -0.421 3.50351E-05 Inclusion 28
RI Arfrp1 ENSMUSG00000038671#chr2#-#181098718|181099103|181098718|181098801|181099015|181099103#I#RI 0.136 0.368 -0.232 2.82471E-09 Inclusion 26
RI Arfrp1 ENSMUSG00000038671#chr2#-#181098718|181099103|181098718|181098801|181099015|181099103#I#RI 0.14 0.403 -0.263 1.01031E-07 Inclusion 28
RI Rtel1 ENSMUSG00000038685#chr2#+#181086280|181086658|181086280|181086404|181086507|181086658#I#RI 0.089 0.579 -0.49 6.60605E-12 Inclusion 26
RI Rtel1 ENSMUSG00000038685#chr2#+#181086280|181086658|181086280|181086404|181086507|181086658#I#RI 0.117 0.519 -0.402 2.7993E-06 Inclusion 28
RI Rccd1 ENSMUSG00000038930#chr7#-#87465187|87466067|87465187|87465584|87465747|87466067#I#RI 0.642 1 -0.358 0.038897274 Inclusion 26
RI Rccd1 ENSMUSG00000038930#chr7#-#87465187|87466067|87465187|87465584|87465747|87466067#I#RI 0.4 1 -0.6 0.002898018 Inclusion 28
RI Ciz1 ENSMUSG00000039205#chr2#+#32226383|32226928|32226383|32226621|32226768|32226928#I#RI 0.435 0.693 -0.258 0.032505825 Inclusion 24
RI Ciz1 ENSMUSG00000039205#chr2#+#32226383|32226928|32226383|32226621|32226768|32226928#I#RI 0.412 0.782 -0.37 4.09865E-05 Inclusion 28
RI D2Wsu81e
ENSMUSG00000039660#chr2#-#30033112|30033485|
30033112|30033241|30033439|30033485#I#RI 0.141 0.348 -0.207 0.009211287 Inclusion 24
RI D2Wsu81e
ENSMUSG00000039660#chr2#-#30033112|30033485|
30033112|30033241|30033439|30033485#I#RI 0.066 0.374 -0.308 1.35579E-11 Inclusion 28
RI Skiv2l ENSMUSG00000040356#chr17#-#34983811|34984269|34983811|34983940|34984087|34984269#I#RI 0.088 0.328 -0.24 0.001183662 Inclusion 24
RI Skiv2l ENSMUSG00000040356#chr17#-#34983811|34984269|34983811|34983940|34984087|34984269#I#RI 0.118 0.392 -0.274 6.19612E-07 Inclusion 26
RI Skiv2l ENSMUSG00000040356#chr17#-#34983811|34984269|34983811|34983940|34984087|34984269#I#RI 0.078 0.371 -0.293 6.28835E-08 Inclusion 28
RI Ankle1 ENSMUSG00000046295#chr8#+#73930760|73931648|73930760|73930872|73931111|73931648#I#RI 0.563 1 -0.437 0.034193751 Inclusion 24
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RI Ankle1 ENSMUSG00000046295#chr8#+#73930760|73931648|73930760|73930872|73931111|73931648#I#RI 0.321 0.637 -0.316 0.029089012 Inclusion 26
RI Zfp672 ENSMUSG00000049755#chr11#-#58132825|58133456|58132825|58133092|58133368|58133456#I#RI 0.339 1 -0.661 0.001541971 Inclusion 26
RI Zfp672 ENSMUSG00000049755#chr11#-#58132825|58133456|58132825|58133092|58133368|58133456#I#RI 0.446 1 -0.554 0.044427403 Inclusion 28
RI Pddc1 ENSMUSG00000051007#chr7#-#148595744|148596784|148595744|148595839|148596676|148596784#I#RI 0.095 0.346 -0.251 0.001822531 Inclusion 24
RI Pddc1 ENSMUSG00000051007#chr7#-#148595744|148596784|148595744|148595839|148596676|148596784#I#RI 0.07 0.493 -0.423 1.11022E-16 Inclusion 26












43511767|43511888|43512114|43512209#I#RI 0.101 0.317 -0.216 0.002051484 Inclusion 28
RI Txlna ENSMUSG00000053841#chr4#-#129308523|129308954|129308523|129308598|129308834|129308954#I#RI 0.052 0.26 -0.208 1.22741E-10 Inclusion 24
RI Txlna ENSMUSG00000053841#chr4#-#129308523|129308954|129308523|129308598|129308834|129308954#I#RI 0.058 0.28 -0.222 0 Inclusion 26
RI Txlna ENSMUSG00000053841#chr4#-#129308523|129308954|129308523|129308598|129308834|129308954#I#RI 0.051 0.311 -0.26 0 Inclusion 28
RI Tmem191c
ENSMUSG00000055692#chr16#+#17277054|17277343|
17277054|17277132|17277286|17277343#I#RI 0.391 1 -0.609 0.019734821 Inclusion 24
RI Tmem191c
ENSMUSG00000055692#chr16#+#17277054|17277343|












106534580|106536060|106537275|106537536#I#RI 0.089 1 -0.911 1.33509E-05 Inclusion 28
RI Cep110
ENSMUSG00000057110#chr2#+#35031057|35031842|
35031057|35031120|35031647|35031842#I#RI 0.199 0.592 -0.393 0.000112248 Inclusion 24
RI Cep110
ENSMUSG00000057110#chr2#+#35031057|35031842|
35031057|35031120|35031647|35031842#I#RI 0.205 0.598 -0.393 1.87152E-08 Inclusion 26
RI Cep110
ENSMUSG00000057110#chr2#+#35031057|35031842|
35031057|35031120|35031647|35031842#I#RI 0.209 0.743 -0.534 1.70719E-08 Inclusion 28
RI Mtfmt ENSMUSG00000059183#chr9#+#65288152|65289495|65288152|65288255|65289419|65289495#I#RI 0.278 0.67 -0.392 0.001966768 Inclusion 26
RI Mtfmt ENSMUSG00000059183#chr9#+#65288152|65289495|65288152|65288255|65289419|65289495#I#RI 0.175 0.58 -0.405 0.004284988 Inclusion 28
RI Slx1b ENSMUSG00000059772#chr7#-#133835252|133835569|133835252|133835337|133835441|133835569#I#RI 0.072 1 -0.928 0.002142478 Inclusion 24
RI Slx1b ENSMUSG00000059772#chr7#-#133835252|133835569|133835252|133835337|133835441|133835569#I#RI 0.087 0.347 -0.26 0.033585697 Inclusion 26
RI Ppox ENSMUSG00000062729#chr1#-#173209560|173210132|173209560|173209705|173209999|173210132#I#RI 0.551 0.883 -0.332 0.000410621 Inclusion 26
RI Ppox ENSMUSG00000062729#chr1#-#173209560|173210132|173209560|173209705|173209999|173210132#I#RI 0.576 0.825 -0.249 0.035772614 Inclusion 28
RI Hdac10
ENSMUSG00000062906#chr15#-#88958023|88958448|
88958023|88958121|88958351|88958448#I#RI 0.182 0.632 -0.45 0.005854858 Inclusion 26
RI Hdac10
ENSMUSG00000062906#chr15#-#88958023|88958448|
88958023|88958121|88958351|88958448#I#RI 0.058 0.741 -0.683 7.6248E-05 Inclusion 28
RI Suds3 ENSMUSG00000066900#chr5#-#117541690|117543040|117541690|117542865|117542954|117543040#I#RI 0.667 0.942 -0.275 0.003483469 Inclusion 24
RI Suds3 ENSMUSG00000066900#chr5#-#117541690|117543040|117541690|117542865|117542954|117543040#I#RI 0.698 0.914 -0.216 0.000223925 Inclusion 26
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RI Clk2 ENSMUSG00000068917#chr3#+#88973536|88974037|88973536|88973624|88973970|88974037#I#RI 0.199 0.421 -0.222 1.3907E-06 Inclusion 26
RI Clk2 ENSMUSG00000068917#chr3#+#88973536|88974037|88973536|88973624|88973970|88974037#I#RI 0.212 0.493 -0.281 5.30586E-07 Inclusion 28
RI H2-Ke6
ENSMUSG00000073422#chr17#-#34164350|34164785|
34164350|34164467|34164567|34164785#I#RI 0.129 0.406 -0.277 0.000886798 Inclusion 26
RI H2-Ke6
ENSMUSG00000073422#chr17#-#34164350|34164785|
34164350|34164467|34164567|34164785#I#RI 0.18 0.697 -0.517 7.724E-06 Inclusion 28
RI Fnbp1 ENSMUSG00000075415#chr2#-#30881725|30888708|30881725|30884403|30888549|30888708#I#RI 0.168 0.395 -0.227 2.84155E-10 Inclusion 26
RI Fnbp1 ENSMUSG00000075415#chr2#-#30881725|30888708|30881725|30884403|30888549|30888708#I#RI 0.168 0.385 -0.217 1.5108E-06 Inclusion 28
RI U2af1l4
ENSMUSG00000078765#chr7#+#31351767|31352519|
31351767|31351955|31352161|31352519#I#RI 0.661 1 -0.339 0.045409142 Inclusion 24
RI U2af1l4
ENSMUSG00000078765#chr7#+#31351767|31352519|
31351767|31351955|31352161|31352519#I#RI 0.562 0.885 -0.323 0.015834381 Inclusion 26
RI Pms2 ENSMUSG00000079109#chr5#+#144688967|144689911|144688967|144689135|144689810|144689911#I#RI 0.105 0.424 -0.319 0.007555295 Inclusion 24
RI Pms2 ENSMUSG00000079109#chr5#+#144688967|144689911|144688967|144689135|144689810|144689911#I#RI 0.104 0.342 -0.238 0.000893702 Inclusion 26
RI Pms2 ENSMUSG00000079109#chr5#+#144688967|144689911|144688967|144689135|144689810|144689911#I#RI 0.071 0.45 -0.379 1.43581E-05 Inclusion 28
RI Med12 ENSMUSG00000079487#chrX#+#98489296|98489514|98489296|98489351|98489426|98489514#I#RI 0.645 0.924 -0.279 0.001485339 Inclusion 26
RI Med12 ENSMUSG00000079487#chrX#+#98489296|98489514|98489296|98489351|98489426|98489514#I#RI 0.638 0.909 -0.271 0.006853576 Inclusion 28
RI Fxc1 ENSMUSG00000089847#chr7#+#112789275|112789742|112789275|112789371|112789541|112789742#I#RI 0.109 0.441 -0.332 3.83637E-08 Inclusion 24
RI Fxc1 ENSMUSG00000089847#chr7#+#112789275|112789742|112789275|112789371|112789541|112789742#I#RI 0.125 0.488 -0.363 0 Inclusion 26
SE Dazap2
ENSMUSG00000000346#chr15#+#100447343|100447462|
100446068|100446155|100448355|100448601#E#SE 1 0.782 0.218 2.25247E-06 Exclusion 24
SE Dazap2
ENSMUSG00000000346#chr15#+#100447343|100447462|
100446068|100446155|100448355|100448601#E#SE 1 0.694 0.306 2.22045E-16 Exclusion 28
SE Epn2 ENSMUSG00000001036#chr11#-#61361509|61361544|61360193|61360413|61367011|61367081#E#SE 0.566 0.255 0.311 0.018567268 Exclusion 26
SE Epn2 ENSMUSG00000001036#chr11#-#61361509|61361544|61360193|61360413|61367011|61367081#E#SE 0.771 0.429 0.342 0.020723293 Exclusion 28
SE Epn2 ENSMUSG00000001036#chr11#-#61361509|61361544|61360193|61360413|61379323|61379396#E#SE 0.897 0.536 0.361 0.034887346 Exclusion 26
SE Epn2 ENSMUSG00000001036#chr11#-#61361509|61361544|61360193|61360413|61379323|61379396#E#SE 0.861 0.469 0.392 0.023004204 Exclusion 28
SE Sec24b
ENSMUSG00000001052#chr3#-#129723455|129723560|
129714709|129714790|129736748|129736892#E#SE 0.362 0.118 0.244 0.001674111 Exclusion 24
SE Sec24b
ENSMUSG00000001052#chr3#-#129723455|129723560|
129714709|129714790|129736748|129736892#E#SE 0.389 0.159 0.23 0.001185177 Exclusion 28
SE Zdhhc4
ENSMUSG00000001844#chr5#-#144090356|144090576|
144090069|144090249|144090844|144090907#I#SE 0.229 0.55 -0.321 0.046075977 Inclusion 24
SE Zdhhc4
ENSMUSG00000001844#chr5#-#144090356|144090576|
144090069|144090249|144090844|144090907#I#SE 0.365 0.641 -0.276 0.049496165 Inclusion 26
SE Ap4e1 ENSMUSG00000001998#chr2#+#126835406|126835611|126834487|126834636|126837526|126837598#I#SE 0.069 0.35 -0.281 0.017315841 Inclusion 24
SE Ap4e1 ENSMUSG00000001998#chr2#+#126835406|126835611|126834487|126834636|126837526|126837598#I#SE 0.031 0.373 -0.342 6.91713E-06 Inclusion 26
SE Syce2 ENSMUSG00000003824#chr8#+#87407329|87407483|87396618|87396731|87409833|87410022#E#SE 0.582 0.254 0.328 0.001435977 Exclusion 24
SE Syce2 ENSMUSG00000003824#chr8#+#87407329|87407483|87396618|87396731|87409833|87410022#E#SE 0.561 0.207 0.354 2.62207E-06 Exclusion 26
SE Syce2 ENSMUSG00000003824#chr8#+#87407329|87407483|87396618|87396731|87409833|87410022#E#SE 0.479 0.149 0.33 2.94951E-05 Exclusion 28
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SE Slc2a9 ENSMUSG00000005107#chr5#-#38808413|38808546|38782952|38783063|38827778|38827924#I#SE 0 1 -1 0.000396184 Inclusion 24
SE Slc2a9 ENSMUSG00000005107#chr5#-#38808413|38808546|38782952|38783063|38827778|38827924#I#SE 0.258 0.903 -0.645 0.04680775 Inclusion 28
SE Eps15l1
ENSMUSG00000006276#chr8#-#74882211|74882344|
74869864|74870070|74891802|74891885#E#SE 0.568 0.326 0.242 0.004258673 Exclusion 26
SE Eps15l1
ENSMUSG00000006276#chr8#-#74882211|74882344|
74869864|74870070|74891802|74891885#E#SE 0.767 0.464 0.303 0.017718588 Exclusion 28
SE Nfib ENSMUSG00000008575#chr4#-#81956206|81956295|81941984|81942715|81966377|81966460#E#SE 0.443 0 0.443 0.000248746 Exclusion 24
SE Nfib ENSMUSG00000008575#chr4#-#81956206|81956295|81941984|81942715|81966377|81966460#E#SE 0.478 0.098 0.38 0.003478256 Exclusion 28
SE Ptprs ENSMUSG00000013236#chr17#-#56568521|56568580|56564302|56564400|56573875|56574020#E#SE 1 0.509 0.491 0.008377683 Exclusion 24












29423194|29423495|29432806|29432893#E#SE 0.851 0.616 0.235 0.010462864 Exclusion 28
SE Rhot1 ENSMUSG00000017686#chr11#+#80071015|80071138|80069363|80069459|80079243|80080246#I#SE 0.504 1 -0.496 0.010992788 Inclusion 24
SE Rhot1 ENSMUSG00000017686#chr11#+#80071015|80071138|80069363|80069459|80079243|80080246#I#SE 0.402 0.665 -0.263 0.025142356 Inclusion 26
SE Rhot1 ENSMUSG00000017686#chr11#+#80071015|80071138|80069363|80069459|80079243|80080246#I#SE 0.332 0.635 -0.303 0.018163417 Inclusion 28
SE Kif3a ENSMUSG00000018395#chr11#+#53404218|53404227|53400336|53400432|53406875|53407032#E#SE 0.968 0 0.968 1.94435E-07 Exclusion 26
SE Kif3a ENSMUSG00000018395#chr11#+#53404218|53404227|53400336|53400432|53406875|53407032#E#SE 0.9 0 0.9 0.000632293 Exclusion 28
SE Mpdu1 ENSMUSG00000018761#chr11#-#69471437|69471523|69471226|69471345|69472067|69472200#E#SE 0.87 0.54 0.33 0 Exclusion 26
SE Mpdu1 ENSMUSG00000018761#chr11#-#69471437|69471523|69471226|69471345|69472067|69472200#E#SE 0.864 0.547 0.317 1.41398E-10 Exclusion 28
SE Mpdu1 ENSMUSG00000018761#chr11#-#69471437|69471558|69471226|69471345|69472067|69472200#E#SE 0.709 0.497 0.212 0.017321821 Exclusion 24
SE Mpdu1 ENSMUSG00000018761#chr11#-#69471437|69471558|69471226|69471345|69472067|69472200#E#SE 0.774 0.393 0.381 0 Exclusion 26
SE Mpdu1 ENSMUSG00000018761#chr11#-#69471437|69471558|69471226|69471345|69472067|69472200#E#SE 0.771 0.4 0.371 2.89501E-10 Exclusion 28
SE Cep57l1
ENSMUSG00000019813#chr10#-#41448433|41448520|
41443666|41443744|41449136|41449214#E#SE 0.408 0.099 0.309 0.001155744 Exclusion 26
SE Cep57l1
ENSMUSG00000019813#chr10#-#41448433|41448520|
41443666|41443744|41449136|41449214#E#SE 0.376 0.081 0.295 0.006486405 Exclusion 28
SE Tmpo ENSMUSG00000019961#chr10#-#90616022|90616142|90615829|90615925|90621492|90621590#E#SE 0.86 0.496 0.364 6.99441E-15 Exclusion 24
SE Tmpo ENSMUSG00000019961#chr10#-#90616022|90616142|90615829|90615925|90621492|90621590#E#SE 0.845 0.509 0.336 0 Exclusion 26
SE Tmpo ENSMUSG00000019961#chr10#-#90616022|90616142|90615829|90615925|90621492|90621590#E#SE 0.855 0.466 0.389 0 Exclusion 28
SE Mdm2 ENSMUSG00000020184#chr10#-#117146709|117146840|117142210|117142285|117147001|117147084#E#SE 0.919 0.473 0.446 0.004113587 Exclusion 24
SE Mdm2 ENSMUSG00000020184#chr10#-#117146709|117146840|117142210|117142285|117147001|117147084#E#SE 0.84 0.454 0.386 0.00167448 Exclusion 28
SE Mdm2 ENSMUSG00000020184#chr10#-#117146755|117146840|117142210|117142285|117147001|117147078#E#SE 0.959 0.692 0.267 0.012711912 Exclusion 24
SE Mdm2 ENSMUSG00000020184#chr10#-#117146755|117146840|117142210|117142285|117147001|117147078#E#SE 0.913 0.621 0.292 0.001732291 Exclusion 28
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SE Clk4 ENSMUSG00000020385#chr11#+#51082270|51082348|51081666|51081733|51084038|51084097#I#SE 0.442 1 -0.558 0.022919972 Inclusion 24
SE Clk4 ENSMUSG00000020385#chr11#+#51082270|51082348|51081666|51081733|51084038|51084097#I#SE 0.539 1 -0.461 0.034313222 Inclusion 26
SE Clk4 ENSMUSG00000020385#chr11#+#51082270|51082348|51081666|51081733|51084038|51084097#I#SE 0.474 1 -0.526 0.022633817 Inclusion 28
SE Eif4enif1
ENSMUSG00000020454#chr11#+#3133990|3134062|3129871|
3130104|3134464|3134648#E#SE 0.72 0.453 0.267 0.002850471 Exclusion 26
SE Eif4enif1
ENSMUSG00000020454#chr11#+#3133990|3134062|3129871|
3130104|3134464|3134648#E#SE 0.759 0.387 0.372 0.000251809 Exclusion 28
SE Rnf144a
ENSMUSG00000020642#chr12#-#27090183|27090257|
27074258|27074440|27099965|27100121#E#SE 0.325 0 0.325 0.000778227 Exclusion 26
SE Rnf144a
ENSMUSG00000020642#chr12#-#27090183|27090257|
27074258|27074440|27099965|27100121#E#SE 0.504 0.179 0.325 0.045154512 Exclusion 28
SE Mink1 ENSMUSG00000020827#chr11#+#70422909|70422933|70422667|70422756|70423055|70423219#E#SE 0.585 0.124 0.461 0.006442368 Exclusion 24
SE Mink1 ENSMUSG00000020827#chr11#+#70422909|70422933|70422667|70422756|70423055|70423219#E#SE 0.395 0.088 0.307 0.000687888 Exclusion 26
SE Mink1 ENSMUSG00000020827#chr11#+#70422909|70422933|70422667|70422756|70423055|70423219#E#SE 0.574 0.241 0.333 0.019414666 Exclusion 28
SE Luc7l3 ENSMUSG00000020863#chr11#-#94153707|94153786|94152642|94152892|94154240|94154346#I#SE 0.499 1 -0.501 5.96026E-06 Inclusion 26
SE Luc7l3 ENSMUSG00000020863#chr11#-#94153707|94153786|94152642|94152892|94154240|94154346#I#SE 0.652 0.945 -0.293 0.041321073 Inclusion 28
SE Lsm12 ENSMUSG00000020922#chr11#-#102025857|102025950|102025265|102025481|102026673|102026800#I#SE 0.03 1 -0.97 0.001238511 Inclusion 24
SE Lsm12 ENSMUSG00000020922#chr11#-#102025857|102025950|102025265|102025481|102026673|102026800#I#SE 0 1 -1 8.75084E-05 Inclusion 28
SE Eif2s1 ENSMUSG00000021116#chr12#+#79980937|79981044|79978078|79978230|79982118|79982216#I#SE 0.338 1 -0.662 7.28297E-06 Inclusion 24
SE Eif2s1 ENSMUSG00000021116#chr12#+#79980937|79981044|79978078|79978230|79982118|79982216#I#SE 0.435 1 -0.565 2.95404E-05 Inclusion 26
SE Erh ENSMUSG00000021131#chr12#-#81738476|81738597|81735008|81735514|81741943|81742031#E#SE 0.872 0.453 0.419 0.000329504 Exclusion 26
SE Erh ENSMUSG00000021131#chr12#-#81738476|81738597|81735008|81735514|81741943|81742031#E#SE 0.876 0.201 0.675 0.001112057 Exclusion 28
SE Isca2 ENSMUSG00000021241#chr12#+#86114742|86114858|86114524|86114627|86115492|86116039#E#SE 0.858 0.607 0.251 0.00315283 Exclusion 24
SE Isca2 ENSMUSG00000021241#chr12#+#86114742|86114858|86114524|86114627|86115492|86116039#E#SE 0.778 0.467 0.311 3.39383E-08 Exclusion 26
SE Isca2 ENSMUSG00000021241#chr12#+#86114742|86114858|86114524|86114627|86115492|86116039#E#SE 0.783 0.576 0.207 0.00805817 Exclusion 28
SE Ylpm1 ENSMUSG00000021244#chr12#+#86369719|86371837|86355650|86356543|86374866|86374984#E#SE 1 0.778 0.222 0.013352701 Exclusion 24
SE Ylpm1 ENSMUSG00000021244#chr12#+#86369719|86371837|86355650|86356543|86374866|86374984#E#SE 1 0.785 0.215 0.000282666 Exclusion 26
SE Fam193b
ENSMUSG00000021495#chr13#-#55665880|55665941|
55657343|55657586|55671065|55672481#I#SE 0.722 1 -0.278 0.030234593 Inclusion 24
SE Fam193b
ENSMUSG00000021495#chr13#-#55665880|55665941|
55657343|55657586|55671065|55672481#I#SE 0.74 1 -0.26 0.001644235 Inclusion 26
SE Erbb2ip
ENSMUSG00000021709#chr13#-#104617986|104618103|
104614799|104615006|104623577|104625108#E#SE 0.929 0.514 0.415 0.000568275 Exclusion 24
SE Erbb2ip
ENSMUSG00000021709#chr13#-#104617986|104618103|
104614799|104615006|104623577|104625108#E#SE 0.843 0.568 0.275 0.000961604 Exclusion 26
SE Brd1 ENSMUSG00000022387#chr15#-#88526790|88527104|88522178|88522314|88531202|88531307#E#SE 1 0.039 0.961 0.00111092 Exclusion 24
SE Brd1 ENSMUSG00000022387#chr15#-#88526790|88527104|88522178|88522314|88531202|88531307#E#SE 1 0.019 0.981 0.012520089 Exclusion 28
SE Tmem44
ENSMUSG00000022537#chr16#-#30549478|30549543|




30547428|30547555|30550448|30550656#I#SE 0.432 0.739 -0.307 0.000795269 Inclusion 28
SE Fam86 ENSMUSG00000022544#chr16#-#5249004|5249138|5248657|5248923|5249439|5249541#E#SE 1 0.77 0.23 0.024958539 Exclusion 26
SE Fam86 ENSMUSG00000022544#chr16#-#5249004|5249138|5248657|5248923|5249439|5249541#E#SE 1 0.675 0.325 0.015627113 Exclusion 28
SE Ntan1 ENSMUSG00000022681#chr16#+#13826975|13827078|13819417|13819529|13827152|13827218#E#SE 0.552 0.32 0.232 0.03901906 Exclusion 24
SE Ntan1 ENSMUSG00000022681#chr16#+#13826975|13827078|13819417|13819529|13827152|13827218#E#SE 0.503 0.265 0.238 8.09534E-05 Exclusion 26
SE Top3b ENSMUSG00000022779#chr16#+#16875161|16875248|16870866|16870922|16877924|16878109#E#SE 1 0 1 0.001490057 Exclusion 24
SE Top3b ENSMUSG00000022779#chr16#+#16875161|16875248|16870866|16870922|16877924|16878109#E#SE 0.398 0.042 0.356 0.007582168 Exclusion 28
SE Top3b ENSMUSG00000022779#chr16#+#16875164|16875248|16870849|16870922|16877924|16878109#E#SE 1 0 1 0.00147932 Exclusion 24
SE Top3b ENSMUSG00000022779#chr16#+#16875164|16875248|16870849|16870922|16877924|16878109#E#SE 0.449 0.043 0.406 0.002518242 Exclusion 28
SE Tmbim6
ENSMUSG00000023010#chr15#+#99230087|99230302|
99223416|99223471|99232010|99232094#E#SE 1 0.09 0.91 5.85925E-07 Exclusion 24
SE Tmbim6
ENSMUSG00000023010#chr15#+#99230087|99230302|
99223416|99223471|99232010|99232094#E#SE 1 0.064 0.936 1.45328E-13 Exclusion 28
SE Tmbim6
ENSMUSG00000023010#chr15#+#99230491|99230638|
99223452|99223471|99232010|99232094#E#SE 1 0.014 0.986 0.001893811 Exclusion 24
SE Tmbim6
ENSMUSG00000023010#chr15#+#99230491|99230638|
99223452|99223471|99232010|99232094#E#SE 1 0.018 0.982 0.021217638 Exclusion 28
SE Csad ENSMUSG00000023044#chr15#-#102010259|102010324|102009951|102010033|102010401|102010518#E#SE 0.918 0.623 0.295 0.000710629 Exclusion 26
SE Csad ENSMUSG00000023044#chr15#-#102010259|102010324|102009951|102010033|102010401|102010518#E#SE 1 0.731 0.269 0.002475197 Exclusion 28
SE Prmt5 ENSMUSG00000023110#chr14#-#55132127|55132291|55130829|55130991|55133433|55133483#E#SE 0.966 0.016 0.95 0 Exclusion 24
SE Prmt5 ENSMUSG00000023110#chr14#-#55132127|55132291|55130829|55130991|55133433|55133483#E#SE 0.859 0.005 0.854 0 Exclusion 26
SE Prmt5 ENSMUSG00000023110#chr14#-#55132127|55132291|55130829|55130991|55133433|55133483#E#SE 0.82 0 0.82 0 Exclusion 28
SE Luc7l ENSMUSG00000024188#chr17#+#26390918|26390989|26389943|26390036|26391975|26392070#I#SE 0.236 0.819 -0.583 0.000123979 Inclusion 24
SE Luc7l ENSMUSG00000024188#chr17#+#26390918|26390989|26389943|26390036|26391975|26392070#I#SE 0.303 0.823 -0.52 2.63809E-10 Inclusion 26
SE Svil ENSMUSG00000024236#chr18#+#5060512|5060608|5059227|5059367|5062159|5062403#I#SE 0.092 0.362 -0.27 0.036996887 Inclusion 24
SE Svil ENSMUSG00000024236#chr18#+#5060512|5060608|5059227|5059367|5062159|5062403#I#SE 0.034 0.293 -0.259 0.00019242 Inclusion 28
SE Bin1 ENSMUSG00000024381#chr18#+#32585877|32586006|32584473|32584621|32591324|32591396#I#SE 0.59 0.883 -0.293 5.57088E-06 Inclusion 26
SE Bin1 ENSMUSG00000024381#chr18#+#32585877|32586006|32584473|32584621|32591324|32591396#I#SE 0.592 0.842 -0.25 0.007655949 Inclusion 28
SE Bin1 ENSMUSG00000024381#chr18#+#32591324|32591396|32585877|32586006|32591636|32591747#E#SE 1 0.6 0.4 0.000249166 Exclusion 24
SE Bin1 ENSMUSG00000024381#chr18#+#32591324|32591396|32585877|32586006|32591636|32591747#E#SE 0.913 0.551 0.362 9.27806E-05 Exclusion 28
SE Tcof1 ENSMUSG00000024613#chr18#-#60991819|60991963|60991427|60991649|60992080|60992278#E#SE 0.869 0.471 0.398 0.005701241 Exclusion 24
SE Tcof1 ENSMUSG00000024613#chr18#-#60991819|60991963|60991427|60991649|60992080|60992278#E#SE 0.863 0.637 0.226 0.033056066 Exclusion 26
SE Fibp ENSMUSG00000024911#chr19#+#5464333|5464431|5464128|5464215|5464924|5465051#E#SE 0.883 0.45 0.433 2.10032E-07 Exclusion 24
SE Fibp ENSMUSG00000024911#chr19#+#5464333|5464431|5464128|5464215|5464924|5465051#E#SE 0.823 0.416 0.407 3.33067E-16 Exclusion 26
 175
SE Fibp ENSMUSG00000024911#chr19#+#5464333|5464431|5464128|5464215|5464924|5465051#E#SE 0.844 0.444 0.4 7.96306E-09 Exclusion 28
SE Terf1 ENSMUSG00000025925#chr1#+#15823481|15823570|15821587|15821647|15828262|15828369#E#SE 0.847 0.625 0.222 0.040552446 Exclusion 24
SE Terf1 ENSMUSG00000025925#chr1#+#15823481|15823570|15821587|15821647|15828262|15828369#E#SE 0.882 0.509 0.373 9.54958E-06 Exclusion 28
SE Pnkd ENSMUSG00000026179#chr1#+#74333665|74333782|74332415|74332584|74393958|74394074#E#SE 0.771 0.516 0.255 0.009396736 Exclusion 24
SE Pnkd ENSMUSG00000026179#chr1#+#74333665|74333782|74332415|74332584|74393958|74394074#E#SE 0.804 0.527 0.277 1.63575E-07 Exclusion 26
SE Rgs7 ENSMUSG00000026527#chr1#-#177006954|177007008|176989866|176989925|177008319|177008409#E#SE 0.48 0.242 0.238 0.02904557 Exclusion 24
SE Rgs7 ENSMUSG00000026527#chr1#-#177006954|177007008|176989866|176989925|177008319|177008409#E#SE 0.41 0.182 0.228 0.000336875 Exclusion 26
SE Atf2 ENSMUSG00000027104#chr2#-#73691851|73691948|73688920|73689039|73701225|73701356#E#SE 0.801 0.359 0.442 6.20958E-05 Exclusion 24
SE Atf2 ENSMUSG00000027104#chr2#-#73691851|73691948|73688920|73689039|73701225|73701356#E#SE 0.787 0.486 0.301 0.002253783 Exclusion 28
SE Stx16 ENSMUSG00000027522#chr2#+#173917902|173918068|173916982|173917123|173918934|173919026#E#SE 0.404 0.175 0.229 0.027725214 Exclusion 24
SE Stx16 ENSMUSG00000027522#chr2#+#173917902|173918068|173916982|173917123|173918934|173919026#E#SE 0.468 0.188 0.28 5.11219E-06 Exclusion 26
SE Crtc2 ENSMUSG00000027936#chr3#+#90063075|90063144|90062386|90062448|90063307|90063414#E#SE 1 0.613 0.387 0.039061297 Exclusion 24
SE Crtc2 ENSMUSG00000027936#chr3#+#90063075|90063144|90062386|90062448|90063307|90063414#E#SE 1 0.603 0.397 0.023554589 Exclusion 28
SE Fbxw7 ENSMUSG00000028086#chr3#+#84668058|84668122|84667885|84667933|84707422|84708001#I#SE 0.025 1 -0.975 2.24471E-06 Inclusion 26
SE Fbxw7 ENSMUSG00000028086#chr3#+#84668058|84668122|84667885|84667933|84707422|84708001#I#SE 0.095 0.511 -0.416 0.020386824 Inclusion 28
SE Trit1 ENSMUSG00000028653#chr4#+#122726394|122726507|122726011|122726123|122726719|122726797#E#SE 0.672 0.378 0.294 0.02021758 Exclusion 26
SE Trit1 ENSMUSG00000028653#chr4#+#122726394|122726507|122726011|122726123|122726719|122726797#E#SE 0.634 0.316 0.318 0.024689211 Exclusion 28
SE Ccdc163
ENSMUSG00000028689#chr4#+#116381844|116381878|
116381113|116381699|116382042|116382224#E#SE 0.854 0.229 0.625 0.00031372 Exclusion 26
SE Ccdc163
ENSMUSG00000028689#chr4#+#116381844|116381878|
116381113|116381699|116382042|116382224#E#SE 1 0.308 0.692 0.021875984 Exclusion 28
SE Tmem234
ENSMUSG00000028797#chr4#+#129278650|129278777|
129278226|129278487|129279113|129279205#I#SE 0.354 0.675 -0.321 0.027544706 Inclusion 26
SE Tmem234
ENSMUSG00000028797#chr4#+#129278650|129278777|
129278226|129278487|129279113|129279205#I#SE 0.396 0.891 -0.495 0.00584456 Inclusion 28
SE Tmem234
ENSMUSG00000028797#chr4#+#129278650|129278869|
129278226|129278487|129279113|129279174#I#SE 0.397 0.755 -0.358 0.041648936 Inclusion 24
SE Tmem234
ENSMUSG00000028797#chr4#+#129278650|129278869|
129278226|129278487|129279113|129279174#I#SE 0.397 0.77 -0.373 0.002564988 Inclusion 26
SE Tmem234
ENSMUSG00000028797#chr4#+#129278650|129278869|
129278226|129278487|129279113|129279174#I#SE 0.366 0.914 -0.548 0.000533567 Inclusion 28
SE Rer1 ENSMUSG00000029048#chr4#-#154457217|154457345|154456796|154456863|154460313|154460491#I#SE 0.248 0.479 -0.231 1.33497E-08 Inclusion 26
SE Rer1 ENSMUSG00000029048#chr4#-#154457217|154457345|154456796|154456863|154460313|154460491#I#SE 0.275 0.526 -0.251 3.25526E-06 Inclusion 28
SE Rer1 ENSMUSG00000029048#chr4#-#154457217|154457426|154456775|154456863|154460313|154460480#I#SE 0.241 0.465 -0.224 5.74452E-09 Inclusion 26
SE Rer1 ENSMUSG00000029048#chr4#-#154457217|154457426|154456775|154456863|154460313|154460480#I#SE 0.259 0.507 -0.248 1.21406E-06 Inclusion 28
SE Ccnl2 ENSMUSG00000029068#chr4#+#155192647|155192773|155192031|155192096|155194437|155194537#I#SE 0.45 0.706 -0.256 3.96673E-05 Inclusion 26
SE Ccnl2 ENSMUSG00000029068#chr4#+#155192647|155192773|155192031|155192096|155194437|155194537#I#SE 0.404 0.803 -0.399 1.0497E-07 Inclusion 28
 176
SE Calu ENSMUSG00000029767#chr6#+#29311293|29311487|29306476|29306697|29311559|29311753#I#SE 0.457 0.732 -0.275 1.91513E-13 Inclusion 24
SE Calu ENSMUSG00000029767#chr6#+#29311293|29311487|29306476|29306697|29311559|29311753#I#SE 0.467 0.736 -0.269 0 Inclusion 26
SE Calu ENSMUSG00000029767#chr6#+#29311293|29311487|29306476|29306697|29311559|29311753#I#SE 0.456 0.666 -0.21 5.42701E-11 Inclusion 28
SE Zfml ENSMUSG00000030016#chr6#+#83931677|83931779|83926195|83926344|83933969|83934068#E#SE 1 0.416 0.584 0.000494583 Exclusion 24
SE Zfml ENSMUSG00000030016#chr6#+#83931677|83931779|83926195|83926344|83933969|83934068#E#SE 0.757 0.364 0.393 0.000173552 Exclusion 26
SE Sh2b1 ENSMUSG00000030733#chr7#-#133611463|133611563|133610507|133611287|133611933|133612155#E#SE 0.795 0.358 0.437 3.56301E-07 Exclusion 26
SE Sh2b1 ENSMUSG00000030733#chr7#-#133611463|133611563|133610507|133611287|133611933|133612155#E#SE 0.726 0.322 0.404 0.001793049 Exclusion 28
SE Eri2 ENSMUSG00000030929#chr7#-#126930917|126930999|126930252|126930341|126931247|126931348#E#SE 0.766 0.472 0.294 0.002314365 Exclusion 26
SE Eri2 ENSMUSG00000030929#chr7#-#126930917|126930999|126930252|126930341|126931247|126931348#E#SE 0.789 0.548 0.241 0.039420566 Exclusion 28
SE Cask ENSMUSG00000031012#chrX#-#13129498|13129567|13128072|13128108|13132003|13132072#E#SE 0.607 0.302 0.305 0.000427601 Exclusion 24
SE Cask ENSMUSG00000031012#chrX#-#13129498|13129567|13128072|13128108|13132003|13132072#E#SE 0.549 0.251 0.298 3.72937E-08 Exclusion 26
SE Cask ENSMUSG00000031012#chrX#-#13129498|13129567|13128072|13128108|13132003|13132072#E#SE 0.614 0.28 0.334 3.99186E-06 Exclusion 28
SE Rbm10 ENSMUSG00000031060#chrX#+#20214551|20214782|20212856|20213040|20216558|20216628#I#SE 0.066 1 -0.934 0.002132515 Inclusion 24
SE Rbm10 ENSMUSG00000031060#chrX#+#20214551|20214782|20212856|20213040|20216558|20216628#I#SE 0.153 1 -0.847 0.000687283 Inclusion 26
SE Slc25a14
ENSMUSG00000031105#chrX#+#45977138|45977374|
45976754|45977005|45982428|45982522#I#SE 0.411 1 -0.589 0.002304089 Inclusion 24
SE Slc25a14
ENSMUSG00000031105#chrX#+#45977138|45977374|
45976754|45977005|45982428|45982522#I#SE 0.393 0.696 -0.303 0.028214158 Inclusion 26
SE Slc25a14
ENSMUSG00000031105#chrX#+#45977138|45977383|
45976754|45977005|45982428|45982522#I#SE 0.408 1 -0.592 0.002913385 Inclusion 24
SE Slc25a14
ENSMUSG00000031105#chrX#+#45977138|45977383|
45976754|45977005|45982428|45982522#I#SE 0.399 0.683 -0.284 0.043809774 Inclusion 26
SE Cenpi ENSMUSG00000031262#chrX#+#130843104|130843172|130842622|130842767|130843265|130843386#E#SE 0.914 0.5 0.414 0.003726632 Exclusion 24
SE Cenpi ENSMUSG00000031262#chrX#+#130843104|130843172|130842622|130842767|130843265|130843386#E#SE 0.848 0.526 0.322 0.024749559 Exclusion 28
SE Nlgn3 ENSMUSG00000031302#chrX#+#98502413|98502473|98497626|98497770|98504095|98504245#E#SE 0.81 0.55 0.26 2.72058E-05 Exclusion 26
SE Nlgn3 ENSMUSG00000031302#chrX#+#98502413|98502473|98497626|98497770|98504095|98504245#E#SE 1 0.632 0.368 1.43885E-12 Exclusion 28
SE Vps37a
ENSMUSG00000031600#chr8#+#41626378|41626447|
41626242|41626301|41629163|41629307#E#SE 1 0.688 0.312 0.00482157 Exclusion 24
SE Vps37a
ENSMUSG00000031600#chr8#+#41626378|41626447|
41626242|41626301|41629163|41629307#E#SE 1 0.676 0.324 0.000919464 Exclusion 28
SE Pkd1 ENSMUSG00000032855#chr17#+#24724123|24724237|24723406|24723533|24724344|24724394#E#SE 0.601 0.323 0.278 0.014405591 Exclusion 24
SE Pkd1 ENSMUSG00000032855#chr17#+#24724123|24724237|24723406|24723533|24724344|24724394#E#SE 0.682 0.372 0.31 3.7366E-06 Exclusion 26
SE Pkd1 ENSMUSG00000032855#chr17#+#24724123|24724237|24723406|24723533|24724344|24724394#E#SE 0.724 0.386 0.338 0.000511508 Exclusion 28
SE Kctd17 ENSMUSG00000033287#chr15#+#78267330|78267424|78266014|78266140|78267587|78268009#E#SE 0.642 0.423 0.219 0.007782032 Exclusion 26
SE Kctd17 ENSMUSG00000033287#chr15#+#78267330|78267424|78266014|78266140|78267587|78268009#E#SE 0.592 0.376 0.216 0.039570667 Exclusion 28
SE Pla2g4b
ENSMUSG00000033852#chr2#+#119857042|119857138|




119856551|119856608|119857310|119857387#E#SE 1 0.478 0.522 0.013242958 Exclusion 28
SE Epn1 ENSMUSG00000035203#chr7#+#5044913|5044988|5044442|5044567|5045500|5045584#E#SE 0.724 0.374 0.35 3.36202E-05 Exclusion 24
SE Epn1 ENSMUSG00000035203#chr7#+#5044913|5044988|5044442|5044567|5045500|5045584#E#SE 0.675 0.413 0.262 9.47728E-07 Exclusion 26
SE Epn1 ENSMUSG00000035203#chr7#+#5044913|5044988|5044442|5044567|5045500|5045584#E#SE 0.714 0.366 0.348 4.81459E-07 Exclusion 28
SE Rnf38 ENSMUSG00000035696#chr4#-#44171774|44171924|44165231|44165425|44200320|44200391#E#SE 0.501 0.077 0.424 0.00275754 Exclusion 24
SE Rnf38 ENSMUSG00000035696#chr4#-#44171774|44171924|44165231|44165425|44200320|44200391#E#SE 0.578 0.222 0.356 0.002243747 Exclusion 26
SE Tbc1d24
ENSMUSG00000036473#chr17#-#24319730|24319794|
24319394|24319490|24320638|24320797#E#SE 1 0.456 0.544 0.010399451 Exclusion 24
SE Tbc1d24
ENSMUSG00000036473#chr17#-#24319730|24319794|
24319394|24319490|24320638|24320797#E#SE 1 0.709 0.291 0.03972514 Exclusion 28
SE Eif2c2 ENSMUSG00000036698#chr15#-#72956876|72956964|72955593|72955741|72957383|72957518#E#SE 1 0.495 0.505 0.003196351 Exclusion 26
SE Eif2c2 ENSMUSG00000036698#chr15#-#72956876|72956964|72955593|72955741|72957383|72957518#E#SE 1 0.46 0.54 0.005919959 Exclusion 28
SE Cuedc2
ENSMUSG00000036748#chr19#-#46412802|46412901|
46407107|46407191|46413058|46413150#E#SE 0.459 0.211 0.248 0.004152205 Exclusion 24
SE Cuedc2
ENSMUSG00000036748#chr19#-#46412802|46412901|
46407107|46407191|46413058|46413150#E#SE 0.413 0.198 0.215 5.2422E-05 Exclusion 26
SE Cuedc2
ENSMUSG00000036748#chr19#-#46412802|46412910|
46407107|46407191|46413058|46413150#E#SE 0.427 0.181 0.246 0.003048638 Exclusion 24
SE Cuedc2
ENSMUSG00000036748#chr19#-#46412802|46412910|
46407107|46407191|46413058|46413150#E#SE 0.384 0.183 0.201 0.000131361 Exclusion 26
SE Tubb4b
ENSMUSG00000036752#chr2#-#25079453|25079564|
25077679|25078888|25079643|25079752#E#SE 1 0.719 0.281 4.03703E-07 Exclusion 26
SE Tubb4b
ENSMUSG00000036752#chr2#-#25079453|25079564|
25077679|25078888|25079643|25079752#E#SE 1 0.788 0.212 0.018871108 Exclusion 28
SE Zfp280c
ENSMUSG00000036916#chrX#-#45946690|45946775|
45944849|45944938|45947540|45947681#I#SE 0.428 1 -0.572 0.001621777 Inclusion 26
SE Zfp280c
ENSMUSG00000036916#chrX#-#45946690|45946775|
45944849|45944938|45947540|45947681#I#SE 0.447 0.926 -0.479 0.01732084 Inclusion 28
SE Paip2 ENSMUSG00000037058#chr18#+#35759698|35759771|35758294|35758413|35772976|35773156#I#SE 0.132 1 -0.868 0.002484313 Inclusion 24
SE Paip2 ENSMUSG00000037058#chr18#+#35759698|35759771|35758294|35758413|35772976|35773156#I#SE 0.321 1 -0.679 0.004300401 Inclusion 28
SE Lsm1 ENSMUSG00000037296#chr8#+#26904148|26904264|26902628|26902697|26912399|26914447#E#SE 0.927 0.148 0.779 1.18291E-05 Exclusion 24
SE Lsm1 ENSMUSG00000037296#chr8#+#26904148|26904264|26902628|26902697|26912399|26914447#E#SE 1 0.695 0.305 0.007335843 Exclusion 28
SE Rps16 ENSMUSG00000037563#chr7#+#29137381|29137429|29137195|29137292|29137512|29137715#I#SE 0.214 1 -0.786 0.01217122 Inclusion 26
SE Rps16 ENSMUSG00000037563#chr7#+#29137381|29137429|29137195|29137292|29137512|29137715#I#SE 0.222 1 -0.778 0.012684275 Inclusion 28
SE Parp11 ENSMUSG00000037997#chr6#+#127421565|127421686|127420719|127420848|127424253|127424329#I#SE 0.473 0.812 -0.339 0.010664565 Inclusion 26
SE Parp11 ENSMUSG00000037997#chr6#+#127421565|127421686|127420719|127420848|127424253|127424329#I#SE 0.43 0.86 -0.43 0.007376735 Inclusion 28
SE Josd2 ENSMUSG00000038695#chr7#+#51723675|51723787|51723445|51723529|51724176|51724339#I#SE 0.38 1 -0.62 0.000230076 Inclusion 26
SE Josd2 ENSMUSG00000038695#chr7#+#51723675|51723787|51723445|51723529|51724176|51724339#I#SE 0.49 1 -0.51 0.032054394 Inclusion 28
SE Atp5l ENSMUSG00000038717#chr9#-#44722733|44722894|44721332|44721549|44728692|44728825#E#SE 0.902 0.487 0.415 0.000191441 Exclusion 26
SE Atp5l ENSMUSG00000038717#chr9#-#44722733|44722894|44721332|44721549|44728692|44728825#E#SE 1 0.344 0.656 0.034160602 Exclusion 28
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SE Rpl12 ENSMUSG00000038900#chr2#+#32819016|32819103|32818504|32818586|32819260|32819373#I#SE 0.49 0.834 -0.344 0.018101149 Inclusion 24
SE Rpl12 ENSMUSG00000038900#chr2#+#32819016|32819103|32818504|32818586|32819260|32819373#I#SE 0.7 0.911 -0.211 0.008595347 Inclusion 26
SE Rpl12 ENSMUSG00000038900#chr2#+#32819016|32819103|32818504|32818586|32819260|32819373#I#SE 0.508 0.876 -0.368 4.69947E-05 Inclusion 28
SE Hexdc ENSMUSG00000039307#chr11#+#121078206|121078390|121076484|121076649|121079401|121079473#I#SE 0.268 1 -0.732 0.0064838 Inclusion 26
SE Hexdc ENSMUSG00000039307#chr11#+#121078206|121078390|121076484|121076649|121079401|121079473#I#SE 0.357 1 -0.643 0.004875086 Inclusion 28
SE Ubn1 ENSMUSG00000039473#chr16#+#5081986|5082076|5081510|5081754|5084148|5086378#E#SE 0.347 0.062 0.285 0.000132041 Exclusion 24
SE Ubn1 ENSMUSG00000039473#chr16#+#5081986|5082076|5081510|5081754|5084148|5086378#E#SE 0.353 0.129 0.224 0.001131072 Exclusion 28
SE Alkbh3 ENSMUSG00000040174#chr2#-#93850419|93850565|93848580|93848749|93850839|93850911#I#SE 0.447 0.785 -0.338 0.040995042 Inclusion 24
SE Alkbh3 ENSMUSG00000040174#chr2#-#93850419|93850565|93848580|93848749|93850839|93850911#I#SE 0.422 0.695 -0.273 0.013274552 Inclusion 26
SE Pitpnc1
ENSMUSG00000040430#chr11#-#107077991|107078110|
107069205|107073972|107087544|107087608#E#SE 0.589 0.264 0.325 5.45456E-05 Exclusion 24
SE Pitpnc1
ENSMUSG00000040430#chr11#-#107077991|107078110|
107069205|107073972|107087544|107087608#E#SE 0.483 0.188 0.295 6.35516E-10 Exclusion 26
SE Bptf ENSMUSG00000040481#chr11#-#106948025|106948211|106943826|106944014|106957029|106957239#I#SE 0.284 0.722 -0.438 4.57611E-05 Inclusion 26
SE Bptf ENSMUSG00000040481#chr11#-#106948025|106948211|106943826|106944014|106957029|106957239#I#SE 0.307 0.708 -0.401 0.001174001 Inclusion 28
SE Bptf ENSMUSG00000040481#chr11#-#106956315|106956504|106943826|106944014|106957029|106957239#I#SE 0.495 0.848 -0.353 0.000105544 Inclusion 26
SE Bptf ENSMUSG00000040481#chr11#-#106956315|106956504|106943826|106944014|106957029|106957239#I#SE 0.53 0.802 -0.272 0.018410714 Inclusion 28
SE Otud6b ENSMUSG00000040550#chr4#-#14749838|14749919|14745322|14745635|14752645|14752800#E#SE 1 0.362 0.638 0.003886242 Exclusion 24
SE Otud6b ENSMUSG00000040550#chr4#-#14749838|14749919|14745322|14745635|14752645|14752800#E#SE 0.81 0.393 0.417 1.6051E-07 Exclusion 26
SE Ranbp17
ENSMUSG00000040594#chr11#-#33400679|33400770|
33393250|33393417|33404681|33404828#E#SE 1 0.096 0.904 0.004285077 Exclusion 24
SE Ranbp17
ENSMUSG00000040594#chr11#-#33400679|33400770|
33393250|33393417|33404681|33404828#E#SE 1 0.291 0.709 0.004775728 Exclusion 28
SE Crocc ENSMUSG00000040860#chr4#-#140577568|140577732|140576188|140576404|140577958|140578079#E#SE 1 0.32 0.68 0.001093178 Exclusion 26
SE Crocc ENSMUSG00000040860#chr4#-#140577568|140577732|140576188|140576404|140577958|140578079#E#SE 1 0.127 0.873 0.000418654 Exclusion 28
SE Rfx3 ENSMUSG00000040929#chr19#-#27997697|27997756|27975268|27975393|28085461|28085656#E#SE 0.609 0.118 0.491 0.031800802 Exclusion 24
SE Rfx3 ENSMUSG00000040929#chr19#-#27997697|27997756|27975268|27975393|28085461|28085656#E#SE 0.696 0 0.696 9.49443E-07 Exclusion 26
SE Uspl1 ENSMUSG00000041264#chr5#+#149999283|149999410|149996242|149996382|149999920|150000049#E#SE 0.42 0.114 0.306 0.003129956 Exclusion 24
SE Uspl1 ENSMUSG00000041264#chr5#+#149999283|149999410|149996242|149996382|149999920|150000049#E#SE 0.41 0.197 0.213 0.004367682 Exclusion 26
SE Uspl1 ENSMUSG00000041264#chr5#+#149999283|149999410|149996242|149996382|149999920|150000049#E#SE 0.442 0.105 0.337 2.92245E-05 Exclusion 28
SE Uspl1 ENSMUSG00000041264#chr5#+#149999283|149999452|149996135|149996382|149999920|150000049#E#SE 0.516 0.15 0.366 0.000280065 Exclusion 24
SE Uspl1 ENSMUSG00000041264#chr5#+#149999283|149999452|149996135|149996382|149999920|150000049#E#SE 0.495 0.237 0.258 0.000272238 Exclusion 26
SE Uspl1 ENSMUSG00000041264#chr5#+#149999283|149999452|149996135|149996382|149999920|150000049#E#SE 0.493 0.19 0.303 0.000485675 Exclusion 28
SE Zfp740 ENSMUSG00000046897#chr15#+#102035659|102035736|102035001|102035314|102038201|102038351#E#SE 0.478 0.242 0.236 0.005051145 Exclusion 26
 179
SE Zfp740 ENSMUSG00000046897#chr15#+#102035659|102035736|102035001|102035314|102038201|102038351#E#SE 0.554 0.216 0.338 0.000269245 Exclusion 28
SE Gphn ENSMUSG00000047454#chr12#+#79594936|79595044|79593024|79593297|79605603|79605738#E#SE 0.664 0.265 0.399 6.28871E-08 Exclusion 24
SE Gphn ENSMUSG00000047454#chr12#+#79594936|79595044|79593024|79593297|79605603|79605738#E#SE 0.53 0.306 0.224 3.78517E-05 Exclusion 26
SE Gphn ENSMUSG00000047454#chr12#+#79594936|79595044|79593024|79593297|79605603|79605738#E#SE 0.524 0.308 0.216 0.000787604 Exclusion 28
SE Tnrc6b ENSMUSG00000047888#chr15#+#80713373|80713532|80709296|80711636|80714636|80714812#I#SE 0.777 1 -0.223 0.018517812 Inclusion 26




































57450193|57450331|57450890|57450935#I#SE 0.091 0.6 -0.509 0.000204069 Inclusion 28
SE Setd8 ENSMUSG00000049327#chr5#+#124895977|124896093|124889938|124890024|124897222|124897379#I#SE 0.207 1 -0.793 0.021326891 Inclusion 24
SE Setd8 ENSMUSG00000049327#chr5#+#124895977|124896093|124889938|124890024|124897222|124897379#I#SE 0.299 1 -0.701 0.035095446 Inclusion 26
SE Setd8 ENSMUSG00000049327#chr5#+#124895977|124896093|124889938|124890024|124897222|124897379#I#SE 0.343 1 -0.657 0.044198707 Inclusion 28
SE Mdm4 ENSMUSG00000054387#chr1#-#134901230|134901298|134900367|134900467|134905713|134905769#E#SE 0.673 0.431 0.242 0.03411172 Exclusion 24
SE Mdm4 ENSMUSG00000054387#chr1#-#134901230|134901298|134900367|134900467|134905713|134905769#E#SE 0.74 0.512 0.228 0.005589267 Exclusion 26
SE Mdm4 ENSMUSG00000054387#chr1#-#134901230|134901298|134900367|134900467|134905713|134905769#E#SE 0.717 0.476 0.241 0.007297668 Exclusion 28
SE Spna2 ENSMUSG00000057738#chr2#+#29869677|29869692|29869195|29869358|29871108|29871240#I#SE 0.445 0.796 -0.351 4.40026E-05 Inclusion 24
SE Spna2 ENSMUSG00000057738#chr2#+#29869677|29869692|29869195|29869358|29871108|29871240#I#SE 0 0.759 -0.759 0 Inclusion 26
SE Palld ENSMUSG00000058056#chr8#-#64013654|64013705|64012150|64012372|64014482|64014581#I#SE 0.193 0.417 -0.224 0.046130036 Inclusion 24
SE Palld ENSMUSG00000058056#chr8#-#64013654|64013705|64012150|64012372|64014482|64014581#I#SE 0.198 0.516 -0.318 5.63603E-05 Inclusion 26
SE Palld ENSMUSG00000058056#chr8#-#64013654|64013705|64012150|64012372|64014482|64014581#I#SE 0.296 0.544 -0.248 0.025509367 Inclusion 28
SE Wdr91 ENSMUSG00000058486#chr6#-#34859676|34859827|34859360|34859540|34860696|34860836#I#SE 0.049 0.316 -0.267 0.006323183 Inclusion 24
SE Wdr91 ENSMUSG00000058486#chr6#-#34859676|34859827|34859360|34859540|34860696|34860836#I#SE 0.036 0.333 -0.297 8.12814E-05 Inclusion 28
SE Wdr91 ENSMUSG00000058486#chr6#-#34859713|34859827|34859460|34859540|34860696|34860842#I#SE 0.047 0.306 -0.259 0.013206463 Inclusion 24
SE Wdr91 ENSMUSG00000058486#chr6#-#34859713|34859827|34859460|34859540|34860696|34860842#I#SE 0.012 0.22 -0.208 0.002818552 Inclusion 28
SE Gtf2i ENSMUSG00000060261#chr5#-#134748393|134748456|134742412|134742526|134750408|134750465#I#SE 0.586 0.824 -0.238 0.000143312 Inclusion 24
 180
SE Gtf2i ENSMUSG00000060261#chr5#-#134748393|134748456|134742412|134742526|134750408|134750465#I#SE 0.68 0.886 -0.206 9.73664E-07 Inclusion 26
SE Lmtk3 ENSMUSG00000062044#chr7#+#53043015|53043124|53042763|53042840|53043273|53043392#E#SE 1 0.407 0.593 0.013705772 Exclusion 24
SE Lmtk3 ENSMUSG00000062044#chr7#+#53043015|53043124|53042763|53042840|53043273|53043392#E#SE 0.668 0.365 0.303 0.033228185 Exclusion 26
SE Lmtk3 ENSMUSG00000062044#chr7#+#53043015|53043124|53042763|53042840|53043273|53043392#E#SE 1 0.407 0.593 0.00431559 Exclusion 28
SE Dzip3 ENSMUSG00000064061#chr16#-#48951655|48952273|48950113|48950146|48953839|48953916#I#SE 0.324 0.705 -0.381 0.00637449 Inclusion 24
SE Dzip3 ENSMUSG00000064061#chr16#-#48951655|48952273|48950113|48950146|48953839|48953916#I#SE 0.317 0.549 -0.232 0.016667737 Inclusion 26
SE Med14 ENSMUSG00000064127#chrX#-#12266454|12266586|12264144|12264327|12270710|12270822#E#SE 0.718 0.513 0.205 0.046360062 Exclusion 24
SE Med14 ENSMUSG00000064127#chrX#-#12266454|12266586|12264144|12264327|12270710|12270822#E#SE 0.659 0.447 0.212 0.0143954 Exclusion 28
SE Nnat ENSMUSG00000067786#chr2#+#157386948|157386975|157385851|157385996|157387277|157388240#E#SE 0.886 0.658 0.228 7.26921E-11 Exclusion 24
SE Nnat ENSMUSG00000067786#chr2#+#157386948|157386975|157385851|157385996|157387277|157388240#E#SE 0.899 0.644 0.255 0 Exclusion 28
SE Nnat ENSMUSG00000067786#chr2#+#157386948|157387024|157385842|157385996|157387277|157387974#E#SE 0.799 0.517 0.282 1.74757E-11 Exclusion 24
SE Nnat ENSMUSG00000067786#chr2#+#157386948|157387024|157385842|157385996|157387277|157387974#E#SE 0.756 0.529 0.227 1.67755E-13 Exclusion 26
SE Nnat ENSMUSG00000067786#chr2#+#157386948|157387024|157385842|157385996|157387277|157387974#E#SE 0.815 0.491 0.324 0 Exclusion 28
SE Nnat ENSMUSG00000067786#chr2#+#157386948|157387029|157385845|157385996|157387277|157388258#E#SE 0.853 0.607 0.246 1.90846E-11 Exclusion 24
SE Nnat ENSMUSG00000067786#chr2#+#157386948|157387029|157385845|157385996|157387277|157388258#E#SE 0.816 0.615 0.201 3.00204E-13 Exclusion 26
SE Nnat ENSMUSG00000067786#chr2#+#157386948|157387029|157385845|157385996|157387277|157388258#E#SE 0.864 0.568 0.296 0 Exclusion 28
SE Csde1 ENSMUSG00000068823#chr3#+#102844363|102844456|102843855|102843965|102845067|102845165#E#SE 1 0.413 0.587 1.85074E-13 Exclusion 24
SE Csde1 ENSMUSG00000068823#chr3#+#102844363|102844456|102843855|102843965|102845067|102845165#E#SE 1 0.5 0.5 0 Exclusion 26
SE Eif2s3y ENSMUSG00000069049#chrY#+#349821|349916|348490|348612|351076|351235#E#SE 0.793 0.516 0.277 0.002716723 Exclusion 24
SE Eif2s3y ENSMUSG00000069049#chrY#+#349821|349916|348490|348612|351076|351235#E#SE 0.826 0.478 0.348 1.4982E-06 Exclusion 28
SE Strada ENSMUSG00000069631#chr11#-#106045875|106045933|106034992|106035095|106048414|106048494#I#SE 0.372 1 -0.628 1.88428E-05 Inclusion 26
SE Strada ENSMUSG00000069631#chr11#-#106045875|106045933|106034992|106035095|106048414|106048494#I#SE 0.24 1 -0.76 0.000149312 Inclusion 28
SE Prss36 ENSMUSG00000070371#chr7#-#135077652|135077794|135077080|135077346|135077903|135078141#I#SE 0.128 0.637 -0.509 0.020482179 Inclusion 24
SE Prss36 ENSMUSG00000070371#chr7#-#135077652|135077794|135077080|135077346|135077903|135078141#I#SE 0.294 1 -0.706 0.00171793 Inclusion 28
SE Chchd2
ENSMUSG00000070493#chr5#-#130359804|130360054|
130358299|130358450|130363067|130363340#E#SE 1 0 1 0.044319689 Exclusion 26
SE Chchd2
ENSMUSG00000070493#chr5#-#130359804|130360054|
130358299|130358450|130363067|130363340#E#SE 1 0 1 0.043527717 Exclusion 28
SE Srsf3 ENSMUSG00000071172#chr17#+#29176398|29176854|29175434|29175569|29177719|29177758#I#SE 0.621 0.828 -0.207 9.96483E-05 Inclusion 26
SE Srsf3 ENSMUSG00000071172#chr17#+#29176398|29176854|29175434|29175569|29177719|29177758#I#SE 0.704 1 -0.296 8.94105E-10 Inclusion 28
SE Tia1 ENSMUSG00000071337#chr6#+#86373599|86373665|86369922|86370405|86374338|86374417#I#SE 0.121 0.337 -0.216 0.001306632 Inclusion 24
SE Tia1 ENSMUSG00000071337#chr6#+#86373599|86373665|86369922|86370405|86374338|86374417#I#SE 0.145 0.407 -0.262 1.15551E-06 Inclusion 28
 181
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SE Dtnb ENSMUSG00000071454#chr12#+#3774569|3774610|3773550|3773640|3779618|3779654#I#SE 0.687 0.955 -0.268 0.039148513 Inclusion 26
SE Dtnb ENSMUSG00000071454#chr12#+#3774569|3774610|3773550|3773640|3779618|3779654#I#SE 0.655 1 -0.345 0.029581831 Inclusion 28
SE Tomm5 ENSMUSG00000078713#chr4#-#45119710|45119760|45118083|45118516|45120784|45120980#I#SE 0 0.237 -0.237 0.000556512 Inclusion 24
SE Tomm5 ENSMUSG00000078713#chr4#-#45119710|45119760|45118083|45118516|45120784|45120980#I#SE 0 0.359 -0.359 3.10973E-12 Inclusion 26
SE Sec61g
ENSMUSG00000078974#chr11#-#16404738|16404841|
16401640|16401810|16406375|16406475#E#SE 1 0.612 0.388 4.95593E-08 Exclusion 26
SE Sec61g
ENSMUSG00000078974#chr11#-#16404738|16404841|
16401640|16401810|16406375|16406475#E#SE 1 0.046 0.954 1.55431E-15 Exclusion 28
SE Rab7 ENSMUSG00000079477#chr6#-#87965625|87965712|87963631|87963692|87995066|87995239#I#SE 0.029 1 -0.971 4.95438E-07 Inclusion 24
SE Rab7 ENSMUSG00000079477#chr6#-#87965625|87965712|87963631|87963692|87995066|87995239#I#SE 0.029 1 -0.971 1.66533E-14 Inclusion 26
SE Hbxip ENSMUSG00000087260#chr3#+#107082787|107082849|107081775|107082031|107084826|107084944#I#SE 0.3 1 -0.7 0.001180992 Inclusion 24


















33954574|33954778|33955506|33955640#E#SE 0.959 0.727 0.232 0.007094722 Exclusion 28
SE Ttbk2 ENSMUSG00000090100#chr2#-#120650977|120651051|120648208|120648344|120675791|120676154#E#SE 0.455 0.148 0.307 0.036596761 Exclusion 26
SE Ttbk2 ENSMUSG00000090100#chr2#-#120650977|120651051|120648208|120648344|120675791|120676154#E#SE 0.68 0 0.68 4.37483E-05 Exclusion 28
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APPENDIX B - Illumina microarray analysis in NPCs!
Gene me ENSEMBL Genomic Location [mm9] logFC AveExpr adj.P.Val
Ass1 ENSMUSG00000076441 chr2:31376010:31376059: 3.564970315 8.207397658 9.11244E-10
Pde1a ENSMUSG00000059173 chr2:79705263:79705312:- 3.435639359 8.704254116 1.08037E-07
Spp1 ENSMUSG00000029304 chr5:104869796:104869845: 3.313298809 9.956529887 6.82138E-07
Ckmt1 ENSMUSG00000000308 chr2:121189400:121189449: 3.265851 8.83116845 3.39061E-09
Pde1a ENSMUSG00000059173 chr2:79705198:79705247:- 3.249381506 8.36479476 1.72272E-08
Diras2 ENSMUSG00000047842 chr13:52599864:52599913:- 3.156059725 9.797755365 1.46631E-08
Reln ENSMUSG00000042453 chr5:21390390:21390439:- 3.133400919 10.73717168 1.00059E-05
Rgs4 ENSMUSG00000038530 chr1:171672462:171672511:- 3.091259594 8.929218969 2.41203E-08
Pde1a ENSMUSG00000059173 chr2:79705238:79705287:- 3.086248947 8.26020787 8.78553E-08
Chchd10 ENSMUSG00000049422 chr10:75400420:75400469: 3.014880548 10.29765602 4.3113E-09
Sst ENSMUSG00000004366 chr16:23889780:23889829:- 3.008862399 10.1509938 8.05448E-06
Tceal5 ENSMUSG00000054034 chrX:132735583:132735632:- 2.924855323 9.921456207 1.19653E-08
Vgf ENSMUSG00000037428 chr5:137508882:137508931: 2.898145305 7.998305687 9.36679E-08
Wfdc2 ENSMUSG00000017723 chr2:164393913:164393962: 2.866010397 8.161025417 3.68859E-06
Cpne4 ENSMUSG00000032564 chr9:104936340:104936389: 2.864780419 8.246749092 6.58829E-07
Chgb ENSMUSG00000027350 chr2:132619745:132619794: 2.849264599 8.230226958 8.35499E-08
Glra2 ENSMUSG00000018589 chrX:161567314:161567363:- 2.826266394 9.462544539 6.51692E-09
Clu ENSMUSG00000022037 chr14:66600225:66600274: 2.816170447 9.216392843 6.38319E-07
Thbs2 ENSMUSG00000023885 chr17:14804242:14804291:- 2.763961706 8.135087879 6.74303E-06
AW555464 ENSMUSG00000072825 chr12:113984610:113984659: 2.719016041 9.080603603 4.3113E-09
Ctgf ENSMUSG00000019997 chr10:24318317:24318366: 2.705294478 8.507877829 9.8647E-07
Islr2 ENSMUSG00000051243 chr9:58044390:58044439:- 2.69224379 10.31961359 1.808E-08
Cntp2 ENSMUSG00000039419 chr6:47249039:47249088: 2.660152103 8.239015728 2.97846E-07
Calb2 ENSMUSG00000003657 chr8:112666522:112666571:- 2.660013342 8.985639029 4.92479E-08
Gpnmb ENSMUSG00000029816 chr6:49006694:49006743: 2.602732928 8.041806321 1.39543E-06
Stmn2 ENSMUSG00000027500 chr3:8561306:8561355: 2.575619451 11.24311788 4.35467E-09
Slc17a6 ENSMUSG00000030500 chr7:58926243:58926291: 2.556824473 8.951167373 2.41203E-08
Atp1b1 ENSMUSG00000026576 chr1:166367693:166367742:- 2.524809565 10.87454203 2.16234E-08
Scg2 ENSMUSG00000050711 chr1:79431994:79432043:- 2.515681693 7.783009742 3.77762E-08
Dcxr ENSMUSG00000039450 chr11:120587073:120587122:- 2.495223756 8.706675964 1.19653E-08
Mmp3 ENSMUSG00000043613 chr9:7455747:7455796: 2.482254928 7.943822559 7.2815E-06
Djc6 ENSMUSG00000028528 chr4:101315165:101315214: 2.474622792 9.914499928 1.47995E-07
Svop ENSMUSG00000042078 chr5:114477006:114477055:- 2.460106771 10.42718912 2.2996E-08
Mmp3 ENSMUSG00000043613 chr9:7451773:7451822: 2.447018327 7.68048952 8.82638E-07
Lgals3 ENSMUSG00000050335 chr14:48005397:48005446: 2.441480013 7.607698099 9.88866E-06
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Tmem130 ENSMUSG00000043388 chr5:145496876:145496925:- 2.43076195 9.338854613 2.16234E-08
Gad1 ENSMUSG00000070880 chr2:70439916:70439965: 2.429121842 8.167205651 1.82629E-06
Grp ENSMUSG00000024517 chr18:66046055:66046104: 2.418855948 7.811330581 2.66787E-08
Cntp4 ENSMUSG00000031772 chr8:115406212:115406261: 2.387562498 8.745875467 4.35467E-09
Pacsin1 ENSMUSG00000040276 chr17:27847915:27847964: 2.342066261 8.735841391 1.35588E-08
Gad1 ENSMUSG00000070880 chr2:70439915:70439964: 2.340566895 7.974658351 1.65063E-06
Djc6 ENSMUSG00000028528 chr4:101315184:101315233: 2.325789271 9.521114953 1.43155E-07
Sv2b ENSMUSG00000053025 chr7:82259830:82259879:- 2.288689286 8.189187745 2.2996E-08
Cav1 ENSMUSG00000007655 chr6:17291157:17291206: 2.288468925 10.0586779 3.87007E-07
Nrip3 ENSMUSG00000034825 chr7:116901635:116901684:- 2.2818558 8.673110708 1.01346E-06
2900011O08Rik ENSMUSG00000044117 chr16:14100833:14100882: 2.270229597 9.314980426 2.79454E-07
Fabp3 ENSMUSG00000028773 chr4:129992430:129992479: 2.262100041 8.834149907 3.39061E-09
Lmo2 ENSMUSG00000032698 chr2:103821843:103821892: 2.254401831 8.190512678 2.16957E-07
Tbr1 ENSMUSG00000035033 chr2:61651395:61651444: 2.238999699 8.070376061 1.77532E-08
Fam131a ENSMUSG00000050821 chr16:20702982:20703031: 2.236614017 9.22712188 1.95452E-07
Ly6h ENSMUSG00000022577 chr15:75395640:75395689:- 2.231833574 10.87706077 4.55059E-08
Rcan2 ENSMUSG00000039601 chr17:44176265:44176314: 2.22182535 8.877080698 1.20269E-08
Kif5c ENSMUSG00000026764 chr2:49630170:49630219: 2.215661607 11.15341511 2.28364E-08
Ly6h ENSMUSG00000022577 chr15:75395616:75395665:- 2.214174919 10.45930638 5.66588E-08
Stmn4 ENSMUSG00000022044 chr14:66976798:66976847: 2.206613039 10.11676564 3.63044E-09
Rtn1 ENSMUSG00000021087 chr12:73337524:73337573:- 2.203553717 11.31133748 4.3113E-09
Gdf10 ENSMUSG00000021943 chr14:34748248:34748297: 2.199188375 7.517560479 4.55059E-08
AI593442 ENSMUSG00000078307 chr9:52484418:52484467:- 2.193317042 9.201835573 2.99635E-06
Rcan2 ENSMUSG00000039601 chr17:44175826:44175875: 2.181336141 8.046769738 1.20269E-08
Nsg2 ENSMUSG00000020297 chr11:31958836:31958885: 2.180971963 10.97788962 1.50773E-07
Caln1 ENSMUSG00000060371 chr5:131315937:131315986: 2.176833972 9.094014491 2.82618E-07
S100a11 chr3:93329926:93329975: 2.169173223 10.41362738 5.49827E-08
Areg ENSMUSG00000029378 chr5:91577301:91577350: 2.167778653 8.026643158 2.92153E-07
Dcxr ENSMUSG00000039450 chr11:120587755:120587804:- 2.166259784 8.505098604 3.35938E-07
Fibcd1 ENSMUSG00000026841 chr2:31668838:31668887:- 2.160798532 7.978420443 1.01294E-06
Mapt ENSMUSG00000018411 chr11:104189419:104189468: 2.146886255 10.75848268 2.81094E-07
Rnf182 ENSMUSG00000044164 chr13:43763797:43763846: 2.141573487 8.367557989 3.45414E-07
2900011O08Rik ENSMUSG00000044117 chr16:14094034:14094083: 2.140480839 8.58436942 1.92911E-07
Stmn4 ENSMUSG00000022044 chr14:66976793:66976842: 2.119520899 9.863605618 8.17687E-08
Sh3gl2 ENSMUSG00000028488 chr4:85035162:85035211: 2.102637762 11.33416393 5.47388E-08
Cend1 ENSMUSG00000060240 chr7:148612756:148612805:- 2.101009031 7.524457548 2.41203E-08
Sult4a1 ENSMUSG00000018865 chr15:83906555:83906604:- 2.099431402 10.11868332 2.61501E-08
Rasgrp1 ENSMUSG00000027347 chr2:117105869:117105918:- 2.098895785 7.242684921 6.97101E-07
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Tspyl3 ENSMUSG00000074671 chr2:153048225:153048274:- 2.09486525 8.40713865 2.2996E-08
Ptpre ENSMUSG00000041836 chr7:142877677:142877726: 2.092092511 8.260696395 3.31362E-08
Mcf2l ENSMUSG00000031442 chr8:13020304:13020353: 2.090551433 9.280508461 2.45465E-07
Slit2 ENSMUSG00000031558 chr5:48696452:48696501: 2.090038756 7.87497841 1.20269E-08
Gap43 ENSMUSG00000047261 chr16:42248877:42248926:- 2.087275437 11.53065336 3.63044E-09
Nuak1 ENSMUSG00000020032 chr10:83834184:83834233:- 2.082625476 10.07655171 3.31476E-07
Thy1 ENSMUSG00000032011 chr9:43856488:43856537: 2.072401495 8.853765382 1.19653E-08
Gpr123 ENSMUSG00000025475 chr7:147063636:147063685: 2.069556471 7.905065947 6.97101E-07
Fas ENSMUSG00000024778 chr19:34401880:34401929: 2.069230899 7.489627834 2.45465E-07
Btbd11 ENSMUSG00000020042 chr10:85122861:85122910: 2.069211427 8.985323271 2.41203E-08
Tmod1 ENSMUSG00000028328 chr4:46127321:46127370: 2.063744541 7.637228926 1.91711E-07
Anxa3 ENSMUSG00000029484 chr5:97274605:97274654: 2.038554257 11.06691478 7.20662E-08
6030405A18Rik ENSMUSG00000056306 chr3:54701160:54701209:- 2.036936031 9.278467266 8.09756E-08
Plch2 ENSMUSG00000029055 chr4:154357524:154357573:- 2.036805881 7.876190957 9.64608E-07
Gabrg2 ENSMUSG00000020436 chr11:41725837:41725886:- 2.030760754 7.928915685 2.06092E-08
Rell2 ENSMUSG00000044024 chr18:38118769:38118817: 2.028252727 9.027106287 3.62344E-08
Mtap1b ENSMUSG00000052727 chr13:100204461:100204510:- 2.025932458 10.42298499 1.96301E-07
Mmp3 ENSMUSG00000043613 chr9:7449846:7449895: 2.02144355 7.474403836 5.58056E-06
Anxa3 ENSMUSG00000029484 chr5:97274679:97274728: 2.020075017 11.54594614 3.63803E-07
Mllt11 ENSMUSG00000053192 chr3:95023109:95023158:- 2.019597566 12.3816904 4.92479E-08
Go1 ENSMUSG00000031748 chr8:96492013:96492062: 2.019141051 9.735326743 1.38868E-07
Eno2 ENSMUSG00000004267 chr6:124710401:124710450:- 2.014026421 9.330140048 4.92479E-08
Hspb8 ENSMUSG00000041548 chr5:116858761:116858810:- 2.010706053 7.789348153 3.31362E-08
Go1 ENSMUSG00000031748 chr8:96492548:96492597: 1.996494418 8.442032524 4.40713E-08
Ccng1 ENSMUSG00000020326 chr11:40564942:40564942:-,chr11:40564813:40564861:- 1.992059501 10.60455415 5.66588E-08
Syngr3 ENSMUSG00000007021 chr17:24822304:24822353:- 1.986896786 9.462028074 4.17833E-08
Tes ENSMUSG00000029552 chr6:17055631:17055680: 1.980681543 8.745767617 4.92479E-08
Pqlc3 ENSMUSG00000045679 chr12:16995838:16995887:- 1.979675954 7.809520414 4.70894E-08
Prickle1 ENSMUSG00000036158 chr15:93329646:93329695:- 1.974491939 9.083180817 6.21833E-08
Eef1a2 ENSMUSG00000016349 chr2:180882407:180882456:- 1.974053655 9.032387031 1.75247E-07
Tuft1 ENSMUSG00000005968 chr3:94416746:94416795:- 1.971944848 8.334717091 4.17833E-08
Dcn ENSMUSG00000019929 chr10:96980254:96980303: 1.971125126 8.067043625 3.13936E-07
Vsnl1 ENSMUSG00000054459 chr12:11332158:11332207:- 1.97088128 8.260572397 4.65576E-08
Ccl27a ENSMUSG00000073888 chr4:41716429:41716478:- 1.968303059 9.347999498 1.42556E-07
A730017C20Rik ENSMUSG00000050875 chr18:59236484:59236533: 1.959522056 8.312304399 2.15232E-07
Ccng1 ENSMUSG00000020326 chr11:40562289:40562338:- 1.958090673 11.37540147 1.21743E-07
Klc1 ENSMUSG00000021288 chr12:113032813:113032862: 1.953449832 10.81504311 1.10868E-06
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Ly6h ENSMUSG00000022577 chr15:75396044:75396093:- 1.952885 9.17657423 5.39063E-07
Gabrg2 ENSMUSG00000020436 chr11:41729812:41729861:- 1.950244774 7.55054332 1.06835E-07
Chst8 ENSMUSG00000060402 chr7:35459805:35459854:- 1.942490644 8.659563204 7.53135E-08
Trnp1 ENSMUSG00000056596 chr4:133047103:133047152:- 1.931656051 9.208277601 6.27541E-07
Adra2a ENSMUSG00000033717 chr19:54123316:54123365: 1.929918993 8.361352755 7.85599E-08
Fezf2 ENSMUSG00000021743 chr14:13174738:13174787:- 1.927942807 8.046576599 7.53135E-08
Rspo3 ENSMUSG00000019880 chr10:29173225:29173274:- 1.923757881 7.945831128 6.86547E-06
Esm1 ENSMUSG00000042379 chr13:114008196:114008245: 1.920289958 7.102896459 2.11362E-05
Cadps ENSMUSG00000054423 chr14:13205204:13205253:- 1.919061869 8.725552828 1.92911E-07
Syp ENSMUSG00000031144 chrX:7230191:7230240: 1.898034595 10.29632774 4.12952E-08
Gabrg2 ENSMUSG00000020436 chr11:41725711:41725760:- 1.892929885 7.43053605 2.2996E-08
Syt1 ENSMUSG00000035864 chr10:107935530:107935579:- 1.89144225 8.438377927 2.15232E-07
Rnf182 ENSMUSG00000044164 chr13:43763554:43763603: 1.8808018 8.13866838 2.79454E-07
Olfm1 ENSMUSG00000026833 chr2:28085714:28085763: 1.875797215 9.995000514 1.92911E-07
Rprm ENSMUSG00000075334 chr2:53936662:53936711:- 1.875294494 10.91626947 8.78918E-08
Arpp21 ENSMUSG00000032503 chr9:111968061:111968110:- 1.870623468 8.296374338 5.39063E-07
Rec8 ENSMUSG00000002324 chr14:56244151:56244200: 1.856569889 7.799583302 0.001091467
Clstn3 ENSMUSG00000008153 chr6:124380896:124380945:- 1.856226438 8.683786153 2.81094E-07
Nt ENSMUSG00000067786 chr2:157387933:157387982: 1.852117025 9.238077986 0.000117476
Cplx1 ENSMUSG00000033615 chr5:108947597:108947646:- 1.851637969 10.97560419 3.36216E-08
Cdkn1a ENSMUSG00000023067 chr17:29237186:29237235: 1.847923667 9.586610038 2.54291E-06
Acaa1b ENSMUSG00000010651 chr9:119057258:119057307:- 1.84155876 7.479317049 3.82088E-08
Sv2a ENSMUSG00000038486 chr3:95998908:95998957: 1.835107906 9.507716889 7.06899E-07
Epb4.9 ENSMUSG00000022099 chr14:71003542:71003591:- 1.834724434 7.798608148 2.62296E-08
Sytl2 ENSMUSG00000030616 chr7:97558600:97558649: 1.831148247 7.861867047 1.41537E-07
Trp53inp1 ENSMUSG00000028211 chr4:11100946:11100995: 1.830298498 10.2655528 1.43155E-07
Klc1 ENSMUSG00000021288 chr12:113032834:113032883: 1.82614945 10.15801374 1.92911E-07
Eef1a2 ENSMUSG00000016349 chr2:180882514:180882563:- 1.823473403 8.75781201 4.36499E-07
Vstm2l ENSMUSG00000037843 chr2:157770386:157770435: 1.81994371 9.294811288 1.3439E-06
Ak1 ENSMUSG00000026817 chr2:32490205:32490254: 1.812141516 8.844321123 1.92801E-08
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Timp2 ENSMUSG00000017466 chr11:118162613:118162662:- 1.810895398 10.19662 2.16234E-08
Olfm1 ENSMUSG00000026833 chr2:28068159:28068207:,chr2:28069621:28069621: 1.799691634 9.920379689 9.21744E-08
Rbfox1 ENSMUSG00000008658 chr16:7409979:7410028: 1.799047784 9.817983368 4.02393E-07
Slc32a1 ENSMUSG00000037771 chr2:158441306:158441355: 1.797771387 8.391259383 8.75626E-05
Kif5a ENSMUSG00000074657 chr10:126662984:126663033:- 1.796077292 8.306379628 1.78496E-07
Blcap ENSMUSG00000067787 chr2:157382437:157382486:- 1.794392733 10.06205957 2.89363E-07
Cckbr ENSMUSG00000030898 chr7:112584663:112584712: 1.785380679 7.146504096 5.07583E-06
Hs3st1 ENSMUSG00000051022 chr5:40005562:40005611:- 1.784891344 8.305792753 2.89363E-07
Mmp10 ENSMUSG00000047562 chr9:7509909:7509958: 1.77959258 7.408360027 1.10242E-05
Sema5a ENSMUSG00000022231 chr15:32625932:32625981: 1.774912009 8.580051923 1.83568E-07
Ociad2 ENSMUSG00000029153 chr5:73714223:73714272:- 1.772175619 8.004075676 4.57133E-07
Ddit4l ENSMUSG00000046818 chr3:137291137:137291186: 1.770586718 10.7134216 1.808E-08
Ralyl ENSMUSG00000039717 chr3:14181876:14181925: 1.768528233 8.628420739 5.18295E-07
Gas6 ENSMUSG00000031451 chr8:13465655:13465704:- 1.76192312 9.880323627 1.41537E-07
Trim2 ENSMUSG00000027993 chr3:83967838:83967887:- 1.755468663 10.08747792 1.42864E-07
Dcx ENSMUSG00000031285 chrX:140290608:140290657:- 1.74119828 10.19251291 8.23796E-07
AI836003 ENSMUSG00000029875 chr15:98000214:98000263: 1.737144718 7.417738872 1.32273E-07
Rab3a ENSMUSG00000031840 chr8:73282334:73282383: 1.727763507 10.3493317 1.18815E-07
Bgn ENSMUSG00000031375 chrX:70741170:70741219: 1.727321379 8.041803099 9.71782E-06
Odz4 ENSMUSG00000048078 chr7:104055104:104055153: 1.724782483 9.161422521 0.000523589
Dync1i1 ENSMUSG00000029757 chr6:5960517:5960566: 1.721550294 7.995802216 8.93206E-07
Rit2 ENSMUSG00000057455 chr18:31134123:31134172:- 1.716299129 7.506507438 9.39361E-07
Calb2 ENSMUSG00000003657 chr8:112676542:112676591:- 1.714541779 7.55915669 1.65208E-06
Ndrg4 ENSMUSG00000036564 chr8:98238732:98238781: 1.708167041 8.18665043 5.48069E-07
Pde4dip ENSMUSG00000038170 chr3:97493882:97493931:- 1.706872128 8.644312708 6.38956E-07
Cartpt ENSMUSG00000021647 chr13:100668836:100668885:- 1.705858647 7.017372228 2.22001E-06
Tmem108 ENSMUSG00000042757 chr9:103387036:103387085:- 1.705048218 8.148300203 1.92911E-07
Angpt2 ENSMUSG00000031465 chr8:18691380:18691429:- 1.702688529 11.81446131 3.07055E-06
Galnt9 ENSMUSG00000033316 chr5:111050240:111050289: 1.700348276 7.662434461 1.01294E-06
Nrn1 ENSMUSG00000039114 chr13:36817911:36817960:- 1.696379964 9.926411511 3.80341E-06
Syt5 ENSMUSG00000004961 chr7:4491693:4491742:- 1.695897671 8.059856393 7.8339E-07
Sv2a ENSMUSG00000038486 chr3:95998899:95998948: 1.692011854 9.347718439 9.45522E-08
Darc ENSMUSG00000037872 chr1:175262178:175262227:- 1.68896904 8.093282292 8.53537E-07
Dync1i1 ENSMUSG00000029757 chr6:5977664:5977713: 1.686579586 8.113504401 1.01346E-06
Dcx ENSMUSG00000031285 chrX:140290666:140290715:- 1.684231646 9.491145661 2.03699E-06
H2afj ENSMUSG00000060032 chr6:136758013:136758062: 1.682298386 8.638101067 2.41203E-08
 187
cad ENSMUSG00000041073 chr11:6498008:6498013:-,chr11:6497869:6497912:- 1.681478401 8.244357866 8.17687E-08
Chst1 ENSMUSG00000027221 chr2:92455211:92455260: 1.680292425 9.101702277 1.18815E-07
Cyb561 ENSMUSG00000019590 chr11:105795289:105795338:- 1.679939117 7.37190712 8.29358E-08
Nol4 ENSMUSG00000041923 chr18:22852231:22852280:- 1.676609433 8.413360579 3.41658E-07
Robo1 ENSMUSG00000022883 chr16:73045994:73046043: 1.675201732 9.610967844 2.1692E-06
Mcf2l ENSMUSG00000031442 chr8:13020401:13020450: 1.669769501 8.399934295 4.92479E-08
cc2 ENSMUSG00000026932 chr2:25911166:25911215:- 1.669124834 9.189241302 1.55536E-07
Cdkn1a ENSMUSG00000023067 chr17:29237369:29237418: 1.667947205 9.877105921 1.46882E-05
Igf2 ENSMUSG00000048583 chr7:149836752:149836801:- 1.664653071 7.828411996 0.000160784
Diras1 ENSMUSG00000043670 chr10:80482348:80482397:- 1.661271066 9.283155282 4.07309E-07
Hba-a1 chr11:32183968:32184017: 1.65715046 7.302464914 2.06092E-08
Tesc ENSMUSG00000029359 chr5:118511628:118511677: 1.656347893 7.611160362 3.41658E-07
St6galc5 chr3:152483122:152483171:- 1.654307502 8.54231315 1.48508E-06
Mmp13 ENSMUSG00000050578 chr9:7283143:7283192: 1.654097488 7.226792443 1.32336E-05
Anxa5 ENSMUSG00000027712 chr3:36348108:36348157:- 1.652881873 9.938127549 1.58257E-06
Lhfpl2 ENSMUSG00000045312 chr13:94965110:94965159: 1.647603006 9.030595991 4.92479E-08
Snca ENSMUSG00000025889 chr6:60681879:60681928:- 1.646299415 11.15278707 1.29019E-07
Slc5a3 ENSMUSG00000039680 chr16:92112240:92112289: 1.636044713 11.99037253 3.44844E-06
Cox6b2 ENSMUSG00000051811 chr7:4703418:4703467:- 1.633173019 8.019840646 9.84059E-08
Ppp2r2c ENSMUSG00000029120 chr5:37345892:37345941: 1.629866551 7.563213571 1.10445E-06
Snca ENSMUSG00000025889 chr6:60681957:60682006:- 1.628258265 9.528202769 5.72287E-07
I chr19:47099097:47099146: 1.625918468 8.521409182 4.00582E-07
Psd2 ENSMUSG00000024347 chr18:36173787:36173836: 1.624943198 8.334698424 4.75685E-07
Apod ENSMUSG00000022548 chr16:31311122:31311171:- 1.62473747 7.086391119 0.000109557
Pnma2 ENSMUSG00000046204 chr14:67538778:67538827: 1.612984572 8.991650905 3.44222E-08
Sgk1 ENSMUSG00000019970 chr10:21719378:21719427: 1.611904857 9.531845493 1.88475E-05
Mmp24 ENSMUSG00000027612 chr2:155643913:155643962: 1.60529566 8.174934961 7.20153E-07
Serpi3n ENSMUSG00000021091 chr12:105652409:105652458: 1.603483213 7.090318409 9.77828E-07
Gabrb3 ENSMUSG00000033676 chr7:65083842:65083891: 1.597145817 9.114008125 3.95405E-07
Ccng1 ENSMUSG00000020326 chr11:40564431:40564480:- 1.594844326 9.478460554 2.36108E-07
Phlda3 ENSMUSG00000041801 chr1:137665353:137665402: 1.592953636 10.20114787 3.13689E-07
Epb4.1l1 ENSMUSG00000027624 chr2:156368591:156368640: 1.591169315 8.462519592 8.05352E-07
Stx1a ENSMUSG00000007207 chr5:135526879:135526928: 1.586208129 9.606395721 2.48585E-07
Celsr3 ENSMUSG00000023473 chr9:108755165:108755214: 1.584060933 8.959934777 0.000465667
Scn3b ENSMUSG00000049281 chr9:40098150:40098199: 1.583803018 7.576340611 1.18815E-07
Asphd1 ENSMUSG00000046378 chr7:134089612:134089661:- 1.580200878 7.429546901 1.33781E-07
Bcl11b ENSMUSG00000048251 chr12:109153448:109153497:- 1.57898357 10.41051396 6.27541E-07
 188
Sparc ENSMUSG00000018593 chr11:55208464:55208512:- 1.577288069 10.2755909 2.82954E-06
Ifitm2 ENSMUSG00000060591 chr7:148141590:148141639:- 1.576071613 9.792638391 8.34197E-06
Slc6a17 ENSMUSG00000027894 chr3:107270475:107270524:- 1.565425808 7.860586166 1.06739E-07
Coro1a ENSMUSG00000030707 chr7:133843446:133843495:- 1.56101597 9.036346817 8.7785E-07
Rab9b ENSMUSG00000043463 chrX:133392799:133392848:- 1.555485033 7.924708364 4.4898E-07
Gabrb1 ENSMUSG00000029212 chr5:72500049:72500075:,chr5:72513188:72513210: 1.554142511 7.179337715 4.71094E-06
Dusp4 ENSMUSG00000031530 chr8:35882724:35882773: 1.552207345 8.645648523 2.13608E-07
Slco1c1 ENSMUSG00000030235 chr6:141517967:141518016: 1.551608474 7.1895859 1.70358E-06
Fam177a ENSMUSG00000095595;ENSMUSG00000094103 chr12:56240502:56240551: 1.551536507 9.148790812 2.85189E-08
Nmbr ENSMUSG00000019865 chr10:14490179:14490228: 1.548290034 6.982584374 7.83822E-06
Actl6b ENSMUSG00000029712 chr5:138008558:138008571:,chr5:138010534:138010569: 1.54816387 7.478642945 4.55059E-08
Sparc ENSMUSG00000018593 chr11:55223447:55223496:- 1.547015555 10.04784233 4.38271E-06
Sphkap chr1:83252297:83252346:- 1.546101086 8.066206811 4.43263E-08
Pfkp ENSMUSG00000021196 chr13:6597149:6597198:- 1.544214761 9.294381995 1.51009E-06
Cd200 ENSMUSG00000022661 chr16:45383222:45383271:- 1.544134724 7.683900329 1.82637E-07
Coro1a ENSMUSG00000030707 chr7:133844098:133844104:-,chr7:133843944:133843986:- 1.540688854 8.616953543 5.05653E-06
C1qtnf4 ENSMUSG00000040794 chr2:90730244:90730293: 1.540108346 8.128104368 3.07055E-06
Erc2 ENSMUSG00000040640 chr14:29291366:29291415: 1.540099182 8.477300469 1.00777E-06
Nol4 ENSMUSG00000041923 chr18:22852007:22852056:- 1.533240258 8.282062745 2.16234E-08
Zcchc18 ENSMUSG00000031428 chrX:133530699:133530748: 1.528742344 11.96649502 1.5662E-07
Rtn1 ENSMUSG00000021087 chr12:73313115:73313164:- 1.528656163 12.76777479 6.78752E-08
Car2 ENSMUSG00000027562 chr3:14895036:14895085: 1.528403416 8.513604886 1.21003E-05
Cyba ENSMUSG00000006519 chr8:124948937:124948986:- 1.527024552 8.36208744 3.40756E-06
Jakmip1 ENSMUSG00000063646 chr5:37516410:37516459: 1.525911926 8.452932689 2.69923E-07
Sema5a ENSMUSG00000022231 chr15:32625930:32625979: 1.524443947 8.165986458 3.91387E-08
Syn1 ENSMUSG00000037217 chrX:20437762:20437811:- 1.521078006 9.319293951 6.48807E-07
Bzrap1 ENSMUSG00000034156 chr11:87599271:87599320: 1.520132559 8.242860785 0.000225839
Crtac1 ENSMUSG00000042401 chr19:42357579:42357628:- 1.518471175 8.259897097 1.75247E-07
Nefm ENSMUSG00000022054 chr14:68738058:68738107:- 1.515836117 8.019515492 2.29911E-07
Fam49a ENSMUSG00000020589 chr12:12382992:12383041: 1.509216845 11.22241568 1.8486E-07
Spnb3 ENSMUSG00000067889 chr19:4752085:4752134: 1.50887686 8.642651972 6.37974E-07
Rbfox3 ENSMUSG00000025576 chr11:118351137:118351186:- 1.503396685 9.591646781 4.44372E-06
Chl1 ENSMUSG00000030077 chr6:103664507:103664556: 1.502304322 8.154101782 3.19656E-06
Cds1 ENSMUSG00000029330 chr5:102252635:102252684: 1.501685973 7.573775576 1.8486E-07
Ank3 ENSMUSG00000069601 chr10:69486582:69486631: 1.498792043 7.727759177 5.0555E-06
Arhgap20 ENSMUSG00000053199 chr9:51661111:51661160: 1.497415601 7.853172965 3.31476E-07
 189
Thrsp ENSMUSG00000035686 chr7:104561925:104561974:- 1.495563566 7.642386893 5.98717E-06
Cxcl12 ENSMUSG00000061353 chr6:117123722:117123771: 1.495442364 7.621409194 1.81894E-05
Srxn1 ENSMUSG00000032802 chr2:151936737:151936786: 1.494015941 8.211751886 3.60929E-07
Actl6b ENSMUSG00000029712 chr5:138010633:138010682: 1.493788159 8.043726136 5.79333E-08
Pdgfa chr5:139452401:139452450:- 1.489629697 10.3562567 3.77845E-06
Ap3b2 ENSMUSG00000062444 chr7:88605505:88605554:- 1.485669753 8.154247865 3.87172E-07
Epb4.1l1 ENSMUSG00000027624 chr2:156368648:156368697: 1.484302248 7.951435058 2.85954E-07
Rab3d ENSMUSG00000019066 chr9:21712036:21712085:- 1.483549804 8.636004454 1.63209E-06
Plcd4 ENSMUSG00000026173 chr1:74611086:74611086:,chr1:74611606:74611654: 1.480037707 7.848661358 9.8647E-07
Pdlim1 ENSMUSG00000055044 chr19:40296825:40296874:- 1.475348383 9.642314335 6.36794E-06
Gria1 ENSMUSG00000020524 chr11:57131239:57131288: 1.474184178 7.53163032 7.11223E-07
Ccdc3 ENSMUSG00000026676 chr2:5151806:5151855: 1.471417515 7.718175262 3.94454E-06
Prokr2 ENSMUSG00000050558 chr2:132197621:132197670:- 1.467953611 7.09159689 7.59591E-07
Fam167a ENSMUSG00000035095 chr14:64084105:64084154: 1.467395127 7.46668127 5.96321E-07
Cryab ENSMUSG00000032060 chr9:50562673:50562722: 1.466903799 7.385390978 1.69477E-07
Bbc3 ENSMUSG00000002083 chr7:16903413:16903462: 1.46653538 10.56195948 8.22587E-06
Scg5 ENSMUSG00000023236 chr2:113616801:113616850:- 1.457333405 9.697319008 8.78553E-08
Spock3 ENSMUSG00000054162 chr8:65835353:65835402: 1.456479203 6.904682613 8.77299E-08
Galt ENSMUSG00000036073 chr4:41705454:41705503: 1.454827289 9.054025247 9.87024E-07
Rps6kl1 ENSMUSG00000019235 chr12:86476728:86476777:- 1.442163396 8.383407709 9.82461E-07
Phlda3 ENSMUSG00000041801 chr1:137665204:137665253: 1.439996307 9.982855904 5.91254E-07
Celf4 ENSMUSG00000024268 chr18:25637894:25637943:- 1.439462875 7.844067149 2.28391E-07
Kctd12 chr14:103377115:103377164:- 1.435034956 8.075549303 3.50466E-08
Tmod2 ENSMUSG00000032186 chr9:75413566:75413615:- 1.43138446 9.93082255 4.19433E-07
Jazf1 ENSMUSG00000063568 chr6:52718931:52718980:- 1.431022232 8.175688136 1.71778E-06
Usp29 ENSMUSG00000051527 chr7:6919760:6919809: 1.430385766 7.596346532 1.77521E-06
Cck ENSMUSG00000032532 chr9:121399159:121399208:- 1.427542075 7.113086974 0.000289589
Trp53inp1 ENSMUSG00000028211 chr4:11101237:11101286: 1.426349506 9.12772851 1.49726E-06
Tcfap2c ENSMUSG00000028640 chr2:172384008:172384057: 1.425742604 7.452751666 1.25778E-06
Gz ENSMUSG00000040009 chr10:74478486:74478535: 1.423760248 9.704529637 8.45842E-05
Rasgef1c ENSMUSG00000020374 chr11:49793566:49793615: 1.417431688 7.136277537 5.58224E-07
Hbegf ENSMUSG00000024486 chr18:36664987:36665036:- 1.417164234 8.571134635 1.18334E-06
Lrp11 ENSMUSG00000019796 chr10:7345037:7345086: 1.41287622 10.14675131 1.99205E-07
Sh3gl2 ENSMUSG00000028488 chr4:85031735:85031784: 1.412166468 8.132421041 5.25526E-06
1700047I17Rik2 chr12:56306718:56306767: 1.409038363 8.263563512 1.95389E-07
Chst2 ENSMUSG00000033350 chr9:95304928:95304977:- 1.406301071 8.640935002 1.25778E-06
Ppp1r13b ENSMUSG00000021285 chr12:113067059:113067108:- 1.403195846 7.698985952 6.27541E-07
 190
Tiam2 ENSMUSG00000023800 chr17:3519205:3519254: 1.398685319 7.925093508 2.79228E-08
D3Bwg0562e ENSMUSG00000044667 chr3:117022692:117022741:- 1.395678491 7.303336329 1.18815E-07
Rell2 ENSMUSG00000044024 chr18:38116138:38116187: 1.395650978 7.327177225 5.58129E-06
Rab15 ENSMUSG00000021062 chr12:77899014:77899063:- 1.38931792 9.36535627 5.85376E-07
Dos ENSMUSG00000035640 chr10:79593419:79593468:- 1.387282526 9.779515792 1.76054E-07
Aak1 ENSMUSG00000057230 chr6:86941544:86941593: 1.383512553 7.931953011 6.05376E-08
Gpr176 ENSMUSG00000040133 chr2:118103002:118103051:- 1.381988986 7.452157119 9.8759E-08
Rab6b ENSMUSG00000032549 chr9:103087402:103087451: 1.381689626 10.79156815 2.86241E-07
Mapk8 ENSMUSG00000021936 chr14:34191151:34191200:- 1.375550118 9.178409896 1.99205E-07
Mmp2 ENSMUSG00000031740 chr8:95377093:95377142: 1.373938797 8.191793923 4.52213E-06
Celf4 ENSMUSG00000024268 chr18:25649671:25649720:- 1.37366297 7.457681447 4.56165E-06
Inpp5f ENSMUSG00000042105 chr7:135839572:135839621: 1.373555807 11.80476951 1.32273E-07
Pqlc3 ENSMUSG00000045679 chr12:17000259:17000303:-,chr12:16999121:16999125:- 1.372368666 7.418043451 1.92911E-07
Adcy2 ENSMUSG00000021536 chr13:68759059:68759108:- 1.371202853 8.537707575 1.67168E-07
Emp3 ENSMUSG00000040212 chr7:53175687:53175736:- 1.371058046 7.105142823 1.24635E-06
Gdap1 ENSMUSG00000025777 chr1:17154189:17154238: 1.367903097 10.07210335 4.13035E-07
Ef5 ENSMUSG00000048915 chr17:62954145:62954194:- 1.367418109 8.724209202 3.93683E-07
Slc17a7 ENSMUSG00000070570 chr7:52431216:52431265: 1.364526413 7.094169546 1.63209E-06
Mapre2 ENSMUSG00000024277 chr18:24052231:24052280: 1.35981669 11.07705071 2.73941E-07
Chd5 ENSMUSG00000005045 chr4:151764083:151764132: 1.357769194 7.739524501 4.70794E-05
Prkcz ENSMUSG00000029053 chr4:154634242:154634291:- 1.35669466 9.496388258 2.85954E-07
Tubb4 ENSMUSG00000062591 chr17:57219644:57219693:- 1.356426947 8.049779824 7.39652E-07
Tagln3 ENSMUSG00000022658 chr16:45711612:45711661:- 1.356336053 10.13445107 7.57474E-05
Rhod ENSMUSG00000041845 chr19:4425825:4425874:- 1.354487382 8.405001253 5.66588E-08
S100a6 ENSMUSG00000001025 chr3:90418228:90418277: 1.351071931 7.563896229 1.80269E-05
Angpt2 ENSMUSG00000031465 chr8:18714160:18714209:- 1.350151067 8.058752108 1.58618E-06
Coro1a ENSMUSG00000030707 chr7:133845556:133845605:- 1.349628477 7.70156967 1.30002E-06
Slco3a1 ENSMUSG00000025790 chr7:81429226:81429275:- 1.349400217 8.2408985 7.13949E-06
Rusc2 ENSMUSG00000035969 chr4:43439820:43439869: 1.346828164 10.36276672 2.30037E-06
Tbc1d9 ENSMUSG00000031709 chr8:85795693:85795742: 1.346614308 8.343568063 1.96301E-07
Hsd11b1 ENSMUSG00000016194 chr1:195048145:195048194:- 1.335865106 6.881133541 3.72559E-07
Col4a1 ENSMUSG00000031502 chr8:11198791:11198840:- 1.335469112 7.793427814 0.000400716
Rtn1 ENSMUSG00000021087 chr12:73313088:73313137:- 1.334567296 12.52604461 7.20153E-07
Serpini1 ENSMUSG00000027834 chr3:75445770:75445819: 1.334123748 7.91217935 1.74444E-06
Fas ENSMUSG00000024778 chr19:34391081:34391130: 1.332737983 7.22823441 1.36462E-06
Rapgef4 ENSMUSG00000049044 chr2:72091024:72091051:,chr2:72094306:72094327: 1.325422057 7.443745187 3.15182E-07
Gdap1 ENSMUSG00000025777 chr1:17153992:17154041: 1.325020748 8.804275455 5.18726E-07
 191
Mbp ENSMUSG00000041607 chr18:82727885:82727934: 1.323972877 7.370259274 2.24903E-05
Romo1 ENSMUSG00000067847 chr2:155970134:155970183: 1.320183577 7.569573201 2.2475E-06
Pcdh20 ENSMUSG00000050505 chr14:88865883:88865932:- 1.31992097 7.514919356 5.63484E-06
Atp6v1g2 ENSMUSG00000024403 chr17:35375614:35375663: 1.318069978 8.899954944 8.57452E-08
March4 ENSMUSG00000039372 chr1:72473836:72473885:- 1.316982598 7.760250943 1.64925E-06
Stxbp1 ENSMUSG00000026797 chr2:32643520:32643569:- 1.315614341 11.63447956 6.14457E-07
Kcnk1 ENSMUSG00000033998 chr8:128554409:128554458: 1.313573053 7.984367798 1.43155E-07
Cxadr ENSMUSG00000022865 chr16:78340631:78340680: 1.30957845 10.41812336 8.28783E-06
Slc24a3 ENSMUSG00000063873 chr2:145467619:145467668: 1.309455893 9.30403583 1.06978E-06
Col6a1 ENSMUSG00000001119 chr10:76171561:76171610:- 1.308545252 6.909411287 4.06391E-05
Elmod1 ENSMUSG00000041986 chr9:53767420:53767469:- 1.307960202 8.031414068 2.96492E-07
Cplx2 ENSMUSG00000025867 chr13:54479987:54480036: 1.302861246 8.335773122 1.50338E-05
Rnf208 ENSMUSG00000044628 chr2:25099692:25099741: 1.301707586 10.35032643 5.35937E-06
Syt4 ENSMUSG00000024261 chr18:31599054:31599103:- 1.298047948 11.22266993 4.98603E-05
Dpysl5 ENSMUSG00000029168 chr5:31101562:31101611: 1.295673273 9.306479972 3.60042E-06
Cav2 ENSMUSG00000000058 chr6:17231898:17231947: 1.294606471 7.687307065 1.35319E-05
Uchl1 ENSMUSG00000029223 chr5:67078100:67078149: 1.294441457 10.67791886 2.30367E-07
Fbll1 ENSMUSG00000051062 chr11:35611270:35611319:- 1.293855876 7.604465482 3.36514E-05
Elavl3 ENSMUSG00000003410 chr9:21822543:21822592:- 1.293782681 8.302549067 4.38271E-06
Vamp2 ENSMUSG00000020894 chr11:68905817:68905866: 1.293750517 10.12071718 1.06739E-07
Sorl1 ENSMUSG00000049313 chr9:41782068:41782117:- 1.291731228 7.668288415 8.46226E-06
Snph ENSMUSG00000027457 chr2:151416409:151416458:- 1.287711392 7.701278948 4.17833E-08
Prkcz ENSMUSG00000029053 chr4:154636543:154636592:- 1.28391557 8.209945629 6.14359E-06
Tmem35 ENSMUSG00000033578 chrX:130839990:130840039: 1.283276939 9.575966528 1.34795E-05
Adora1 ENSMUSG00000042429 chr1:136098200:136098249:- 1.282920327 8.62133925 3.06116E-07
Abat ENSMUSG00000057880 chr16:8621538:8621587: 1.281425983 9.350388983 0.000139825
Epb4.9 ENSMUSG00000022099 chr14:71003803:71003852:- 1.280267586 7.060330299 2.15232E-07
Mpped1 ENSMUSG00000041708 chr15:83688601:83688650: 1.277337091 9.582032616 2.43317E-06
Elmo1 ENSMUSG00000041112 chr13:20698099:20698148: 1.275431738 10.98764753 1.09268E-07
Rasl11b ENSMUSG00000049907 chr5:74595297:74595346: 1.274306407 9.297467333 7.28793E-06
Lm ENSMUSG00000028063 chr3:88287992:88288041:- 1.273096152 9.126791671 4.17603E-06
Stmn3 ENSMUSG00000027581 chr2:181041947:181041996:- 1.272809242 10.27669129 2.19763E-06
Mast1 ENSMUSG00000053693 chr8:87435893:87435942:- 1.272014436 7.868236767 4.94047E-06
Scg3 ENSMUSG00000032181 chr9:75491634:75491683:- 1.271694144 9.714292127 1.0313E-06
Vamp8 ENSMUSG00000050732 chr6:72335493:72335542:- 1.270303121 7.089104023 1.75247E-07
Prmt2 ENSMUSG00000020230 chr10:75670186:75670235:- 1.270205989 11.42276125 3.60929E-07
1300014I06Rik ENSMUSG00000021411 chr13:34720338:34720387:- 1.267420337 7.703133413 2.76475E-06
Prmt2 ENSMUSG00000020230 chr10:75670130:75670179:- 1.265601024 11.81964109 1.78211E-07
 192
Nell2 ENSMUSG00000022454 chr15:95050515:95050564:- 1.265417024 8.969848739 4.17582E-05
Stxbp2 ENSMUSG00000004626 chr8:3642663:3642712: 1.263570768 7.701598744 0.000122338
Dlg2 ENSMUSG00000052572 chr7:99597248:99597297: 1.262277712 7.358898574 5.19344E-08
Klk8 ENSMUSG00000064023 chr7:51059063:51059112: 1.261505047 7.600696854 6.46152E-07
Olfml2b ENSMUSG00000038463 chr1:172612689:172612738: 1.260819968 8.088075454 1.3439E-06
Rab11fip5 ENSMUSG00000051343 chr6:85285117:85285166:- 1.258884826 8.779356843 2.97106E-07
Dusp8 ENSMUSG00000037887 chr7:149267582:149267631:- 1.258654284 8.940153621 5.36415E-07
Serpinf1 ENSMUSG00000000753 chr11:75223539:75223588:- 1.25393558 7.885276043 0.002544778
Dpysl3 ENSMUSG00000024501 chr18:43487995:43488044:- 1.252911247 11.88338934 2.28101E-06
Gprasp1 ENSMUSG00000043384 chrX:132337741:132337790: 1.252576236 11.0612465 1.8922E-06
Arhgdib ENSMUSG00000030220 chr6:136872439:136872488:- 1.250141948 6.995491172 3.02802E-06
Prl2c3 ENSMUSG00000056457 chr13:12892287:12892336:- 1.247544524 7.007402757 8.82584E-05
Wnt8b ENSMUSG00000036961 chr19:44586929:44586978: 1.246763115 6.958548289 0.000126085
Pik3r3 ENSMUSG00000028698 chr4:115975245:115975294: 1.245068267 10.66864486 1.43155E-07
Ctsk ENSMUSG00000028111 chr3:95313042:95313091: 1.244188763 7.340596606 0.000100508
Ifi27l1 ENSMUSG00000064215 chr12:104678303:104678352: 1.242461905 7.175148119 5.2773E-06
Gprin1 ENSMUSG00000069227 chr13:54838057:54838106:- 1.237231092 10.98180776 2.19747E-06
Ctxn1 ENSMUSG00000048644 chr8:4257928:4257977:- 1.236871713 9.2591253 4.18521E-06
Myt1l ENSMUSG00000061911 chr12:30604856:30604903:,chr12:30605206:30605207: 1.236591188 8.265914648 2.90382E-05
Spsb1 ENSMUSG00000039911 chr4:149270463:149270512:- 1.236521099 8.380636787 1.6236E-06
Cd200 ENSMUSG00000022661 chr16:45382738:45382786:- 1.2363346 7.042267836 1.13944E-06
Trnp1 ENSMUSG00000056596 chr4:133047240:133047289:- 1.232447852 6.972821237 4.07739E-05
6330403K07Rik chr11:70845729:70845778:- 1.230742455 11.09344496 5.30344E-06
Mapre2 ENSMUSG00000024277 chr18:24051899:24051948: 1.228591411 8.578536096 9.39161E-08
Srxn1 ENSMUSG00000032802 chr2:151935522:151935571: 1.227383729 7.722699703 5.6218E-06
Crmp1 ENSMUSG00000029121 chr5:37682791:37682840: 1.22439088 9.984347251 2.39855E-06
Gucy1a3 ENSMUSG00000033910 chr3:81896463:81896512:- 1.220010881 8.984168401 4.30393E-05
Fam164a ENSMUSG00000043542 chr3:7553480:7553529: 1.219125027 10.47978003 3.57661E-07
Nxph2 ENSMUSG00000069132 chr2:23257259:23257308: 1.219081543 7.615116785 8.96466E-05
Otx2 ENSMUSG00000021848 chr14:49278180:49278229:- 1.217321625 7.0359337 1.22393E-05
Ifi27l1 ENSMUSG00000064215 chr12:104678265:104678314: 1.216913799 7.214111122 3.57536E-06
Sh3gl2 ENSMUSG00000028488 chr4:85031737:85031786: 1.215425653 7.695029734 1.09035E-05
Klhl8 ENSMUSG00000029312 chr5:104291504:104291553:- 1.214253516 7.740338518 1.67693E-07
Arpp21 ENSMUSG00000032503 chr9:112083679:112083728:- 1.213058344 8.429542804 2.24243E-07
Cdh13 ENSMUSG00000031841 chr8:121836613:121836635:,chr8:121837873:121837899: 1.212331985 9.633227147 1.07729E-05
cad ENSMUSG00000041073 chr11:6498272:6498318:-,chr11:6498128:6498130:- 1.211379897 8.044227192 8.09128E-07
Phactr1 ENSMUSG00000054728 chr13:43233690:43233739: 1.210085368 8.078660952 5.6305E-07
 193
Id4 ENSMUSG00000021379 chr13:48358659:48358708: 1.210044041 8.245098317 4.2001E-06
Rbbp6 ENSMUSG00000030779 chr7:130123025:130123074: 1.209714598 7.445424293 1.75009E-06
Plcd4 ENSMUSG00000026173 chr1:74589552:74589601: 1.206752698 7.097562626 1.21213E-07
Syn1 ENSMUSG00000037217 chrX:20437659:20437708:- 1.203838733 9.537161951 2.03699E-06
Id2 ENSMUSG00000020644 chr12:25779265:25779314:- 1.203785981 9.670603036 2.90449E-07
Adcy8 ENSMUSG00000022376 chr15:64530760:64530809:- 1.202148231 7.703459064 2.44118E-06
Cxadr ENSMUSG00000022865 chr16:78340725:78340774: 1.201837502 11.03273792 8.03394E-06
Lum ENSMUSG00000036446 chr10:97034583:97034632: 1.200760011 7.004516209 2.60538E-05
Tceal1 ENSMUSG00000049536 chrX:133243792:133243841: 1.20033471 7.731393934 9.85798E-06
Camkv ENSMUSG00000032936 chr9:107851695:107851744: 1.196565894 7.654221297 5.79895E-06
St8sia5 ENSMUSG00000025425 chr18:77493863:77493912: 1.196541567 6.92856957 5.85376E-07
Ldb2 ENSMUSG00000039706 chr5:44864103:44864152:- 1.195744856 8.912185152 2.21865E-06
Atp2b2 ENSMUSG00000030302 chr6:113695955:113696004:- 1.193905287 7.056737059 1.61284E-06
Col4a2 ENSMUSG00000031503 chr8:11448896:11448945: 1.191543517 7.194201709 9.78857E-05
Palm ENSMUSG00000035863 chr10:79283446:79283495: 1.190643215 8.960902778 1.82394E-07
Serpinb6a ENSMUSG00000060147 chr13:34009975:34010024:- 1.189409927 9.070390334 1.14104E-05
Rab3b ENSMUSG00000003411 chr4:108615728:108615777: 1.188529433 7.389992947 1.58504E-06
Pqlc3 ENSMUSG00000045679 chr12:16995783:16995832:- 1.187662818 6.846165999 7.71069E-06
6430598A04Rik ENSMUSG00000045348 chr5:138172497:138172546:- 1.186636715 7.609538558 1.92911E-07
Kalrn ENSMUSG00000061751 chr16:33975469:33975518:- 1.18626242 7.515412479 0.00052405
Reep5 ENSMUSG00000005873 chr18:34504768:34504817:- 1.184406492 9.967773343 5.19708E-07
Sphk1 ENSMUSG00000061878 chr11:116397901:116397950: 1.183056931 8.618935771 2.49425E-05
Rprml ENSMUSG00000046215 chr11:103511773:103511822: 1.181451273 7.079403068 7.66899E-05
Wdr6 ENSMUSG00000066357 chr9:108475117:108475166:- 1.180246342 10.03662804 8.72337E-06
Cxcl12 ENSMUSG00000061353 chr6:117121533:117121582: 1.179035478 7.42130637 0.000154668
Sgip1 ENSMUSG00000028524 chr4:102643467:102643516: 1.178858742 7.58809274 7.2815E-06
Hist2h2aa1 ENSMUSG00000064220;ENSMUSG00000063954 chr3:96043643:96043692:- 1.178507308 7.226670962 8.78918E-08
Synm ENSMUSG00000030554 chr7:74877798:74877847:- 1.178397335 7.312797775 1.21743E-07
Enpp5 ENSMUSG00000023960 chr17:44223309:44223358: 1.17830953 9.18641706 4.13157E-07
Ercc5 ENSMUSG00000026048 chr1:44237738:44237787: 1.175718861 10.17316826 1.79293E-06
4833424O15Rik ENSMUSG00000033342 chr3:117392050:117392099: 1.175180651 7.946386105 2.56275E-06
Hsbp1 ENSMUSG00000031839 chr8:121872380:121872429: 1.174229731 11.20518592 3.67453E-06
Lix1 ENSMUSG00000047786 chr17:17539897:17539946: 1.173748386 8.519456963 8.82102E-06
Cort ENSMUSG00000028971 chr4:148499316:148499365:- 1.170936202 6.976043168 5.56538E-05
Dcn ENSMUSG00000019929 chr10:96969288:96969337: 1.170439863 7.080771308 1.73367E-05
Fam155a ENSMUSG00000079157 chr8:9206089:9206138:- 1.165354038 8.981435061 4.07309E-07
AI593442 ENSMUSG00000078307 chr9:52482564:52482613:- 1.164136503 7.001704068 5.65904E-06
 194
Sema4f ENSMUSG00000000627 chr6:82862085:82862134:- 1.163708915 6.994479849 7.52977E-06
Zbtb8b ENSMUSG00000048485 chr4:129103778:129103827:- 1.162733033 7.090001746 3.2831E-07
Fam49b ENSMUSG00000022378 chr15:63760888:63760937:- 1.161429943 9.223330008 1.63209E-06
Gxylt2 ENSMUSG00000030074 chr6:100754964:100755013: 1.160697045 7.193890867 2.37713E-05
Pmaip1 ENSMUSG00000024521 chr18:66624125:66624174: 1.160419603 7.098515009 2.91874E-07
Fbxo32 ENSMUSG00000022358 chr15:58011999:58012048:- 1.158871143 7.519761486 2.76761E-06
Sln ENSMUSG00000042045 chr9:53701457:53701506: 1.157411443 6.681577648 0.000255785
Pak3 ENSMUSG00000031284 chrX:140225796:140225845: 1.154347945 10.27632821 9.8647E-07
Ptpro ENSMUSG00000030223 chr6:137411117:137411166: 1.15414939 9.48725861 5.87305E-06
Mgst3 ENSMUSG00000026688 chr1:169302611:169302660:- 1.153721953 9.467994701 4.02025E-05
Smarca2 ENSMUSG00000024921 chr19:26852604:26852653: 1.150417294 11.14579806 5.5677E-07
Col6a1 ENSMUSG00000001119 chr10:76171758:76171807:- 1.148078218 6.823241547 4.38345E-05
Fry ENSMUSG00000056602 chr5:151299954:151300003: 1.14618966 7.596902742 2.79454E-07
Sparcl1 ENSMUSG00000029309 chr5:104508469:104508518:- 1.145820148 7.77112248 2.23255E-05
Gpr83 ENSMUSG00000031932 chr9:14673626:14673675: 1.145135438 7.284610618 5.14922E-06
Ube2n ENSMUSG00000074781 chr10:95007923:95007972: 1.14436195 10.20606701 9.39361E-07
D10Bwg1379e ENSMUSG00000019852 chr10:18308109:18308158:- 1.141355001 7.322052304 7.6288E-06
Apoe ENSMUSG00000002985 chr7:20281959:20282008:- 1.139814357 8.740644181 4.6615E-05
Gprasp1 ENSMUSG00000043384 chrX:132337156:132337205: 1.138972528 9.034103337 4.51532E-06
Rusc2 ENSMUSG00000035969 chr4:43439817:43439866: 1.136552022 10.11118859 1.96301E-07
Cdh13 ENSMUSG00000031841 chr8:121029560:121029609: 1.136438408 8.992381257 2.20225E-05
Cxxc4 ENSMUSG00000044365 chr3:133924778:133924827: 1.134660786 8.039421107 2.9149E-05
Znrf2 ENSMUSG00000058446 chr6:54839346:54839395: 1.132034522 10.10767121 3.52166E-05
Sulf1 ENSMUSG00000016918 chr1:12850255:12850304: 1.131128778 7.098593743 0.001623072
Lm ENSMUSG00000028063 chr3:88287147:88287196:- 1.130215095 10.01034502 6.46952E-06
Fam129b ENSMUSG00000026796 chr2:32780677:32780726: 1.127959717 9.274671248 1.154E-06
Rasl11b ENSMUSG00000049907 chr5:74595389:74595438: 1.126473351 9.102526341 9.92881E-06
1110008P14Rik ENSMUSG00000039195 chr2:32234748:32234797:- 1.125247243 9.703635023 2.81678E-06
Arg2 ENSMUSG00000021125 chr12:80257029:80257078: 1.124801131 6.786326544 3.32465E-05
Nell2 ENSMUSG00000022454 chr15:95126620:95126669:- 1.124423921 7.683971936 1.62642E-05
Cdk5r1 ENSMUSG00000048895 chr11:80294579:80294628: 1.121093637 12.2981684 6.97101E-07
Ptprd ENSMUSG00000028399 chr4:75587440:75587489:- 1.120868899 9.627907625 9.58355E-05
Sez6l2 ENSMUSG00000030683 chr7:134111756:134111770:,chr7:134113567:134113601: 1.120868514 7.365234441 2.81277E-05
Slc8a1 ENSMUSG00000054640 chr17:81785132:81785181:- 1.11945554 8.586064591 1.41562E-06
Rab11fip5 ENSMUSG00000051343 chr6:85285122:85285171:- 1.119145441 8.361165204 1.72526E-07
Prokr1 ENSMUSG00000049409 chr6:87528629:87528678:- 1.118350685 7.84538473 6.56165E-05
Palm ENSMUSG00000035863 chr10:79283071:79283120: 1.117068433 7.696684805 9.37161E-06
 195
Ephx4 ENSMUSG00000033805 chr5:107848803:107848852: 1.115932796 7.801309688 2.39935E-05
Runx1t1 ENSMUSG00000006586 chr4:13818157:13818206: 1.11440567 8.411079559 4.38271E-06
S100a10 ENSMUSG00000041959 chr3:93368411:93368460: 1.113590756 9.359746261 0.000115617
Cartpt ENSMUSG00000021647 chr13:100668905:100668954:- 1.113379666 6.948556243 3.11239E-05
Dapk1 ENSMUSG00000021559 chr13:60864054:60864103: 1.109155155 7.54707686 5.99411E-06
Slc40a1 ENSMUSG00000025993 chr1:45965105:45965154:- 1.108896015 7.005308082 0.000385845
Stac ENSMUSG00000032502 chr9:111463994:111464043:- 1.108149493 7.824796282 1.55474E-06
Akr1c13 chr13:4193303:4193352: 1.107900576 6.887981086 7.52511E-05
Apbb1 ENSMUSG00000037032 chr7:112707107:112707156:- 1.106281268 9.728152909 1.22799E-06
Rufy3 ENSMUSG00000029291 chr5:89071420:89071469: 1.105323489 10.2103124 7.00624E-07
Enc1 ENSMUSG00000041773 chr13:98022565:98022614: 1.104067136 11.39710176 4.35628E-06
Aplp1 ENSMUSG00000006651 chr7:31220310:31220359:- 1.102967891 8.021406656 2.01231E-06
Cacng5 ENSMUSG00000040373 chr11:107736236:107736285:- 1.100982584 8.829165747 0.00294654
Sel1l3 ENSMUSG00000029189 chr5:53498590:53498639:- 1.100142722 8.094248516 5.14922E-06
Emid2 ENSMUSG00000004415 chr5:137217674:137217723:- 1.100047935 7.558294677 9.63396E-05
Lix1 ENSMUSG00000047786 chr17:17580656:17580705: 1.098708703 8.192972569 0.00026867
Larp6 ENSMUSG00000034839 chr9:60586214:60586263: 1.098290039 7.96587205 5.25347E-06
Nuak1 ENSMUSG00000020032 chr10:83834497:83834546:- 1.097022448 7.296151585 2.21532E-05
Prkar1b ENSMUSG00000025855 chr5:139493573:139493622:- 1.096412313 7.458235581 8.336E-07
Ccnd2 ENSMUSG00000000184 chr6:127079637:127079686:- 1.096115927 12.70141098 1.50742E-06
Parp6 ENSMUSG00000025237 chr9:59497979:59498028: 1.095095201 9.694326566 1.13944E-06
Igfbp7 ENSMUSG00000036256 chr5:77778386:77778435:- 1.094953039 7.657986969 0.001616895
Stx7 ENSMUSG00000019998 chr10:23908324:23908373: 1.094155907 11.09567248 4.55649E-06
Mapkapk3 ENSMUSG00000032577 chr9:107157498:107157547:- 1.092445947 7.77487617 8.43085E-07
Crhbp ENSMUSG00000021680 chr13:96201660:96201709:- 1.092408343 7.290267069 0.002868347
Gstt3 ENSMUSG00000001665 chr10:75236901:75236950:- 1.092385507 6.964957921 3.9429E-05
Hecw2 ENSMUSG00000042807 chr1:53987687:53987736:- 1.092055365 7.192433843 1.45705E-06
Gria1 ENSMUSG00000020524 chr11:57140964:57141013: 1.087885038 7.110642657 5.66565E-05
Atp2a2 ENSMUSG00000029467 chr5:122903757:122903806:- 1.087702029 10.67066389 1.53688E-05
Tmem120a ENSMUSG00000039886 chr5:136211545:136211594:- 1.087234515 9.950136743 3.60257E-07
Fbxo25 ENSMUSG00000038365 chr8:13940328:13940377: 1.087198249 9.534788223 4.74937E-06
Ngfr ENSMUSG00000000120 chr11:95430274:95430323:- 1.087172322 7.117541049 7.70466E-06
Pja2 ENSMUSG00000024083 chr17:64632511:64632560:- 1.087139933 11.2141633 1.87919E-06
gk ENSMUSG00000034744 chr6:83746931:83746980: 1.085525666 9.901334309 0.001035789
Eif4a2 ENSMUSG00000022884 chr16:23111608:23111657: 1.085381392 11.557299 1.93493E-05
Ppp2r2b ENSMUSG00000024500 chr18:43058456:43058505:- 1.085320239 8.651709637 6.21925E-06
Bhlhe22 ENSMUSG00000025128 chr3:17957205:17957254: 1.085215013 7.359952608 0.000178421
 196
Iqsec3 ENSMUSG00000040797 chr6:121323200:121323249:- 1.084965664 7.018813918 1.87993E-05
G14 ENSMUSG00000024697 chr19:16685191:16685240: 1.082088409 7.716171721 9.08256E-05
Trafd1 ENSMUSG00000042726 chr5:121821820:121821869:- 1.081813239 10.45758887 9.93102E-06
Mpp3 ENSMUSG00000052373 chr11:101861578:101861627:- 1.080429838 7.92407837 6.3613E-06
Pfkp ENSMUSG00000021196 chr13:6620232:6620281:- 1.077939556 8.059127223 1.66477E-06
Rac3 ENSMUSG00000018012 chr11:120584580:120584629: 1.077133122 8.379488042 5.36767E-07
Ccnd1 ENSMUSG00000070348 chr7:152115983:152116032:- 1.07519144 13.5660612 0.000180837
Csdc2 ENSMUSG00000042109 chr15:81781303:81781352: 1.074477496 8.49910616 3.38843E-06
Sat1 ENSMUSG00000025283 chrX:151647992:151648041:- 1.070942068 9.85732332 6.43262E-05
Gria1 ENSMUSG00000020524 chr11:57140966:57141015: 1.067557804 7.058504797 7.31322E-05
Sqstm1 ENSMUSG00000015837 chr11:50014169:50014218:- 1.067440308 10.85734629 5.21435E-06
Slc1a1 ENSMUSG00000024935 chr19:28988294:28988343: 1.06705227 8.380297679 5.25347E-06
Ptprd ENSMUSG00000028399 chr4:75587454:75587503:- 1.064120575 9.554428797 3.25708E-05
Pltp ENSMUSG00000017754 chr2:164665235:164665284:- 1.062746883 7.136324081 9.16173E-07
Dclk1 ENSMUSG00000027797 chr3:55340502:55340551: 1.057431805 10.06283318 6.11286E-07
Prr13 ENSMUSG00000023048 chr15:102293096:102293145: 1.057205197 11.29868501 8.34197E-06
Dkk3 ENSMUSG00000030772 chr7:119259613:119259662:- 1.057088807 8.496529464 0.001301342
Ica1l ENSMUSG00000026018 chr1:60045940:60045989:- 1.056035679 7.040963418 4.72036E-06
Gatsl3 ENSMUSG00000020424 chr11:4122291:4122340: 1.0550861 7.175078265 8.16337E-07
Ccl27a ENSMUSG00000073888 chr4:41716717:41716766:- 1.054164876 7.512302365 6.65037E-07
Eps8 ENSMUSG00000015766 chr6:137430688:137430737:- 1.050554472 7.895311834 7.11223E-07
Npas4 ENSMUSG00000045903 chr19:4984596:4984645:- 1.049277863 6.803222313 0.000276507
Cstb ENSMUSG00000005054 chr10:77890170:77890219: 1.048619923 12.09120066 1.02855E-06
Plcd4 ENSMUSG00000026173 chr1:74611689:74611738: 1.04722381 6.9386931 1.83188E-05
Ifitm3 ENSMUSG00000025492 chr7:148195586:148195635:- 1.042435134 9.114646336 0.000483992
Dlk2 ENSMUSG00000047428 chr17:46440050:46440099: 1.041723002 8.181758378 4.56165E-06
Timp1 ENSMUSG00000001131 chrX:20451675:20451724: 1.041297459 8.7373742 6.83928E-06
Ptpro ENSMUSG00000030223 chr6:137368850:137368899: 1.041244916 7.35270241 8.34197E-06
Socs2 ENSMUSG00000020027 chr10:94875043:94875092:- 1.040983584 9.659035929 1.80427E-05
Thsd7b ENSMUSG00000042581 chr1:132115331:132115380: 1.038537762 6.988896771 0.00012788
Igdcc4 ENSMUSG00000032816 chr9:64985471:64985520: 1.036649703 10.29119683 0.000315707
Pacs2 ENSMUSG00000021143 chr12:114312520:114312569: 1.035613472 10.96122974 1.7982E-05
Zmat3 ENSMUSG00000027663 chr3:32234129:32234178:- 1.035397164 9.612406487 4.57133E-07
Adam23 ENSMUSG00000025964 chr1:63642598:63642647: 1.035055482 8.357449063 6.15243E-05
Gjd2 ENSMUSG00000068615 chr2:113835489:113835538:- 1.034890708 7.836450647 1.7499E-05
Icam1 ENSMUSG00000037405 chr9:20832883:20832932: 1.034839477 7.200974952 4.11575E-05
Pkia ENSMUSG00000027499 chr3:7445021:7445070: 1.033923828 11.35959782 1.50742E-05
Slc19a2 ENSMUSG00000040918 chr1:166195371:166195420: 1.03384507 9.826623397 3.69223E-05
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B930041F14Rik ENSMUSG00000074738 chr4:155070519:155070568: 1.033707554 10.60424715 2.5741E-06
Dgkg ENSMUSG00000022861 chr16:22468713:22468762:- 1.032296702 7.426642123 5.96541E-05
6430548M08Rik ENSMUSG00000031824 chr8:122687226:122687275: 1.031936959 7.9324255 1.16253E-05
Eef1a2 ENSMUSG00000016349 chr2:180888469:180888518:- 1.030176096 7.113901872 2.55842E-05
Crabp1 ENSMUSG00000032291 chr9:54620793:54620842: 1.029543237 6.937298937 0.000111538
Map1lc3a ENSMUSG00000027602 chr2:155103551:155103600: 1.028580479 8.527965607 7.23075E-06
Pcyt1b ENSMUSG00000035246 chrX:90995029:90995078: 1.027892115 7.860160376 5.00916E-07
Ccnd1 ENSMUSG00000070348 chr7:152115984:152116033:- 1.027430893 13.90117783 5.97026E-05
Stk32b ENSMUSG00000029123 chr5:37838136:37838185:- 1.027097819 7.688086238 8.03394E-06
Crym ENSMUSG00000030905 chr7:127330118:127330167:- 1.027035505 7.329239933 1.80269E-05
Fam164a ENSMUSG00000043542 chr3:7553489:7553538: 1.026690743 9.197989202 1.67875E-06
Lrdd ENSMUSG00000025507 chr7:148624604:148624653:- 1.024909806 7.962387124 9.85903E-05
Garnl3 ENSMUSG00000038860 chr2:32841966:32842015:- 1.023981073 9.019203059 6.16492E-05
Dennd2c ENSMUSG00000007379 chr3:102973452:102973501: 1.023394523 6.990510663 1.63209E-06
Aard ENSMUSG00000068522 chr15:51876950:51876999: 1.022770801 9.591164012 7.01036E-06
Ccdc120 ENSMUSG00000031150 chrX:7309030:7309079:- 1.02199943 8.725002034 7.32449E-06
Mgst3 ENSMUSG00000026688 chr1:169303925:169303974:- 1.021528166 8.645402067 0.000544659
Ldoc1l ENSMUSG00000055745 chr15:84383915:84383964:- 1.021015128 9.737816102 1.46805E-06
Abhd4 ENSMUSG00000040997 chr14:54888630:54888679: 1.020656086 9.663407838 4.49151E-05
Mdm2 ENSMUSG00000020184 chr10:117126367:117126416:- 1.018563015 10.77290141 8.38192E-05
Scrn1 chr6:54456378:54456427:- 1.016017202 8.559903734 1.55474E-06
Gucy1a3 ENSMUSG00000033910 chr3:81898142:81898191:- 1.014962762 7.433012358 4.5124E-05
Nr4a2 ENSMUSG00000026826 chr2:56960685:56960734:- 1.014867399 7.533006185 2.25111E-06
Tnfaip8 ENSMUSG00000062210 chr18:50251038:50251087: 1.014361514 9.388022887 8.21975E-06
Epha3 ENSMUSG00000052504 chr16:63545096:63545145:- 1.013868792 7.669479845 1.14775E-05
Arhgap44 ENSMUSG00000033389 chr11:64815676:64815725:- 1.013154067 9.013647005 1.57679E-06
Alcam ENSMUSG00000022636 chr16:52251265:52251314:- 1.012628857 8.81559121 1.22525E-05
Thsd7b ENSMUSG00000042581 chr1:132115759:132115808: 1.012294263 6.683921153 0.000112084
Pdp1 ENSMUSG00000049225 chr4:11887874:11887923:- 1.011464755 7.364492239 3.11239E-05
Stmn1 ENSMUSG00000028832 chr4:134029501:134029550: 1.011239026 10.39796925 0.000144941
Mcc ENSMUSG00000071856 chr18:44585165:44585214:- 1.010951264 8.164994583 2.55796E-06
Ecm1 ENSMUSG00000028108 chr3:95538235:95538284:- 1.010083887 7.037412751 0.001700642
Ankrd12 ENSMUSG00000034647 chr17:66317159:66317208:- 1.00986178 8.637215608 3.94215E-05
6430527G18Rik ENSMUSG00000034168 chr12:88222183:88222232:- 1.009407294 11.62769253 1.79091E-06
Dpp10 ENSMUSG00000036815 chr1:125229254:125229303:- 1.008826453 7.047104511 5.00698E-06
Pdrg1 ENSMUSG00000027472 chr2:152834936:152834985:- 1.008603747 9.437571982 1.37773E-05
Gng3 ENSMUSG00000071658 chr19:8911455:8911504:- 1.007187638 8.089659068 5.35393E-06
Syt16 ENSMUSG00000044912 chr12:75368796:75368845: 1.00654766 9.269396181 1.05952E-05
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Adcy1 ENSMUSG00000020431 chr11:7078133:7078182: 1.005842213 7.417828672 5.01536E-06
Msx1 ENSMUSG00000048450 chr5:38212320:38212369:- 1.005568583 6.966939988 3.90199E-06
Cdkl2 ENSMUSG00000029403 chr5:92435511:92435560:- 1.005271428 6.928563249 1.13944E-06
Nol4 ENSMUSG00000041923 chr18:22928294:22928343:- 1.004117209 6.832311232 1.5405E-05
Larp6 ENSMUSG00000034839 chr9:60586262:60586311: 1.003044126 7.702907546 2.20535E-05
Mmd ENSMUSG00000003948 chr11:90139693:90139742: 1.002174603 10.48487024 2.56275E-06
Bcl2l1 ENSMUSG00000007659 chr2:152607465:152607514:- 1.002037914 7.829413577 2.86385E-06
Klf6 ENSMUSG00000000078 chr13:5864529:5864578: 1.00160062 8.180322059 7.98638E-06
Tulp4 chr17:6240371:6240420: 1.000878007 10.84762611 5.25347E-06
Tmem179 ENSMUSG00000054013 chr12:113738703:113738752:- 1.000231275 7.071015846 4.42007E-07
Rapgef5 ENSMUSG00000041992 chr12:118994896:118994945: 0.999952219 7.13574528 1.18334E-06
Gjd2 ENSMUSG00000068615 chr2:113835526:113835575:- 0.996463644 7.273988962 4.35753E-05
Adcyap1 ENSMUSG00000024256 chr17:93604568:93604617: 0.996381396 6.728338246 2.11362E-05
Dcaf4 ENSMUSG00000021222 chr12:84882576:84882625: 0.996046404 9.191224006 2.16109E-06
ENSMUSG0000
0068790 ENSMUSG00000096775 chr14:4144118:4144167: 0.995492532 10.5675665 6.14359E-06
Tnfsf18 ENSMUSG00000066755 chr1:163435049:163435098: 0.994568374 6.686800425 0.000658834
Pnck ENSMUSG00000002012 chrX:70901475:70901524:- 0.994332474 7.59123021 1.95873E-05
Hecw2 ENSMUSG00000042807 chr1:53989973:53990022:- 0.993621297 7.341638614 2.70334E-05
Sybu ENSMUSG00000022340 chr15:44503819:44503868:- 0.992289792 10.28439975 4.70245E-05
Plcl2 ENSMUSG00000038910 chr17:50827594:50827643: 0.990851562 8.355435201 4.51532E-06
Fam158a ENSMUSG00000022217 chr14:56200387:56200436:- 0.990670452 7.487879208 7.93511E-06
Atp6v0d1 ENSMUSG00000013160 chr8:108048801:108048850:- 0.989646267 11.37180649 4.25348E-05
Pmm1 ENSMUSG00000022474 chr15:81781844:81781893:- 0.986239427 10.15552829 0.000300113
Rufy3 ENSMUSG00000029291 chr5:89071591:89071640: 0.984960224 11.00534267 1.38331E-06
Gng4 ENSMUSG00000021303 chr13:13919897:13919946: 0.98370821 7.232216778 4.90167E-05
Lm ENSMUSG00000028063 chr3:88288537:88288543:-,chr3:88288034:88288076:- 0.983441486 8.502422883 6.97101E-07
Cort ENSMUSG00000028971 chr4:148499369:148499418:- 0.981128967 7.088652281 0.003370594
Ramp3 ENSMUSG00000041046 chr11:6576648:6576697: 0.980164861 6.740087622 2.80683E-06
March4 ENSMUSG00000039372 chr1:72474375:72474424:- 0.978727818 7.169694914 9.87678E-05
Enox1 ENSMUSG00000022012 chr14:78121036:78121085: 0.97688083 8.637822114 7.33617E-07
Renbp ENSMUSG00000031387 chrX:71167468:71167517:- 0.976797312 8.903936897 3.28229E-05
Sh3kbp1 ENSMUSG00000040990 chrX:156411741:156411790: 0.976085572 8.425645859 4.35628E-06
Djb9 ENSMUSG00000014905 chr12:45307126:45307175:- 0.974918366 9.027008895 4.0223E-05
Atp9a ENSMUSG00000027546 chr2:168460278:168460327:- 0.973794481 8.351198473 7.67341E-06
Mtap1b ENSMUSG00000052727 chr13:100194560:100194609:- 0.971840533 7.31561818 2.47165E-06
Vat1l ENSMUSG00000046844 chr8:116897837:116897886: 0.971514633 8.493506396 2.12155E-06
Lhx5 ENSMUSG00000029595 chr5:120891110:120891159: 0.970756804 6.577408693 2.95929E-05
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Ubtd1 ENSMUSG00000025171 chr19:42109022:42109071: 0.969846158 8.086881931 1.24549E-05
Rundc3b ENSMUSG00000040570 chr5:8490647:8490696:- 0.969785381 7.565198602 0.000158505
Bclp2 chr3:105820901:105820950:- 0.969329405 6.495268832 1.00961E-06
Gsta4 ENSMUSG00000032348 chr9:78056899:78056948: 0.968068573 8.046238974 6.20973E-05
Spnb2 ENSMUSG00000020315 chr11:30000576:30000625:- 0.967727277 8.950023542 9.33058E-05
Pmm1 ENSMUSG00000022474 chr15:81782387:81782436:- 0.96718094 10.52771609 0.000794498
Rhof ENSMUSG00000029449 chr5:123568488:123568537:- 0.966786694 7.150177499 3.26225E-06
Higd2a ENSMUSG00000025868 chr13:54692328:54692377: 0.966253894 12.94434885 1.16241E-06
Ankrd12 ENSMUSG00000034647 chr17:66373464:66373513:- 0.966218437 8.134381304 1.39069E-05
Gng7 ENSMUSG00000048240 chr10:80411412:80411461:- 0.965758155 8.634830803 7.9599E-06
Stard10 ENSMUSG00000030688 chr7:108494530:108494579: 0.964723353 7.796664514 9.80047E-05
Slc27a3 ENSMUSG00000027932 chr3:90189181:90189230:- 0.96367723 9.44561106 5.97999E-07
Jph4 ENSMUSG00000022208 chr14:55726278:55726327:- 0.961449181 7.51826511 4.88002E-06
Cxxc4 ENSMUSG00000044365 chr3:133903528:133903577: 0.960964801 7.93207269 0.000206858
Magee1 ENSMUSG00000031227 chrX:102319145:102319194: 0.960368035 10.67664664 4.52213E-06
Cbs ENSMUSG00000024039 chr17:31749945:31749994:- 0.958954813 8.482256981 1.03934E-05
Nrxn1 ENSMUSG00000024109 chr17:90458838:90458887:- 0.958727374 8.937867794 0.00101094
Sema3f ENSMUSG00000034684 chr9:107583840:107583889:- 0.957858903 8.403542174 4.21889E-06
Ercc5 ENSMUSG00000026048 chr1:44237820:44237869: 0.956987855 10.79657823 3.91025E-06
Tubg2 ENSMUSG00000045007 chr11:101023031:101023080: 0.956474761 9.117788067 1.12997E-05
Pqlc3 ENSMUSG00000045679 chr12:17000267:17000316:- 0.955994935 6.870937019 1.51563E-05
Sh3bgrl3 ENSMUSG00000028843 chr4:133683597:133683646:- 0.955638199 10.78768523 2.02003E-05
Atp6v1h ENSMUSG00000033793 chr1:5152255:5152304: 0.95454429 11.77276463 2.19344E-05
Whrn ENSMUSG00000039137 chr4:63075996:63076045:- 0.954158616 9.01818669 0.000374584
Rapgefl1 ENSMUSG00000038020 chr11:98714234:98714283: 0.953388846 7.842876932 3.69994E-05
Bag3 ENSMUSG00000030847 chr7:135690226:135690275: 0.952471219 10.90216247 9.16173E-07
Gpr21 ENSMUSG00000053164 chr2:37374669:37374718: 0.95191246 7.127473256 5.8406E-06
Akap12 ENSMUSG00000038587 chr10:5987476:5987525:- 0.951707735 11.07424877 4.47591E-06
Camk1d ENSMUSG00000039145 chr2:5218078:5218127:- 0.950087419 6.946439262 1.57218E-06
Scn3b ENSMUSG00000049281 chr9:40096479:40096528: 0.949041076 6.810942662 9.61659E-07
Gpr12 ENSMUSG00000041468 chr5:147394028:147394077:- 0.948645288 6.964560962 7.53441E-05
Mdm2 ENSMUSG00000020184 chr10:117126034:117126083:- 0.948467177 11.27631973 0.00014475
Sema3f ENSMUSG00000034684 chr9:107583842:107583891:- 0.947485366 7.890275622 3.66765E-06
Cpped1 ENSMUSG00000065979 chr16:11803871:11803920:- 0.947243756 9.885276689 0.00023336
Dynll2 ENSMUSG00000020483 chr11:87794143:87794192:- 0.94497895 8.937824979 8.71449E-06
Pcsk2 ENSMUSG00000027419 chr2:143641826:143641875: 0.944976934 7.098396349 4.80499E-06
Nin ENSMUSG00000021068 chr12:71120083:71120132:- 0.944207452 8.795957396 0.000100068
Slc25a45 ENSMUSG00000024818 chr19:5885609:5885658: 0.943930088 7.431038551 1.38357E-05
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4833424O15Rik ENSMUSG00000033342 chr3:117392212:117392261: 0.940814893 7.326425517 1.1715E-05
St8sia3 ENSMUSG00000056812 chr18:64431431:64431480: 0.940237613 6.826623781 6.72228E-06
Lrrc24 ENSMUSG00000033707 chr15:76545808:76545857:- 0.939375516 7.610403828 7.01036E-06
Itm2a ENSMUSG00000031239 chrX:104594929:104594978:- 0.937271095 9.342972497 1.36009E-05
Ngef ENSMUSG00000026259 chr1:89373684:89373733:- 0.936832466 6.809044447 3.80086E-05
Grip1 ENSMUSG00000034813 chr10:119512355:119512404: 0.935850507 8.78493297 0.000178279
Scoc ENSMUSG00000063253 chr8:85958954:85959003:- 0.935833029 10.4634643 3.50004E-05
Dapk1 ENSMUSG00000021559 chr13:60864045:60864094: 0.933988277 7.885393687 3.07055E-06
Mansc1 ENSMUSG00000032718 chr6:134559329:134559378:- 0.933940164 7.40395863 2.33636E-05
Ldb2 ENSMUSG00000039706 chr5:44863928:44863977:- 0.933693722 7.69821311 1.87583E-06
Sp47 ENSMUSG00000009894 chr11:59235030:59235079:- 0.932398065 8.796546993 0.000204761
Pld3 ENSMUSG00000003363 chr7:28318674:28318723:- 0.93183493 9.362710614 6.87988E-06
Timp1 ENSMUSG00000001131 chrX:20451683:20451732: 0.931393958 8.597507316 3.59119E-05
Acot7 ENSMUSG00000028937 chr4:151645779:151645828: 0.930350313 11.43365262 2.25016E-06
Upp1 ENSMUSG00000020407 chr11:9035989:9036038: 0.92985506 10.39287525 9.43604E-05
Kifap3 ENSMUSG00000026585 chr1:165846972:165847021: 0.929438822 9.908245351 2.81356E-06
Spock1 ENSMUSG00000056222 chr13:57528162:57528211:- 0.929277991 6.885399104 7.47995E-05
Coro2b ENSMUSG00000041729 chr9:62267571:62267620:- 0.928157113 9.023336971 3.19253E-05
Atp6v0d1 ENSMUSG00000013160 chr8:108054743:108054792:- 0.927752498 10.694813 7.45757E-06
Snrpn chr7:67128022:67128071:- 0.927629151 12.5782002 1.00423E-06
Clip1 chr5:124027902:124027951:- 0.927255438 9.253566308 1.87778E-05
Nfe2l2 ENSMUSG00000015839 chr2:75516564:75516613:- 0.924974446 8.397299908 5.05362E-05
Cish ENSMUSG00000032578 chr9:107204093:107204142: 0.924723538 8.092292894 2.12699E-05
Fahd1 ENSMUSG00000045316 chr17:24985961:24986010:- 0.921574509 9.287755903 0.000122151
Upp1 ENSMUSG00000020407 chr11:9035167:9035216: 0.921195738 8.392761661 5.14156E-05
3110035E14Rik ENSMUSG00000067879 chr1:9616688:9616737: 0.919890388 8.428174283 0.000107397
Cotl1 ENSMUSG00000031827 chr8:122333250:122333299:- 0.919719959 10.8879986 6.31544E-06
Ss18l1 ENSMUSG00000039086 chr2:179804711:179804760: 0.918928935 7.941364682 8.53537E-07
Adap1 ENSMUSG00000056413 chr5:139748063:139748112:- 0.918717238 6.799616656 2.80683E-06
Lingo2 ENSMUSG00000045083 chr4:35654808:35654857:- 0.918149828 6.895545044 4.68774E-07
Ss18l1 ENSMUSG00000039086 chr2:179802804:179802853: 0.918001553 7.288435313 4.51532E-06
Plk2 ENSMUSG00000021701 chr13:111190807:111190856: 0.916805327 9.740779689 7.19196E-05
Nsg1 ENSMUSG00000029126 chr5:38528564:38528613:- 0.916307678 7.858460152 0.00080241
Dic1 ENSMUSG00000061322 chr4:41585070:41585119: 0.916140459 7.071885692 2.8601E-05
Tcea3 ENSMUSG00000001604 chr4:135827154:135827203: 0.916132679 6.871341287 6.36787E-06
Dt ENSMUSG00000024302 chr18:23762656:23762705: 0.916006011 8.461911983 0.000300924
Mt3 ENSMUSG00000031760 chr8:96676667:96676716: 0.915897887 10.24638475 0.001156848
Loxl1 ENSMUSG00000032334 chr9:58136500:58136549:- 0.915652647 8.416315901 0.002011966
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Bace2 ENSMUSG00000040605 chr16:97646156:97646205: 0.914796737 7.323675151 2.06339E-05
Atp6v1e1 ENSMUSG00000019210 chr6:120745343:120745392:- 0.913569937 12.90390951 3.50156E-06
Casp1 ENSMUSG00000025888 chr9:5306714:5306763: 0.913174383 6.638348655 7.31725E-07
Ooep ENSMUSG00000032346 chr9:78225317:78225366:- 0.913011846 6.836691014 1.22152E-05
Slitrk4 ENSMUSG00000046699 chrX:61522862:61522911:- 0.912812833 7.194046282 0.000946497
Klf6 ENSMUSG00000000078 chr13:5866959:5867008: 0.912335455 11.53937165 2.34127E-05
Elavl2 ENSMUSG00000008489 chr4:90917663:90917712:- 0.911991749 8.993615265 6.21643E-06
Rgs17 ENSMUSG00000019775 chr10:4505259:4505269:,chr10:4513400:4513438: 0.911658044 8.017651718 1.17201E-05
Rhoj ENSMUSG00000046768 chr12:76502356:76502405: 0.911265978 8.560935732 1.6524E-05
Laptm5 ENSMUSG00000028581 chr4:130491984:130492033: 0.909393381 7.179262879 0.005760164
Hsd11b1 ENSMUSG00000016194 chr1:195048163:195048212:- 0.908911035 6.750824262 3.94218E-06
Gabrg2 ENSMUSG00000020436 chr11:41724340:41724389:- 0.903516361 6.754996656 2.20535E-05
Nub1 ENSMUSG00000028954 chr5:24215900:24215949: 0.902919969 8.996579307 3.59119E-05
Syne1 ENSMUSG00000019769;ENSMUSG00000096054 chr10:5009299:5009348: 0.902568789 6.711042608 2.24217E-05
Usp16 ENSMUSG00000025616 chr16:87481148:87481197: 0.902486959 9.292158206 5.64834E-06
Cadps2 ENSMUSG00000017978 chr6:23212864:23212913:- 0.902294332 7.988321182 6.63059E-06
Apba2 ENSMUSG00000030519 chr7:71889330:71889379: 0.902094635 8.073317192 3.03086E-06
Kifap3 ENSMUSG00000026585 chr1:165846921:165846970: 0.899575743 8.664664753 1.22525E-05
Csrnp3 ENSMUSG00000044647 chr2:65861141:65861190: 0.899380701 7.297920558 8.01428E-05
Apba2 ENSMUSG00000030519 chr7:71898512:71898561: 0.899217112 8.177504683 2.80683E-06
Lm ENSMUSG00000028063 chr3:88288560:88288609:- 0.899014613 8.485420112 5.48338E-06
Fbxw7 ENSMUSG00000028086 chr3:84756223:84756272: 0.898883161 6.894798147 4.29506E-06
BC031353 ENSMUSG00000034858 chr9:74879634:74879683: 0.898282801 9.320928604 0.000144297
Cntp4 ENSMUSG00000031772 chr8:115405817:115405866: 0.8981716 6.95038722 9.62497E-07
Chst15 ENSMUSG00000030930 chr7:139427967:139428016:- 0.897447898 7.483541963 1.86626E-05
Fam78b ENSMUSG00000060568 chr1:169020823:169020872: 0.897109175 6.84328752 7.08722E-06
Sema6b ENSMUSG00000001227 chr17:56262526:56262575:- 0.896886515 7.876169519 6.44893E-06
Slc35f3 ENSMUSG00000057060 chr8:128919284:128919333: 0.896450099 7.154187708 1.22525E-05
Upp1 ENSMUSG00000020407 chr11:9034860:9034909: 0.895385967 9.004827789 9.33058E-05
Fsd1 ENSMUSG00000011589 chr17:56136175:56136224: 0.894394162 9.27530651 3.35131E-05
Ntsr1 ENSMUSG00000027568 chr2:180279550:180279599: 0.894351697 7.336695482 2.97253E-06
Adamts18 chr8:116221698:116221747:- 0.893399481 6.856782515 3.97559E-06
Kcnip1 ENSMUSG00000053519 chr11:33530536:33530585:- 0.892917107 7.225856387 6.13636E-05
Crct1 ENSMUSG00000027913 chr3:92818270:92818319:- 0.891051103 6.712340541 0.000255785
Gabarap ENSMUSG00000018567 chr11:69807994:69808043: 0.889721443 11.80910408 0.000119521
Sorcs2 ENSMUSG00000029093 chr5:36360281:36360330:- 0.889647096 7.064146278 6.41859E-06
Coro1a ENSMUSG00000030707 chr7:133843835:133843884:- 0.889219848 7.006545716 6.76762E-06
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Tes ENSMUSG00000029552 chr6:17015262:17015311: 0.888901915 6.816459851 0.000270039
Zic3 ENSMUSG00000067860 chrX:55289010:55289059: 0.888787525 7.648490668 0.004413007
Ei24 ENSMUSG00000062762 chr9:36587116:36587165:- 0.88819438 10.9739756 1.43366E-05
Mtpn ENSMUSG00000029840 chr6:35459533:35459582:- 0.884870966 10.16675257 1.33675E-05
Gpr85 ENSMUSG00000048216 chr6:13785205:13785254:- 0.88472905 9.570643547 3.49244E-05
Lix1 ENSMUSG00000047786 chr17:17580655:17580704: 0.884404773 7.756729933 0.00085315
Gm5468 chr15:25344482:25344531: 0.883792195 7.068654422 1.97925E-06
Npy ENSMUSG00000029819 chr6:49779390:49779439: 0.882982919 7.330375987 0.000998783
Galt ENSMUSG00000036073 chr4:41704400:41704449: 0.882730515 6.952078692 1.30802E-06
Trim3 ENSMUSG00000036989 chr7:112759204:112759253:- 0.881792726 8.658074063 4.47591E-06
Bdh2 ENSMUSG00000028167 chr3:134967304:134967353: 0.880582789 7.793825124 0.000160784
Syn2 ENSMUSG00000009394 chr6:115224937:115224986: 0.880484065 8.982362709 7.67341E-06
Snx16 ENSMUSG00000027534 chr3:10418817:10418866:- 0.879248016 8.167155429 5.70907E-05
Itga11 ENSMUSG00000032243 chr9:62631670:62631719: 0.878449223 6.817752667 7.37877E-05
Ryr3 ENSMUSG00000057378 chr2:112472282:112472331:- 0.878372958 6.678314395 0.000922727
Zfp238 ENSMUSG00000063659 chr1:179380235:179380284: 0.877378015 10.7478225 9.89424E-06
Cbln1 ENSMUSG00000031654 chr8:89992824:89992873:- 0.877301335 9.026178041 0.000153481
Arl4c ENSMUSG00000049866 chr1:90597624:90597673:- 0.876408795 8.860695704 1.12716E-05
Xpo7 chr14:71060330:71060379: 0.876407984 7.187398884 5.57448E-06
Dner ENSMUSG00000036766 chr1:84366549:84366598:- 0.875879085 12.06008897 5.20695E-06
Hpca ENSMUSG00000028785 chr4:128789088:128789137:- 0.874805192 7.552393903 0.000652129
Dusp6 ENSMUSG00000019960 chr10:98729743:98729792: 0.874638777 9.572200566 0.000400377
Smpd1 ENSMUSG00000037049 chr7:112706757:112706806: 0.87343138 10.56519382 1.75682E-06
Abcb9 ENSMUSG00000029408 chr5:124511928:124511977:- 0.872851496 8.031276949 0.000138459
Atp6v1f ENSMUSG00000004285 chr6:29420447:29420496: 0.872666355 11.79722424 7.26742E-05
Ezr ENSMUSG00000052397 chr17:6942897:6942946:- 0.870161857 9.2292443 5.32968E-05
Pdlim7 ENSMUSG00000021493 chr13:55599781:55599830:- 0.869734368 7.836925901 0.002965086
Rnf11 ENSMUSG00000028557 chr4:109125503:109125552:- 0.868437856 11.09012335 2.14908E-05
Macrod2 chr2:142218051:142218100: 0.868376392 7.143434369 8.89542E-05
Camta2 ENSMUSG00000040712 chr11:70482998:70483047:- 0.868271932 10.7818744 0.00211072
Ncdn ENSMUSG00000028833 chr4:126421238:126421287:- 0.868222228 7.996491203 0.000129506
Wnt7b ENSMUSG00000022382 chr15:85365991:85366040:- 0.868126931 10.39626296 0.000115324
Fgf13 ENSMUSG00000031137 chrX:56315651:56315700:- 0.868092647 9.107324429 4.38345E-05
Ywhag ENSMUSG00000051391 chr5:136384367:136384416:- 0.868042031 11.5746942 7.42983E-06
Spock2 ENSMUSG00000058297 chr10:59596584:59596633: 0.867931538 7.494076265 4.43669E-06
Bach2 ENSMUSG00000040270 chr4:32668044:32668093: 0.867645467 10.79158413 0.001377143
Lypd6b ENSMUSG00000026765 chr2:49804193:49804242: 0.866350414 7.066362915 0.000157114
Atp6v0d1 ENSMUSG00000013160 chr8:108048457:108048506:- 0.866320251 11.92102934 8.8601E-06
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Nrp1 ENSMUSG00000025810 chr8:131027112:131027161: 0.866230822 8.716062922 0.000920976
Ehd4 ENSMUSG00000027293 chr2:119915286:119915335:- 0.865860765 8.706882823 2.27809E-06
Eif4a2 ENSMUSG00000022884 chr16:23113891:23113940: 0.864548285 12.48096173 0.000221186
Grip1 ENSMUSG00000034813 chr10:119512517:119512566: 0.864286551 9.49293407 0.000129185
Sp91 ENSMUSG00000033419 chr9:86660092:86660141:- 0.863659604 7.102956925 0.000605855
AI413582 ENSMUSG00000062753 chr17:27701094:27701114:-,chr17:27700933:27700961:- 0.863189555 8.470543342 1.35319E-05
Abr ENSMUSG00000017631 chr11:76230498:76230547:- 0.861789906 8.671619263 7.64192E-05
Trp53inp2 ENSMUSG00000038375 chr2:155215184:155215233: 0.861481412 9.123096476 7.31728E-06
Prkce ENSMUSG00000045038 chr17:87029433:87029482: 0.861469596 7.046171126 4.43859E-05
Tceb1 chr1:16632247:16632296:- 0.861331015 9.702572784 2.94192E-05
Smpd3 ENSMUSG00000031906 chr8:108776826:108776875:- 0.860185871 8.335067457 7.26183E-05
Dok5 ENSMUSG00000027560 chr2:170704710:170704759: 0.8585895 7.585348801 3.80086E-05
Rac3 ENSMUSG00000018012 chr11:120584578:120584627: 0.856954056 8.130868629 5.55766E-05
Cacng5 ENSMUSG00000040373 chr11:107736307:107736356:- 0.856848977 7.709809207 0.002302231
Pja2 ENSMUSG00000024083 chr17:64630413:64630462:- 0.855914463 11.15592972 3.47657E-06
Rasgrf1 ENSMUSG00000032356 chr9:89921695:89921744: 0.855679755 6.745630838 1.7172E-05
D0H4S114 ENSMUSG00000042834 chr18:33596731:33596780:- 0.854874704 12.97763518 6.79894E-05
Pcdhb3 ENSMUSG00000045498 chr18:37463497:37463546: 0.854447196 6.94771767 2.42539E-06
Dusp15 ENSMUSG00000042662 chr2:152771166:152771215:- 0.853674343 7.315503772 7.61785E-05
Cbs ENSMUSG00000024039 chr17:31749952:31750001:- 0.853516614 8.481764718 4.24328E-05
Rufy3 ENSMUSG00000029291 chr5:89071595:89071644: 0.85329674 10.40563271 1.98432E-05
Id1 ENSMUSG00000042745 chr2:152562859:152562908: 0.852259241 9.719755539 0.000206198
Ccnd1 ENSMUSG00000070348 chr7:152117120:152117169:- 0.852102248 11.81833178 1.87091E-05
Lynx1 ENSMUSG00000022594 chr15:74578304:74578353:- 0.851733739 8.770405914 9.32947E-06
Lrrc28 ENSMUSG00000030556 chr7:74658397:74658446:- 0.85120276 9.793014951 8.10582E-05
Sema7a ENSMUSG00000038264 chr9:57810525:57810574: 0.85057094 7.93591552 2.68793E-05
Cdc42ep3 ENSMUSG00000036533 chr17:79733511:79733560:- 0.850200842 8.15329686 5.64834E-06
Akap7 ENSMUSG00000039166 chr10:24889980:24890029:- 0.849487895 9.183162349 1.85643E-05
Rln1 ENSMUSG00000039097 chr19:29406395:29406444:- 0.849313821 7.361235195 1.34303E-05
Ntm ENSMUSG00000059974 chr9:28816831:28816880:- 0.848188493 9.258445557 1.34306E-05
Gpr27 ENSMUSG00000072875 chr6:99643684:99643733: 0.847233847 7.095344658 5.21557E-05
Itga3 ENSMUSG00000001507 chr11:94905825:94905874:- 0.846865572 6.672354701 5.20078E-05
Uba5 ENSMUSG00000032557 chr9:103951571:103951620:- 0.846462555 10.62657631 1.59834E-05
Pramef8 ENSMUSG00000046862 chr4:143010804:143010853: 0.845789052 8.400763057 0.000217721
Kif1b ENSMUSG00000063077 chr4:148550737:148550786:- 0.845553983 11.15924347 0.000120638
Snrk ENSMUSG00000038145 chr9:122078708:122078757: 0.845549474 9.927011938 4.80499E-06
Arhgap23 ENSMUSG00000049807 chr11:97363401:97363450: 0.845520295 8.132365788 4.38921E-06
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Map3k12 ENSMUSG00000023050 chr15:102329960:102330009:- 0.844869407 9.179239469 6.56156E-05
Rgmb ENSMUSG00000048027 chr17:15943286:15943335:- 0.844733814 7.174154506 6.44947E-06
Nrp1 ENSMUSG00000025810 chr8:131027106:131027155: 0.84466288 8.928614425 0.002842096
Igtp ENSMUSG00000078853 chr11:58020810:58020859: 0.844279461 6.769651815 7.11642E-06
Atp6v0d1 ENSMUSG00000013160 chr8:108063311:108063360:- 0.844031425 10.64323604 1.49155E-05
Dynlrb1 ENSMUSG00000047459 chr2:155075682:155075731: 0.843708689 11.96531507 8.30675E-06
Gabarapl1 ENSMUSG00000030161 chr6:129492032:129492081: 0.843387766 9.99767267 5.25448E-06
Slc39a12 ENSMUSG00000036949 chr2:14416079:14416128: 0.84315337 6.829604232 0.000124834
1110012L19Rik ENSMUSG00000045237 chrX:67642222:67642271: 0.843085068 8.117694913 0.000119729
Nelf ENSMUSG00000006476 chr2:24918187:24918236: 0.842052964 9.956961936 3.55678E-05
Sh3kbp1 ENSMUSG00000040990 chrX:156411830:156411879: 0.841889127 8.600582632 1.22901E-05
Pitpnm2 ENSMUSG00000029406 chr5:124568794:124568843:- 0.841077304 8.155644133 0.001916181
Psme1 ENSMUSG00000022216 chr14:56200177:56200226: 0.840867779 10.1871996 1.32441E-05
Arhgdig ENSMUSG00000073433 chr17:26336559:26336608:- 0.839565517 8.914446745 0.000356674
Trafd1 ENSMUSG00000042726 chr5:121823199:121823248:- 0.839447513 7.874280315 5.57448E-06
Fam19a1 ENSMUSG00000059187 chr6:96604865:96604914: 0.839439528 6.511963006 1.63053E-05
Cntn6 ENSMUSG00000030092 chr6:104813152:104813201: 0.839150729 7.094426269 8.61998E-05
Armcx1 ENSMUSG00000033460 chrX:131256132:131256181: 0.838427509 8.765193339 0.001288078
Mff ENSMUSG00000026150 chr1:82738415:82738464: 0.837179222 8.71757931 6.65954E-06
Iqgap1 ENSMUSG00000030536 chr7:87857713:87857762:- 0.836718606 10.22691013 0.000245812
Tbc1d25 ENSMUSG00000039201 chrX:7731880:7731929:- 0.836146991 7.787441551 3.23895E-05
Tmem38a ENSMUSG00000031791 chr8:75110907:75110956: 0.836068062 8.010551165 0.000213252
Spag6 ENSMUSG00000022783 chr16:16753228:16753277:- 0.834794213 7.021196324 0.000158556
Gas7 ENSMUSG00000033066 chr11:67498226:67498275: 0.833988615 7.25071822 2.19199E-06
Fnbp1l ENSMUSG00000039735 chr3:122241852:122241901:- 0.833561614 11.53407201 1.16254E-05
Has3 ENSMUSG00000031910 chr8:109406619:109406668: 0.832833724 6.885868936 8.05125E-06
Slc7a4 ENSMUSG00000022756 chr16:17573197:17573246:- 0.832804469 7.51076319 0.000137415
Dt ENSMUSG00000024302 chr18:23755978:23756027: 0.832394756 7.99075435 0.000484968
March1 ENSMUSG00000036469 chr8:68994108:68994157: 0.831131554 6.972674159 1.21003E-05
Sh3bp2 ENSMUSG00000054520 chr5:34906187:34906236: 0.831029215 8.94857442 6.14359E-06
Slc2a13 ENSMUSG00000036298 chr15:91098458:91098507:- 0.830054881 7.804687981 6.63399E-05
1110012L19Rik ENSMUSG00000045237 chrX:67639259:67639308: 0.829919539 8.629108888 0.000730919
PGC-1v ENSMUSG00000029167 chr5:51849328:51849377:- 0.829511424 8.813005156 3.31226E-05
Neurod1 ENSMUSG00000034701 chr2:79292820:79292869:- 0.828777325 6.818767383 5.2773E-06
Rusc1 ENSMUSG00000041263 chr3:88888056:88888105:- 0.828423817 7.54371918 1.22638E-05
Wsb2 ENSMUSG00000029364 chr5:117828263:117828312: 0.827718543 11.94627437 4.44372E-06
Scrn1 ENSMUSG00000019124 chr6:54458993:54459042:- 0.827506341 7.256386625 9.39815E-05
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Pnpo ENSMUSG00000018659 chr11:96803737:96803786:- 0.827378691 7.138108436 2.21585E-05
Slc7a8 ENSMUSG00000022180 chr14:55341288:55341337:- 0.824651046 6.727414509 0.000102792
Kcnma1 ENSMUSG00000063142 chr14:24119139:24119188:- 0.822327359 6.941908411 0.00046422
Abcb9 ENSMUSG00000029408 chr5:124511927:124511976:- 0.820780372 7.731207001 0.000353577
Dos ENSMUSG00000035640 chr10:79593574:79593623:- 0.82044181 7.612210536 2.55348E-05
Tmtc4 ENSMUSG00000041594 chr14:123319259:123319308:- 0.819821003 6.827806992 3.64217E-05
Elmo1 ENSMUSG00000041112 chr13:20565046:20565095: 0.819811569 7.195101066 3.17733E-05
Spink2 ENSMUSG00000053030 chr5:77634151:77634200:- 0.81962952 6.980755271 4.60868E-05
Jph3 ENSMUSG00000025318 chr8:124314410:124314459: 0.818345689 7.053094996 5.49288E-06
Parm1 ENSMUSG00000034981 chr5:92052926:92052975: 0.817952384 7.863036388 6.48925E-05
Itsn1 ENSMUSG00000022957 chr16:91909480:91909529: 0.817944636 7.162209742 8.51917E-06
2310035C23Rik ENSMUSG00000026319 chr1:107637041:107637090: 0.817719553 7.857272594 2.33912E-05
P2ry1 ENSMUSG00000027765 chr3:60812677:60812726: 0.816774494 7.367571802 1.18054E-05
Tnfrsf10b ENSMUSG00000022074 chr14:70182289:70182338: 0.816665723 6.841151356 3.43981E-06
Ppp3cb ENSMUSG00000021816 chr14:21319408:21319457:- 0.816464103 11.8399039 7.01026E-06
Crip2 ENSMUSG00000006356 chr12:114383649:114383698: 0.816422477 12.66082841 5.41661E-06
Zfp597 ENSMUSG00000039789 chr16:3861578:3861627:- 0.814525558 8.800192608 5.3745E-06
Mapk9 ENSMUSG00000020366 chr11:49699461:49699510: 0.814484511 10.78086421 7.66954E-06
Tceal6 ENSMUSG00000031409 chrX:131743421:131743470:- 0.814467377 8.051972254 1.21674E-05
Mapk8ip2 ENSMUSG00000022619 chr15:89292754:89292803: 0.814201241 8.985469117 4.15873E-05
Ccdc92 ENSMUSG00000037979 chr5:125315426:125315475:- 0.813036212 9.842324681 5.25347E-06
Nell2 ENSMUSG00000022454 chr15:95061728:95061734:-,chr15:95059697:95059739:- 0.812691761 7.243888174 0.000655046
Dusp1 ENSMUSG00000024190 chr17:26642678:26642727:- 0.810999283 10.91670997 0.000105995
Bid ENSMUSG00000004446 chr6:120843364:120843413:- 0.810276739 7.571444482 2.28101E-06
Mdk ENSMUSG00000027239 chr2:91770094:91770143:- 0.810199945 10.6534514 0.000424324
Rab40c ENSMUSG00000025730 chr17:26019146:26019195:- 0.810021362 10.57677936 8.17398E-07
Cd151 ENSMUSG00000025510 chr7:148657124:148657173: 0.809430817 10.78324772 1.60453E-05
Gnb5 ENSMUSG00000032192 chr9:75193427:75193476: 0.80837872 9.331174077 1.81894E-05
Wdr37 ENSMUSG00000021147 chr13:8856116:8856165:- 0.803970607 7.865626583 1.37369E-05
Tnfrsf12a ENSMUSG00000023905 chr17:23812760:23812809:- 0.80357269 10.111318 5.87019E-05
Rab6 ENSMUSG00000030704 chr7:107778384:107778433: 0.803154933 11.08399031 1.21003E-05
Fhdc1 ENSMUSG00000041842 chr3:84248086:84248135:- 0.802700302 7.29097131 0.000319551
Pak7 ENSMUSG00000039913 chr2:135907997:135908046:- 0.800849174 6.905539053 2.52513E-05
Pygb ENSMUSG00000033059 chr2:150657139:150657188: 0.799781648 9.72304404 0.000188609
Prr7 ENSMUSG00000034686 chr13:55574366:55574415: 0.799703998 8.970712044 0.000897961
Acot7 ENSMUSG00000028937 chr4:151635078:151635127: 0.799350403 9.491435984 1.7465E-05
Pth2r ENSMUSG00000025946 chr1:65435261:65435310: 0.799127731 6.577650845 0.000191227
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Sept3 ENSMUSG00000022456 chr15:82122180:82122229: 0.796133318 9.273672388 2.79591E-05
Col5a1 ENSMUSG00000026837 chr2:27892889:27892938: 0.795125343 9.780078314 0.00364271
Ednra ENSMUSG00000031616 chr8:80186996:80187045:- 0.794593661 7.69326501 2.28482E-05
Thra ENSMUSG00000058756 chr11:98625661:98625710: 0.79455317 9.417687916 1.64094E-05
Shh ENSMUSG00000002633 chr5:28783901:28783950:- 0.793959266 6.590459445 0.000103156
Klhl26 ENSMUSG00000055707 chr8:72974246:72974295:- 0.793908941 10.15390425 4.41412E-06
Acta2 ENSMUSG00000035783 chr19:34316067:34316116:- 0.793864577 8.554580165 0.004667752
Hsd11b1 ENSMUSG00000016194 chr1:195048157:195048206:- 0.793810423 6.653753889 6.82259E-05
Cac2d1 ENSMUSG00000040118 chr5:15876791:15876840: 0.7917091 8.723669364 0.002239501
Psme2 ENSMUSG00000079197;ENSMUSG00000078153 chr14:56209737:56209786:- 0.79170225 8.695732328 0.000160784
Cxx1c ENSMUSG00000051851 chrX:50911209:50911258: 0.790803324 8.328913983 1.9213E-05
Phactr1 ENSMUSG00000054728 chr13:42778114:42778163: 0.790681697 6.586957598 6.0154E-06
nos1 ENSMUSG00000072437 chr19:60833889:60833938: 0.790434463 8.318124937 0.000163327
Trp53bp1 ENSMUSG00000043909 chr2:121024187:121024236:- 0.79041131 10.77520644 5.86024E-05
Sbk1 ENSMUSG00000042978 chr7:133438414:133438463: 0.790165922 12.61840764 9.82791E-06
Cltb ENSMUSG00000047547 chr13:54694868:54694917:- 0.789931538 8.28152114 8.78646E-06
Fgd4 ENSMUSG00000022788 chr16:16422840:16422889:- 0.789590431 6.686046719 8.34197E-06
gk ENSMUSG00000034744 chr6:83751510:83751559: 0.789216644 8.363567073 1.60246E-05
Sgsm2 ENSMUSG00000038351 chr11:74663048:74663097:- 0.788967554 7.273948516 0.0004075
Slc1a2 ENSMUSG00000005089 chr2:102621822:102621871: 0.788747395 7.777681923 1.2421E-05
Sept5 ENSMUSG00000072214 chr16:18622572:18622621:- 0.788501631 8.376418262 6.18708E-05
Exoc4 ENSMUSG00000029763 chr6:33922238:33922287: 0.788091356 9.544752234 6.14359E-06
Atp9a ENSMUSG00000027546 chr2:168475059:168475108:- 0.7876573 7.597515583 7.66899E-05
Wnk2 ENSMUSG00000037989 chr13:49131734:49131783:- 0.786209242 8.320950547 0.000219837
E130309F12Rik ENSMUSG00000063446 chr4:49336299:49336348: 0.785332267 8.440793447 2.40044E-05
Rabgef1 ENSMUSG00000025340 chr5:130690108:130690157: 0.785213707 10.01432861 1.48065E-05
Fbxo32 ENSMUSG00000022358 chr15:58039548:58039597:- 0.785197228 6.637281375 5.50447E-05
Pgrmc1 ENSMUSG00000006373 chrX:34145704:34145753: 0.785166258 9.518613373 0.000924667
Kndc1 ENSMUSG00000066129 chr7:147127344:147127393: 0.785098405 7.411489892 0.001160715
Ccdc80 ENSMUSG00000022665 chr16:45127495:45127544: 0.784562404 7.242794764 0.000133117
Elk3 ENSMUSG00000008398 chr10:92712317:92712366:- 0.784308304 10.53006683 5.21435E-06
Gmpr ENSMUSG00000000253 chr13:45641365:45641414: 0.78310861 7.702614612 3.55808E-05
Scamp1 ENSMUSG00000021687 chr13:94971463:94971512:- 0.782417602 11.57625713 6.32647E-06
Slco3a1 ENSMUSG00000025790 chr7:81463394:81463443:- 0.78192301 6.782618464 0.000218952
AK197526 chr6:87949393:87949442:- 0.781243154 11.02679052 1.03663E-06
Gpr85 ENSMUSG00000048216 chr6:13785556:13785605:- 0.781131337 7.556745284 0.000411771
Lm ENSMUSG00000028063 chr3:88287969:88288014:-,chr3:88287865:88287868:- 0.780843864 7.450567584 0.000199441
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Ssu72 ENSMUSG00000029038 chr4:155107711:155107760: 0.78004445 11.92221371 1.39645E-05
Triobp ENSMUSG00000033088 chr15:78836241:78836290: 0.779511351 12.01979227 4.29222E-05
gk ENSMUSG00000034744 chr6:83751119:83751168: 0.779389427 8.211218029 2.95571E-05
Ifngr2 ENSMUSG00000022965 chr16:91563208:91563257: 0.778840696 8.191212971 0.000100655
Nfix ENSMUSG00000001911 chr8:87245559:87245608:- 0.778476166 11.65139776 0.000457177
Sgip1 ENSMUSG00000028524 chr4:102643594:102643643: 0.778122872 7.378563098 0.000230305
Atg16l1 ENSMUSG00000026289 chr1:89688708:89688757: 0.778093451 9.659199573 0.00076889
Pak1 ENSMUSG00000030774 chr7:105059723:105059772: 0.777988918 8.07015843 0.00065469
Triobp ENSMUSG00000033088 chr15:78836224:78836273: 0.777413466 12.10131732 4.53668E-05
Hpcal1 ENSMUSG00000071379 chr12:17798250:17798299: 0.776788709 8.228963295 0.00011215
Trafd1 ENSMUSG00000042726 chr5:121822263:121822312:- 0.776704728 7.6497469 9.13411E-05
Atp2a2 ENSMUSG00000029467 chr5:122903580:122903629:- 0.775412983 10.63278584 0.000254836
Gq ENSMUSG00000024639 chr19:16459714:16459763: 0.774716443 10.1044874 0.000158791
Nln chr13:104813400:104813449:- 0.774638015 9.203643089 3.22732E-05
Chrnb2 ENSMUSG00000027950 chr3:89557752:89557801:- 0.774247909 6.759546737 3.11239E-05
Cdh7 ENSMUSG00000026312 chr1:112035299:112035348: 0.773847686 6.458387819 1.0738E-05















chr13:23622965:23623014: 0.771932892 8.054387743 4.5124E-05
St18 ENSMUSG00000033740 chr1:6850950:6850999: 0.771793293 6.675256032 6.14359E-06
Zic4 ENSMUSG00000036972 chr9:91283696:91283745: 0.771703404 6.345426826 0.000209544
Rnf14 ENSMUSG00000060450 chr18:38477304:38477353: 0.771247022 11.47732069 4.73555E-06
Arf2 ENSMUSG00000062421 chr11:103846532:103846581: 0.771121091 10.25752374 3.48932E-05
Rasl10b ENSMUSG00000020684 chr11:83234351:83234400: 0.770143054 7.06254933 8.5082E-06
Gdap1l1 ENSMUSG00000017943 chr2:163279593:163279642: 0.769326593 8.349796491 0.000231197
Mast1 ENSMUSG00000053693 chr8:87436113:87436162:- 0.768649935 7.053224282 2.7116E-05
Tex264 ENSMUSG00000040813 chr9:106561142:106561191:- 0.767872219 9.790956121 1.87113E-05






Fam110b ENSMUSG00000049119 chr4:5726858:5726907: 0.766930852 8.939837505 3.11239E-05
Kcnu1 ENSMUSG00000031576 chr8:27048294:27048343: 0.765833963 6.938779693 0.000122701







Prkcd ENSMUSG00000021948 chr14:31408860:31408909:- 0.76480391 7.653096354 8.09835E-05
Nln ENSMUSG00000021710 chr13:104813559:104813608:- 0.764170614 9.779210722 6.96286E-05
Prkag2 ENSMUSG00000028944 chr5:24368859:24368908:- 0.764086 8.867218433 2.26855E-05
Caskin1 ENSMUSG00000033597 chr17:24645466:24645515: 0.763928165 8.196464603 0.000372172
Ntrk2 ENSMUSG00000055254 chr13:59230780:59230829: 0.763504901 7.262585357 0.008702071
Zfp238 ENSMUSG00000063659 chr1:179374882:179374931: 0.762885426 7.574101622 0.002142684
Isca1 ENSMUSG00000044792 chr13:59857302:59857351:- 0.762487929 10.39626838 8.08528E-06
Ppp1r14c ENSMUSG00000040653 chr10:6922971:6923020:- 0.762218524 8.210336213 0.000454807
8430410K20Rik ENSMUSG00000041124 chr9:4386549:4386598: 0.761876908 10.95013897 1.64094E-05
Glipr2 ENSMUSG00000028480 chr4:43991772:43991821: 0.76106945 9.233889938 0.007807577
Gnpda1 ENSMUSG00000052102 chr18:38497793:38497842:- 0.760480662 8.615600687 0.000411505
Aifm2 ENSMUSG00000020085 chr10:61201321:61201370: 0.75957148 7.903198205 1.884E-05
4931408A02Rik ENSMUSG00000039903 chr16:90894825:90894874: 0.759021717 7.836746563 0.000579782
6030419C18Rik ENSMUSG00000066607 chr9:58347387:58347436: 0.758851048 7.805057974 1.55132E-05
Ctnnbip1 ENSMUSG00000028988 chr4:148940343:148940392: 0.75798405 10.44741247 0.000321738
Fam101a ENSMUSG00000037962 chr5:125492697:125492746: 0.757949018 8.76589969 0.000894032
Lancl1 ENSMUSG00000026000 chr1:67053511:67053560:- 0.757807726 9.887055618 2.04407E-05
Atp5g1 ENSMUSG00000006057 chr11:95934857:95934906:- 0.757748904 12.60431168 3.40832E-05
Cadm1 ENSMUSG00000032076 chr9:47660926:47660975: 0.757379989 9.971627871 0.002350675
Gri ENSMUSG00000022564 chr15:76080253:76080302: 0.757270973 12.81020963 6.31387E-05
Rnf11 ENSMUSG00000028557 chr4:109125525:109125574:- 0.756829449 10.04498301 0.000145004
Ank1 ENSMUSG00000031543 chr8:24260696:24260745: 0.756471087 7.005073071 4.54136E-05
Pld3 ENSMUSG00000003363 chr7:28317272:28317321:- 0.75625539 7.915101215 2.15688E-05
Bend6 ENSMUSG00000042182 chr1:33909014:33909063:- 0.75608451 7.770499913 5.96139E-05
Wdr37 ENSMUSG00000021147 chr13:8804495:8804544:- 0.755724988 7.539506386 6.08761E-05
Ppp2r5b ENSMUSG00000024777 chr19:6228265:6228314:- 0.75546318 7.62734195 5.31279E-05
Ube2e2 ENSMUSG00000058317 chr14:19406237:19406286:- 0.754654483 11.03512959 2.01022E-06
Chrm3 ENSMUSG00000046159 chr13:9875922:9875971:- 0.753430141 6.934504158 5.72906E-06
Syngr1 ENSMUSG00000022415 chr15:79949508:79949557: 0.75318719 6.894945508 1.37327E-05
Ankrd56 ENSMUSG00000045314 chr5:93470452:93470501:- 0.752640706 6.511211823 0.000115484
Dok5 ENSMUSG00000027560 chr2:170704709:170704758: 0.752465596 7.347949093 2.54678E-05
Tcfap2c ENSMUSG00000028640 chr2:172383694:172383743: 0.752356943 6.781272131 2.49812E-05
Camk2b ENSMUSG00000057897 chr11:5869822:5869871:- 0.750924974 11.40718642 0.000757592
Gpr158 ENSMUSG00000045967 chr2:21751924:21751973: 0.749935367 7.226679852 6.53719E-06
Atp5sl ENSMUSG00000057229 chr7:26410337:26410386: 0.749896332 7.730584553 9.53938E-06
Hagh ENSMUSG00000024158 chr17:25000641:25000690: 0.749718291 8.710431507 1.70004E-05
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Lix1 ENSMUSG00000047786 chr17:17594522:17594571: 0.748904265 7.571886644 0.001295217
Sgsm1 ENSMUSG00000042216 chr5:113672531:113672580:- 0.748549942 7.270335457 0.001010835
Insr ENSMUSG00000005534 chr8:3153647:3153696:- 0.748519373 9.129473053 6.59974E-05
Atat1 ENSMUSG00000024426 chr17:36036989:36037038:- 0.748405932 8.653124831 5.57783E-06
Vat1 ENSMUSG00000034993 chr11:101320320:101320369:- 0.748163081 8.077564265 0.000144941
Caskin1 ENSMUSG00000033597 chr17:24645242:24645291: 0.748134671 7.400035481 0.00017487
Atp6v1b2 ENSMUSG00000006273 chr8:71637332:71637381: 0.748014697 11.42066716 4.53231E-06
Arntl ENSMUSG00000055116 chr7:120457242:120457291: 0.748002689 8.907677681 2.19625E-06
Pfn2 ENSMUSG00000027805 chr3:57646214:57646263:- 0.747893571 11.72070985 8.34197E-06
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APPENDIX C - RNA-sequencing differential gene expression analysis in 
NPCs!
Gene Name RPKM EtOH RPKM OHT log2 Fold Change p-value
Tgm6 0 0.0169779 1,7977E+308 0.0177378
Slc5a11 0 0.0203926 1,7977E+308 0.0276792
Best3 0 0.016824 1,7977E+308 0.0296258
2310033E01Rik 0 0.0758708 1,7977E+308 0.0309638
9330175E14Rik 0 0.0287291 1,7977E+308 0.0355302
Cntnap3 0 0.00787291 1,7977E+308 0.0398235
Myl2 0 0.0784582 1,7977E+308 0.042654
Lrrc69 0 0.0340313 1,7977E+308 0.0436869
Rxfp4 0 0.0328147 1,7977E+308 0.0437014
Ly6d 0 0.0674338 1,7977E+308 0.0447141
Ptprv 0.137966 2.8184 4.3525 0
Rec8 0.3924 6.01404 3.93794 0
Them5 0.0112913 0.169986 3.91213 0.0119719
Scn4b 0.00330738 0.0453996 3.77892 0.0107074
Perp 0.40015 4.63691 3.53455 0
Cd80 0.0394448 0.438148 3.47351 1.67616E-06
Lao1 0.00652136 0.0708602 3.44173 0.0320764
D730039F16Rik 0.019861 0.215123 3.43715 5.91003E-05
Serpinb11 0.00692503 0.073397 3.40583 0.043482
Ltb4r1 0.0125669 0.132662 3.40005 0.0152619
Grhl3 0.0645272 0.671497 3.3794 1.17684E-13
Icam1 0.143347 1.48232 3.37027 0
Shh 0.05045 0.500066 3.30919 8.77881E-10
Ptk2b 0.0448615 0.440644 3.29606 1.88982E-12
Adm2 0.0354349 0.340663 3.2651 0.00113635
BC037703 0.100894 0.933804 3.21027 0
Gria1 0.18761 1.72966 3.20467 0
St14 0.0498824 0.456991 3.19556 1.51879E-13
Gbp11 0.00524351 0.0471304 3.16805 0.036406
Car10 0.161162 1.37538 3.09324 0
Cidea 0.0389013 0.325058 3.06281 0.00402924
Sec14l5 0.210763 1.7556 3.05827 0
H2-Eb1 0.051101 0.421556 3.0443 3.59235E-06
Cryab 2.78743 22.6075 3.0198 0
Ckmt1 1.67982 13.5343 3.01024 0
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Wnt2 0.0149405 0.118546 2.98815 0.00387934
Rhbdf2 0.0853297 0.670265 2.97361 4.44089E-16
Rcsd1 0.0209156 0.160915 2.94365 0.000912852
1700007K13Rik 1.72415 13.1889 2.93536 0
Prrg4 0.50922 3.87266 2.92697 0
Fas 1.19862 9.06643 2.91916 0
Cd177 0.00591874 0.0446608 2.91565 0.0423124
Adrb3 0.0132804 0.0984189 2.88964 0.00235066
Casp14 0.012095 0.0869958 2.84654 0.00920128
Podn 0.102711 0.724041 2.81748 1.15463E-14
Ptpn7 0.0539875 0.3784 2.80922 1.74139E-09
Cox6a2 0.443871 3.07179 2.79087 1.01971E-10
Crybb1 0.0313041 0.215477 2.78311 0.0201249
Crispld2 0.72721 4.96886 2.77247 0
Gm5424 0.691794 4.70006 2.76426 0
Pm20d1 0.025439 0.172553 2.76193 1.10183E-05
Cyp4f14 0.0301555 0.203694 2.75591 0.000169947
P2ry6 0.0140695 0.0949933 2.75526 0.0148858
Itgb2 0.0148974 0.0968157 2.70018 0.00250393
Hsd17b1 0.0584125 0.378965 2.69771 0.00013373
Sp9 0.0293469 0.190147 2.69584 4.23879E-05
9530053A07Rik 0.168059 1.07405 2.67602 0
Tnfsf18 0.486002 3.09191 2.66946 0
Cpz 0.011597 0.0737669 2.66923 0.0222818
4833427G06Rik 0.0443226 0.281346 2.66623 0.0146571
Eef1a2 0.131877 0.829852 2.65366 8.90688E-11
Tslp 0.0880286 0.548021 2.63819 6.20056E-05
Svop 1.8844 11.6321 2.62593 0
Cend1 2.12866 13.0512 2.61616 0
Ankrd34c 0.0494855 0.300419 2.6019 2.92529E-06
Serpinb8 0.0229934 0.139038 2.59619 0.00205111
Tshr 0.0696974 0.42122 2.5954 2.45801E-11
Mal 0.0440199 0.264556 2.58735 6.18367E-05
Cyyr1 0.0450659 0.269564 2.58052 0.000051296
Trp73 0.00994603 0.0580874 2.54603 0.0451651
Gjc2 0.0168785 0.0985687 2.54594 0.0330894
Tmc3 0.0343167 0.198978 2.53562 4.98959E-07
Rgs8 0.0958673 0.548183 2.51555 1.9984E-15
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Fam26e 0.0606927 0.34574 2.51009 6.38751E-05
Plscr2 0.0609364 0.342613 2.4912 4.45152E-05
Dusp15 0.667175 3.73607 2.48539 1.51367E-05
Ysk4 0.00657678 0.0365295 2.47361 0.0300825
Shpk 0.423183 2.3102 2.44866 0
March4 0.0973181 0.529632 2.44421 1.92801E-12
Klhdc7a 0.716789 3.81012 2.41022 0
Abca13 0.00245959 0.0128308 2.38313 0.0091811
Ppp2r2c 1.12662 5.87155 2.38174 0
Dsp 0.0050619 0.026319 2.37835 0.00422101
Thbs2 0.194815 1.00995 2.37411 0
Ddo 0.0208975 0.107839 2.36748 0.00167301
Hsf4 0.0219991 0.11304 2.36131 0.0215703
Epx 0.0171572 0.0879173 2.35733 0.00756985
Alox5 0.189946 0.971985 2.35535 6.7768E-13
Calhm2 0.062581 0.320017 2.35435 2.04738E-05
Fbln5 0.173963 0.888137 2.352 0
Nupr1 2.10435 10.7319 2.35046 0
Mag 0.18034 0.919461 2.35007 1.4396E-11
Gstt3 0.499852 2.54583 2.34856 0
ORF63 0.0389362 0.195013 2.32439 0.00244193
Trib3 0.666839 3.33319 2.32149 0
Sucnr1 0.0183281 0.0912121 2.31517 0.0406026
Gfap 0.221188 1.0971 2.31035 9.61958E-09
Espn 0.115627 0.564825 2.28832 0.00745824
Rhbdl2 0.109578 0.533114 2.28249 4.96797E-05
Gjb6 0.0169592 0.0820863 2.27507 0.0411475
Abca1 0.932046 4.48229 2.26576 0
Enpep 0.0143139 0.0683886 2.25634 0.00310717
5033411D12Rik 0.0241546 0.115372 2.25592 0.0162918
Gad1 0.110088 0.525241 2.25433 6.86821E-10
Slc39a12 0.864032 4.08113 2.23981 0
Parp10 0.0371282 0.175134 2.23788 0.000511985
Cdh18 0.0249284 0.117447 2.23614 0.00222123
Tmem130 0.012984 0.0611225 2.23497 0.024887
Nipal4 0.0628831 0.295936 2.23454 5.13257E-07
Scg2 0.0438093 0.206033 2.23356 0.000165042
Def6 0.101807 0.473505 2.21755 2.89644E-07
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Col22a1 0.0934463 0.433349 2.21332 5.79181E-12
Pdk4 0.246775 1.13725 2.20427 2.17604E-14
Tgfbi 0.0275718 0.126692 2.20006 0.00187223
Creb3l1 0.893183 4.09057 2.19527 0
9930013L23Rik 0.258393 1.18068 2.19198 0
Tcea3 0.607967 2.76091 2.18308 1.32783E-12
Npas2 0.111934 0.506568 2.17811 1.91315E-10
Cd38 0.0598413 0.268443 2.1654 5.90018E-06
Pla2g5 0.0302863 0.135089 2.15718 0.0119152
Ass1 0.0769896 0.343012 2.15552 0.00015255
Prdm1 0.324025 1.44323 2.15512 0
Mbp 2.34746 10.4377 2.15263 0
A330076H08Rik 0.413407 1.82576 2.14287 1.43552E-12
AW555464 0.914223 4.02672 2.13899 0
Chchd10 0.906825 3.99076 2.13777 1.43441E-12
Il7 0.0299053 0.131504 2.13663 0.00253934
A730017C20Rik 0.152866 0.663943 2.11879 0.000530391
Pla2r1 0.0111337 0.0483091 2.11736 0.00521004
Fut1 0.0216066 0.0937236 2.11694 0.00917906
P2rx6 0.150025 0.647404 2.10946 2.61181E-05
Klk13 0.0427106 0.184114 2.10793 0.0274638
Xkrx 0.0343797 0.148118 2.10711 0.000670888
Mmp28 0.0401109 0.172214 2.10214 0.00563205
Kcnj15 0.0168242 0.0720939 2.09934 0.00471817
Lpin3 0.100106 0.428913 2.09916 4.68067E-08
Slc7a3 2.45215 10.4372 2.08962 0
Pltp 0.921519 3.9171 2.0877 0.000476086
Casp1 0.164328 0.69787 2.08638 1.16851E-06
Ggta1 0.547011 2.31164 2.07927 7.50733E-13
Gypa 0.0566676 0.239164 2.07741 0.000770931
Glp2r 0.0152479 0.0643482 2.07729 0.00286527
St18 0.00829512 0.0349474 2.07485 0.0139976
Diras2 0.563105 2.36304 2.06917 0
Tap1 1.5329 6.39227 2.06006 0
Zbtb8b 0.0224495 0.0935185 2.05857 0.00348164
Hs3st2 0.179778 0.739527 2.04039 1.22052E-08
Atp13a4 0.0319663 0.13139 2.03923 0.000514152
Olfr287 4.11909 16.9186 2.03821 0
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Extl1 0.130193 0.534327 2.03707 8.65567E-10
Fbxo32 1.2488 5.11695 2.03474 0
Ccdc114 0.0197693 0.0809414 2.03362 0.0188698
S1pr3 0.0908122 0.370577 2.02881 1.32842E-08
Gdf15 1.26572 5.1601 2.02745 6.32827E-14
Aldh1a1 0.214718 0.8659 2.01176 1.27233E-08
Kndc1 0.0471396 0.189682 2.00857 6.03013E-08
Agt 0.524515 2.10568 2.00523 3.73301E-12
Fgf18 0.128593 0.51495 2.00162 0.000362416
Apobec1 4.24891 16.8879 1.99083 0
Hmgcll1 0.226392 0.89686 1.98606 1.68752E-11
Adrb2 0.125149 0.492664 1.97695 1.58604E-06
Olfml1 0.0439026 0.17272 1.97606 0.0031771
Pygm 1.45261 5.66831 1.96427 0
Sp6 0.0698306 0.270688 1.9547 4.65516E-06
Slc26a3 0.0203851 0.0790091 1.9545 0.0186874
Slco1c1 0.0230897 0.0888917 1.9448 0.0373116
Efna3 0.839623 3.22534 1.94164 1.55393E-11
Tnfrsf10b 2.52663 9.68553 1.93862 0
E030003E18Rik 0.111596 0.426019 1.93263 0.00126829
Cd55 0.0947709 0.361737 1.93243 7.75607E-06
Scnn1a 0.0319623 0.121521 1.92676 0.0010336
Agbl2 0.0792505 0.300897 1.92478 1.85708E-06
Pqlc3 1.27083 4.81102 1.92057 3.9968E-15
Pla2g7 31.8714 120.521 1.91895 0
Gimap8 0.084552 0.315286 1.89875 2.12558E-06
Ermn 0.0161434 0.0599757 1.89343 0.0184281
5430435G22Rik 0.0562105 0.208715 1.89262 0.000406674
Apod 0.0454461 0.168455 1.89013 0.00545978
Gpr75 0.380525 1.40911 1.88872 9.64503E-09
Clu 2.6888 9.9567 1.8887 0
Pvrl4 0.0466378 0.172677 1.88851 0.00033784
Rab42-ps 0.10213 0.377562 1.88631 0.0152549
Kcnk13 0.09289 0.343146 1.88523 3.10473E-05
Fndc5 1.42255 5.21401 1.87391 0
Celf5 1.03616 3.78302 1.8683 0
Pamr1 0.0237197 0.0863713 1.86447 0.0125298
Sod3 0.427017 1.53945 1.85005 5.67024E-10
 215
Cftr 0.0278861 0.100497 1.84953 0.000115734
Olfr288 0.278406 1.00133 1.84666 2.15636E-08
Scube3 0.0151193 0.0542552 1.84337 0.0429941
Rasgef1a 0.135447 0.485221 1.84091 1.83041E-07
Mmp2 0.665702 2.379 1.83741 9.10383E-15
Adra2a 0.0305217 0.107995 1.82306 0.00165254
Wdr72 0.0239773 0.0848053 1.82249 0.00123443
Ank3 1.16886 4.12957 1.82089 0
Ky 0.0984402 0.345871 1.81291 5.2633E-08
P2rx3 0.143777 0.504877 1.8121 2.33219E-08
Apob48r 0.0268667 0.0942441 1.81059 0.00426181
Syne1 0.0876188 0.307232 1.81002 1.51631E-08
Rspo3 0.0242028 0.0848403 1.80958 0.0251262
Mapk13 0.0408943 0.143239 1.80846 0.0310055
Thrsp 3.94065 13.7937 1.8075 0
Synpo 0.121582 0.422191 1.79597 5.54415E-05
Pacsin1 0.418458 1.4403 1.78321 1.29528E-05
Rln1 0.366795 1.25992 1.78029 0.000111694
Irgm2 0.0421171 0.144289 1.77648 0.000755001
Rarb 1.99584 6.81511 1.77174 0
Nr5a2 0.0888029 0.303205 1.77161 8.45461E-06
Trim34 0.0254202 0.0867777 1.77135 0.0198198
Sgca 0.0894378 0.304317 1.76662 0.00239395
Arhgef19 0.283257 0.961767 1.76358 9.28003E-10
Stmn2 0.032 0.108269 1.75848 0.027862
Zfr2 0.0851474 0.287476 1.75541 1.50778E-05
Glp1r 0.0622077 0.209878 1.75439 0.00857912
Gm4659 0.11639 0.390533 1.74648 9.02261E-06
Plxdc2 1.81903 6.10118 1.74591 0
Mr1 0.151594 0.505923 1.73871 2.8126E-06
Gda 0.00923917 0.0308332 1.73865 0.0442314
Fibin 0.0278153 0.0925856 1.73491 0.0337675
Olfm3 0.109101 0.363057 1.73453 1.28754E-06
Ndrg4 9.04006 30.0806 1.73443 0
Ephx2 0.251745 0.837064 1.73338 4.27635E-07
Cdkn1a 65.0609 215.997 1.73115 0
Kcna4 0.110143 0.364261 1.7256 2.6356E-07
Plek2 0.150705 0.498137 1.72481 0.000110099
 216
Dcxr 7.47083 24.6371 1.72149 0
Cgref1 3.55609 11.6961 1.71766 4.44089E-15
Abcc8 0.0117485 0.0385843 1.71553 0.0304978
Notum 0.0268959 0.088231 1.7139 0.0422035
Robo3 0.0677218 0.222046 1.71317 9.30031E-06
Cnga3 0.0311429 0.101851 1.70949 0.00438578
Areg 0.471107 1.54065 1.70942 5.67493E-07
9230105E10Rik 0.0914454 0.298964 1.70899 8.61922E-06
Slc4a10 0.0586484 0.191595 1.70789 1.06057E-05
Prss35 0.105233 0.343572 1.70702 7.06551E-05
Pitpnm3 0.0315705 0.102792 1.70307 0.000302296
Spata22 0.0505667 0.16436 1.7006 0.0334771
A230057D06Rik 0.237636 0.772255 1.70032 1.57347E-06
Lrp1b 0.204682 0.66499 1.69995 1.33227E-15
Akr1c14 0.0354879 0.115063 1.69702 0.0118505
Atp1b1 10.0872 32.628 1.69358 0
Hic1 0.232707 0.752354 1.6929 4.92186E-06
Abca12 0.0163922 0.0527583 1.68639 0.00171411
Bhlhe41 0.484883 1.55831 1.68427 1.82414E-07
Kcna1 0.0366004 0.117272 1.67993 1.23407E-05
Fam131a 2.935 9.37891 1.67606 5.4845E-14
Agpat9 0.0374706 0.119712 1.67574 0.00591925
Esr2 0.0242349 0.0774022 1.67529 0.0257169
Rbp1 1.34243 4.28208 1.67346 2.02061E-14
Syt4 0.0558578 0.178152 1.67327 0.000179025
Pdgfb 0.0199931 0.0637325 1.67253 0.0381478
Epb4.9 0.112807 0.359584 1.67247 3.19722E-05
Egfl6 0.120968 0.385266 1.67123 1.95023E-05
Fn3k 0.149417 0.47573 1.6708 0.00774935
Islr 0.150686 0.478608 1.6673 0.00189373
Tlr5 0.0519977 0.164363 1.66036 0.000947922
Cp 1.65276 5.22086 1.65941 4.15823E-12
Lama3 0.0228708 0.0721909 1.65831 0.000110044
Ajap1 0.208548 0.651355 1.64306 3.92535E-07
Fam20a 0.304334 0.950329 1.64277 1.02786E-07
Kcnt1 0.203685 0.635575 1.64172 4.46013E-05
Abat 8.92364 27.7446 1.6365 0
Igtp 0.369092 1.14666 1.63539 1.87269E-07
 217
Pmaip1 3.19457 9.89306 1.6308 0
Tmem200a 0.354073 1.09441 1.62804 3.51997E-10
Sytl2 0.984854 3.04381 1.6279 1.78837E-08
Tlr4 0.0532083 0.164251 1.62618 0.000417946
Calb1 0.0268134 0.0827202 1.62528 0.0217076
Htra3 0.300562 0.926225 1.6237 1.29301E-05
Sdc4 5.71032 17.5828 1.62252 0
Fam101a 3.37129 10.3568 1.6192 0
P2rx7 3.76064 11.5262 1.61587 2.39808E-14
Acot11 0.512885 1.56803 1.61225 1.11022E-13
Osmr 0.0518316 0.157566 1.60405 0.000170725
Grm1 0.101341 0.307717 1.60238 0.000908446
Gbp9 0.692495 2.09775 1.59897 1.60094E-12
Hbegf 4.01069 12.0617 1.58851 0
Palm3 0.258661 0.775984 1.58497 1.06566E-05
Pdcd4 6.60458 19.8121 1.58484 7.06604E-09
Hrc 0.190094 0.569922 1.58405 1.44046E-05
Arhgef37 0.0338579 0.100945 1.57601 0.009003
Afap1l2 0.951877 2.83119 1.57256 1.98752E-12
Rai2 1.6334 4.832 1.56474 3.38871E-11
Chac1 3.12007 9.205 1.56084 1.9984E-15
Synpr 0.803791 2.36898 1.55937 8.22988E-11
Bfsp2 0.740172 2.18007 1.55844 3.2943E-08
Lrp2bp 0.136644 0.401763 1.55592 1.02888E-05
Kcnt2 0.152562 0.445792 1.54697 2.65674E-06
Spock1 0.0405505 0.118331 1.54504 0.0367156
Slc24a4 0.0543866 0.158526 1.5434 0.0104228
Cacna1e 0.0697064 0.202635 1.53952 2.01998E-07
Hif3a 0.0735119 0.21301 1.53487 8.72322E-06
Slc17a8 0.0395961 0.114536 1.53237 0.00186715
St8sia5 0.499097 1.44096 1.52964 1.32311E-05
Anxa5 8.21784 23.652 1.52513 0
Fcgrt 0.0800634 0.230139 1.52329 0.00658745
Mylk3 0.0355768 0.101988 1.51939 0.0122612
Nlrc5 0.0707463 0.202386 1.51638 1.11194E-05
Ccdc153 0.144367 0.412392 1.51428 0.00560226
4931408A02Rik 1.45201 4.13686 1.51049 2.63216E-10
Rgs16 2.98784 8.49754 1.50794 0
 218
Bbc3 1.7024 4.8395 1.50728 2.80087E-12
Ptprt 1.79567 5.09908 1.50572 0
Epha2 0.714084 2.02457 1.50345 1.68006E-11
Cox7a1 3.37774 9.57307 1.50292 2.56062E-06
Apoe 21.1874 60.006 1.5019 0
Gbp2 0.324312 0.916967 1.49949 1.17409E-06
Sept4 5.16031 14.5693 1.4974 0
Trim12 0.0473863 0.133485 1.49413 0.0496445
Rnase1 0.134035 0.377383 1.49341 0.0127947
Ikbke 0.17536 0.493712 1.49335 9.38954E-06
Tmtc1 0.346799 0.975116 1.49147 0.00325372
Npy2r 0.0400908 0.112676 1.49084 0.00749091
P2ry2 0.0488806 0.137309 1.49009 0.0056055
Slc5a8 0.0207456 0.0582228 1.48878 0.0131814
Far2 0.68272 1.91443 1.48755 0.0106948
Tmem132b 0.322685 0.903906 1.48605 3.9075E-11
Cyp27a1 0.129228 0.361402 1.48368 0.000762212
BC031353 2.77622 7.75908 1.48276 0
H2-Ab1 0.324919 0.907962 1.48255 0.00013476
Fosb 0.0385603 0.10751 1.47929 0.00559956
Slc35f3 0.271529 0.755261 1.47587 2.38985E-06
C3 0.0219666 0.06096 1.47255 0.0169246
Ryr2 0.110699 0.307176 1.47242 1.79468E-09
Aox1 0.415243 1.15006 1.46968 3.34908E-09
Fgf1 4.46894 12.3502 1.46653 0
Mxd4 14.5422 40.1303 1.46445 0
Efhc1 0.112729 0.310913 1.46366 0.000752987
Grin2a 0.0840398 0.231665 1.4629 0.000101372
Sulf1 0.611814 1.68277 1.45967 3.9627E-11
Il34 0.146236 0.401274 1.45629 0.00136097
Fst 0.344976 0.946356 1.45589 2.68041E-06
Ifit1 0.0321633 0.0882032 1.45541 0.0388322
Fgd4 0.279586 0.766476 1.45495 0.000256074
Bace2 0.71135 1.94724 1.4528 1.08977E-10
Ddr2 1.66305 4.55182 1.45261 0
Anxa3 5.74598 15.7206 1.45203 0
Krt1 0.0662174 0.180679 1.44815 0.00521511
Rnasel 0.454645 1.24031 1.44789 9.40724E-10
 219
Ryr3 0.409844 1.11772 1.44741 1.33227E-15
Angpt2 8.75081 23.8351 1.4456 0
Klf4 0.452305 1.22972 1.44296 8.42543E-08
A3galt2 0.215976 0.585975 1.43997 4.77249E-06
Rgs4 0.132372 0.358444 1.43715 0.000122002
Slc7a11 1.92066 5.20034 1.43701 0
6030405A18Rik 3.41387 9.24242 1.43686 0
Dapk1 4.27006 11.5535 1.436 0
Pik3ip1 1.97854 5.33046 1.42982 8.8396E-13
Krt222 0.0464004 0.125005 1.42977 0.0125524
Cytip 0.0148454 0.0399587 1.42849 0.0388582
Slc6a3 0.0313204 0.0840485 1.42412 0.0198773
Abcg1 0.0379795 0.101644 1.42024 0.00172753
Cacna1g 0.354478 0.947617 1.41861 8.81412E-08
Lgals4,Lgals6 0.341619 0.906699 1.40823 0.000193084
Tekt2 0.328107 0.869787 1.4065 0.000093262
Htr2a 0.227984 0.603982 1.40557 1.37277E-05
5031414D18Rik 0.0422656 0.111963 1.40547 0.0207303
Trp53inp1 25.3755 67.0182 1.40112 0
Slc16a14 0.286963 0.756427 1.39834 1.74836E-05
Enpp6 0.165306 0.435725 1.39828 8.19566E-05
Gm973 0.269871 0.711123 1.39783 2.03812E-06
Nkain2 0.945396 2.48921 1.3967 5.61701E-08
Lif 0.39093 1.02901 1.39628 2.20009E-07
Ctsf 3.8784 10.2034 1.39552 3.55271E-15
Gpc5 0.244769 0.643796 1.39518 1.23259E-05
Ldhd 0.0377522 0.0989445 1.39006 0.0455389
Ptprn 0.249027 0.652615 1.38993 4.19042E-06
Sorl1 0.536585 1.40122 1.38481 2.81144E-11
Il6ra 0.0570564 0.148915 1.38402 0.00410178
Mfap3l 2.85663 7.45149 1.38322 2.22045E-16
Dmrtb1 11.9155 31.0171 1.38023 0
Isg20 0.551958 1.43677 1.3802 0.00828716
Phyh 4.99384 12.992 1.3794 1.46549E-14
Ddit4 16.3602 42.5274 1.3782 0
Pstpip1 0.061116 0.158512 1.37497 0.0255539
Tuba8 0.12473 0.32344 1.37469 0.00789363
Ptpn14 3.43435 8.90527 1.37462 0
 220
Txlnb 0.462879 1.19848 1.3725 1.22634E-08
Ano3 3.63701 9.40807 1.37115 5.66658E-13
C030044B11Rik 6.74068 17.425 1.3702 4.44089E-16
Clca1 0.0589519 0.152223 1.36858 0.00578415
Aass 0.0663694 0.171149 1.36666 0.00170759
Adrbk2 5.60673 14.4169 1.36253 1.55431E-15
Scn3a 0.133992 0.342682 1.35472 5.95217E-07
Prr16 0.104748 0.267768 1.35406 0.00298305
Plcd4 22.5595 57.6182 1.35279 3.49136E-08
Mapkapk3 3.74156 9.54066 1.35045 2.22045E-16
Serpinb5 0.512707 1.30609 1.34905 8.60569E-07
P2rx5 0.0638544 0.162594 1.34842 0.0133415
Tm4sf1 0.635111 1.61653 1.34782 2.06175E-06
Synm 0.234315 0.595356 1.34531 9.94947E-06
Kcnk3 0.112787 0.286105 1.34294 0.000225358
Klhdc8a 0.0671561 0.170151 1.34122 0.00111585
Tceal5 0.193477 0.48986 1.3402 0.00780574
Upk1a 0.440569 1.11335 1.33746 0.000125567
Pigz 0.0703425 0.177536 1.33565 0.0124459
Myt1l 0.135826 0.342609 1.33481 1.28706E-05
Mamdc2 3.78962 9.55841 1.33472 0
Scn1b 3.89523 9.81793 1.33371 2.88436E-12
Adc 0.755279 1.89904 1.33019 9.67517E-07
Tyr 0.0466039 0.117166 1.33003 0.0116782
Oplah 0.929449 2.33562 1.32936 2.58394E-10
Rnf182 0.833386 2.09395 1.32917 2.58261E-09
Foxj1 2.73077 6.84397 1.32553 1.50102E-13
Ptgfr 0.105119 0.262743 1.32162 0.000255309
Cyp27b1 0.0436463 0.109015 1.32059 0.0350946
Kcp 0.0216154 0.0539797 1.32036 0.0336265
Tiam2 0.49528 1.23519 1.31842 9.38845E-07
Ifi27l1 0.392199 0.976975 1.31673 0.00519476
Sesn2 19.1339 47.6428 1.31613 0
Adamts14 1.57891 3.91667 1.3107 4.24105E-14
Stard5 4.49177 11.1302 1.30912 1.9984E-15
Ccdc3 0.294959 0.72957 1.30653 3.12448E-05
Slc2a9 1.40886 3.48327 1.30591 2.13214E-09
Adora2a 0.318875 0.786241 1.30198 3.85684E-05
 221
Cav1 2.03852 5.01375 1.29837 2.81959E-11
Pdk2 2.55781 6.28884 1.29788 6.11777E-12
Golga7b 1.10909 2.72143 1.29499 3.8001E-09
Ddit4l 12.0958 29.6764 1.29481 0
P4ha3 0.154962 0.379785 1.29327 0.000779524
Arhgef5 0.0192387 0.0471072 1.29194 0.0385063
Kcnq3 0.26879 0.65681 1.289 4.84738E-05
Rab40b 0.431748 1.05332 1.28669 4.37433E-05
Arpp21 0.993737 2.42292 1.28581 7.31335E-06
Gpr68 0.324185 0.788442 1.28219 0.0025655
1500015O10Rik 1.56965 3.81686 1.28195 5.08112E-06
Tec 0.178736 0.434169 1.28043 0.026265
Ccng1 92.2311 223.878 1.27939 7.99361E-15
Vwa1 0.701931 1.7035 1.2791 9.97712E-08
Kcnj11 0.131972 0.31985 1.27717 0.000605963
Slc35d2 0.0961563 0.232633 1.2746 0.00578553
Cacng5 2.83326 6.84649 1.2729 3.39728E-14
Sparcl1 48.9043 118.114 1.27214 0
Ccrl1 0.920978 2.22359 1.27165 0.00158962
Ak1 27.298 65.863 1.27067 0
Scn3b 2.86235 6.90464 1.27037 1.09912E-13
Atp2a3 0.0719333 0.173368 1.26911 0.0149167
Parp14 0.081321 0.195955 1.26882 0.000150412
Nmnat2 3.36463 8.07979 1.26387 2.22045E-16
Ang,Rnase4 0.32685 0.784419 1.263 0.00650779
Tmem88b 0.150281 0.36039 1.2619 0.000284677
Ccdc106 1.40393 3.36461 1.26097 2.95776E-08
Rasal1 0.0669957 0.160463 1.2601 0.00657082
Plp1 2.83525 6.78896 1.25971 2.54663E-12
Kcnc4 1.62661 3.89347 1.25919 1.29317E-10
Ercc5 11.2166 26.7707 1.25503 0
9230114K14Rik 2.00626 4.7823 1.2532 8.45995E-10
Chrna4 7.77078 18.4606 1.24832 0
Isoc2b 0.305548 0.72549 1.24756 0.00322693
Styk1 0.544637 1.29285 1.24719 7.01478E-07
Rnf169 4.4301 10.5155 1.2471 0
Gpc4 7.96504 18.8895 1.24583 0
Snph 0.856672 2.02939 1.24423 1.26255E-09
 222
Elovl7 0.416993 0.987284 1.24344 1.51729E-07
Dkk3 0.426488 1.00948 1.24304 3.80912E-06
Arhgap6 0.452584 1.06901 1.24002 8.16144E-05
Stard10 2.36349 5.5758 1.23826 8.81325E-08
Rerg 0.274535 0.646902 1.23656 0.0108762
H2afj 5.43352 12.7569 1.23131 3.32623E-13
Abhd4 48.8479 114.66 1.231 0
Cmya5 0.110619 0.25965 1.23097 7.75792E-06
Slc22a4 0.14141 0.331531 1.22925 0.00253506
Ptgr2 5.45145 12.7783 1.22898 6.66134E-16
Pyroxd2 0.314311 0.736623 1.22874 3.37777E-05
Klhdc8b 1.08871 2.5505 1.22816 0.0010152
Cacna1i 0.0110923 0.0259494 1.22614 0.0433648
Osgin1 0.0914368 0.213568 1.22385 0.0163102
Ston1 1.57972 3.68857 1.2234 6.87037E-10
As3mt 0.662832 1.54592 1.22175 0.000021857
Mcf2 0.0707676 0.16499 1.22122 0.00449644
Sec16b 0.18407 0.427656 1.2162 0.00112753
Aqp4 1.00067 2.32469 1.21607 3.74515E-10
Nacc2 3.17451 7.36765 1.21467 4.44089E-16
Slc16a9 0.211395 0.489908 1.21257 0.000132177
Ociad2 1.37526 3.1871 1.21254 8.98798E-08
Adamts19 0.365904 0.846287 1.20968 2.52446E-06
Npvf 0.623693 1.44232 1.20949 0.00491006
Kcnma1 1.5565 3.59931 1.20942 5.54379E-12
4930486G11Rik 0.0833349 0.19245 1.20749 0.00552086
Kcnn2 0.963636 2.22148 1.20496 1.48247E-06
Plcxd3 0.201821 0.46501 1.20418 0.00183295
Slitrk6 0.0862907 0.198617 1.20271 0.00170432
Cyp7b1 1.211 2.78715 1.20259 2.18189E-07
Fam83h 0.116824 0.268317 1.1996 0.000661894
Itgb5 16.9155 38.7411 1.19552 0
Ipw 5.28838 12.1026 1.19442 7.48322E-08
Aspa 0.311923 0.713536 1.1938 0.00105985
Nrxn3 0.325945 0.744553 1.19175 8.00671E-07
Bdkrb2 0.252503 0.576389 1.19074 0.00184155
Disp2 0.9961 2.27045 1.18861 8.57194E-11
Gck 0.120502 0.274411 1.18728 0.00557179
 223
Layn 0.747032 1.70051 1.18673 2.08064E-05
Ypel2 0.328307 0.747084 1.18623 5.09041E-06
Cyp4v3 0.2461 0.559992 1.18616 0.000244772
Rarg 1.27584 2.89863 1.18392 3.56808E-07
Galt 1.08031 2.45401 1.18369 1.37486E-06
Eno2 0.716683 1.62709 1.18289 2.82441E-06
Lrrc28 5.01151 11.3653 1.18132 7.56424E-10
Neu4 0.0269097 0.0609895 1.18043 0.0459186
Gpr123 0.860903 1.95087 1.1802 8.54214E-09
Mertk 1.46487 3.31759 1.17937 1.12196E-09
Chgb 0.181615 0.411065 1.17849 0.00093867
C1qtnf6 5.46447 12.3582 1.17732 1.04612E-11
Nptx1 8.28801 18.7404 1.17705 0
Phlda3 26.3583 59.5741 1.17643 0
Mfsd7c 0.151916 0.343344 1.17638 0.000812433
P4htm 1.90288 4.29929 1.17591 6.95171E-08
Fam13a 2.26184 5.10835 1.17536 2.48646E-12
Aldh4a1 9.78053 22.0452 1.17248 0
Nfkbid 0.165631 0.37297 1.17109 0.00360263
Gm1060 0.330173 0.742485 1.16914 0.000182678
Fam189a2 1.05264 2.36375 1.16706 4.31916E-07
Pex5l 1.11048 2.49173 1.16596 1.08854E-06
Klhl4 0.136754 0.306711 1.1653 0.00184251
Dysf 0.266437 0.597297 1.16465 2.97871E-05
Abca4 0.0296772 0.0665029 1.16406 0.0112296
Tmem37 1.36438 3.05636 1.16358 4.25873E-05
Trim66 0.271921 0.607253 1.15911 5.07901E-05
Cth 3.45661 7.71126 1.15761 9.07128E-10
Mgmt 4.97227 11.0842 1.15653 9.05494E-08
Ppfibp2 2.82984 6.30681 1.15619 4.05047E-11
Sepp1 22.0127 49.0431 1.15571 6.66134E-16
Cplx1 6.33013 14.0923 1.15461 2.92433E-13
Mpeg1 0.196273 0.436712 1.15382 0.000171069
Lama2 0.0492448 0.109431 1.15199 0.00116946
Pdlim4 1.68225 3.73471 1.1506 9.96643E-06
Ereg 0.0324493 0.0719524 1.14886 0.0431917
Dennd2c 0.480399 1.0626 1.14529 1.16336E-06
Parp3 1.25787 2.78094 1.14459 1.76862E-07
 224
Larp6 0.224268 0.49577 1.14445 0.0015235
Esrrg 0.316867 0.700245 1.14398 1.02369E-05
Zfp641 1.36683 3.01877 1.14312 5.11044E-09
Kcng4 0.0376411 0.0829997 1.1408 0.039303
Cpne7 2.10311 4.63437 1.13984 8.86836E-09
Eda2r 21.4103 47.1679 1.1395 1.28766E-11
Pnrc1 3.49335 7.69398 1.13912 6.88462E-10
Gas6 10.3218 22.7333 1.13911 3.33067E-15
Fam19a1 0.14608 0.321725 1.13907 0.00199918
Apc2 1.78506 3.92972 1.13845 1.18709E-09
Lzts1 0.303299 0.667552 1.13814 0.00123415
Casp12 0.0587033 0.129113 1.13712 0.0385684
Acaa1b 1.4648 3.22023 1.13646 2.0478E-06
Rapgef4 3.73597 8.20816 1.13558 5.16653E-12
Cpt1c 10.3558 22.7364 1.13457 2.22045E-15
Igfbp5 2.3049 5.05553 1.13316 7.36078E-13
Procr 0.178813 0.392097 1.13276 0.0099563
Sorcs2 6.83448 14.9606 1.13027 8.88178E-16
Pde4a 0.245942 0.538025 1.12935 0.00181562
Atf3 0.552462 1.20645 1.12682 0.000134211
Sgcd 0.246513 0.538302 1.12675 0.00564518
Dio2 0.335792 0.732893 1.12603 5.96451E-06
Creg2 0.178551 0.389076 1.12372 0.000123579
Ifitm3 3.89399 8.47968 1.12276 7.80007E-06
Gstt1 14.3268 31.1572 1.12085 2.39853E-12
Tmem53 0.540113 1.17457 1.12079 0.00239635
Kcnk1 2.3351 5.07002 1.11851 8.46282E-09
Rassf5 0.104999 0.227843 1.11766 0.00407661
Sparc 32.9041 71.3708 1.11707 2.22045E-15
Emid2 0.288316 0.625073 1.11637 0.000449005
Pck2 6.85783 14.8587 1.11548 2.93099E-14
Dnahc8 0.0792555 0.171484 1.11349 8.41015E-05
Csdc2 4.85183 10.4909 1.11253 9.41314E-12
Dnahc7b 0.240678 0.520141 1.1118 6.16878E-07
Egr3 0.362187 0.782457 1.11128 0.00208015
Cav2 3.09058 6.67343 1.11055 5.33238E-10
Bhlhe22 0.0425408 0.0918221 1.11 0.0496931
Lrrc17 0.16378 0.353329 1.10925 0.00594447
 225
Fos 4.07652 8.7885 1.10828 2.69914E-10
Mcf2l 0.949723 2.04553 1.10689 7.22315E-06
Gbp4 0.104877 0.225735 1.10593 0.0023282
Ctgf 0.4157 0.893536 1.10398 0.000254369
Grina 20.2762 43.579 1.10384 6.21725E-15
Olfr1314 0.177413 0.380729 1.10165 0.0464061
Camta2 3.65744 7.83562 1.09921 1.27582E-11
Plekha6 0.194823 0.417155 1.09842 0.00179372
Reps2 0.314731 0.673463 1.09748 3.18514E-06
Hyal1 1.0849 2.3206 1.09694 4.90387E-06
Cpne2 9.11261 19.4184 1.09149 2.57794E-13
Zfp874 2.01504 4.29235 1.09096 3.42575E-09
Hist2h3c2-ps 0.246709 0.525133 1.08987 0.0187107
H2-M3 0.158508 0.337159 1.08888 0.0213865
Ssh3 0.348792 0.741565 1.08821 0.000323956
1200009I06Rik 0.11252 0.239029 1.08701 0.00709263
Fa2h 0.0891575 0.189225 1.08568 0.0196256
Fbxw9 8.67211 18.3977 1.08507 3.33422E-12
Efemp1 0.186089 0.3944 1.08367 0.00527077
Mdm2 18.2903 38.7133 1.08175 1.9984E-15
Pcolce 0.89185 1.8875 1.08161 0.000105764
Hnmt 0.337784 0.714749 1.08133 0.00212304
Samd9l 0.101191 0.214098 1.08118 0.0018828
Nrg1 0.609314 1.28888 1.08086 0.000129509
Npy1r 0.114493 0.241969 1.07956 0.00633093
4933437F05Rik 0.268543 0.567315 1.079 0.00678868
Mxra7 3.54571 7.48645 1.07821 1.45901E-08
Abhd3 1.20251 2.5374 1.0773 9.85002E-06
Pdgfrl 0.472258 0.996049 1.07664 0.0011849
Lrdd 6.77654 14.2783 1.0752 7.10099E-13
Fhit 0.410805 0.865476 1.07504 0.023796
Rab3b 13.1803 27.745 1.07385 1.67644E-13
Ptrf 5.13639 10.7907 1.07097 3.96061E-12
Fam129a 0.0405578 0.084867 1.06522 0.0433314
Pacrg 1.867 3.906 1.06497 9.1591E-06
Loxl4 0.0731984 0.1531 1.06459 0.0265027
Polk 3.28997 6.87751 1.06381 1.45477E-11
Adamts15 0.0924203 0.193063 1.06279 0.00241097
 226
Scn7a 0.04619 0.0963893 1.06129 0.00691414
Rfx5 4.42241 9.22125 1.06013 1.73417E-12
Tnip2 1.84116 3.83474 1.05851 9.81753E-07
Rab26 2.72841 5.68139 1.05818 1.51743E-06
1700003E16Rik 0.152283 0.31709 1.05814 0.010429
Serpinb9 0.089798 0.186948 1.05788 0.0101214
Parm1 0.528429 1.0994 1.05694 0.000335223
9030617O03Rik 8.48435 17.6467 1.05652 1.52545E-13
Bdh2 0.588135 1.22076 1.05356 0.0243015
Fam167a 0.261828 0.543296 1.05312 0.000396329
Tap2 1.21363 2.51566 1.05161 3.26799E-06
Arhgap28 0.0918861 0.190408 1.05117 0.00350837
Aifm2 1.54279 3.19569 1.05058 0.0298219
Bzrap1 0.468547 0.969788 1.04947 9.18624E-07
Syt17 0.407579 0.843594 1.04947 0.001901
Tob1 8.14636 16.8538 1.04885 4.20508E-12
Mtm1 3.0696 6.35061 1.04885 2.44039E-09
Man2b2 2.68664 5.55368 1.04764 1.05158E-09
Tifa 0.478777 0.9897 1.04764 0.000452537
Frmpd4 0.0410686 0.0848891 1.04754 0.00731547
Spsb1 1.37632 2.84417 1.04719 4.67488E-07
Pvalb 0.212482 0.439089 1.04717 0.0483575
Cdc42bpg 1.75476 3.62556 1.04693 2.9025E-10
Fbln7 1.3323 2.75087 1.04597 7.26162E-07
4922501L14Rik 0.582046 1.2012 1.04527 0.000298002
Id1 4.10576 8.46946 1.04462 2.48826E-06
Wipi1 2.3236 4.7918 1.04421 5.40594E-07
Fmn1 0.0408926 0.084291 1.04354 0.00382913
Ankrd45 0.177765 0.366267 1.04292 0.00178786
Sgsm2 4.47536 9.21657 1.04222 1.69686E-12
Chd5 0.413965 0.85227 1.0418 2.83303E-06
Ttyh2 4.21322 8.66912 1.04096 3.31555E-11
Avil 0.0809557 0.166218 1.03787 0.0220876
Fam189a1 1.2019 2.46588 1.03678 3.48196E-05
Sema5a 1.07949 2.21458 1.03669 2.54758E-10
Slc24a2 0.0950668 0.194883 1.0356 0.00815968
Mansc1 0.186334 0.3818 1.03493 0.00564563
Arl5c 0.314255 0.643434 1.03385 0.00477677
 227
Lpo 9.43649 19.305 1.03265 6.71241E-13
A230065H16Rik 0.450909 0.921577 1.03127 0.0239351
Cyp4f17 1.34823 2.75272 1.02979 2.64448E-05
Rasl10b 5.03936 10.2786 1.02833 1.54547E-11
Plau 1.08446 2.2101 1.02713 1.39398E-05
Fam38a 1.78714 3.64 1.02628 7.03993E-08
Zfp456 0.288255 0.587056 1.02615 0.000350126
4930402H24Rik 5.40622 11.0069 1.02571 4.86167E-12
Lrrc7 1.70012 3.45875 1.02461 1.09159E-09
Fam83f 0.0727175 0.147625 1.02156 0.0287584
Cpeb1 0.289909 0.588439 1.02129 0.00152216
Snhg11 0.291666 0.591835 1.02088 8.07424E-05
Mir705,Rab11fip5 2.115 4.29058 1.02051 2.81763E-07
Scn11a 0.0757739 0.153672 1.02008 0.00542049
Tmem108 0.404934 0.820914 1.01954 0.000177781
Pde1c 1.88392 3.81888 1.01941 2.78812E-07
1700120K04Rik 0.721426 1.46217 1.01919 0.0164374
Ptchd2 0.463415 0.938404 1.0179 9.00233E-07
Cml1 2.74958 5.55789 1.01533 2.05027E-05
Whrn 3.45098 6.97272 1.01472 5.59231E-07
Zmat3 10.9752 22.1697 1.01434 2.09166E-13
E130309D14Rik 0.118835 0.239562 1.01144 0.00515585
Folh1 0.0905498 0.182537 1.01141 0.0254753
Il33 0.453305 0.913618 1.01111 0.000944661
Ubtd1 4.04771 8.14436 1.00869 1.69864E-07
Adm 7.55983 15.2107 1.00866 4.01345E-09
Nid1 1.20553 2.42464 1.00811 2.34705E-08
Ppm1h 0.920635 1.85118 1.00775 6.81582E-07
Amy1 0.315805 0.634798 1.00727 0.00541427
6330403K07Rik 3.89016 7.81697 1.00678 1.29044E-07
Slc30a10 0.469751 0.943524 1.00616 1.28809E-05
Celsr3 0.69099 1.38668 1.00489 1.13454E-08
Zbtb7b 3.36815 6.75618 1.00425 5.85E-10
Psmb8 0.310248 0.621661 1.00271 0.0116093
Galntl4 1.45274 2.91089 1.00268 3.47288E-06
Igdcc4 11.8978 23.8275 1.00193 1.54765E-13
Ctsd 97.212 194.685 1.00193 6.53055E-12
Col18a1 2.09386 4.18765 0.999979 2.71971E-08
 228
Mocos 0.0918041 0.183538 0.99945 0.0208781
Kcnc2 0.0439738 0.0878549 0.998477 0.0182431
Prkcd 0.0982452 0.196202 0.997882 0.0253971
Adamtsl1 0.0646225 0.128984 0.997085 0.00478897
Gpr146 0.427549 0.85231 0.995287 0.0278997
Tubb3 4.81267 9.59292 0.995131 2.72773E-08
Slc27a3 4.52497 9.01767 0.994846 4.42095E-09
Csmd1 0.144348 0.287443 0.993719 5.61747E-05
Fam70a 1.31711 2.61953 0.991935 1.05824E-06
Camk2b 33.1112 65.8238 0.991291 3.09406E-10
Cox6b2 6.45716 12.8286 0.99039 0.000410397
Mical2 4.7228 9.37836 0.989695 1.54136E-10
Gabrr2 0.281545 0.559007 0.989498 0.00610884
Dsc2 1.63409 3.24416 0.989356 4.67134E-08
Synj2 4.47112 8.87433 0.989 1.09154E-08
Myrip 0.0987454 0.195947 0.988682 0.00653894
Stk32c 1.1215 2.22391 0.987673 0.00192671
Rgs6 0.0880079 0.174506 0.987569 0.0321857
Gstm1 33.8326 66.9877 0.985483 1.9682E-12
Car12 0.453373 0.897314 0.984915 0.000177351
Gm4349 0.33883 0.670267 0.984176 0.0176505
Sh2d4a 0.137221 0.271425 0.984054 0.0112554
Kcnk2 2.04766 4.04595 0.982501 8.24732E-07
Kcnd1 0.167206 0.330329 0.982275 0.016299
Cdkn2b 2.31442 4.57053 0.981706 0.000015793
Vwa5b1 0.187055 0.369084 0.980486 0.00260277
Als2cl 1.29675 2.55739 0.979776 2.99886E-07
Ghitm 59.1384 116.618 0.979623 3.23985E-12
Cd14 0.569194 1.12166 0.978644 0.00207901
Rhod 4.09828 8.07499 0.978441 8.50981E-07
Slc37a2 3.15522 6.21521 0.978061 6.46782E-10
Cdk18 0.090471 0.178201 0.977979 0.0215842
Cpped1 15.7716 31.065 0.977964 2.33769E-12
Ccnd2 144.074 283.549 0.976792 2.63857E-06
Fbxl20 1.56908 3.08806 0.976786 7.08928E-10
Slc19a2 8.75262 17.2248 0.976702 4.94693E-12
Npnt 1.86915 3.67688 0.976103 5.80404E-06
Ano1 0.0704115 0.138508 0.97609 0.019649
 229
Scml4 0.565135 1.11063 0.974707 2.77342E-05
Lrfn2 0.225762 0.442923 0.972251 0.00335324
Greb1 0.454496 0.891193 0.971471 5.10215E-06
Usp2 4.37729 8.57831 0.970655 3.53422E-10
Dhrs11 1.93996 3.80128 0.970461 4.08718E-05
Il15ra 2.11027 4.13431 0.970215 0.000318293
Lrrc16a 5.35076 10.4719 0.968713 1.19316E-11
Fam65b 0.21559 0.421751 0.968105 0.0151334
Renbp 2.64695 5.17765 0.96797 0.000067544
Frmpd1 2.78858 5.44601 0.96567 1.29801E-09
Olfr1317 0.252412 0.492469 0.964254 0.043951
Tmem38a 19.6712 38.3603 0.963529 6.96043E-12
Rimbp2 0.344897 0.672317 0.962976 0.000387919
Mgat5b 3.10258 6.03742 0.960461 2.11373E-09
Stard8 0.108609 0.210912 0.957491 0.00619249
Jhdm1d 1.96985 3.82318 0.956686 1.76555E-10
Mmd2 11.3291 21.9878 0.956672 6.04701E-11
Luzp2 3.28491 6.37498 0.956565 3.70702E-10
Txnip 0.649479 1.25959 0.955602 0.00473614
Stxbp2 0.0797742 0.15461 0.95464 0.0434885
Tmem163 0.0986276 0.190867 0.952505 0.0361586
Ecm2 0.480453 0.929476 0.952023 0.0105776
Micalcl 0.241149 0.465741 0.949603 0.00546292
Faim2 0.103058 0.198878 0.948433 0.0111403
Tns1 1.53856 2.96828 0.948046 9.8701E-10
Acad11 3.40045 6.56014 0.948 5.2729E-08
Adamtsl4 0.0609863 0.117527 0.946433 0.037005
D10Bwg1379e 0.0449336 0.0865619 0.945936 0.014806
Megf10 2.51262 4.83927 0.945596 2.97871E-10
Efhd1 3.89322 7.49465 0.944897 3.80624E-07
Ttpa 4.23381 8.14676 0.944271 4.72024E-09
Fblim1 0.632288 1.2158 0.943252 0.00025071
Myh14 1.1821 2.2729 0.943179 1.57066E-07
Tlr2 0.104881 0.201595 0.942704 0.0237713
1300014I06Rik 4.10459 7.87676 0.940362 2.79278E-07
Frem1 0.126373 0.242408 0.939756 0.0010149
S1pr1 7.35093 14.0913 0.938812 1.98957E-10
9330129D05Rik 0.514979 0.986993 0.938527 0.00110649
 230
Astn2 3.15985 6.0537 0.93796 2.55307E-05
Serpina3n 0.656842 1.258 0.93752 0.00160787
Akap17b 3.0839 5.90337 0.936781 4.60238E-10
A430110N23Rik 0.493403 0.944308 0.93649 0.00017362
Pcp4l1 32.429 62.0257 0.93558 1.21527E-11
Card10 0.242844 0.463825 0.933552 0.00130647
Ctsh 1.97856 3.77766 0.93304 0.000058857
Abcg4 3.29589 6.28909 0.932184 1.20022E-08
Ldhb 77.3383 147.569 0.932137 7.93365E-12
H2-DMa 1.85297 3.53414 0.931518 0.00122691
Dpp6 5.36732 10.2364 0.931429 2.17231E-10
Rnf43 0.125019 0.238409 0.931289 0.0085594
Tspan18 0.245502 0.468057 0.930947 0.00292839
Ctso 3.11702 5.94207 0.9308 2.48312E-08
Lgals3bp 0.350752 0.668635 0.930768 0.00424824
AA415398 0.443776 0.845756 0.930409 0.0034833
Slc5a3 5.72341 10.9071 0.930324 6.38134E-12
Cul9 1.38176 2.63035 0.928748 2.22162E-08
Tcfcp2l1 0.024991 0.0475635 0.928443 0.0393856
Slc6a15 0.678347 1.28841 0.925501 0.000106128
Irak2 0.247928 0.470862 0.925385 0.0236403
Dixdc1 0.407093 0.772948 0.925013 0.000122407
Tcn2 12.9041 24.5008 0.924998 3.52546E-09
Ache 0.295395 0.560592 0.924304 0.00666481
Fzd1 6.11945 11.6054 0.923328 1.78027E-10
Gucy1a3 1.53457 2.91005 0.923208 4.68345E-07
Smad3 5.43361 10.2981 0.922395 1.3474E-10
Ccdc88c 11.047 20.9336 0.92217 1.80853E-11
Srsf13b 0.534138 1.01179 0.921623 0.000602702
Mpa2l 0.0938808 0.177796 0.921319 0.0152241
Samd12 1.60466 3.03828 0.920984 0.00112118
Arntl 10.146 19.1805 0.918729 1.12526E-10
Atp2b2 0.228769 0.432399 0.918474 0.00238767
Cx3cl1 5.68814 10.7511 0.918456 1.72394E-09
Tnfrsf25 0.194463 0.367484 0.918185 0.0323676
Lmna 5.02525 9.48572 0.916562 2.74997E-05
Chst8 0.140529 0.265086 0.91559 0.0241707
Itga3 0.113789 0.214528 0.914804 0.00882995
 231
Ntm 20.2493 38.1524 0.913901 7.50044E-11
Itga2b 0.110884 0.208804 0.913101 0.0200454
Rtn4rl1 2.10002 3.95357 0.912751 9.29437E-07
Sv2a 2.90113 5.45775 0.911689 3.52101E-08
Slc25a18 42.7546 80.4245 0.911556 2.22351E-11
Car5b 0.336474 0.632788 0.911227 0.00169172
Cdkl3 1.89591 3.5653 0.911137 0.000574314
Efna5 0.206218 0.387388 0.909607 0.0104225
AI854703 0.27595 0.518334 0.909475 0.00258746
Plcl1 1.62218 3.0455 0.908743 4.96384E-08
Fmnl1 0.199591 0.374074 0.906279 0.00572959
Fgl2 0.41599 0.779603 0.906191 0.000803229
Pfkp 5.08586 9.5285 0.905758 0.00263554
Ednrb 85.971 160.916 0.904386 3.20087E-07
Mpped1 0.116553 0.218026 0.903514 0.0201243
AA986860 0.33846 0.633003 0.903228 0.00288524
Gm8615 3.54231 6.62395 0.903002 8.95074E-07
Aqp9 0.185233 0.346277 0.902581 0.0134635
Palm2 0.192551 0.359871 0.902238 0.000706032
Cpeb3 0.448689 0.838352 0.901842 0.000118617
Ppargc1a 8.45014 15.7725 0.900364 1.10136E-10
Fahd1 6.94699 12.9629 0.899924 2.20676E-07
Dnahc1 0.0300463 0.0560571 0.899708 0.0193439
BC066028 0.382299 0.713193 0.899594 0.000912571
Neurod1 0.349251 0.65079 0.897928 0.00456117
Mtap1b 7.16043 13.336 0.897203 4.24767E-11
Atp2b4 1.80287 3.35757 0.897119 7.2279E-07
Cybrd1 9.01048 16.7611 0.895442 5.90628E-11
C130074G19Rik 0.188225 0.349468 0.892704 0.0120778
B930059L03Rik 0.223192 0.414325 0.892478 0.040966
Rnls 0.46254 0.858511 0.892259 0.0428367
Vldlr 4.62048 8.55794 0.889221 1.52798E-09
Scn2b 0.200752 0.371577 0.888246 0.00400243
Postn 0.213732 0.395513 0.887922 0.00796165
Dhdpsl 0.397814 0.735495 0.886623 0.0134188
Gria3 9.13397 16.8792 0.885932 9.09048E-11
Usp53 1.18258 2.18519 0.885817 1.13871E-05
Gem 0.529514 0.978361 0.885699 0.00233103
 232
Tceal6 1.50159 2.76807 0.882394 0.00124105
Gnpda1 11.1458 20.5453 0.882302 1.31118E-09
Pbxip1 36.929 68.0714 0.882294 6.03448E-10
St6galnac5 3.11785 5.74196 0.880989 3.96415E-06
Nos1ap 0.637469 1.1736 0.880508 0.0253193
Iffo1 4.57091 8.4045 0.878682 7.63587E-07
Plxna4 0.380772 0.699269 0.876922 1.25059E-05
Cela1 0.510261 0.936389 0.875872 0.0157581
Ano4 0.309517 0.567916 0.875657 0.00201534
Ampd3 0.894663 1.637 0.871636 0.000053832
Gpr156 0.144534 0.264455 0.871613 0.0092133
Slc3a2 56.7604 103.852 0.871568 9.88919E-10
Ddc 0.23483 0.429391 0.870675 0.0209762
Ramp1 6.35529 11.6204 0.870632 3.35983E-05
Flnc 1.30694 2.38864 0.869999 1.11638E-07
Ehd4 3.8474 7.02852 0.869336 9.13052E-08
Oxr1 27.9267 51.0059 0.869018 1.59633E-08
Dbx2 13.6285 24.8833 0.868546 1.07916E-09
Ifi30 2.2238 4.06008 0.868478 0.000728554
Atp5sl 2.38523 4.35273 0.86779 8.47412E-06
Rasgrp1 0.0740441 0.135096 0.867528 0.0251762
N4bp2l1 0.650978 1.18719 0.866866 0.00270441
Cyp46a1 0.700912 1.2766 0.865001 0.00168822
Ampd2 15.6219 28.4317 0.863934 2.33601E-10
Pde3a 0.830681 1.51042 0.862585 8.61292E-05
Hspb8 2.55142 4.63765 0.862095 3.47507E-05
Hmox1 24.893 45.2417 0.861913 7.68449E-10
Ppp1r3b 0.312695 0.568086 0.861354 0.00230411
Crim1 3.44846 6.2631 0.860923 8.52962E-09
Tbc1d2 0.104746 0.190129 0.860087 0.0208075
Ednra 1.38375 2.51129 0.85985 1.64411E-05
A330023F24Rik,Mir29
b-2,Mir29c 0.0727327 0.13186 0.858333 0.0277713
Thsd1 0.34552 0.62639 0.858292 0.00531864
Cdc42ep3 0.772087 1.39938 0.857955 0.00188115
Fam161a 0.229683 0.416145 0.857444 0.0230196
Slc25a45 0.720075 1.30444 0.857209 0.00266991
Tgfbr3 0.134266 0.243225 0.857201 0.00675166
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Fam46a 1.09373 1.98102 0.856989 0.000073736
Cyp2u1 0.978766 1.77273 0.856939 0.000505945
Dennd3 0.3696 0.666918 0.851545 0.000816525
Prkar1b 1.15456 2.08274 0.851145 0.000202946
Mylk 1.10983 2.00087 0.850289 1.13407E-06
Gmpr 3.16336 5.69993 0.849488 3.62095E-05
Chst2 20.2043 36.4038 0.849428 9.04685E-10
Asah2 0.377321 0.679091 0.84781 0.00104376
Ifitm2 6.75129 12.1402 0.84656 0.000174748
Flt1 0.0658113 0.11831 0.84616 0.0254953
Wdr52 0.0489762 0.0879729 0.844976 0.0384759
Vamp8 0.987163 1.77124 0.843401 0.0133645
Dnaja4 1.10086 1.97473 0.843019 0.000157834
Cobll1 5.07693 9.1029 0.842369 3.12843E-08
Muc1 0.984072 1.76314 0.841313 0.000743435
Gpr179 0.269451 0.482614 0.840846 0.000439569
Klhl24 6.66105 11.9274 0.840463 8.9493E-10
4933426M11Rik 12.877 23.0528 0.840143 5.6237E-10
Susd4 4.34555 7.77776 0.839816 2.15758E-06
Tmem19 6.65606 11.9123 0.839716 2.42094E-08
Dnaic2 0.13641 0.244076 0.839382 0.0310393
Pygl 0.124821 0.223329 0.839308 0.0360509
Npr2 1.43431 2.56512 0.838667 2.29478E-05
2210403K04Rik,Mir22 0.953849 1.70507 0.837998 0.00188648
Kcnc1 21.9976 39.3074 0.837453 4.74861E-08
Slc7a5 58.2393 103.979 0.836232 1.32934E-08
Pik3r3 14.274 25.4567 0.83466 6.39775E-10
Gm10825 0.462725 0.824757 0.833815 0.000824148
Stac2 0.1255 0.223333 0.831506 0.03517
Cdhr1 0.348253 0.619017 0.829842 0.00233113
Kank4 0.891869 1.58511 0.829682 6.65706E-05
Kcnn1 0.371346 0.659847 0.829368 0.00234136
Acy3 0.971021 1.72521 0.829198 0.00316016
Cygb 0.206202 0.366352 0.829174 0.0249878
Nbeal2 0.827065 1.46941 0.829165 5.3823E-06
Pgcp 3.90869 6.94376 0.829033 1.18707E-05
1500015A07Rik 1.23642 2.19268 0.826522 0.000849156
Ogdhl 10.0273 17.779 0.826239 3.90173E-09
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Trafd1 13.6091 24.0707 0.822712 4.24049E-08
Usp35 1.2844 2.2717 0.822673 3.72527E-05
Pkib 0.0951343 0.168106 0.82133 0.0247858
Carns1 0.129072 0.227806 0.819624 0.023495
Nefl 0.986675 1.74003 0.818462 0.00155294
Lhfpl2 4.56668 8.05324 0.818425 5.31361E-08
Rev1 10.0067 17.6466 0.818425 0.000419611
Arhgap23 0.740261 1.30507 0.818021 0.000107277
Snhg10 1.67886 2.95699 0.816648 0.0198616
Pla2g16 2.33544 4.10644 0.814196 5.23596E-06
Fosl2 0.969964 1.70511 0.813862 0.000027729
Adrb1 3.39761 5.97262 0.813842 5.05357E-06
Matn4 0.21267 0.37364 0.813033 0.0390952
Ccdc30 0.206432 0.362607 0.812742 0.0239547
Lgals3 0.421937 0.740782 0.812021 0.0298206
Cpe 98.5774 173.062 0.811958 2.33484E-08
Egr2 0.852293 1.49565 0.811356 0.000716969
Leprel1 1.98949 3.49074 0.81113 0.000104328
Aatk 2.45153 4.29672 0.809557 6.17219E-07
Slc4a11 0.168021 0.294316 0.808725 0.023037
Cd151 18.5618 32.5007 0.808133 2.5716E-07
Syne1 1.29859 2.27326 0.807816 8.60157E-06
Aldh1l1 67.7269 118.499 0.807079 2.74948E-08
Zfp677 0.175558 0.306932 0.805973 0.0277353
Srgap3 7.37045 12.8829 0.805633 2.55918E-09
Pnpo 0.370701 0.647816 0.805328 0.014643
Plekha4 0.572889 1.00055 0.804471 0.00325445
Cfb 0.331319 0.578575 0.804283 0.0104141
Mt3 298.934 521.15 0.801873 5.27574E-09
Trp53inp2 35.5843 62.0214 0.801524 8.00056E-09
Tnfaip2 0.201326 0.350793 0.801082 0.0155907
Dusp14 2.15017 3.745 0.800516 0.000584127
Cd36 0.263935 0.459624 0.800271 0.0164141
Mitf 0.822384 1.43184 0.799991 0.000155058
Slc43a2 2.25554 3.92679 0.79988 3.2465E-06
Rnf144b 0.595866 1.03697 0.799314 0.00605493
Bdnf 0.421944 0.734271 0.799261 0.0221299
Tek 0.0803912 0.139862 0.798895 0.0409021
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Mkl2 5.19331 9.02867 0.79786 0.00105439
Pim2 2.71727 4.72388 0.797814 5.57242E-05
Smox 11.7472 20.4142 0.797251 6.72583E-06
Igfbp2 369.224 641.619 0.797221 2.4286E-06
C2 1.65551 2.87634 0.796958 0.000134806
Alpk1 0.217473 0.377423 0.795344 0.00774708
1700084C01Rik 0.853446 1.48091 0.795117 0.00680533
0610010O12Rik 3.41194 5.91796 0.794509 0.00386922
Dcaf4 10.3995 18.0206 0.793139 3.68735E-07
Tmem35 34.915 60.4796 0.7926 4.8812E-09
Pdk1 1.125 1.94866 0.792557 4.08354E-05
Park2 0.163338 0.282811 0.791976 0.0279405
Fam135b 0.881435 1.52456 0.790467 0.000191687
Dyx1c1 0.274449 0.474597 0.790165 0.049593
Tmco4 0.248501 0.429687 0.790035 0.0136375
Kirrel3 5.75449 9.94994 0.79 2.59101E-06
Axl 3.55984 6.15144 0.789115 5.50605E-07
Slc4a4 22.7989 39.37 0.788136 5.52711E-08
Mfap2 5.49946 9.4956 0.787969 7.83073E-05
Svep1 0.912748 1.57566 0.787666 3.16377E-06
Arfgef2 4.85472 8.37799 0.787217 1.06863E-08
Ptpre 0.509225 0.878674 0.787026 0.000773322
Mtus2 0.069449 0.119743 0.785917 0.0343473
Col4a2 0.428989 0.73965 0.785901 0.000765377
Grn 17.2371 29.6967 0.784786 2.00146E-08
Ndrg2 12.7849 22.0231 0.784577 4.39525E-07
Ppp1r13b 0.405353 0.697653 0.783332 0.00283328
Prkcc 0.230204 0.396055 0.782785 0.0233147
Dnajc6 0.15675 0.269671 0.782732 0.0149295
Cadm2 1.57392 2.70704 0.782358 6.45434E-07
Scrg1 4.89489 8.41483 0.781656 0.000929081
Ephx1 63.5022 109.158 0.781542 9.34496E-09
Kcnip1 3.60957 6.20454 0.781495 2.80885E-05
Adcy2 1.28437 2.20693 0.780981 7.32759E-05
Dlgap1 1.246 2.1405 0.780649 0.000287796
Nek3 2.5727 4.41963 0.780643 0.000432475
Myo5b 0.0744453 0.127836 0.780045 0.0343334
Fam195a 10.3867 17.8276 0.779378 2.79471E-05
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Celf3 0.399831 0.686146 0.779123 0.00934764
Steap1 0.531011 0.911112 0.778887 0.0266773
Adamts8 0.645511 1.10714 0.778319 0.00146582
Esrrb 1.73419 2.97325 0.777775 2.74814E-05
Plekha7 2.85124 4.88819 0.777712 2.04811E-06
Lrrk2 1.09759 1.8817 0.777699 7.60245E-06
Il11ra1 4.70828 8.06924 0.777232 2.36952E-05
Elavl3 3.44576 5.89956 0.775783 4.53366E-07
Vwa5a 4.07003 6.96499 0.77508 5.16461E-07
Gse1 5.37838 9.20143 0.774686 7.80261E-06
Phyhipl 16.9055 28.8945 0.773302 1.21381E-05
Jag1 6.53449 11.1685 0.773289 3.89563E-08
Tnfrsf12a 16.543 28.2601 0.772548 0.00029436
Phf21b 6.16119 10.5226 0.772206 2.03283E-07
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90310029|90310183|90311466|90311548#I#A3SS 0.491 1 -0.509 6.99E-09 Inclusion 163
A3SS Tsc2 ENSMUSG00000002496#chr17#-#24741772|24741937|24741772|24741934|24744381|24744476#I#A3SS 0.571 0.938 -0.367 0.04829085 Inclusion 159
A3SS Tsc2 ENSMUSG00000002496#chr17#-#24741772|24741937|24741772|24741934|24744381|24744476#I#A3SS 0.143 0.846 -0.703 0.006973165 Inclusion 161
A3SS Yars2 ENSMUSG00000022792#chr16#+#16306555|16306711|16306590|16306711|16304628|16304796#I#A3SS 0.529 0.777 -0.248 0.028688997 Inclusion 159
A3SS Yars2 ENSMUSG00000022792#chr16#+#16306555|16306711|16306590|16306711|16304628|16304796#I#A3SS 0.621 1 -0.379 0.001039232 Inclusion 163
A3SS Tcf7l2 ENSMUSG00000024985#chr19#+#55991828|55991969|55991843|55991969|55987048|55987135#E#A3SS 0.405 0.053 0.352 0.005158893 Exclusion 159












112199275|112199324|112201385|112201586#I#A3SS 0.571 1 -0.429 0.005378088 Inclusion 163
A3SS Plekhg2
ENSMUSG00000037552#chr7#-#29155256|29156061|
29155256|29155516|29156133|29156264#I#A3SS 0.234 0.549 -0.315 0.013388647 Inclusion 159
A3SS Plekhg2
ENSMUSG00000037552#chr7#-#29155256|29156061|
29155256|29155516|29156133|29156264#I#A3SS 0.332 1 -0.668 0.023213596 Inclusion 161
A3SS Iffo1 ENSMUSG00000038271#chr6#+#125101812|125102789|125102631|125102789|125101402|125101543#I#A3SS 0.487 0.928 -0.441 0.016862446 Inclusion 159
A3SS Iffo1 ENSMUSG00000038271#chr6#+#125101812|125102789|125102631|125102789|125101402|125101543#I#A3SS 0.31 1 -0.69 0.001315389 Inclusion 161
A3SS Pprc1 ENSMUSG00000055491#chr19#+#46136630|46136780|46136633|46136780|46135892|46136066#I#A3SS 0.182 0.432 -0.25 0.043830745 Inclusion 159
A3SS Pprc1 ENSMUSG00000055491#chr19#+#46136630|46136780|46136633|46136780|46135892|46136066#I#A3SS 0 0.286 -0.286 0.0062657 Inclusion 161
A3SS Pprc1 ENSMUSG00000055491#chr19#+#46136630|46136780|46136633|46136780|46135892|46136066#I#A3SS 0 0.414 -0.414 0.007167437 Inclusion 163
A3SS Psma3 ENSMUSG00000060073#chr12#+#72084305|72084429|72084310|72084429|72079719|72079802#I#A3SS 0 0.921 -0.921 0 Inclusion 159
A3SS Psma3 ENSMUSG00000060073#chr12#+#72084305|72084429|72084310|72084429|72079719|72079802#I#A3SS 0 0.931 -0.931 0 Inclusion 163
A5SS Mll1 ENSMUSG00000002028#chr9#-#44641980|44642103|44641989|44642103|44640943|44641128#E#A5SS 0.431 0.073 0.358 0.018109848 Exclusion 159
A5SS Mll1 ENSMUSG00000002028#chr9#-#44641980|44642103|44641989|44642103|44640943|44641128#E#A5SS 0.525 0 0.525 0.025635193 Exclusion 161
A5SS Usp9x ENSMUSG00000031010#chrX#+#12742397|12742658|12742397|12742610|12743757|12743853#E#A5SS 1 0.079 0.921 2.14E-08 Exclusion 159
A5SS Usp9x ENSMUSG00000031010#chrX#+#12742397|12742658|12742397|12742610|12743757|12743853#E#A5SS 1 0.024 0.976 1.9E-11 Exclusion 161
A5SS Psma3 ENSMUSG00000060073#chr12#+#72079719|72079826|72079719|72079802|72084305|72084429#E#A5SS 1 0.038 0.962 2.22E-16 Exclusion 159
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90310029|90310183|90311466|90311548#I#RI 0.474 1 -0.526 3.88E-09 Inclusion 163
RI Mettl17
ENSMUSG00000004561#chr14#+#52508416|52509310|
52508416|52508511|52509202|52509310#E#RI 0.864 0.407 0.457 0.01552353 Exclusion 159
RI Mettl17
ENSMUSG00000004561#chr14#+#52508416|52509310|
52508416|52508511|52509202|52509310#E#RI 1 0.534 0.466 0.036967053 Exclusion 161
RI Rasa4 ENSMUSG00000004952#chr5#+#136577113|136577559|136577113|136577264|136577494|136577559#I#RI 0.215 0.498 -0.283 2.86E-06 Inclusion 159
RI Rasa4 ENSMUSG00000004952#chr5#+#136577113|136577559|136577113|136577264|136577494|136577559#I#RI 0.199 0.514 -0.315 0.000117487 Inclusion 161
RI Rasa4 ENSMUSG00000004952#chr5#+#136577113|136577559|136577113|136577264|136577494|136577559#I#RI 0.197 0.41 -0.213 0.027462934 Inclusion 163
RI Tctex1d2
ENSMUSG00000014075#chr16#+#32425326|32427007|
32425326|32425396|32426943|32427007#I#RI 0.041 1 -0.959 1.14E-07 Inclusion 159
RI Tctex1d2
ENSMUSG00000014075#chr16#+#32425326|32427007|
32425326|32425396|32426943|32427007#I#RI 0.075 1 -0.925 0.048520477 Inclusion 163
RI Fhod1 ENSMUSG00000014778#chr8#-#107855541|107856092|107855541|107855724|107855936|107856092#I#RI 0.163 0.457 -0.294 0.000507332 Inclusion 159




33675012|33675118|33675208|33675355#I#RI 0.483 0.734 -0.251 0.02227738 Inclusion 159
RI Adamts10
ENSMUSG00000024299#chr17#+#33675012|33675355|
33675012|33675118|33675208|33675355#I#RI 0.391 0.769 -0.378 0.030084472 Inclusion 163
RI Lrdd ENSMUSG00000025507#chr7#-#148627510|148628463|148627510|148627720|148628049|148628463#I#RI 0.602 1 -0.398 0.021545053 Inclusion 159












26013605|26013684|26013894|26014114#I#RI 0.375 0.666 -0.291 0.030938342 Inclusion 163
RI Wdr75 ENSMUSG00000025995#chr1#+#45874107|45875109|45874107|45874288|45875014|45875109#I#RI 0.045 1 -0.955 7.39E-10 Inclusion 161
RI Wdr75 ENSMUSG00000025995#chr1#+#45874107|45875109|45874107|45874288|45875014|45875109#I#RI 0.03 1 -0.97 1.72E-11 Inclusion 163
RI Fam98b
ENSMUSG00000027349#chr2#+#117083369|117085091|
117083369|117083515|117084956|117085091#E#RI 1 0.016 0.984 0.00946378 Exclusion 159
RI Fam98b
ENSMUSG00000027349#chr2#+#117083369|117085091|
117083369|117083515|117084956|117085091#E#RI 1 0.009 0.991 0.034267236 Exclusion 163
RI Stoml2 ENSMUSG00000028455#chr4#-#43041809|43042230|43041809|43041938|43042150|43042230#I#RI 0.059 0.316 -0.257 0.003094312 Inclusion 159
RI Stoml2 ENSMUSG00000028455#chr4#-#43041809|43042230|43041809|43041938|43042150|43042230#I#RI 0.103 1 -0.897 0.014584486 Inclusion 163
RI Aebp2 ENSMUSG00000030232#chr6#+#140599276|140601347|140599276|140599303|140599836|140601347#I#RI 0.427 1 -0.573 1.46E-09 Inclusion 159
RI Aebp2 ENSMUSG00000030232#chr6#+#140599276|140601347|140599276|140599303|140599836|140601347#I#RI 0.352 1 -0.648 1.87E-08 Inclusion 161
RI Phkg2 ENSMUSG00000030815#chr7#+#134721048|134721543|134721048|134721224|134721488|134721543#I#RI 0.19 0.396 -0.206 0.020375842 Inclusion 159
RI Phkg2 ENSMUSG00000030815#chr7#+#134721048|134721543|134721048|134721224|134721488|134721543#I#RI 0.179 0.602 -0.423 0.005852126 Inclusion 163
RI Nono ENSMUSG00000031311#chrX#+#98640026|98640673|98640026|98640129|98640633|98640673#I#RI 0.035 1 -0.965 0 Inclusion 159
RI Nono ENSMUSG00000031311#chrX#+#98640026|98640673|98640026|98640129|98640633|98640673#I#RI 0.028 1 -0.972 0 Inclusion 161
RI Nono ENSMUSG00000031311#chrX#+#98640026|98640673|98640026|98640129|98640633|98640673#I#RI 0.035 1 -0.965 0 Inclusion 163
RI Parl ENSMUSG00000033918#chr16#-#20285837|20287142|20285837|20285908|20286992|20287142#I#RI 0.019 1 -0.981 5.36E-09 Inclusion 161
RI Parl ENSMUSG00000033918#chr16#-#20285837|20287142|20285837|20285908|20286992|20287142#I#RI 0.025 1 -0.975 1.58E-06 Inclusion 163
RI Mrps17
ENSMUSG00000034211#chr5#+#130221558|130222741|
130221558|130221785|130222601|130222741#I#RI 0.256 0.501 -0.245 0.002485041 Inclusion 159
RI Mrps17
ENSMUSG00000034211#chr5#+#130221558|130222741|
130221558|130221785|130222601|130222741#I#RI 0.193 0.429 -0.236 0.000676491 Inclusion 161
RI Galt ENSMUSG00000036073#chr4#+#41703385|41703684|41703385|41703434|41703554|41703684#I#RI 0.16 0.483 -0.323 1.4E-05 Inclusion 159
RI Galt ENSMUSG00000036073#chr4#+#41703385|41703684|41703385|41703434|41703554|41703684#I#RI 0.262 0.48 -0.218 0.033746741 Inclusion 161
RI Galt ENSMUSG00000036073#chr4#+#41703385|41703684|41703385|41703434|41703554|41703684#I#RI 0.282 0.526 -0.244 0.043508979 Inclusion 163
RI Ankrd13b
ENSMUSG00000037907#chr11#-#77285950|77286379|
















51505678|51505710|51505982|51507682#I#RI 0.255 1 -0.745 0.000157901 Inclusion 163
RI Ppox ENSMUSG00000062729#chr1#-#173209560|173210132|173209560|173209705|173209999|173210132#I#RI 0.43 0.697 -0.267 0.003046848 Inclusion 159
RI Ppox ENSMUSG00000062729#chr1#-#173209560|173210132|173209560|173209705|173209999|173210132#I#RI 0.452 0.743 -0.291 0.01594661 Inclusion 161
RI Fxc1 ENSMUSG00000089847#chr7#+#112789275|112789742|112789275|112789371|112789541|112789742#I#RI 0.159 0.427 -0.268 2.49E-06 Inclusion 159
RI Fxc1 ENSMUSG00000089847#chr7#+#112789275|112789742|112789275|112789371|112789541|112789742#I#RI 0.089 0.333 -0.244 2.4E-07 Inclusion 161
RI Fxc1 ENSMUSG00000089847#chr7#+#112789275|112789742|112789275|112789371|112789541|112789742#I#RI 0.224 1 -0.776 1.36E-08 Inclusion 163
SE Med25 ENSMUSG00000002968#chr7#-#52135936|52136008|52135621|52135840|52136292|52136481#E#SE 0.937 0.489 0.448 0.000505472 Exclusion 161
SE Med25 ENSMUSG00000002968#chr7#-#52135936|52136008|52135621|52135840|52136292|52136481#E#SE 1 0.401 0.599 0.002366841 Exclusion 163
SE Mettl17
ENSMUSG00000004561#chr14#+#52508821|52508892|
52508416|52508511|52509202|52509310#E#SE 0.938 0.567 0.371 0.009800963 Exclusion 159
SE Mettl17
ENSMUSG00000004561#chr14#+#52508821|52508892|
52508416|52508511|52509202|52509310#E#SE 1 0.635 0.365 0.012873464 Exclusion 161
SE Mettl17
ENSMUSG00000004561#chr14#+#52508821|52508892|
52508416|52508511|52509202|52509310#E#SE 1 0.659 0.341 0.034602983 Exclusion 163
SE Mettl17
ENSMUSG00000004561#chr14#+#52508821|52509072|
52508416|52508511|52509202|52509310#E#SE 0.901 0.488 0.413 0.015678773 Exclusion 159
SE Mettl17
ENSMUSG00000004561#chr14#+#52508821|52509072|
52508416|52508511|52509202|52509310#E#SE 1 0.528 0.472 0.021804689 Exclusion 161
SE Ptbp1 ENSMUSG00000006498#chr10#+#79322861|79322939|79322525|79322700|79323568|79323714#E#SE 0.647 0.122 0.525 0 Exclusion 161
SE Ptbp1 ENSMUSG00000006498#chr10#+#79322861|79322939|79322525|79322700|79323568|79323714#E#SE 1 0.188 0.812 1.69E-06 Exclusion 163
SE Mdm2 ENSMUSG00000020184#chr10#-#117146709|117146840|117142210|117142285|117147001|117147084#E#SE 0.786 0.563 0.223 0.000162174 Exclusion 159
SE Mdm2 ENSMUSG00000020184#chr10#-#117146709|117146840|117142210|117142285|117147001|117147084#E#SE 0.716 0.506 0.21 0.013302913 Exclusion 161
SE Tlk2 ENSMUSG00000020694#chr11#+#105071858|105071954|105071107|105071151|105082499|105082667#E#SE 0.584 0 0.584 4.37E-08 Exclusion 161
SE Tlk2 ENSMUSG00000020694#chr11#+#105071858|105071954|105071107|105071151|105082499|105082667#E#SE 1 0.701 0.299 0.008860646 Exclusion 163
SE Erbb2ip
ENSMUSG00000021709#chr13#-#104620267|104620411|
104614799|104615006|104623577|104625108#E#SE 1 0.634 0.366 0.017961793 Exclusion 159
SE Erbb2ip
ENSMUSG00000021709#chr13#-#104620267|104620411|
104614799|104615006|104623577|104625108#E#SE 0.791 0.317 0.474 0.021143176 Exclusion 161
SE Dph3 ENSMUSG00000021905#chr14#-#32898092|32898167|32896354|32896432|32898595|32898795#E#SE 0.7 0.406 0.294 0.00016138 Exclusion 161
SE Dph3 ENSMUSG00000021905#chr14#-#32898092|32898167|32896354|32896432|32898595|32898795#E#SE 0.826 0.533 0.293 0.001426256 Exclusion 163
SE Dph3 ENSMUSG00000021905#chr14#-#32898092|32898293|32893754|32896432|32898595|32898795#E#SE 0.348 0.116 0.232 0.000126514 Exclusion 159
SE Dph3 ENSMUSG00000021905#chr14#-#32898092|32898293|32893754|32896432|32898595|32898795#E#SE 0.344 0.082 0.262 5.04E-06 Exclusion 161
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SE Dph3 ENSMUSG00000021905#chr14#-#32898092|32898293|32893754|32896432|32898595|32898795#E#SE 0.537 0.11 0.427 2.1E-06 Exclusion 163
SE Prmt5 ENSMUSG00000023110#chr14#-#55132127|55132291|55130829|55130991|55133433|55133483#E#SE 1 0 1 0 Exclusion 159
SE Prmt5 ENSMUSG00000023110#chr14#-#55132127|55132291|55130829|55130991|55133433|55133483#E#SE 1 0 1 0 Exclusion 161
SE Prmt5 ENSMUSG00000023110#chr14#-#55132127|55132291|55130829|55130991|55133433|55133483#E#SE 1 0 1 0 Exclusion 163
SE Bin1 ENSMUSG00000024381#chr18#+#32585877|32586006|32584473|32584621|32591324|32591396#I#SE 0.511 0.902 -0.391 0.001632665 Inclusion 161
SE Bin1 ENSMUSG00000024381#chr18#+#32585877|32586006|32584473|32584621|32591324|32591396#I#SE 0.512 1 -0.488 0.023492464 Inclusion 163
SE Tcof1 ENSMUSG00000024613#chr18#-#60991819|60991963|60991427|60991649|60992080|60992278#E#SE 0.96 0.453 0.507 1.21E-05 Exclusion 159
SE Tcof1 ENSMUSG00000024613#chr18#-#60991819|60991963|60991427|60991649|60992080|60992278#E#SE 0.932 0.661 0.271 0.046558874 Exclusion 161
SE Tcf7l2 ENSMUSG00000024985#chr19#+#56001173|56001246|56000466|56000539|56005923|56006699#I#SE 0.132 1 -0.868 0.049763268 Inclusion 159
SE Tcf7l2 ENSMUSG00000024985#chr19#+#56001173|56001246|56000466|56000539|56005923|56006699#I#SE 0 1 -1 0.006657726 Inclusion 161
SE Pycr1 ENSMUSG00000025140#chr11#-#120504472|120504601|120504205|120504276|120504993|120505018#E#SE 1 0.746 0.254 0.011179095 Exclusion 161
SE Pycr1 ENSMUSG00000025140#chr11#-#120504472|120504601|120504205|120504276|120504993|120505018#E#SE 1 0.754 0.246 0.035487878 Exclusion 163
SE R3hdm2
ENSMUSG00000025404#chr10#+#126918748|126918811|
126913575|126913754|126921031|126921274#I#SE 0.087 1 -0.913 7.48E-07 Inclusion 161
SE R3hdm2
ENSMUSG00000025404#chr10#+#126918748|126918811|
126913575|126913754|126921031|126921274#I#SE 0.085 1 -0.915 0.000271221 Inclusion 163
SE R3hdm2
ENSMUSG00000025404#chr10#+#126918748|126918850|
126913575|126913754|126921031|126921274#I#SE 0.13 1 -0.87 2.23E-09 Inclusion 161
SE R3hdm2
ENSMUSG00000025404#chr10#+#126918748|126918850|
126913575|126913754|126921031|126921274#I#SE 0.068 1 -0.932 3.6E-05 Inclusion 163
SE Mllt10 ENSMUSG00000026743#chr2#+#18047760|18047856|18045345|18045439|18068403|18068499#E#SE 1 0.563 0.437 0.037612404 Exclusion 159
SE Mllt10 ENSMUSG00000026743#chr2#+#18047760|18047856|18045345|18045439|18068403|18068499#E#SE 1 0.516 0.484 0.009089319 Exclusion 161
SE Fam188a
ENSMUSG00000026767#chr2#-#12325624|12325795|
12322685|12322703|12327486|12327547#E#SE 0.941 0.636 0.305 0.02836364 Exclusion 161
SE Fam188a
ENSMUSG00000026767#chr2#-#12325624|12325795|
12322685|12322703|12327486|12327547#E#SE 1 0.639 0.361 0.016127839 Exclusion 163
SE Mtfr1 ENSMUSG00000027601#chr3#+#19108490|19108527|19106451|19106550|19111467|19111583#E#SE 1 0.085 0.915 2.01E-06 Exclusion 159
SE Mtfr1 ENSMUSG00000027601#chr3#+#19108490|19108527|19106451|19106550|19111467|19111583#E#SE 1 0.11 0.89 1.91E-05 Exclusion 163
SE Tpm3 ENSMUSG00000027940#chr3#+#89894934|89895013|89893931|89894001|89903449|89904487#E#SE 1 0.068 0.932 0 Exclusion 159
SE Tpm3 ENSMUSG00000027940#chr3#+#89894934|89895013|89893931|89894001|89903449|89904487#E#SE 1 0.068 0.932 2.63E-13 Exclusion 163
SE Pacrgl ENSMUSG00000029089#chr5#+#48771362|48771470|48770568|48770703|48773025|48773106#E#SE 0.586 0.236 0.35 0.007569231 Exclusion 161
SE Pacrgl ENSMUSG00000029089#chr5#+#48771362|48771470|48770568|48770703|48773025|48773106#E#SE 1 0.266 0.734 0.000227565 Exclusion 163
SE Tpm4 ENSMUSG00000031799#chr8#+#74670955|74671018|74670350|74670426|74671096|74671166#I#SE 0.791 1 -0.209 0.000353879 Inclusion 159
 242
!!!!!!!!!!!
SE Tpm4 ENSMUSG00000031799#chr8#+#74670955|74671018|74670350|74670426|74671096|74671166#I#SE 0.722 1 -0.278 0.000335202 Inclusion 161
SE Tbc1d24
ENSMUSG00000036473#chr17#-#24319730|24319794|
24319394|24319490|24320638|24320797#E#SE 1 0.77 0.23 0.033548402 Exclusion 159
SE Tbc1d24
ENSMUSG00000036473#chr17#-#24319730|24319794|
24319394|24319490|24320638|24320797#E#SE 1 0.543 0.457 0.00362161 Exclusion 161
SE Upf3b ENSMUSG00000036572#chrX#-#34639060|34639099|34636852|34637013|34639501|34639684#E#SE 0.529 0.153 0.376 0.001349992 Exclusion 161
SE Upf3b ENSMUSG00000036572#chrX#-#34639060|34639099|34636852|34637013|34639501|34639684#E#SE 0.247 0.032 0.215 0.039314304 Exclusion 163
SE Ubap2l ENSMUSG00000042520#chr3#-#89835217|89835292|89832246|89832299|89837986|89838099#E#SE 1 0.586 0.414 0 Exclusion 161
SE Ubap2l ENSMUSG00000042520#chr3#-#89835217|89835292|89832246|89832299|89837986|89838099#E#SE 1 0.611 0.389 3.85E-09 Exclusion 163
SE Ubap2l ENSMUSG00000042520#chr3#-#89835232|89835292|89832246|89832299|89837986|89838099#E#SE 1 0.614 0.386 0 Exclusion 161
SE Ubap2l ENSMUSG00000042520#chr3#-#89835232|89835292|89832246|89832299|89837986|89838099#E#SE 1 0.637 0.363 7.39E-09 Exclusion 163
SE Zfp740 ENSMUSG00000046897#chr15#+#102035659|102035736|102035001|102035314|102038201|102038351#E#SE 0.701 0.402 0.299 0.037814574 Exclusion 161
SE Zfp740 ENSMUSG00000046897#chr15#+#102035659|102035736|102035001|102035314|102038201|102038351#E#SE 1 0.321 0.679 0.00210974 Exclusion 163
SE Immt ENSMUSG00000052337#chr6#+#71816719|71816734|71813134|71813264|71818573|71818797#I#SE 0 0.393 -0.393 3.71E-12 Inclusion 159
SE Immt ENSMUSG00000052337#chr6#+#71816719|71816734|71813134|71813264|71818573|71818797#I#SE 0 0.39 -0.39 1.75E-09 Inclusion 161
SE Tia1 ENSMUSG00000071337#chr6#+#86373599|86373665|86369922|86370405|86374338|86374417#I#SE 0.105 0.384 -0.279 0.000310484 Inclusion 161
SE Tia1 ENSMUSG00000071337#chr6#+#86373599|86373665|86369922|86370405|86374338|86374417#I#SE 0.066 0.269 -0.203 0.008705428 Inclusion 163
SE Rpl23 ENSMUSG00000071415#chr11#-#97643119|97643203|97642647|97642776|97643657|97643751#E#SE 0.946 0.719 0.227 0.000938556 Exclusion 161
SE Rpl23 ENSMUSG00000071415#chr11#-#97643119|97643203|97642647|97642776|97643657|97643751#E#SE 1 0.746 0.254 0.004915888 Exclusion 163
SE Rpl23 ENSMUSG00000071415#chr11#-#97643119|97643355|97642717|97642776|97643657|97643696#E#SE 0.87 0.411 0.459 4.37E-06 Exclusion 161
SE Rpl23 ENSMUSG00000071415#chr11#-#97643119|97643355|97642717|97642776|97643657|97643696#E#SE 1 0.476 0.524 0.003301076 Exclusion 163
SE Ppia ENSMUSG00000071866#chr11#+#6318103|6318317|6315878|6315982|6319115|6319288#E#SE 1 0.15 0.85 1.22E-14 Exclusion 161
SE Ppia ENSMUSG00000071866#chr11#+#6318103|6318317|6315878|6315982|6319115|6319288#E#SE 1 0.068 0.932 6.66E-16 Exclusion 163
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APPENDIX E - RNA-sequencing differential gene expression analysis 
in MEFs!!
Gene Name RPKM EtOH RPKM OHT log2 Fold Change p-value
Tacstd2 0 0.0303614 1,7977E+308 0.0334078
Cxcl13 0 0.0477452 1,7977E+308 0.0361027
Atp12a 0.139931 0.569464 2.02489 0.00420945
Fstl4 0.0227818 0.084724 1.89489 0.0289782
Fhl5 0.0926733 0.343413 1.88972 0.0215137
Stx1b 0.0441243 0.16198 1.87617 0.0382404
Odz1 0.0727036 0.242652 1.73879 0.013117
Rxfp1 0.102136 0.312853 1.61499 0.0297757
Wscd2 0.100913 0.296347 1.55417 0.0260662
Adamts17 0.0257874 0.0740318 1.52148 0.0357099
B4galnt3 0.0505701 0.140948 1.47881 0.0466124
Npr3 1.61094 4.1743 1.37363 0.00158393
Svop 0.447327 1.10699 1.30724 0.018683
Ppp2r2c 0.113451 0.277208 1.2889 0.0412102
Arhgap20 1.10346 2.64705 1.26236 0.00416448
Ptprv 0.693821 1.64581 1.24616 0.00691612
St8sia2 0.59413 1.38888 1.22507 0.0201751
Hecw1 0.0714833 0.1642 1.19978 0.046185
Rgs4 8.90464 20.0584 1.17158 0.000724996
Rsad2 1.23833 2.76211 1.15738 0.0401883
Cobl 0.638261 1.40369 1.13701 0.0211189
Myh2 0.969693 2.04349 1.07543 0.0156773
Myh11 8.24732 17.2164 1.06179 0.000901497
Rgs5 3.76049 7.73211 1.03994 0.0157622
Dsp 0.81854 1.66983 1.02858 0.0138056
Arsi 3.63422 7.40905 1.02764 0.0284811
Eln 25.3039 51.1334 1.01491 0.013654
Ano3 4.3123 8.68382 1.00987 0.0166723
Oasl2 4.49211 9.01476 1.0049 0.0424619
Nrk 1.4056 2.81048 0.999628 0.0149673
9930111J21Rik1 1.75252 3.46801 0.984678 0.0222986
Ptprq 1.85436 3.66334 0.982241 0.0120129
Nell2 1.76514 3.45896 0.970557 0.034331
Grid2 2.00129 3.85399 0.945423 0.0374579
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Pappa 3.4297 6.57532 0.938979 0.0034493
Slc5a7 2.64796 5.0672 0.936307 0.014472
Mest 71.6641 136.362 0.928115 0.0404224
Adamtsl1 1.37344 2.58095 0.910109 0.0219848
Itga8 8.28484 15.4837 0.902203 0.00662816
Hmcn1 1.06943 1.98536 0.892563 0.0123426
Kank4 4.2849 7.8282 0.869418 0.0162982
Adamts12 9.1692 16.5103 0.848496 0.00714401
Parm1 5.47556 9.78147 0.837044 0.03186
Prrg4 4.26624 7.60609 0.834189 0.0316062
Hcn1 1.38482 2.44098 0.817759 0.043332
Dmd 1.19443 2.08385 0.802926 0.0268856
Ptprd 4.03077 7.02217 0.800862 0.0233514
Jag1 5.15148 8.77508 0.768424 0.0233608
Fat4 10.0276 16.9437 0.756778 0.0206636
Ptprz1 1.69252 2.84921 0.751391 0.043784
Sorbs1 13.3546 22.0709 0.724802 0.0317293
Prelp 21.0046 34.712 0.724731 0.0228304
Mylk 4.04263 6.59222 0.705471 0.0363073
Adamts10 8.22209 13.3416 0.69835 0.0343244
Limch1 6.27819 10.1383 0.691398 0.0402788
Adamtsl3 11.9411 18.7418 0.65032 0.0423629
Cdk1 26.2514 16.7182 -0.650975 0.0440137
Fam162a 304.179 190.105 -0.678123 0.046474
Tacc3 22.559 14.0828 -0.679776 0.0402007
Hmgn2 55.3778 34.5395 -0.681061 0.0439556
Mcm5 15.8966 9.79982 -0.697887 0.0366464
Mcm3 21.1849 13.0475 -0.699265 0.03347
Phyh 40.9464 25.0288 -0.710148 0.0468132
Stmn1 50.5804 30.2537 -0.741467 0.0313387
Top2a 34.2268 20.4477 -0.743191 0.017107
Mad2l1 18.1809 10.8542 -0.744172 0.0426701
Mif 199.533 118.652 -0.749898 0.0302281
Fkbp11 39.8184 23.6651 -0.750672 0.0492266
H2afz 103.702 60.7806 -0.770769 0.0164272
Aurkb 10.8272 6.30994 -0.778964 0.0474733
Pdk1 12.2814 7.08908 -0.79281 0.0281187
Pold1 5.79077 3.34138 -0.793313 0.0446752
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Melk 6.8331 3.91924 -0.801967 0.0440782
Cenpa 19.2792 11.0299 -0.805624 0.0369871
Fam64a 12.7679 7.2982 -0.806905 0.0470281
Ube2c 32.1624 18.1688 -0.823915 0.0297321
Bnip3 58.5182 32.8033 -0.835046 0.0250806
Cbr2 177.669 99.0383 -0.843137 0.0225261
Ccnb2 20.1048 11.1416 -0.851586 0.0224155
Tnfsf11 25.045 13.7701 -0.862987 0.0264277
Fbxo5 9.48801 5.21159 -0.864382 0.0376515
Cdca3 23.7327 12.9647 -0.872291 0.0171457
2700094K13Rik 34.1401 18.5886 -0.877045 0.0491597
Birc5 39.5336 21.4229 -0.883924 0.0212829
Slc16a1 31.2609 16.904 -0.886999 0.0213703
Cdca5 5.52812 2.92313 -0.919272 0.0442206
Zc3h12a 15.5439 8.20195 -0.92231 0.0338929
Rnd1 26.9907 14.2336 -0.92316 0.0124259
Irak3 5.61935 2.9508 -0.929297 0.043878
Hmgb2 11.8318 6.21234 -0.929459 0.0116522
Slc16a3 41.8726 21.9627 -0.930955 0.0195588
Ptx3 241.389 125.415 -0.944644 0.0300247
Ccl20 141.689 72.8744 -0.959248 0.0484533
Mybl2 2.682 1.36117 -0.978467 0.0334606
D2Ertd750e 7.65623 3.87782 -0.981388 0.0118728
Cdkn3 9.39876 4.63735 -1.01917 0.0472117
Mt1 263.993 128.02 -1.04413 0.00492678
2610002D18Rik 4.02322 1.93059 -1.05931 0.0452433
Tk1 18.9498 8.80188 -1.1063 0.00986533
Enpp2 12.1137 5.476 -1.14545 0.0165817
Hp 76.243 34.4357 -1.1467 0.0195752
Wfdc2 5.18083 2.17748 -1.25053 0.0411823
Chi3l1 6.41443 2.60056 -1.3025 0.0308098
Cxcl3 20.7705 8.2938 -1.32443 0.00938076
Mt2 503.458 200.556 -1.32787 0.00230525
Rasl12 1.70011 0.660826 -1.36328 0.0225872
Traf1 1.28574 0.471385 -1.44762 0.0484318
U90926 70.0902 21.8933 -1.67873 0.00148449
Gm4349 0.295966 0.0880027 -1.74981 0.0442952
Pgr 0.0244941 0.00609293 -2.00722 0.0431482
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Prmt5 20.9639 3.76423 -2.47748 2.51893E-10
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